Acta Pharmaceutica Hungarica 2018 by unknown
Established in 1925. by Pál Lipták
Scientific Journal of the Hungarian Society for Pharmaceutical Sciences
A C T A
PHARMACEUTICA
H U N G A R I C A
3.
2018
APHGAO 88, (043) 85–212. (2018)
Book of Abstracts
LXXXVIII.  85–212.  ISSN 001-6659
Budapest, Condita an
no:
 19
24
So
ci
et
as
 S
cie
nti
aru
m Pharmaceuticarum
 Hungarica
A C T A
PHARMACEUTICA
H U N G A R I C A
Editor in chief
Béla Noszál; Department of Pharmaceutical Chemistry, 
Semmelweis University, Budapest, Hungary
Hőgyes Endre Street 7-9, Budapest, 1092 Hungary
Phone: (+36-1) 217-0891; 
E-mail: noszal.bela@pharma.semmelweis-univ.hu
Managing editor: 
Romána Zelkó; University Pharmacy Department of Pharmacy 
Administration, Semmelweis University, Budapest, Hungary
Hőgyes Endre Street 7-9, Budapest, 1092 Hungary
Phone: (+36-1) 217-0927; 
E-mail: zelko.romana@pharma.semmelweis-univ.hu
Editorial advisory board
Rita Ambrus, Mária Báthori, Anikó Borbás, Györgyi Horváth, 
Pál Perjési, László Tóthfalusi
Correspondence:
Acta Pharmaceutica Hungarica
Hőgyes Endre Street 7-9, Budapest, 1092 Hungary
Editor:
Zoltán Hankó HSPS, 
Gyu lai Pál u. 16., Bu da pest, 1085 Hungary
Phone: (+36-1) 235-0999; fax: (+36-1) 235-0998
Contents
Greeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  87
Committ ees  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  88
Curriculum vitaes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  90
Plenary Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  95
Oral presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  102
Poster sections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  115
Poster Section P1- Dermal and Transdermal Delivery 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  115
Poster Section P2- Nanoparticles 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  124
Poster Section P3- Ocular/Nasal/Pulmonar Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  132
Poster Section P4- Buccal Delivery and Printing Technologies  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  141
Poster Section P5- Oral Controlled Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  149
Poster Section P6- Dermal and Transdermal Delivery 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  158
Poster Section P7- Nanoparticles 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  167
Poster Section P8- Solid Dosage Forms  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  176
Poster Section P9- Quality by Design and in-silico modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  184
Poster Section P10- Preformulation and excipients  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  194
Poster Section P11- Regulatory Aﬀ airs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  202
Sponsors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  236
Scientific Journal of the Hungarian Society for Pharmaceutical Sciences
ACTA-1803-CESPT.indb   85 2018. 09. 10.   10:12
86 Acta Pharmaceutica Hungarica – CESPT Edition – Contents 2018/3.
Acta Pharmaceutica Hungarica: www.mgyt.hu
„Acta Pharmaceutica Hungarica” Scientifi c papers of the Hungarian Society for Pharmaceutical Sciences
Published by the Hungarian Society for Pharmaceutical Sciences, represented by Prof. Éva Szökő
Gyu lai Pál u. 16., Bu da pest, 1085 Hungary, Phone: (+36-1) 235-09-99; 
E-mail: szerkesztoseg@mgyt.hu
Subscibtion: Hungarian Society for Pharmaceutical Sciences, Gyu lai Pál u. 16., Bu da pest, 1085 Hungary by international banktransfer
(OTP bank account number: 11708001-20530530) – Mailing address: 1447 Budapest, Pf. 480
Informations for international banktransfer:
Account holder: OTP Bank Ltd. - Nádor utcai Kereskedelmi Banki Centrum 
Account Number: 11708001-20530530
Bankadress: H-1051 Budapest, Nádor u. 6.
IBAN: HU20 1170 8001 2053 0530 0000 0000
Swift Code (BIC): OTPVHUHBaz MGYT átutalási számlájára: OTP VIII. kerületi fi ók, Budapest, József krt. 33.
Subscibtion fee: HUF 6000 + HUF 300 VAT
Published quaterly
Typesett ing: Csaba Oláh
Printing: ColorToys Bt.
ACTA-1803-CESPT.indb   86 2018. 09. 10.   10:12
 2018/3. Acta Pharmaceutica Hungarica – CESPT Edition – Greeting 87
 Acta Pharmaceutica Hungarica – CESPT Edition – Greeting 88. 87 2018.
Greeting
On behalf of the Organizing Committ ee I am pleased to welcome you 
among the participants of the 12th Central European Symposium on 
Pharmaceutical Technology and Regulatory Aﬀ airs held in Hungary 
second time.
The conference series started in 1995 under the patronage of EUFEPS 
and the goal of the founders was to give a platform for colleagues from 
the Central European region working on the fi eld of pharmaceutical 
technology in the industry, universities or academic institutes. In the 
past conferences the original goals were extended, and the conference 
topics covered also pharmaceutical biotechnology or as in this confer-
ence, the regulatory aspects of drug development and manufacturing.
This scientifi c forum traditionally gathers colleagues from all over 
Europe but especially from the Central- and Eastern-European region 
and serves as a strong and stable background for permanent dialogue 
between pharmacists and other scientists working in the fi elds of phar-
maceutical R&D or manufacturing.
The conference provides the possibility for the participants to present 
their results, discuss the new developments and the future directions of the pharmaceutical technology 
and manufacturing.
It oﬀ ers a good opportunity to promote scientifi c achievements for talented young pharmacists, initi-
ate common research projects, and fostering the application of the results of new approaches for the ac-
celerated development and introduction of safer and more eﬀ ective medicines.
I am pleased that we have 250 colleagues registered for this symposium. The program contains 10 
plenary and keynote lectures, 25 verbal and 152 poster presentations.
Looking forward to seeing you in Szeged and having a fruitful and vivid conference!
Assoc. Prof. Ildiko Csoka
President of the 12th Central European Symposium 
on Pharmaceutical Technology and Regulatory Aﬀ airs
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President of the Symposium
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Curriculum Vitae of Invited Speakers
Andreas Bernkop-Schnürch
University of Innsbruck, Austria
Prof. Andreas Bernkop-Schnürch was educated in pharmacy at the Institute of 
Pharmacy (M.Sc.) and in microbiology and genetics at the Institute of Microbiolo-
gy and Genetics (D.Sc.), University of Vienna, fi nishing his doctorate in 1994. In 
2003 he was appointed to a chair in pharmaceutical technology at the University 
of Innsbruck, Austria. From 2006 to 2013 he served as dean of the Faculty of 
Chemistry and Pharmacy at the University of Innsbruck. His research interest is 
in the area of mucoadhesive polymers, nanocarriers, peptide drug delivery and 
self-emulsifying drug delivery systems (SEDDS). He developed thiolated poly-
mers (thiomers) and zeta-potential changing nanocarrier systems. Dr. Bernkop-
Schnürch is author of over 370 research articles and reviews as well as editor and 
(co-)author of several books. He is the founder of Mucobiomer GmbH (now part of the Croma-Pharma 
Holding), Thiomatrix GmbH and Green River Polymers GmbH.
Andreas Zimmer
Karl-Franz University of Graz, Austria
Prof. Andreas Zimmer (1963) studied Pharmacy at the Johann Wolfgang Goethe-
University Frankfurt am Main, Germany. He stayed with a PhD program and did 
part of the work which focused on the evaluation of nanoparticles as ophthalmic 
drug delivery systems at the University of Wisconsin with Joe Robinson, Madison 
WI, USA. After the PhD at Jörg Kreuter’s lab in Frankfurt he continued with a 
university career at the Biocenter at the University of Frankfurt in the fi eld of drug 
delivery and pharmaceutical nanotechnology. 1999 he joined the group of Robert 
Gurny in Geneva, Switz erland, as guest scientist and from 2000 on he moved to 
the University of Graz, fi rst as guest lecturer and later as full professor. Since 2004 
he is leading the Department of Pharmaceutical Technology and Biopharmacy at 
the Karl-Franzens-University in Graz, Austria. His research is focused on drug delivery and drug target-
ing devices and specialized on nanoparticles used for DNA- and RNA-drugs as well as for peptides and 
proteins.
Chris Vervaet
Gent University, Belgium
Prof. Chris Vervaet is head of the Laboratory of Pharmaceutical Technology (Faculty of Pharmaceutical 
Sciences, Ghent University, Belgium), a research group focusing on the development and characteriza-
tion of pharmaceutical solid dosage forms (granules, tablets, pellets, sustained release matrices). Over 
the last 10 years continuous manufacturing of solid dosage forms has been the one of main research 
topics of the team of Prof. Vervaet, focusing on processes such hot-melt extrusion, injection molding, 
wet granulation, tableting and blending. By evaluating the impact of formulation and process parame-
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ters on the performance of these continuous processes key information was ob-
tained to smoothen the transition within the pharmaceutical industry from batch 
processing to continuous manufacturing. By combining the expertise of the Lab-
oratory of Pharmaceutical Technology with the implementation of PAT tools dur-
ing continuous manufacturing (in collaboration with Prof. De Beer, Laboratory of 
Pharmaceutical Process Analytical Technology, Ghent University) a bett er insight 
into the fundamental material behavior during continuous manufacturing was 
gained. This has resulted in multiple international collaborations, at an academic 
level as well as with large and small pharmaceutical companies. About 100 re-
search papers have been published by the research group of Prof. Vervaet on the 
topic of continuous manufacturing of pharmaceuticals.
Jörg Breitkreutz 
Heinrich Heine University, Düsseldorf, Germany
Prof. Jörg Breitkreutz  studied Pharmacy from 1987 to 1991 at the Westphalian 
Wilhelms-University of Münster, Germany. He fi nished his PhD in 1996 at the 
Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under 
supervision of Prof. Rüdiger Gröning. From 1996 to 1997 he joined Thiemann Ar-
zneimitt el GmbH in Waltrop, Germany, as the head of Product Coordination. In 
1997 he went back to the university in Münster to work on his habilitation thesis 
(2004) on pediatric drug formulations. In 2004 he became professor for pharma-
ceutical technology at the Institute of Pharmaceutics and Biopharmaceutics at the 
Heinrich-Heine-University in Düsseldorf, Germany, and today is the director of 
this institute. Joerg Breitkreutz  serves as external expert for various regulatory 
bodies and companies. He is presently heading the Paediatric Formulation group at the European Di-
rectorate for the Quality of Medicines and Healthcare (EDQM). Since 2010 he is president of the non-for-
profi t International Association of Pharmaceutical Technology (APV). His research focuses on pediatric 
and geriatric drug formulations, drug printing technologies, orphan drugs, process analytical technolo-
gies, green and sustainable medicinal products.
Katalin Varjú
ELI–ALPS Research Institute, Hungary
Dr. Katalin Varjú started her physics education graduating with a diploma in 
physics with distinction from the University of Kent, Canterbury, UK in 1996, fol-
lowed by a MSc in physics with distinction at JATE University, Szeged, Hungary 
in 1999. She graduated with a theoretical physics PhD from the University of Kent 
in 2000. 
She has worked at the University of Szeged, from 1999, where she holds now 
an associate professorship, leading a research group, and teaching actively. She 
has been a visiting scientist at Lund University in Sweden (2003-2005) in the Ma-
rie Curie Programme. She habilitated at the University of Szeged in 2015.
Dr. Varjú has been working for the ELI programme from the beginning. She 
was active in the preparatory stages of the ELI proposals (ELI PP and ELITRAIN ITN) and co-edited the 
fi rst Scientifi c Case for ELI-ALPS in 2011. She is currently the head of the Att osecond Sources Division 
responsible for developing the att osecond pulse secondary sources.
She has published 52 papers in refereed journals, has been cited 1175 times, her h-index is 17.
Her main research interests are in optical and atomic physics: concerning the propagation of femto-
second laser pulses, high-order harmonic generation and att osecond pulse (train) generation.
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Niklas Sandler
Åbo Akademi University, Turku, Finland
Prof. Niklas Sandler received his M.Sc. (Pharm.) in 1998 from University of Hel-
sinki, Finland. He got his Ph.D. in pharmaceutical technology from the Univer-
sity of Helsinki 2003. He was lecturer at the Pharmaceutical Technology Division, 
Helsinki between 2003-2005 and in 2005-2006 he was a postdoctoral researcher at 
the University of Otago, New Zealand, focusing on research on solid-state char-
acterization of drugs. He became an adjunct professor in Pharmaceutical Technol-
ogy at the University of Helsinki in 2007. Between 2006 and 2008 he had a senior 
researcher position at AstraZeneca, Pharmaceutical and Analytical R&D in the 
UK. From September 2008 until July 2009 was a temporary professor in Indus-
trial Pharmacy at the University of Helsinki. Since August 2009 he has been full 
professor in Pharmaceutics at Åbo Akademi University (ÅAU), Turku, Finland and heads the research 
group in drug-delivery and pharmaceutical technology. He has pioneered in research around printable 
drug-delivery systems. The current aim of his research group is to increase the understanding of material 
behaviour in fabrication of printed drug-delivery systems and to explore various printing techniques in 
drug manufacture. He is the president of the Finnish Pharmaceutical Society since 2012. Vice rector re-
sponsible for research aﬀ airs and innovations of Åbo Akademi University since 2015. He is the president 
of the Finnish Pharmaceutical Society since 2012. He has been an Executive Board Member of EUFEPS 
from 2013 onwards. 
Márk Oláh
Gedeon Richter Plc., Hungary
Dr. Márk Oláh is a medical project manager at Richter Gedeon Plc. since 2014, focusing on original drug 
development in the central nervous system (CNS) fi eld, including global medical 
coordination and clinical support for drug research and development. He is an 
active contributor to the in-house original CNS medical strategy, including target 
product profi le development, indication portfolio development, and competitive 
landscape analysis. He received his M.D. in 2002 from Semmelweis University in 
Budapest, and began his early medical carrier as a clinical physician in the 2nd 
Department of Internal Medicine. In 2011, he obtained his Ph.D in neuroscience, 
with particular interest in the neuro-endocrine molecular regulation of pituitary 
hormone secretion. He was an assistant professor in the Department of Anatomy, 
Histology and Developmental Biology at Semmelweis University. In 2011-2012 he 
continued his professional career with a postdoctoral visiting fellowship at the National Institutes of 
Health (USA), where he studied the transcriptional regulation of pituitary and adrenal hormone secre-
tion during the stress reaction, both in vivo and in vitro. He is committ ed to all clinical fi elds of person-
alized medicine as an active member of the Hungarian Personalized Medicine Society.
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Odon Planinšek
University of Ljubljana, Slovenia
Prof. Odon Planinšek has fi nished his studies as pharmacist (M.Sc) at the Faculty 
of Pharmacy, University of Ljubljana in 1996. He recieved PhD degree in 1999 on 
the same University. He is working in the Department of Pharmaceutical Tech-
nology since 1994. He became assistant professor in 2001, associate professor in 
2006 and since 2012 he is a full pofessor of the Department of Pharmaceutical 
Technology. In 2001 and 2002 he performed postdoctoral studies in University of 
London, Faculty of Pharmacy. He is a member of the Slovenian Pharmaceutical 
Society and between 2005 and 2015 he served as associate editor of the Acta Phar-
maceutica journal. His main research interest is preformulation, deformulation 
and formulation of solid paricles and tablets.
Piroska Szabó-Révész
University of Szeged, Hungary
Prof. Piroska Szabó-Révész has got her diploma as pharmacist in Albert Szent-Györgyi Medical Univer-
sity of Szeged in 1975. She has got her university doctorate in the same University 
in 1979 and in the same year she became a specialist pharmacist in pharmaceutical 
technology. She has got her PhD degree in Semmeweis University, Budapest in 
1992. She has done her habilitation in Albert Szent Györgyi Medical University 
of Szeged in 1996. She became the Doctor of Sciences (D.Sc.) in 2006. She was 
nominated as full professor in 2004 and served as the Head of the Department of 
Pharmaceutical Technology, University of Szeged between 2005 and 2016. She is 
the Head of Pharmaceutical Technological Program at the PhD School for Phar-
maceutics and Chair of the Habilitation Committ ee of the Pharmaceutical Sciences 
in University of Szeged. She is the Head of the Nanotechnological research team 
at the Institute of Pharmaceutical Technology and Regulatory Aﬀ airs. She was the supervisior of 16 PhD 
thesis and 25 diploma works. She is doing reviewing activity for 10 journals. She is the leader of numer-
ous national and international projects. She has given 130 lectures at national and international scientifi c 
events, participated in more than 60 industrial research-development projects, was the author of 3 books, 
10 book chapters, 3 university hand-outs, 221 papers and 2 patents Her main fi elds of interest are particle 
engineering, micronization, nanonization and amorphization of crystalline pharmaceutical agents, solid-
phase analysis, development of drug delivery systems for nasal and pulmonary administration. 
Sarah Barthold
Glatt  Pharmaceutical Services GmbH & Co. KG
Dr. Sarah Barthold has studied pharmaceutical sciences at the University of Re-
gensburg and ETH Zurich before she fi nalized her education with a PhD in Phar-
maceutical Technology at the Helmholtz -Institute of Pharmaceutical Research 
Saarland/Saarland University. 
From 2015 to 2017 she worked at the institute of Biopharmacy and Pharmaceuti-
cal Technology at Saarland University dealing with nanoparticulate dosage forms. 
In 2017 she joined Glatt  GmbH as project manager in the Pharmaceutical De-
velopment Division of Glatt  Pharmaceutical Services Binzen / Germany.
Glatt  Pharmaceutical Services activities include the pharmaceutical develop-
ment of solid dosage forms with a focus on multiparticulate dosage forms and 
controlled release applications.
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Tamás L. Paál
National Institute of Pharmacy and Nutrition and University of Szeged, Hungary
Prof. Tamás L. Paál graduated in Pharmacy, postgraduated in drug control and 
chemical engineering then received his Ph.D. at diﬀ erent Universities, all in Buda-
pest. Having worked 11 years for the Hungarian pharmaceutical industry he joined 
the National Institute of Pharmacy, the Hungarian medicines regulatory authority 
in 1978. He was Director-General of the Institute between 1984 and 2008. Having 
been retired he has been scientifi c adviser of the agency (now National Institute of 
Pharmacy and Nutrition). He has been promoted Professor in 1984. He has worked 
in the Postgraduate Medical University then the Semmelweis University, Budapest 
until his retirement in 2013. Parallelly he was invited to create the Institute of Drug 
Regulatory Aﬀ airs at the Faculty of Pharmacy, University of Szeged and directed 
this between 2002 and 2008. He became Professor emeritus (at present at the Institute of Pharmaceutical 
Technology and Regulatory Aﬀ airs) in 2013. He worked on diﬀ erent regulatory missions for UNIDO, 
WHO and the EU PHARE Project in Central America, Central Asia, Africa and Eastern Europe. He re-
ceived, among others, the Life-long membership award from TOPRA (The Organisation of Profession-
als in Regulatory Aﬀ airs) and was awarded also by DIA (Drug information Association) and RAPS (the 
Regulatory Aﬀ airs Professionals Society). He is member of the European Academy of Sciences and Arts.
He published 230 papers, mainly on chemistry and regulatory aﬀ airs.
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Plenary Lectures
PL-1
The Changing Landscape of Personalized 
Medicine
OLÁH, M.
Gedeon Richter Plc, Budapest, Hungary
Personalized medicine has the potential to pro-
foundly improve medical treatment. Until now, 
most medical treatments have been designed for 
the “average” patient. As a result of this “one-size-
fi ts-all” approach, treatments can be very success-
ful for some patients but not for others. Personal-
ized (precision) medicine is an innovative ap-
proach that takes into account individual diﬀ er-
ences in people’s genes, environments, and life-
styles. It gives medical professionals the required 
resources to target specifi c treatments of the ill-
nesses, tailored to specifi c characteristics, such as 
a person’s genetic makeup, or the genetic profi le of 
an individual’s tumor. For instance, varied pheno-
types may exist which have a single underlying 
genetic variant leading to a possibility of a single 
personalized targeted therapy.
 The European Commission has recently ad-
dressed the policy perspective on personalized 
medicine, aiming for a paradigm change in health-
care. Personalized approaches face multiple chal-
lenges today, including technology and know-
how. Next-generation sequencing is one of the 
most widely used methods in personalized medi-
cine, generating gigabytes of data from each pa-
tient. Beyond collection, storage, and availability 
of genetic and clinical data, further ethical, social, 
and legal concerns have emerged during the last 
decade.
We will also provide a global update on the cur-
rent clinical achievements, and on newly market-
ed innovative products in diﬀ erent indications. 
We will pay special att ention to orphan diseases 
and the clinical reclassifi cation of patient popula-
tions in contrast to previously used diagnostic ap-
proaches, which were based mainly on the pheno-
type. Furthermore, we demonstrate the possibili-
ties of implementing personalized medicine as-
pects into future industrial drug research and de-
velopment.
PL-2
Regulatory approach in the pharmaceutical R&D
PAÁL, T. L.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
Faculty of Pharmacy, University of Szeged, Szeged, Hungary
While diverse defi nitions of regulatory science 
can be found in the literature they agree that the 
target of this applied science is to develop and ad-
just drug investigation methods to regulatory 
needs. Diﬀ erences in the performance of regulato-
ry science between the academic and regulatory 
(at the same time: industrial) researchers in rela-
tion to their aim, starting points and target are 
pointed out. The basis of the academic research is 
the scientifi c literature while regulatory require-
ments appear in the hard (mostly indirectly) and 
the soft laws (guidelines) as well as in the current 
regulatory practice (the latt er is mostly neglected 
by the academic research).  This is illustrated by 
the European Union rules governing medicinal 
products. The aim of the academic research is to 
produce always something new while regulatory 
requirements expect working strictly in line with 
the guidelines unless a very good reason is prov-
en. However, the regulatory world needs the aca-
demic medicine research directed to new methods 
as well as the latt er needs the incorporation of the 
regulatory thinking. The solution could be a care-
ful combination of the two approaches and selec-
tion of research topics giving priorities to those of 
recent regulatory interest. 
The fi rst example originates from the European 
“regulatory sameness” fi ction (diﬀ erent salts, es-
ters, etc. of active principles as well as similar im-
mediate release dosage forms can be “the same” 
and bioequivalent). By contrast, “suprabioavail-
ability” (often target of technological research) 
may not permit the “generic”, only the “hybrid” 
route of authorisation, oﬀ ering not more than a re-
duced amount of the active principle in the dos-
age-form with its price gain plus less environmen-
tal exposition. The benefi t of “suprabioavailable” 
substances should be evaluated case-by-case.
The second example covers bibliographic (well-
established use) applications when the relevance 
of literature data of the already marketed, similar 
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medicines to the claimed product must be proven. 
This is simple for BCS I and III active principles, 
but the recent regulatory practice is more de-
manding in case of BCS II and IV ones. Limita-
tions of the present dissolution test methods and 
the way of the possible solution is discussed.
KN-1
ELI ALPS – The next generation of att osecond 
sources
VARJÚ, K.
ELI-ALPS Research Institute, Szeged, Hungary
The Extreme Light Infrastructure – Att osecond 
Light Pulse Source (ELI-ALPS), the Hungarian pil-
lar of ELI, is the fi rst of its kind that operates by 
the principle of a user facility, supporting laser 
based fundamental and applied researches in 
physical, biological, chemical, medical and materi-
als sciences at extreme short time scales. 
This goal is realized by the combination of spe-
cialized primary lasers which drive nonlinear fre-
quency conversion and acceleration processes in 
more than twelve diﬀ erent secondary sources. 
Any light pulse source can act as a research tool 
by itself or, with femtosecond synchronization, in 
combination with any other of the sources. Thus a 
uniquely broad spectral range of the highest pow-
er and shortest light pulses becomes available for 
the study of dynamic processes on the att osecond 
time scale in atoms, molecules, condensed matt er 
and plasmas. 
The ground-breaking laser systems together 
with the subsequent outstanding secondary sourc-
es generate the highest possible peak power at the 
highest possible repetition rate in a spectral range 
from the E-UV through visible and near infrared 
to THz. The facility – besides the regular scientifi c 
staﬀ  - will provide accessible research infrastruc-
ture for the international scientifi c community 
user groups from all around the world. 
The att osecond secondary sources are based on 
advanced techniques of Higher-order Harmonic 
Generation (HHG). Other secondary sources pro-
vide particle beams for plasma physics and radio-
biology. A set of state-of-the-art endstations will 
be accessible to those users who do not have ac-
cess or do not wish to bring along their own 
equipment. 
The realization of the ELI-ALPS facility has 
commenced recently with the inauguration of the 
new building complex in May 2017. Step by step 
the lasers are now commissioned, trialed and 
handed over for user operation. 
REFERENCE:
1. Kuhn S. et al. Journal of Physics B. 50, 132002 
(2017)
KN-2
Are printing technologies completely changing 
drug manufacturing of the future?
SANDLER, N.
Pharmaceutical Sciences Laboratorym Åbo Akademi University, 
Turku, Finland
Diﬀ erent types of printing methods have att racted 
interest as emerging technologies for fabrication 
of drug delivery systems (DDS). Examples from 
the past decade include the use of diverse types of 
inkjet (IJ) printers. for depositing drug-loaded 
inks to produce accurately and precisely dosed 
units of active pharmaceutical ingredients (APIs). 
Furthermore, the exploitation of extrusion based 
printers and a combination of technologies has 
been reported. Diﬀ erent additive manufacturing 
technologies or three-dimensional printing ap-
proaches also play an integral role in future fabri-
cation scenarios. Many types of options for print-
ed dosage form exist. The concepts include on the 
simplest level accurately deposited doses of drug 
substances and one-layer fi lms. On the other 
hand, printing technologies allow the manufac-
ture of advanced multi-layer membranes, various 
type of stacked systems, and integrated multi-
compartment systems with bioactive components. 
These can comprise of integrated combinations of 
diverse materials to form sophisticated bio-func-
tional constructs. Moreover, computer aided de-
sign allows endless opportunities to create suit-
able geometries with tailored functionality e.g. 
through controlling the release properties of one 
or multiple drug substances. This talk will present 
examples on the use of printing technologies that 
are of potential interest in printing of bioactive 
substances. Many of ideas in the use of this type 
of technology in drug manufacturing is based on 
the ideas that development and fabrication of 
pharmaceuticals in a tailored manner to meet 
some of the foreseen personalization needs of 
treatments for patients. This optimally means 
more possibilities to accomplish on-demand fabri-
cation of custom-made medications.  This talk will 
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present examples on the use of printing technolo-
gies that are of potential interest in personaliza-
tion of drug products and future manufacturing.
KN-3
Oral peptide drug delivery: What intestinal 
barriers fear the most
BERNKOP-SCHNÜRCH, A.
Institute of Pharmacy, University of Innsbruck, Innsbruck, 
Austria
Oral delivery of peptide drugs is a great challenge 
as various barriers being encountered with the GI-
tract have to be overcome in order to reach the 
systemic circulation. Especially the enzymatic 
barrier (I) being based on secreted and membrane 
bound peptidases, the sulfh ydryl barrier (II) caus-
ing unintended thiol/disulphide exchange reac-
tions between thiols being present in the GI-tract 
and peptide drugs, the mucus gel barrier (III) re-
stricting peptides and formulations containing 
them from reaching the absorption membrane 
and the absorption membrane barrier (IV) are re-
sponsible for a comparatively poor oral bioavail-
ability. To overcome these barriers, numerous 
strategies including structural modifi cations of 
peptides in order to improve their stability to-
wards peptidases, enzyme inhibitors, permeation 
enhancers, multifunctional polymers and diﬀ er-
ent nanocarrier systems were adopted. Among 
these strategies in particular self-emulsifying 
drug delivery systems (SEDDS) have received con-
siderable att ention within recent years. Despite 
their hydrophilic character therapeutic peptides 
can be incorporated in the lipophilic phase of 
SEDDS via complexation with lipophilic excipi-
ents that are mainly surfactants. Due to such com-
plexations the lipophilic character of peptides can 
be even 100,000-fold increased. Once emulsifi ed in 
the GI-tract to oily droplets in the size of 30-200 
nm, SEDDS provide a protective eﬀ ect towards 
peptidases as digestive enzymes are too hydro-
philic to penetrate the oily droplets and to reach 
the incorporated peptide drug. By contrast to co-
administered enzyme inhibitors, the risk of any 
formulation derived side eﬀ ects can be excluded. 
As sulfh ydryl bearing nutrients and endogenous 
glutathione can also not penetrate the oily drop-
lets, the incorporated peptide drugs are protected 
towards their att ack. Moreover, in order to over-
come the mucus gel barrier the oily droplets can 
be made highly slippery. In particular the use of 
PEGylated surfactants assembling on the surface 
of the oily droplets makes them mucoinert and 
mucus permeating. Having reached the absorp-
tion membrane, the improved lipophilic character 
of the peptide drug having been obtained via 
complexation with lipophilic excipients can now 
show its real potential. Due to the raised lipophilic 
character peptides can more easily permeate the 
absorption membrane and reach the systemic cir-
culation. The great potential of the SEDDS-tech-
nology for oral peptide drug delivery could mean-
while be demonstrated via various in vivo studies 
showing an oral bioavailability around 10%. Ac-
cording to these recent developments and results, 
SEDDS can be regarded as game changing ap-
proach for oral peptide drug delivery.
KN-4
Drug Delivery of microRNA
ZIMMER, A.
Institute of Pharmaceutical Sciences, Department of 
Pharmaceutical Technology and Biopharmacy, University of 
Graz, Graz, Austria
INTRODUCTION: More than two decade has 
passed since the discovery of RNA interference, 
followed by exploration of the fi rst non-coding mi-
croRNA (miR) and endogenous so called small in-
terfering RNAs (siRNAs) [1]. Since these major 
fi ndings the fi eld of microRNA biology has ex-
panded considerably and the roles of miRs in 
pharmaceutical development and disease applica-
tion have made miRs att ractive tools and APIs as 
antimiRs for novel therapeutic approaches. In ad-
dition, up to now about 194 clinical studies were 
conducted with focus on miR and since about 10 
years all together 682 clinical trials were initiated 
in the fi eld of cancer, auto-immune diseases, re-
spiratory- and infectious diseases, such as hepati-
tis and others (ClinicalTrials.gov).
MATERIALS AND METHODS: During 
drug development it soon became obvious that 
miRs as unmodifi ed RNA in naked form is not 
suitable for a systemic application due to rapid 
degradation or insuﬃ  cient PK/PD properties. 
Therefore, in early studies strategies for chemical 
modifi cation as well as formulation with drug car-
riers were investigated. During this lecture I will 
give an overview about current delivery methods 
which will include also drug targeting strategies 
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to improve the eﬃ  cacy of the miR-therapeutics. 
These include non-viral carries such as liposomes 
and lipid-nanoparticles, polymeric nanoparticles 
and combinations between lipid and polymeric 
carries, as well as metal nanoparticles and in op-
posite, more biology driven vehicles like exo-
somes. 
RESULTS: Due to the increased complexity of 
the drug formulation the combination of two rath-
er new ingredients, the miR and the drug carrier, 
in early studies chemically modifi ed miRs were 
applied. Santaris, now a part of Roche was leading 
the fi eld with so called locked nucleic acids 
(LNAs). However, also liposomes which were 
used as drug carriers for cancer medication be-
fore, reached clinical trials. Focusing on cancer ap-
plication Mirna Therapeutics investigated lipo-
somes as miR carriers. Further, miR-145 is a cur-
rent example for such miR-liposomal formulation. 
In this case, a complex between protamine, a cat-
ionic DNA binding peptide and the miR-145 fol-
lowed by packaging into liposomes was shown in 
2016, a strategy which was originally investigated 
and published by our research group for the fi rst 
time in 2005. Other drug delivery polymers like 
polyethylenimin, dendrimers or biopolymers like 
chitosan are reported as potential miR carriers. 
Examples of our research will be also shown and 
will demonstrate the potential application of miR-
27 in lipid metabolic diseases. 
REFERENCES: 
1. Fire, A. et al. Nature 391, 806–811 (1998)
KN-5
Particles design and solid dosage forms
PLANINŠEK, O.
Chair of Pharmaceutical Technology, University of Ljubljana, 
Ljubljana, Slovenia
Particulate formulations represent a large propor-
tion of pharmaceutical products and the concept 
of engineering materials with improved proper-
ties is widely applied in pharmaceutical technolo-
gy. The performance of these products is a func-
tion of their composition, but also of their partic-
ulate structure, properties, and att ributes. We 
need to understand and control a range of key 
unit manufacturing operations such as crystalli-
zation, milling, granulation, powder mixing and 
compression which can be very challenging. Par-
ticles are being designed especially as powders 
for direct compression and for dry powder inhal-
ers. Their optimization lead to decrease of pro-
duction costs (improved processability) and de-
sired active pharmaceutical ingredient (API) per-
formance. It is expected that optimal drug deliv-
ery system transport a selected medication 
through a specifi c path in a live body to reach an 
organ and react there at a desired rate. There are 
continuous eﬀ orts to improve every single step of 
the process of its formulation. Desired properties 
of particles incorporated into solid dosage forms 
can be achieved with diﬀ erent top down and bot-
tom up methods. Obtained particles can be com-
posed of single, two or more components which 
can be API(s), excipient(s) or their combination. 
Particles are being designed also from the molec-
ular structure point of view with the emphasis on 
oral bioavailability of poorly water-soluble APIs 
enhancement. Beside traditional crystal modifi ca-
tions approaches, salt or hydrate formation co-
crystals and co-amorphous systems gained sig-
nifi cant att ention recently. In the lecture some in-
teresting concepts of particles design that can be 
relatively simply transferred to industrial scale 
such as spherical crystallization, precipitation of 
particles in microfl uidic reactor and continuous 
heterogeneous crystallization on excipient surfac-
es will be presented.
KN-6
CONTINUOUS PROCESSING OF SOLID 
DOSAGE FORMS
VERVAET, C.
Department of Pharmaceutical Technology, Gent University, 
Gent, Belgium
Over the past decade signifi cant advancements 
have been made to support the implementation of 
continuous manufacturing of dosage forms with-
in the pharmaceutical industry. Continuous pro-
cessing is considered as an essential aspect to 
modernize pharmaceutical manufacturing as this 
concept - compared to traditional batch manufac-
turing-  provides several opportunities to improve 
product quality and to increase manufacturing 
fl exibility: shorter production times, smaller foot-
print, faster product development, on-line product 
monitoring and control, enhanced process under-
standing, real time release, … Continuous manu-
facturing also allows to easier accommodate sup-
ply needs as production volume can be increased 
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without scale-up issues since it is controlled by 
time, not equipment. 
As a result several newly engineered fully inte-
grated continuous manufacturing lines of solid 
dosage forms have been introduced by equipment 
vendors, e.g. integrated powder-to-tablet lines 
linked all unit operation into a single continuous 
process. This presentation presents some of these 
concepts and highlights some of the essential as-
pects that must be covered to ensure the success-
ful introduction of a continuous manufacturing 
line within the pharmaceutical industry (e.g. ma-
terial residence time distribution throughout the 
continuous manufacturing line, implementation 
of Process Analytical Technology (PAT) for pro-
cess monitoring and feed-back/feed-forward pro-
cess control, potential of surrogate approach dur-
ing initial process development). 
KN-7
Modifying the physicochemical properties of 
NSAIDs for nasal administration
SZABÓ-RÉVÉSZ, P.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
The presentation summarizes the nasal delivery 
of NSAIDs (non-steroidal anti-infl ammatory 
drugs) for fast onset analgesia and for the poten-
tial prevention of Alzheimer’s disease. It will be 
discussed how the physicochemical properties of 
NSAIDs can be modifi ed with respect to the bio-
logical characteristics of the target site and what 
innovative technology and/or nasal compositions 
can promote an eﬀ ective therapy.
Intranasal administration is a potential route of 
delivering NSAIDs through the trans-epithelial 
absorption into the systemic circulation (“nose-to-
blood”) and/or central nervous system (CNS) 
through the blood-brain-barrier. NSAIDs can be 
delivered directly from the nasal cavity into the 
CNS through the axonal transport (“nose-to-
brain”).
NSAIDs are poorly dissolved at the nasal mem-
brane (pH: 5.3-5.6), increasing their solubility and/
or the rate of dissolution is a challenge to over-
come in the development of nasal dosage forms, 
in order to enhance bioavailability. Solubility may 
be improved by using salt forms, solubility-en-
hancing or complexing agents. The dissolution 
rate may be increased by particle size reduction or 
by breaking of crystal structure (amorphous form, 
applicable for a liquid or gel form containing the 
suspended active agent). Also, the residence time, 
i.e. the length of time the formulation spends in 
the nasal cavity should be lengthened by using 
mucoadhesive agents.
Nanotechnology is a new opportunity for the 
above considerations. Reducing the particle size to 
the nano range and researching and developing 
nanostructured units can help the successful nasal 
application of NSAIDs.
ACKNOWLEDGEMENT: This work was 
supported by GINOP project (2.3.2-15-2016-
00060), Hungary.
REFERENCES:
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2.  Horvát S. et al. Eur. J. Pharm. Biopharm. 72, 
252–259 (2009)
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IL-1
Drug delivery in the pediatric and geriatric 
patient population – speaking about 
multiparticulates
BARTHOLD, S.
Glatt  Pharmaceutical Services GmbH & Co. KG
During lifetime, abilities and capabilities change 
from age to age. Children and elderly people have 
special needs that should be addressed when think-
ing about oral drug product development.  Visual, 
motoric, and swallowing capabilities are amongst 
the major age-related changes. Multiparticulates, 
covering micropellets, pellets and mini-tablets thus 
present a feasible approach for convenient and pa-
tient friendly medication. Moreover, one bulk for-
mulation oﬀ ers the possibility of a broad range of fi -
nal drug products, applying well-established man-
ufacturing technologies at viable cost.
The rationale of multiparticulate formulations 
and associated manufacturing technologies will 
be demonstrated and explained with a focus on 
(micro)pellets. Time permitt ing, one development 
project will be shown as case study with regards 
to the idea and the technological realisation of a 
multiparticulate formulation for the treatment of a 
rare disease in the pediatric population, starting 
from patient’s needs until market launch.  
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SP-1
Non-destructive quantifi cation of impurities in 
100 mg pharmaceutical samples using energy-
dispersive X-ray fl uorescence (EDXRF)
RAYNER M., XIAO, Y., KEMPENAERS, L.
Malvern Panalytical
INTRODUCTION: Energy-dispersive X-ray fl uo-
rescence (EDXRF) is a versatile technique for qual-
itative and quantitative elemental analysis, typi-
cally without the need for complicated sample 
preparation steps. It has been used in many indus-
tries for years but has only recently been accepted 
by the Pharmaceutical industry with the imple-
mentation of USP [1]. Pharmaceutical laboratories 
often struggle with small sample masses, espe-
cially during development. Elemental quantifi ca-
tion by EDXRF with small sample masses requires 
long measurement times, often making it imprac-
tical for routine operation. Recent advances in 
EDXRF technology have yielded signifi cant im-
provements in sensitivity. Our work demonstrates 
that these improvements now allow the non-de-
structive quantifi cation of 17 impurities in phar-
maceuticals in 1 hour or less, using only 100 mg of 
material [2].
MATERIALS AND METHODS: Measurements 
were performed with an Epsilon 4 EDXRF spec-
trometer, equipped with a 15 W, 50 kV silver (Ag) 
anode X-ray tube and an SDD30 silicon drift de-
tector. Loose powder standards and routine sam-
ples (100 mg) were placed in special small-mass 
sample cells, assembled using 6 μm polypropyl-
ene fi lms. Calibrations for Cd, Pb, As, Hg, Co, V, 
Ni, Tl, Pd, Ir, Rh, Ru, Se, Pt, Mo, Cu and Cr were 
developed using in-house cellulose standards. All 
measurements were performed in air, with a total 
measurement time of 1 hour per sample.
RESULTS: We were able to demonstrate that the 
Epsilon 4 EDXRF spectrometer meets the accep-
tance criteria for calibration linearity, accuracy 
and specifi city, repeatability, intermediate preci-
sion, quantitation limits and robustness specifi ed 
by USP. In addition, the set of calibration stan-
dards allows for the development of wide calibra-
tion ranges. We were also able to demonstrate 
LOQ values lower than those specifi ed by ICH 
Q3D [3] based on 1 g daily doses for all of the in-
cluded impurities and Calculations suggest that 
the ICH Q3D criteria could also be met with a 
21-minute measurement time.
CONCLUSION: Thanks to swift technological 
development, EDXRF has become an eﬀ ective and 
compliant tool for the analysis of impurities in 
pharmaceuticals where only small masses are 
available.
REFERENCES:
1.  USP40-NF35, United States Pharmacopeia, 
United States (2017)
2.  Impurities in Pharmaceuticals (application 
note), Malvern Panalytical, the Netherlands 
(2018)
3.  ICH Q3D Step 4 Guidelines: Guideline for Ele-
mental Impurities, ICH, Geneva, Switz erland 
(2014)
SP-2
Safe Handling of Cytostatic Drugs
ZSÁK, P.
DuPont De Nemours (Luxembourg) Sarl
The handling and production of Hazardous 
Drugs, like Cytostatics, requests cautious prepara-
tions to prevent the contamination of the sample 
and have a proper protection of the handling staﬀ .
For the protection of the product, it is essential 
to have a barrier against any contamination agent 
by the handling personnel, but it is also equally 
important to provide a barrier for the handler 
against the dust, mist created by the handling of 
cytostatic raw materials.
The Personal Protective Equipment must fulfi l 
both functions, it must protect the product and the 
handler and it should not make the work process 
harder or make the productivity worth.
Strict standards are used in the clean environ-
ments and strict regulations regulate the handling 
of dangerous chemicals (QuapoS - Quality Stan-
dard for the Oncology Pharmacy - defi nes the re-
quirements for the Personal Protective Equip-
ment).
The best balance between the protection of the 
product and the handling personnel oﬀ ered by 
DuPont™ Tyvek® products through the widely 
used solutions, as they oﬀ er dust and liquid repel-
lence and breathability, which increase the com-
fort through the day of usage.
The material of Tyvek® provides a protective bar-
rier by its own structure, not like the microporous 
fi lm or the SMS material, that›s mean that the rapid 
hand movements and continuously abrasion in the 
armpit do not decrease its protective properties.
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The Tyvek® does not lint, so it fulfi ls the re-
quirements of cleanroom regulations GMP C/D, 
ISO 7/8/9 without any cleaning necessary.
The DuPont™ Tyvek® material was tested against 
many cytostatic drugs and it reached the highest 6/6 
class measured by independent laboratories, cur-
rently, this is the only one garment, which gives a 
proper protection against the cytostatics.
The market leader DuPont™ Tyvek®, the clean-
room tailor-made Tyvek® based solution IsoClean® 
and the most robust, Tyvek® based Tychem chemi-
cal protective garments provide the greatest pro-
tection and comfort for 50 years.
SP-3
Balancing Competing Requirements of Dose 
Form Robustness, Disintegration Time and 
Organoleptics when formulating ODTs with 
high doses of API.
MACLEOD, G.S.1, LECLERCQ, B.2
1SPI Pharma, Wilmington, DE, USA
2Medelpharm, Beynost, France 
INTRODUCTION: Orally Disintegrating Tablets 
(ODTs) are a well-established dosage form that 
improve patient convenience. Most of these com-
mercialized products are low dose and/or rea-
sonably palatable without need for substantial 
taste masking. However for drugs with doses 
greater than 100mg the formulation challenges 
increase as the formulator strives to ensure the 
CQA’s of the ODT are maintained and the organ-
oleptic aspects of the dose form remain pleasant. 
This study investigates the relationship between 
drug loading and tablet CQA’s (Tensile Strength, 
Disintegration Time and Friability) and relates 
them to practical targets that go beyond those 
discussed in the FDA Guideline1 for the specifi c 
challenge related to higher dose API tablet for-
mulation.
MATERIALS AND METHODS: ODT formu-
lations based on the ODT platform Pharmaburst® 
and the taste masked API paracetamol (Acti-
mask®) were compressed on a Styl’One™ evolu-
tion fully instrumented single punch tableting in-
strument. A study of the compression characteris-
tics was performed on Styl’One using the Analis™ 
software. True density of each formulation was 
measured using a helium pycnometer which with 
the other dimensional data obtained enabled tab-
let porosity to be calculated and analysed. Formu-
lations were blended for 10 minutes in a Turbula 
Mixer prior to compression. The formulations 
were compressed and the resultant tablets were 
then assessed for the CQAs. TS was calculated by 
measuring thickness, diameter and hardness on a 
WHT tester. Friability and DT were obtained ac-
cording to the USP Methods. 
RESULTS: The results show that meeting a DT 
target of 30 seconds and retaining suﬃ  cient tablet 
robustness is challenging, especially as the API dose 
exceeds 125mg. However by careful formulation 
design and use of higher porosity systems such as 
Pharmaburst acceptably robust tablets can be for-
mulated that have DT’s around the 30 sec target. 
CONCLUSIONS: Detailed understanding of the 
tableting profi les and rapid formulation screening 
is necessary for successful development of this 
more challenging group of ODT’s.
REFERENCES:
1.  Guidance for Industry – Orally Disintegrat-
ing Tablets FDA CDER. 2008.
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OP-1
Speed it up, slow it down – bicalutamide release 
from 3D printed tablets
JAMRÓZ, W.1, KUREK, M.1, SZAFRANIEC, J .1, 
2, CZECH, A.1, GAWLAK, K.2, JACHOWICZ, R.1 
1Department of Pharmaceutical Technology and 
Biopharmaceutics, Jagiellonian University Medical College, 
Krakow, Poland;
2Department of Physical Chemistry and Electrochemistry, 
Jagiellonian University, Krakow, Poland
INTRODUCTION: The current 3D printing 
achievements in the fi eld of pharmaceutical tech-
nology include the preparation of various person-
alized dosage forms and drug delivery systems 
with accelerated or controlled release of API [1]. 
Fused deposition modelling (FDM) is a low-cost 
3D printing technique which has shown a lot of 
potential to manufacture drug formulations with 
desirable drug release profi le.
The aim of this study was to evaluate the possi-
bility of obtaining 3D-printed bicalutamide tablets 
with desired release characteristics by co-extru-
sion of API-loaded water soluble fi lament with a 
non-soluble drug free fi lament as well as physico-
chemical characterization of the printed tablets.
MATERIALS AND METHODS: Bicalutamide 
(BCL, Hangzhou Hyper Chemicals Ltd., China) 
was used as a model drug substance and Kollicoat 
® IR (BASF, Germany) was used as a fi lament 
forming polymer. The BCL-loaded fi lament was 
prepared by hot-melt extrusion with Noztek® Pro 
fi lament extruder (UK) at 175 °C. Commercially 
available PLA fi lament (3D Color, Poland) was ad-
mixed by co-extrusion at the printing stage to 
modify the API dissolution. ZMorph® 2.0 SX 3D 
printer (Poland) was used to produce tablets. Dis-
solution studies were performed with paddle 
method in either sink or non-sink conditions us-
ing Vision Elite 8 (Hanson Research, USA). Sam-
ples were analyzed spectrophotometrically at 
λ=272 nm using a Shimadzu UV-1800 (Japan). 
Crystallinity of the API was determined using 
XRPD studies with Rigaku Mini Flex II (Japan).
RESULTS: The fi laments with crystalline BCL 
were successfully produced for FDM 3D printing, 
however the partial amorphization was identifi ed 
after printing stage. The non-sink dissolution 
studies confi rmed that it enhanced the dissolution 
of BCL from 3D-printed tablets. Co-extrusion with 
diﬀ erent amounts of PLA fi lament resulted in con-
trolled release tested the sink conditions. The 
physical and mechanical properties of fi laments 
and tablets were also evaluated.
CONSLUSION: 3D printing can be successful-
ly utilized to modify BCL release from tablets pre-
pared from feedstock fi lament by either API amor-
phization or co-extrusion with insoluble fi lament 
to from a mixed matrix.
ACKNOWLEDGEMENTS: Authors acknowl-
edge Polish Ministry of Higher Education and Sci-
ence for the fi nancial support.
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OP-2
Production of Highly Drug-Loaded 
Orodispersible Films 
Using Extrusion Based 3D-Printing
EL AITA, I .1, YILDIR, E.2, BREITKREUTZ, J .1, 
QUODBACH, J .1
1Heinrich Heine University Duesseldorf, Institute of 
Pharmaceutics and Biopharmaceutics, Duesseldorf, Germany;
2Abo Akademi University Turku, Pharmaceutical Sciences 
Laboratory, Turku, Finland
INTRODUCTION: 3D printing and orodispers-
ible fi lms (ODFs) show potential for individual-
ized medicine. The main disadvantage of the com-
mon production of ODFs is the low drug loading 
[1]. Aim of this study was to produce high drug 
loaded ODFs via 3D printing.
MATERIALS AND METHODS: Levetiracetem 
as model drug, polyvinylalcohol/polyethylene 
glycol copolymer, glycerol and purifi ed water 
were used to form a semi-solid printing formula-
tion.
Design and Extrusion based 3D printing of 
ODFs
ODFs (6 cm2) were designed using 3D-CAD-
software Inventor (Autodesk). Two diﬀ erent de-
signs were chosen: 0.35 mm (1 Layer) and 1 mm (2 
Layer) distance between the printed strands. In 
case of the one layered ODF the structure is print-
ed completely without any pores whereas for the 
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two layered ODFs the single strands are printed in 
90° to each other and results therefore in regular 
pores. ODFs were printed using 3D-Bioplott er 
(EnvisionTec) with 4.5 bar, printing speed of 30 
mm/s and layer thickness of 0.2 mm.
Uniformity of mass and thickness
10 ODFs were weighed and the thickness was 
determined using micrometer screw (Mitutoyo). 
Mechanical properties and Disintegration time
Tensile strength and elongation to break were 
calculated using texture analyzer (Stable Micro 
Systems) [2]. Disintegration time of ODFs was an-
alyzed using a modifi ed disintegration tester 
(PharmaTest) (n=6) [3].
Content uniformity
Content Uniformity of ODFs was analyzed by 
HPLC (VWR). 10 ODFs were dissolved in 100 ml 
water and the content determined.
RESULTS: 3D-printing of ODFs with diﬀ erent 
infi ll design was feasible. ODFs are fl exible and 
can be handled without breaking. One layered 
ODFs have a higher mass whereas two layered 
ODFs are thicker as expected. One layered ODFs 
show a higher force and therefore a higher punc-
ture strength compared to two layered ODFs. Two 
layered ODFs show a faster disintegration because 
of their structure. In both cases the ODFs disinte-
grate within 30 sec and can be classifi ed as orodis-
persible. Drug load of more than 30 mg for both 
ODF designs could be easily achieved.
CONCLUSION: Production of ODFs using 3D 
printing with a high drug loaded was feasible and 
provides a suitable method for the production of 
individiualized batches.
REFERENCES:
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liv. 8, 299316 (2011)
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OP-3
3D fl oating tablets: appropriate 3D design from 
the perspective of diﬀ erent in vitro dissolution 
testing methodologies
ILYÉS, K.1, BALOGH, A.2, BORBÁS, E.2, 
CASIAN, T.1, DÉMUTH, B.2, KOVÁCS, N. K.3, 
MAROSI, GY.2, TOMUTĂ, I .1, NAGY ZS. K.2
1Department of Pharmaceutical Technology and Biopharmacy, 
Faculty of Pharmacy, University of Medicine and Pharmacy 
„Iuliu Hatieganu”, Cluj-Napoca, Romania;
2Department of Organic Chemistry and Technology, Faculty of 
Chemical Technology and Biotechnology, Budapest University 
of Technology and Economics, Budapest, Hungary; 3Department 
of Polymer Engineering, Faculty of Mechanical Engineering, 
Budapest University of Technology and Economics, Budapest, 
Hungary
INTRODUCTION: Gastro-retentive drug deliv-
ery systems (GRDDS) are acknowledged to in-
crease the success rate of the oral administration 
route, however due to production diﬃ  culties and 
quality control-biorelevance inconsistencies only a 
few products have made their way on to the phar-
maceutical market [1]. Three dimensional printing 
(3DP), a representative of the FDA’s emerging tech-
nologies program, is set to modernize pharmaceu-
tical manufacturing by simplifying the technologi-
cal fl ow as to give bett er control over the process. 
Fused deposition modelling (FDM), represents a 
cost-eﬀ ective 3DP technique that enables the sim-
ple production of porous structures, which may 
present fl oating capabilities [2]. The study pro-
posed to develop carvedilol loaded 3DP fl oating 
tablets with the concomitant evaluation of the criti-
cal design features that are set to assure robust-
ness to the fi nal dosage form.
MATERIALS AND METHODS: Carvedilol, 
molecule with absorption window within the up-
per intestinal region, was incorporated into a poly-
meric matrix via hot melt extrusion (HME) (Haake 
Minilab, Thermo Fisher Scientifi c, USA) and print-
ed into a porous structure via FDM (Craftbot Plus, 
Craftunique, Hungary). Design features (infi ll, 
shell structure, layer height) were submitt ed for 
evaluation. Dissolution kinetics and structural in-
tegrity was assessed from three separate dissolu-
tion test perspectives: one recommended by disso-
lution apparatus suppliers, one simulating simple 
in vivo fl oatability and one dissolution stress test.
RESULTS: Results confi rmed that robustness 
is dependent upon structural integrity. Floating 
capabilities are governed by infi ll, while struc-
tural integrity is infl uenced by layer height and 
shell structure. The 3DP tablets presented in-
stant fl oatation, with low dose dumping risks 
and dissolution kinetics with controlled release 
potential.
CONCLUSION: High fl oating capability dos-
age forms could be obtained by HME+FDM, serv-
ing as alternative, extended release delivery sys-
tems for carvedilol as opposed to Coreg CR. The 
dissolution tests showed diﬀ erent outcomes, 
proving that for in vivo relevance the formulation 
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and quality control for fl oating systems should be 
carefully considered.
REFERENCES:
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OP-4
Design of experiment (DOE) based methodology 
for designing polymeric NPs encapsulating 
Liraglutide for oral delivery
ISMAIL, R., SOVÁNY, T., CSÓKA, I .
University of Szeged, Faculty of Pharmacy, Institute of 
Pharmaceutical Technology and Regulatory Aﬀ airs, Szeged, 
Hungary
INTRODUCTION: Liraglutide, a fatt y acid modi-
fi ed glucagon like peptide-1 (GLP1) analog, with 
97% amino acid sequence similarity to native GLP-
1. This peptide drug was approved as a powerful 
treatment for type 2 diabetes mellitus in addition 
to chronic overweight management. Since this 
API is still administered parenterally, consider-
able eﬀ ort must be devoted toward development 
of an oral delivery system from this drug. This 
work aims to design Lira encapsulated in poly-
meric nanoparticles for oral administration imple-
menting DOE based strategy within the QbD 
framework.
MATERIALS AND METHODS: Liraglutide was 
loaded in PLGA nanoparticles by means of double 
emulsion solvent evaporation method and freeze-
dried using lyoprotectans for further investiga-
tons. This study evaluted the eﬀ ect of PLGA 
amount, liraglutide theoritical loading, PVA con-
centration, 2nd step sonication time, lyoprotectant 
type and concentration in addition to external 
aqueous phase to organic phase w2/o ratio on the 
mean particle size of the prepared NPs. For this 
purpose; a 7-factor 2-level 8-run Plackett  Burman 
design was applied using STATISTICA software, 
and analysis of variance (ANOVA) was applied to 
determine the statistical signifi cance of each model 
coeﬃ  cient, which was signifi cant at 95% level (P < 
0.05). 
RESULTS: Statistical analysis of the obtained re-
sults revealed that all the examined parameters 
have a signifi cant eﬀ ect on the Z-average of the 
prepared NPs, while the selected levels of theorit-
cal drug loading have only a fuzzy eﬀ ect on it. 
Moreover; the highest infl uential parameters af-
fecting the mean particle size are the stabilizer 
and polymer levels.
CONCLUSION: Plackett  Burman screening DOE 
was sucessfully implemented to understand the 
eﬀ ect of CPPs and CMAs on the size of Liraglutide 
loaded PLGA NPs with limited number of runs.
REFERENCES:
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OP-5
Probiotic encapsulation technologies to protect 
and deliver microorganisms to specifi c target 
location
MIRTIČ, J .1, ZUPANČIČ, Š.1, RIJAVEC, T.2, 
ZVONAR POBIRK, A.1, LAPANJE, A.2, 
KOCBEK, P.1, KRISTL, J .1 
1Faculty of Pharmacy, University of Ljubljana, Slovenia;
2Institute Josef Stefan, Ljubljana, Slovenia
INTRODUCTION: Probiotics can prevent or 
treat several diseases by shaping the local micro-
biota or by interaction with host cells. To have 
benefi cial health eﬀ ects they must be delivered in 
viable state. The challenge is what delivery system 
to use for probiotic bacteria that would promote 
their prolonged survival, eﬃ  cient revival and suc-
cessful colonisation of the target location.
MATERIALS AND METHODS: Two diﬀ erent 
delivery systems were investigated; [1] Ca-algi-
nate microcapsules produced by prilling followed 
by the lyophilisation and [2] polymer nanofi bers 
produced by electrospinning that led to the dry 
end product. Both delivery systems were thor-
oughly characterized from physico-chemical and 
biological viewpoint, focusing on the use of state-
of-the-art microscopies, e.g. scanning electron mi-
croscopy (SEM), stimulated emission depletion 
(STED) microscopy, time-lapse optical microsco-
py.
RESULTS: With probiotic microencapsulation 
120 - 150 μm sized microcapsules were produced, 
with positive or negative zeta potential (depend-
ing on the additional chitosan coating). Up to 
1×10^8 (vegetative form) or 1×10^10 (spore form) 
of colony forming units per gram of dry microcap-
sules was encapsulated. Alginate matrix was suﬃ  -
cient for bacteria entrapment, allowed the inward 
diﬀ usion of nutrients and oxygen, and was simply 
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disentangled to enable fast cell release. Surpris-
ingly, already nanometer thin chitosan layer, rep-
resented a barrier, which enabled also sustained 
release of bacteria [1]. The electrospinning process 
is a good alternative to microencapsulation since 
it is only one step process and is usually having 
really high encapsulation yield of spores; up to 
1×10^12 of colony forming units per gram of nano-
fi bers. Again, with the diﬀ erent formulation com-
position (diﬀ erent polymers and ratios) the probi-
otic outgrowth and release could be modifi ed [2].
CONCLUSION: Both, microcapsules and 
nanofi bers, proved to be useful for the purpose of 
probiotic local delivery, with some distinct prop-
erties that can be exploited to fi nely tune the pro-
biotic survival and release.
REFERENCES:
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Solid formulation of living Clostridium 
butyricum by electrospinning
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MAROSI, GY.1, NAGY, ZS. K. 1
1Budapest University of Technology and Economics, Budapest, 
Hungary;
2Oral Solids Development, Janssen R&D, Beerse, Belgium
INTRODUCTION: It has been shown that the 
gut microbiota plays a key role in human health 
and disease. Therefore, the interest in microbi-
ome-based therapeutics has surged in the recent 
years [1]. The growing therapeutic role of microbi-
ome drugs requires the maintenance of viability 
of bacteria during long-term storage. This goal is 
preferably achieved through drying, resulting in 
new challenges to the solid formulation technolo-
gists due to the sensitive nature of microbiome-
based drugs.
Electrospinning provides a gentle and fast de-
hydration besides being a continuous and low en-
ergy consumption process resulting in an econom-
ically viable drying process alternative to the most 
commonly used drying technologies, such as 
freeze-drying and spray drying [2]. In this re-
search the applicability of electrospinning was in-
vestigated to produce bacteria-containing solid 
formulations for oral administration while pre-
serving the activity of the microbiome-based drug.
MATERIALS AND METHODS: The electros-
pun material was prepared by high-speed electro-
spinning [3]. PVA, PEO and mannitol were used 
as matrix materials in the electrospinning solu-
tion. The morphology of the fi bers was studied by 
scanning electron microscopy. A commensal bac-
terium, Clostridium butyricum was used as the 
model drug. The viability of the bacteria was eval-
uated by the colony forming units counting meth-
od.
RESULTS: Electrospinning of the model bacte-
rium, Clostridium butyricum was successful. Sur-
vival of the bacteria after the drying process was 
more than 92%. The electrospun bacteria contain-
ing fi brous material was stored at diﬀ erent tem-
peratures and the viability of the bacteria was 
evaluated periodically. The fi bers contained 
6.5x108 CFU/g living bacteria after 1 month stor-
age at 4 °C, which is a suﬃ  cient amount for a solid 
oral dosage form.
CONCLUSION: The present work shows that 
electrospinning is a capable drying method for 
producing stable solid formulation of microbi-
ome-based drugs and is an alternative to freeze 
drying and spray drying.
REFERENCES: 
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OP-7
Development of particles with double pH-
dependant release of model compound for 
application of suspension via feeding tubes
DREU, R., RAČIČ, A.
Chair of Pharmaceutical Technology, Faculty of Pharmacy, 
University of Ljubljana, Ljubljana, Slovenia
INTRODUCTION: Physiological condition of 
specifi c groups of patients, such as prematurely 
born children or critically ill people in the inten-
sive care units, often demands usage of (naso)gas-
tric tubes for drug administration, feeding or both 
[1]. Active substances sensitive to acidic hydrolysis 
(e.g. proton pump inhibitors) require delayed re-
lease of drug as well as stability of such delivery 
system prior to application. The objective of the 
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study is to develop a particulate delivery system 
which would allow application of ‘ex tempore’ 
prepared multiple dose oral suspension via feed-
ing tubes. For this purpose pharmaceutical parti-
cles with two functional coatings are designed. In-
terior coating provides gastro-resistance, while 
the exterior coating prevents dissolution in neu-
tral or slightly alkaline medium of suspension.
MATERIALS AND METHODS: Granules with 
model compound tartrazine were prepared via 
high shear granulation, while micro pellets and 
pellets via layering with tartrazine. Particles were 
then fi lm coated in three successive stages using a 
Wurster process unit with a swirl generator. Inte-
rior coating (Eudragit® L 30 D-55) provided gas-
tro-resistance, while the exterior coating (Kolli-
coat® Smartseal 30D) prevented dissolution in a 
neutral medium. Intermediate barrier coating con-
sisted of HPMC. The functionality of applied coat-
ings was assessed by dissolution testing.
RESULTS: The results revealed that coated 
granules and micro pellets deliver the required re-
lease profi le in neutral (pH=7.2), acidic (pH=1.2) 
and fi nally in slightly acidic medium (pH=6.8). 
Demonstrated release profi les allow for up to two 
hour ‘ex tempore’ suspension handling prior to 
administration. Simple preparation of aqueous 
suspension out of coated particles and powdered 
polymers mixture is possible by usage of magnetic 
stirrer. Only suspension with coated granules 
demonstrated suitable uniformity of dose after re-
peated withdraws with syringe, while both gran-
ule and micro pellet based systems were success-
fully pushed through Ch 10 feeding tube.
CONSLUSION: The concept of dual pH de-
pendant drug release profi le of coated particles 
compatible with feeding tubes was confi rmed.
REFERENCES:
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OP-8
Combination Products: Balancing Innovation 
and Regulatory Constraints
CARAMELLA C. M.
Department of Drug Sciences, University of Pavia, Pavia, Italy
INTRODUCTION: The modern concept of drug 
delivery systems partially overlaps with the 
emerging fi eld of combination products (CPs). CPs 
are indeed complex products with a regulatory 
status and a wide market share. Diﬀ erent types of 
CPs are classifi ed in the regulatory documents.
FIXED-DOSE COMBINATION (FDC) PROD-
UCTS are formulations combining two or more 
actives in certain respective fi xed doses in a single 
dosage form.
DRUG-DEVICE OR DEVICE-DRG COMBINA-
TION PRODUCTS (DDCP) typically include a 
medical device and a drug. DDCP might be con-
sidered the modern evolution of drug delivery 
systems whereas one component (device) is func-
tional to the performance of the other (drug). 
Thus, CPs increasingly incorporate cutt ing edge, 
novel technologies that hold great promise for ad-
vancing patient care.
The aim of the presentation is to show how in-
novation can be implemented in CPs and to indi-
cate a road map to pharmaceutical development 
while respecting regulatory constraints.
MATERIALS AND METHODS: 1st STEP: the 
regulatory frame of EU scenario will be consid-
ered [1-3].
2nd STEP: the formulation development of two 
new FDC products will be unrolled, revealing the 
strategies adopted. One is a multiple unit dosage 
form, the other a tablet based on an enabling dis-
solution technology. The innovative module as-
sembling technology is also proposed for FDCs.
3rd STEP: two fully-integrated DDCs will be 
presented. One is an innovative powder inhaler 
and the other a solid dosage form incorporating 
an ingestible sensor to check adherence to thera-
py. 
RESULTS: The unrolled examples of new FDC 
products a stepwise approach should be adopt-
ed, keeping the formulation as simple and fl exi-
ble as possible. In the development of DDCPs, a 
holistic approach is needed to take into account 
the interplay of both components not to forget 
the fi nal goal of improved therapy and risk/bene-
fi t ratio.
CONCLUSION: A scientifi cally based pharma-
ceutical development is crucial for the success of 
any product. In the case of DDCPs customized 
performance tests capable of controlling the quali-
ty att ributes relevant to in vivo performance may 
be needed. Overall the regulatory compliance 
should be considered during the whole develop-
ment process.
REFERENCES:
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OP-9
The transparency principle for pharmacopoeial 
reference standards
VOLOVYK, N., LEONTIEV, D., GRYZODUB, O.
Ukrainian Scientifi c Pharmacopoeial Center for Quality of 
Medicines, Kharkiv, Ukraine
INTRODUCTION: Regulatory bodies expect 
pharmaceutical companies to demonstrate trace-
ability of the medicinal product content values to 
internationally recognised references, such as phar-
macopoeial reference standards (PhRS), to guaran-
tee comparability of measurement results both over 
time and between laboratories, which can only be 
done if the uncertainty of the assigned value is 
known [1-3]. However, the uncertainties of the as-
signed values for PhRS are normally not stated. 
Moreover, the use of PhRS is typically limited to 
assessing compliance of medicinal products with 
pharmacopoeial specifi cations, which creates diﬃ  -
culties for users in providing analytical support for 
non-pharmacopoeial applications, such as pharma-
ceutical development, quality monitoring, using 
“guard bands” narrower than pharmacopoeial, cer-
tifying secondary reference standards for in-house 
use, and so on. Therefore, the need for developing 
the concept of certifi cation and use of PhRS suitable 
for quality control tasks that are outside the phar-
macopoeial monographs in compliance with con-
temporary regulatory requirements is apparent.
MATERIALS AND METHODS: Mathematical 
statistics, pharmacopoeial assays and purity tests.
RESULTS AND DISCUSSION: The transpar-
ency principle for PhRS was formulated. Based on 
the intended use, the values of target measurement 
uncertainty (MUtarget) were set for the main pharma-
copoeial tests. For PhRS intended for quantitative 
tests, the expanded measurement uncertainty of 
certifi ed value (MUmax) should not exceed 0.32 of 
MUtarget (i.e. should be negligible). The certifi cate of 
PhRS should contain the intended use of PhRS 
(tests, the narrowest content limits for assays, ana-
lytical methods); MUmax and the method used for 
evaluating the actual value of MU; the minimum 
sample weight for which the homogeneity of PhRS 
was confi rmed (if necessary). Using the transparen-
cy principle, the State Pharmacopoeia of Ukraine 
(SPhU) has certifi ed about 800 PhRS. The metrolog-
ical base of certifi cation and use of reference stan-
dards of SPhU is described in the General Text 
5.12N “Reference Standards” of SPhU.
CONCLUSION: The set of properties of PhRS 
should ensure the correctness of their use outside 
pharmacopoeial monographs by regulatory re-
quirements. Users should be informed about the 
suitability of PhRS for their tasks.
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OP-10
The application of artifi cial neural networks 
for the development of topical fl urbiprofen 
microemulsions
MESUT, B.1, GÜRBÜZ, A.1, ERDAL, M. S.1, 
AKSU, B. M.2, ÖZSOY, Y.1, GÜNGÖR, S.1 
1Istanbul University, Faculty of Pharmacy, Department of 
Pharmaceutical Technology, Istanbul, Turkey;
2Altinbaş University, Faculty of Pharmacy, Department of 
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INTRODUCTION: Microemulsions are colloidal 
nano-carriers and their use as topical delivery sys-
tems derives from their multiple advantages com-
pared to other dermatological formulations, such as 
ease of preparation, thermodynamic stability and 
penetration enhancing features [1]. In order to sim-
plify the formulation of microemulsion-based col-
loidal drug carriers, there is a growing interest of 
researchers for the development of artifi cial neural 
network (ANN) models to predict and optimize the 
phase behavior of microemulsion systems using 
limited number of experiments and inputs [2, 3].
This study aims to develop fl urbiprofen (FLB) 
loaded topical microemulsions by creating ANN 
combined with Genetic Expression Programming 
(GEP) and to investigate the skin penetration of 
FLB from the optimized microemulsions in com-
parison with the commercial topical product of 
the drug.
MATERIALS AND METHODS: The Critical 
Quality Att ributes (CQAs) were microemulsion 
droplet size, pH, conductivity, refractive index, 
viscosity, and FLB skin deposition. Critical For-
mulation Parameters (CFPs) were oil, surfactant/
co-surfactant (SAA/CoS), and water percentages. 
The commercially available INForm V5.1 ANN 
(Intelligensys, UK) was used to optimize the gen-
erated data. 
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RESULTS: The obtained results show that opti-
mized ANN in combination with GEP may limit 
the experimental eﬀ ort for the formulation of 
pharmaceutically acceptable microemulsion vehi-
cles of FLB. In addition, the in vitro skin deposi-
tion of FLB from the optimized microemulsions 
was up to 5,9 fold higher when compared to the 
commercial gel formulation.
CONCLUSION: The ANN enhanced with GEP 
could be accepted as an eﬀ ective tool to reduce re-
search time and development cost for characteriz-
ing microemulsion properties. The ANN opti-
mized microemulsions improved the skin pene-
tration of FLB and hence could be useful alterna-
tives to its conventional topical products.
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OP-11 
Our experiences with freeze-dried fecal 
supernatant capsules in 
Clostridium diﬃ  cile infection
VARGA, A., KOCSIS, B., SIPOS, D., VIGVÁRI, 
SZ., KÁSA, P., PÁL, SZ., PÉTERFI, Z.
University of Pécs, Pécs, Hungary
INTRODUCTION: Clostridium diﬃ  cile infection 
(CDI) is widely known as a consequence of the 
broad-spectrum antibiotic use. Treatment att empts 
by antibiotics are gett ing less eﬀ ective, as more 
and more cases are found to be resistant to the 
therapy, or recurring.
Our fi rst and second line drugs both have major 
drawbacks: metronidazol has a decreasing success 
rate and by now it is evident that the use of vanco-
mycin facilitates the spreading of vancomycin re-
sistant Enterococcus fecalis/faecium (VRE). Fidax-
omicin is known for its decent results in the treat-
ment of CDI. Fecal microbiota transplant (FMT) has 
similar success rate to fi daxomicin, although sever-
al factors make this method circumstantial. We 
think that a reliable and more tolerable formulation 
of FMT could facilitate the use of the method and 
could also simplify the way to other perspectives.
MATERIALS AND METHODS: We adminis-
tered soft gelatin capsules to CDI patients, fi lled 
with freeze-dried fecal supernatant. The stool was 
received from healthy donors. We also conducted 
metagenomic analysis of the stool of the donor and 
the recipients to determine the shifts in the gut mi-
crobiota after the treatment.
RESULTS: Our patients found this way of ad-
ministration much more convenient and accept-
able than our former method, the nasogastric 
tube. We found the success rate non-inferior to 
our former att empts with nasogastric tube. The 
metagenomic analysis showed signifi cant changes 
in the composition of the gut microbiota. The fi nal 
results will be discussed in the presentation.
CONCLUSION: Based on our observations, we 
think that using freeze-dried fecal supernatant 
capsules in Clostridium diﬃ  cile infection is a 
promising fi eld of research. We recently noticed a 
decrease in the number of our new CDI patients, 
therefore it is diﬃ  cult to fi nd an appropriate num-
ber of cases for our further investigations.
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OP-12 
Antimicriobial and cytotoxic interactions 
between diﬀ erent pharmaceutical excipients in 
liquid preparations
NEMES, D.1, MEZŐ, M.1, POCZOK, N.1, 
UJHELYI, Z.1, FEHÉR, P.1, BODNÁR, R.2, 
NAGY, F.2, VECSERNYÉS, M.1, BÁCSKAY, I .1 
1Department of Pharmaceutical Technology, Faculty of 
Pharmacy, University of Debrecen, Debrecen, Hungary;
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University of Debrecen, Debrecen, Hungary
INTRODUCTION: Preservatives are the essential 
part of any orally administered liquid pharmaceu-
tical product as a solution, suspension, emulsion 
or syrup. However, these chemicals are cheap and 
considered to be relatively safe, recent publica-
tions question the way we use them. Either the in-
suﬃ  cient antimicrobial protection [1], or the new 
toxic eﬀ ects [2] highlight that the traditional pre-
servative policy must be reconsidered. The aim of 
our research is to discover new antimicrobial and 
cytotoxic interactions between diﬀ erent compo-
nents of a liquid formulation. The diﬀ erent solu-
tions of preservatives, surfactants and solvents are 
mixed and systematically tested to screen for any 
occurring positive or negative eﬀ ect.
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MATERIALS AND METHODS: We planned 
two independent experiment to fi nd interaction 
between diﬀ erent pharmaceutical excipients. In 
the fi rst, we formulated to complex co-solvent sys-
tems with a co-solvent and a surfactant in each, 
adding equal concentrations of parabens (methyl, 
ethyl, propyl, butyl) into both. At the second, we 
tested sorbates, benzoates, propionates (acidic 
form, sodium, potassium, calcium salt) at diﬀ erent 
pH values (pure solution in water, adding HCl or 
NaOH). In case of both experiments cytotoxicity 
and antimicrobial properties were detected. We 
measured cytotoxicity with a colorimetric cell-via-
bility assay, the MTT-test and the time-dependent 
toxicity with a real time cell electronic sensing de-
vice. Caco-2 human adenocarcinomal cells were 
used for a representation of the gastro-intestinal 
tract. The inhibitory eﬀ ects of the diﬀ erent solu-
tions were measured on C. albicans, C. glabrata, 
C. parapsilosis and E. coli, P. aureginosa, S. aure-
us with simple microdilution method.
RESULTS: The two complex co-solvents sys-
tems could change the relative toxicity of para-
bens on human cells and in certain cases they 
could greatly enhance or slightly reduce the anti-
microbial properties of these esters. The other 
group of preservatives showed pH dependency in 
case of toxicity and inhibitory activity and even 
paradoxical eﬀ ect could be detected.
CONSLUSION: Finding the positive and 
avoiding the negative interactions between diﬀ er-
ent pharmaceutical excipients are a key to lower 
the required amount of total excipients, thus in-
crease microbial stability and decrease toxicity.
REFERENCES.
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OP-13
The impact of supercritical drying of 
microcrystalline cellulose on its tableting 
characteristics
POTPARA, J ., IVANOVIC, J ., MAKSIMOVIC, 
Z., IBRIC, S.
University of Belgrade, Serbia
INTRODUCTION: Due to its outstanding dry 
binding properties, microcrystalline cellulose 
(MCC) is one of the most important tableting excip-
ients, that enables the manufacture of tablets by di-
rect compression [1]. It is commonly manufactured 
by spray drying of the neutralized aqueous slurry 
resulting from the treating α - cellulose from plant 
material with mineral acids [2]. Present work was 
aimed to investigate the eﬀ ect of supercritical dry-
ing of the MCC on its tableting properties. 
MATERIALS AND METHODS: Wheat straws 
were milled, purifi ed with hexane and methanol, 
followed by processes of delignifi cation and 
bleaching by using NaOH and NaClO2. Bleached 
cellulose pulp was hydrolyzed with sulphuric 
acid. A semi-continuous drying process was car-
ried out in the Autoclave Engineers SCE Screening 
System, using supercritical CO2 (20 MPa, 40 °C). 
Dynamic powder compaction analyzer (Gamlen 
Tableting Ltd., UK) was used to tablet samples 
and measure their tableting properties. The results 
were compared with commercial MCC (Vivapur®, 
PH101, JRS Pharma, USA).
RESULTS: The neto compression work, ejection 
stress and tablet tensile strength of the MCC samples 
were measured and compared. The results indicated 
that MCC derived from wheat straw has similar neto 
compression work (0.42±0.005 – 1.17±0.001 N*m) to 
Vivapur® (0.30±0.003 – 1.07±0.02 N*m). Therefore, we 
can assume that both have good compressibility. In 
addition, no signifi cant diﬀ erences in tensile strength 
and ejection stress of the tablets prepared from all the 
samples were evidenced.
CONCLUSION: A similar compressibility, 
compactability and manufacturability of all the 
MCC samples, which are obtained from wheat 
straw and dried using supercritical CO2 to Viva-
pur® was demonstrated. Accordingly, it can be 
concluded that supercritical drying has no nega-
tive impact on tableting properties of the wheat 
derived MCC samples. Moreover, it represents a 
good alternative to spray drying method used for 
the commercial MCC.
REFERENCES:
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OP-14 
Processing of amorphous solid dispersions 
containing itraconazole
GALATA, D. L.1, DÉMUTH, B.1, BALOGH, 
A.1, VIGH, T. 2, MENSCH, J .2, VERRECK, G.2, 
MAROSI, GY.1, NAGY ZS. K.1
1Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Hungary;
2Janssen Research and Development, Beerse, Belgium
INTRODUCTION: Electrostatic spinning is a 
promising technology in the production of amor-
phous solid dispersions (ASDs). The high surface 
area of the electrospun nanofi bers and the fact that 
the drug is in amorphous form both contribute to 
the increased dissolution achieved by ASDs. The 
aim of the current study is to produce tablets con-
taining an ASD of itraconazole, a systemic antifun-
gal drug and two diﬀ erent matrix polymers, hy-
droxypropyl methylcellulose (HPMC) or vinylpyr-
rolidone-vinyl acetate copolymer (PVPVA).
MATERIALS AND METHODS: HPMC 2910 
or PVPVA 64 was used as matrix polymer. ASDs 
were produced using the high speed electrospin-
ning method [1]. Before compression into tablets, 
ASDs were processed using various methods, in-
cluding hammer milling, oscillatory milling, 
pressing through a sieve and roller compaction. 
Tablets were compressed on a single punch tablet 
press equipped with 14 mm concave punches. In 
vitro dissolution measurements were carried out 
in pH 1.2 HCl solution on a Pharmatest PTWS600 
dissolution apparatus.
RESULTS: It was observed that magnesium 
stearate, the lubricant used in the tablets deterio-
rates dissolution when PVPVA is used as matrix 
polymer, while HPMC can prevent this phenome-
non [2]. On the other hand, compression into tab-
lets is more feasible in the case of PVPVA. There-
fore several formulations were developed which 
combine the benefi ts of the two matrix polymers 
by adding various forms of HPMC to PVPVA-
based ASDs. These include using HPMC as excipi-
ent, as fi lm coating of the tablets and a new ASD 
which uses both polymers as matrix in a 2:1 PVP-
VA to HPMC ratio. These formulations signifi -
cantly improved dissolution compared to the case 
where only PVPVA is present. An eﬀ ort was also 
made to improve the processability of HPMC-
based ASDs by applying roller compaction to the 
electrospun material.
CONCLUSION: In order to produce an appro-
priate tablet formulation, we either need to utilize 
the benefi ts of both matrix polymers or to signifi -
cantly improve the processability of HPMC-based 
ASDs.
REFERENCES:
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OP-15
“One for All - All for One”: simultaneous 
control of polymorph outcome and particle 
engineering of caﬀ eine-anthranilic-acid cocrystal 
through polymer-assisted grinding
NHETA, E.1, ARMITAGE, R.1, RUPARELIA, 
K.1, JONES, W.2, HASA, D.1
1Leicester School of Pharmacy, De Montfort University, 
Leicester, UK
2Department of Chemistry, University of Cambridge, UK
INTRODUCTION: Cocrystallization technology 
is gaining popularity especially in the formation 
of new materials as well as providing an opportu-
nity to synthesise organic solids by design [1]. On 
the other hand, polymer-assisted grinding (PO-
LAG) is demonstrated to provide a new class of 
catalysts for improving reaction rate and increas-
ing product diversity during solid-state cocrystal-
lization reactions [2]. Here, we propose the use of 
POLAG for the simultaneous control of product 
polymorphic form and powder particle character-
istics during mechanochemical cocrystal forma-
tion.
MATERIALS AND METHODS: We selected 
the caﬀ eine-anthranilic acid as a model cocrystal 
since it has been previously explored for the pro-
duction of diﬀ erent polymorphic forms [3]. Diﬀ er-
ent polyethylene glycol (PEG) polymers (liquids 
and solids) with molecular weight from 200 to 
20,000 were selected as catalysts for POLAG. PEGs 
fi nd a wide range of applications both in the 
chemical and pharmaceutical industries. All the 
materials were purchased from Sigma-Aldrich 
Company, Ltd. (UK) and used without any fur-
ther purifi cation.
RESULTS: The results suggested that low 
amounts of long chain PEGs promote the forma-
tion of the metastable polymorph Form III, while 
PEGs with a shorter chain length produced co-
ACTA-1803-CESPT.indb   110 2018. 09. 10.   10:12
 2018/3. Acta Pharmaceutica Hungarica – CESPT Edition – Oral presentations 111
crystal Form II. Form I depended on the amount 
of the polymer used. The powder particle size was 
equally correlated to both the amount of the poly-
mer used and polymer chain length. 
CONCLUSION: By varying the amount of the 
polymers employed to the solid reactants as well 
as modifying the number of monomer units, it 
was possible to access to all the known polymor-
phic forms of the model system selected in this 
study. Additionally, it was possible controlling 
the powder particle characteristics of the fi nished 
products.
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OP-16
Impact of particle morphology and multi-scale 
hierarchical structures on tabletability
KLEINEBUDDE, P., GROTE, S.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich 
Heine University, Düsseldorf, Germany
INTRODUCTION: Tabletability describes the re-
lation between compression pressure and tensile 
strength of tablets. Tabletability diﬀ ers highly be-
tween diﬀ erent types of material. However, tablet-
ability can vary widely even for the same type of 
material depending on the morphology of the 
starting material and/or an intermediate granula-
tion process. The multi-scale hierarchical struc-
ture (primary particle, agglomerate, granule, tab-
let) of starting materials, intermediate granules 
and fi nal tablets has been discussed in [1]. Pores 
can be present on each scale, which can aﬀ ect the 
mechanical properties of a material. The purpose 
of the study is to fi nd common patt erns in starting 
material properties, which are relevant for its 
tabletability.
MATERIALS AND METHODS: Diﬀ erent 
types of dibasic calcium phosphate [1], calcium 
carbonate [2], lactose [3] and isomalt [4] were 
compressed to tablets directly or after roll com-
paction/ dry granulation. The starting materials 
were characterized by particle size distribution, 
specifi c surface area and particle density. Tensile 
strength and porosity of tablets were measured.
RESULTS: For all tested materials the tabletabili-
ty depended on the morphology of the starting ma-
terials. Highly functionalized excipients like Fujica-
lin or Omyapharm 500-OG resulted in high tablet-
ability. Although dibasic calcium phosphate and 
calcium carbonate are known as britt le materials, 
the functionalized qualities resulted in tablet behav-
ior like more plastic materials after roll compaction. 
By studying the properties of the intermediate rib-
bons and granules, this behavior can be explained.
CONCLUSION: Not only the chemical type of 
a material, but also the physical morphology of 
the particles infl uences its tabletability. This opens 
new perspectives for a tailored particle design.
REFERENCES:
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Near Infra-Red spectroscopy for content 
uniformity of powder blends- focus on 
calibration set development, orthogonality 
transfer and robustness testing
CASIAN, T. 1, IURIAN, S.1, GAVAN, A.1, 
REVNIC, C.2, PORAV, S.3, PORFIRE, A.1, 
VLASE, L.1, TOMUTA, I .1 
1Department of Pharmaceutical Technology and Biopharmacy, 
Faculty of Pharmacy, University of Medicine and Pharmacy 
„Iuliu Hatieganu”, Cluj Napoca;
2Department of Mathematics and Computer Science, Faculty 
of Pharmacy, University of Medicine and Pharmacy „Iuliu 
Hatieganu”, Cluj-Napoca;
3National Institute for Research and Development of Isotopic and 
Molecular Technologies, Cluj-Napoca, Romania
INTRODUCTION: NIR spectroscopy is frequent-
ly applied in pharmaceutical fi eld, ranging appli-
cations from raw material identifi cation to in-line 
process monitoring, however its eﬃ  cient applica-
tion relies on the method development phase [1, 
2]. The objective of this work was to develop and 
validate a NIR method for the quantifi cation of 
three active ingredients from powder blends, fol-
lowed by the evaluation of method’s robustness to 
factors not included in the calibration.
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MATERIALS AND METHODS: Calibration 
set was built based on a D-optimal experimental 
design with three factors (ibuprofen, paracetamol, 
caﬀ eine) and fi ve variation levels (80-90-100-110-
120%), ensuring orthogonal variation between in-
gredient concentration. Prior to model develop-
ment the eﬀ ect of pre-processing method was as-
sessed by decomposing spectral varibility into 
predictive and orthogonal parts. Robustness of the 
method to diﬀ erent active ingredient suppliers 
and relative humidity was tested following a DOE 
approach.
RESULTS: Comparing the distribution of for-
mulations in spectral vs concentration space aided 
the selection of an appropriate pre-processing 
method and highlighted concentration combina-
tions with biased predictions. NIR method was 
validated on the full calibration range using ± 5% 
acceptability limits for paracetamol/ibuprofen, 
and ± 10% limits for caﬀ eine. Robustness testing 
results showed that the accuracy of caﬀ eine con-
tent predictions was infl uenced by relative humid-
ity, while paracetamol/ibuprofen predictions were 
robust to all factors.
CONCLUSION: Redefi nition of interfering fac-
tor variation level was benefi cial to reduce the bias 
in caﬀ eine content predictions making the method 
suitable for routine use.
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OP-18 
Non-destructive spectroscopic analysis and 
artifi cial intelligence for dissolution prediction 
of pharmaceutical tablets
NAGY, B., FARKAS, A., DULICHÁR, P., 
MAGYAR, K., NAGY, ZS. K., MAROSI, GY.
Budapest University of Technology and Economics, Budapest, 
Hungary
INTRODUCTION: By the advent of continuous 
manufacturing, the need for fast and accurate 
characterization of product quality has become a 
major interest. Utilizing a combination of process 
controls and in-process measurements, real-time 
release testing (RTRT) systems can be established, 
which provide assurance that the product is of in-
tended quality based on process data, product and 
process understanding and control [1]. This work 
introduces the application of NIR and Raman 
spectroscopy and artifi cial neural networks to 
serve as a surrogate for destructive dissolution 
prediction and analyze crushing strength and fri-
ability.
MATERIALS AND METHODS: The applica-
bility of Raman and NIR spectroscopy to predict 
tablet properties were tested in two diﬀ erent mod-
el systems, namely a three-component immediate 
release tablet manufactured in a continuous pow-
der blending and tableting line and in four-com-
ponent extended-release tablets. Design of experi-
ment approach was applied to fi t response surfac-
es to characterize the infl uence of critical quality 
att ributes (e.g. tableting pressure, lubrication 
properties, constitution of the tablets) on tablet 
properties. Then, Raman and NIR spectra were 
measured and chemometric models and neural 
networks were developed to establish predictive 
relationships between the spectra and the dissolu-
tion, crushing strength and friability of the tablets. 
RESULTS: The developed spectroscopic meth-
ods were applicable to non-destructively charac-
terize lubrication properties, e.g. reveal overlubri-
cation in the continuous manufacturing line as 
well as predict dissolution of extended-release 
tablets, solely based on the measured vibrational 
spectra. 
CONCLUSIONS: Our study demonstrated that 
Raman and NIR spectroscopy can complement 
each other and eﬀ ectively contribute to the predic-
tion of tablet physical properties and dissolution 
in a fast and non-destructive manner. Conse-
quently, by extending it to further manufacturing 
steps and coupled with adequate control, they can 
be eﬀ ective tools for RTRT strategies.
ACKNOWLEDGMENTS: This project was 
supported by the National Research, Develop-
ment and Innovation Fund of Hungary in the 
frame of FIEK_16-1-2016-0007 (Higher Education 
and Industrial Cooperation Center).
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OP-19
Polymeric patches as a drug carrier for dermal 
delivery of dexamethasone and voriconazole 
– the eﬀ ects of physicochemical and structural 
properties of the patch on the adhesiveness
MIKOLASZEK, B., KOZLOWSKA, E., 
SZCZEPANSKA, M., SZNITOWSKA, M.
Pharmaceutical Technology Department, Medical University of 
Gdansk, Poland
INTRODUCTION: In traditional semi-solid for-
mulations, only limited amount of drug substance 
applied on the skin is delivered to the target site 
e.g. due to vehicle removal. Patch as a drug carrier 
provides sustained drug delivery with prolonged 
skin contact and improved compliance due to de-
creased dosing frequency [1]. Still, formulating a 
polymeric matrix that will retain good skin con-
tact with no unwanted interaction with the drug 
remains a constant challenge [2]. Current project 
focused on the search for a matrix carrier for two 
model drugs, where physicochemical characteris-
tics of polymer blends and fi lm surface structure 
on the patch adhesiveness is examined. 
MATERIALS AND METHODS: PDMS 
(polydimethylosiloxane, MG 7-9850, Dow Corn-
ing, USA) or copolymer of methyl methacrylate 
and ethyl acrylate (Evonic, Germany) with a plas-
ticizer (ethylene citrate) were used as patch form-
ing material. Polymer blends with dexamethasone 
or voriconazole (1% and 5% w/w) were prepared 
in planetary mixer (Thinky ARE-250, Japan) and 
formed into thin fi lms (200 μm - 500 μm) by cast-
ing. Fluorescence microscopy and SEM were used 
for imaging of the fi lms structure, whereas atomic 
force microscopy (AFM) provided detailed topo-
graphical information. Additionally, a two level 
full factorial design (23) was performed to estimate 
the eﬀ ect of formulation physicochemical parame-
ters (composition, thickness and roughness) on 
the patch adhesiveness, assessed by tack test and 
90° peel test (texture analyser TA.XT Plus, UK).
RESULTS AND DISCUSSION: Voriconazole 
showed incompatibility with PDMS. Both poly-
acrylic and PDMS patches with dexamethasone ex-
hibited homogenous structure with suﬃ  cient ad-
hesiveness. AFM imaging revealed fi lms’ diverse 
surface structure, which was found weakly related 
to the adhesiveness. Results also showed that high 
content of a plasticiser aﬀ ected the adhesiveness 
considerably more than the fi lm thickness.
CONCLUSIONS: Multifactorial approach al-
lowed to preliminary identify properties of the 
patches, which impact patch adhesiveness. This 
work contributes to the design and optimisation 
of polymeric dermal patches.
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Eﬀ ect of diﬀ erent glidant types on fl ow 
properties of pharmaceutical excipients – 
A comparison of Neusilin® and Aerosil®
TRAN, D. T., KOMÍNOVÁ, P., ZÁMOSTNÝ, P.
University of Chemistry and Technology Prague, Prague, Czech 
Republic
INTRODUCTION: Flow properties are one of the 
most important characteristics of pharmaceutical 
powder blends due to their infl uence on the con-
tent and weight uniformity of the fi nal product – 
tablets or capsules. In order to improve fl owability 
of powders, fl ow enhancers or glidants are widely 
incorporated in solid dosage forms [1]. Traditional 
glidants, such as colloidal silica (e.g. Aerosil®), are 
surface-active particles and their action is very 
sensitive to formulation and process parameters 
of the mixing operation [2]. The work was aimed 
at comparing mechanism of improving excipient 
fl ow properties using novel family of glidants - 
magnesium aluminosilicate materials (commer-
cially available e.g. as Neusilin®) to Aerosil®.
MATERIALS AND METHODS: Several blends 
comprising the model excipient and model gli-
dants were prepared and their fl ow properties 
were characterized using a powder rheometer FT4 
(Freemantech, UK). The blends were formulated to 
represent the eﬀ ects of particle size, glidant load-
ing, and mixing time. After pre-conditioning, the 
fl ow properties were measured using shear test, 
compressibility, and fl ow energy measurements.
RESULTS: Unlike Aerosil®, the mixtures incor-
porating Neusilin® exhibited proportional im-
provement of fl ow properties without any maxi-
ma. Therefore, there is no risk of glidant over-
loading for those excipients. Moreover, it was 
found that Neusilin® retains its negative cohesion 
values even in the mixture with other com-
pounds, i.e. Neusilin® particles tend to separate 
from each other and hence, no need of glidant de-
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aggregation was required. As a result, the equilib-
rium of fl ow properties was reached in the mix-
tures containing Neusilin® only after a short mix-
ing time.
CONCLUSIONS: The mechanism of Neusi-
lin® action was found to be diﬀ erent compared 
to Aerosil®, having less process sensitivity, so 
that Neusilin® utilization as glidant could be 
advantageous for the formulation perfor-
mance.
ACKNOWLEDGEMENT: Financial support 
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SVV/2018)
REFERENCES:
1.  Meyer K. et al. Powder Technol. 139, 40–54 
(2004)
2.  Majerová D. et al. Eur. J. Pharm. Biopharm. 
106, 2–8 (2016)
OP- 21
Pulsed laser ablation in liquid (PLAL) as a 
suitable particle engineering technique to 
modify the physicochemical properties of 
meloxicam
AMBRUS, R.1, SZABÓ-RÉVÉSZ, P.1, NAGY, E.2, 
PETÁK, F.2, SMAUSZ, T.2, HOPP, B.2
1Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged
2Department of Optics and Quantum Electronics, University of 
Szeged, Szeged, Hungary
INTRODUCTION: Pulsed laser ablation in liquid 
(PLAL) could oﬀ er a new challenge in the fi eld of 
pharmaceutical technology by controlled fabrica-
tion of micro- and nanoparticles. PLAL is there-
fore a non-conventional approach in drug formu-
lation as a simple and fast wet grinding method 
(1). The motivation of this work was to introduce 
the eﬀ ect of PLAL technique (with diﬀ erent laser 
fl uence (4.2-9.4 J cm-2) and stabilizer (Polyvinyl al-
cohol (PVA)) concentration 0; 0.5; 5 w/w%) on the 
size decreasing of drug therefore to modify its 
physicochemical properties.
MATERIALS AND METHODS: A poorly wa-
tersoluble drug, meloxicam (Egis Plc., Hungary) 
was used as model drug. Polyvinyl alcohol 3-88 
(PVA) was purchased from ISP Customer service 
GmbH, Germany.
A frequency doubled Q-switched Nd:YAG laser 
beam (Model: G-NY, GBL Optic-Electronic CO., 
Ltd, λ=532 nm, FWHM=8ns) was used by varied 
laser fl uences using meloxicam pastilles placed in 
20 ml of aqueous solution. Morphology and size 
of the generated meloxicam particles were deter-
mined by Scanning Electron Microscopy (SEM) 
image analysis. Moreover, their structure (XRD, 
FTIR and DSC), solubility and dissolution were 
also investigated.
RESULTS: Morphological investigation 
showed that the main parameters of the produced 
suspension contained particles between 0.1 μm 
-10 μm depend on the laser fl uence and PVA con-
tent. According to the structural characterization 
of the prepared samples chemically identical with 
the raw drug was observed, however with the 
presence of PVA the crystalline structure of 
meloxicam was turned to amorphous form which 
also improved its dissolution rate.
CONCLUSION: Based on our results we can 
concluded, that PLAL process is suitable for pro-
duction of micro- and nanoparticles as superior 
intermediate product to develop traditional and 
innovative drug formulation.
ACKNOWLEDGEMENTS: This work was 
supported by the GINOP-2.3.2-15-2016-00036 
(`Development and application of multimodal op-
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P1- DERMAL AND TRANSDERMAL 
DELIVERY 1.
P1/1
Development and Characterization of Fusidic 
Acid Loaded Thermosensitive In Situ Gels
AKSU, N. B.1, YOZGATLI, V.2, USTUNDAG 
OKUR, N.2
1University of Altinbaş, School of Pharmacy, Department of 
Pharmaceutical Technology, Turkey;
2University of Istanbul Medipol, School of Pharmacy, 
Department of Pharmaceutical Technology, Turkey
INTRODUCTION: Burn wound is one of the 
painful physical injuries and it has very complex 
treatment procedure [1]. Fusidic acid (FA), which 
is an antimicrobial agent with a special working 
mechanism, is used for the treatment of burn 
wound [2]. In situ gel systems are liquid aqueous 
solutions at room temperature and they have the 
ability of converting their liquid aqueous phase 
into gel form once they administered to the relat-
ed physiological area [3]. The aim of the present 
study is to formulate and evaluate FA loaded topi-
cal in situ gels in order to be used in the treatment 
of burn wound.
MATERIALS AND METHODS: Poloxamer 
407, Poloxamer 188 and Poloxamer 338 were used 
as polymers for preparation of in situ gels. In situ 
gels were prepared by using the cold method [3]. 
The formulations were prepared by completely 
dissolving the diﬀ erent concentrations of polox-
amers in water. Diﬀ erent concentrations of polox-
amers, FA (2%), alcohol (5%) and distilled water 
(qs.100) are the components of formulations. For 
characterization and evaluation of the in situ gels, 
gelling temperature, pH, clarity, gelation capacity, 
spreadability, drug content, rheology parameters 
of prepared formulations were measured.
RESULTS: As result of the preformulation 
studies, the gelling temperatures of the formula-
tions were determined in between 26.4±0.1-
47.3±0.1°C. Characterization studies of the ideal 
formulations showed that the gelling temperature 
of the formulations were in between 31.36±0.66-
32.46±0,21°C. This indicates that the formulations 
can convert their structure into the gel when they 
are administered to the skin surface. The pH of 
the formulations ranged between 5.7±0.07 and 
6.05±0.1. All the formulations showed fair unifor-
mity of drug content which ensures adequacy of 
the method of the in situ gel preparation. The rhe-
ology values of formulations were varying from 
99.43±0.75 to 175.33±0.05 cP. Results of clarity and 
gelling capacities parameters of the developed for-
mulations were acceptable.
CONSLUSION: The present study showed that 
FA loaded in situ gels can successfully be pre-
pared with cold method. In conclusion, this study 
showed that developed in situ gel formulations 
could be alternatively used as topical delivery of 
FA for the treatment of burn wound.
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Evaluation of Emulsion Forms via Quality by 
Design (Qbd) Approach
AKSU, N. B.1, KALAYI, M.1, YEGEN, G.1, 
YOZGATLI, V.2
1Altinbas University, Faculty of Pharmacy, Istanbul, Turkey;
2Medipol University, Faculty of Pharmacy, Istanbul, Turkey
INTRODUCTION: For a long time, drug delivery 
through the skin has been a favorable concept [1]. 
In this study diclofenac sodium has been used as 
an active pharmaceutical ingredient. The aim of 
the study was to ensure the product has desired 
quality att ributes during the development of semi-
solid topical product after implementing QbD ap-
proach.
MATERIALS AND METHODS: Materials: Di-
clofenac, EDTA, Carbopol 940, Triethanolamine, 
Tween 80, Span 20, Ethanol, Propylene glycol, Liq-
uid Paraﬃ  n, Oleic Acid.
Methods: The hydrogel of emulsion gel was pre-
pared by dispersing Carbopol 940 in purifi ed water. 
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EDTA, Triethanolamine, and Tween80 was added. 
The oil phase was prepared by span 20, Ethanol, 
Propylene Glycol, with Liquid Paraﬃ  n in some for-
mulation and Oleic Acid in other. Diclofenac sodi-
um was dissolved in oil phase. Both oil phase and 
hydrogel were separately heated to 70 to 80 °C then 
the oil phase was added to hydrogel with continu-
ous stirring until it cooled to room temperature 25 
°C (2). After that optimized formulation was pre-
pared with the help of artifi cial neural network 
(ANN) program by using the same method.
RESULTS: The mean Diameter (μm) of the for-
mulations are ranged from 0,700 to 2,085 and the 
SD of the formulations are ranged from 0,20 to 
0,91. The pH values of the formulations ranged 
from 5.9 to 7.1 and the Electrical Conductivity val-
ues ranged from 20 to 210 μS-1. The viscosity val-
ues (Maps) of the formulations are ranged from 
130 to 5250. Optimized formula was prepared and 
tested. Viscosity of formula is 4600, pH value is 
6.7, electrical conductivity is 120 μS-1, and particle 
diameter is 0,989 μm.
CONSLUSION: Preformulation were pre-
formed, the next step of the study to evaluate the 
datas with the help of ANN program and to fi nd 
optimum formulation composition. The optimal 
formulation was found and prepared. The results 
were ideal. Although, the artifi cial intelligence 
programs are not enough to build and develop 
formulations by itself, but they play a good rule in 
the formulation developing.
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DSC compatibility study in binary physical 
mixtures of adapalene, levofl oxacin, meloxicam, 
and miconazole
RUSU, A.1, BÎRSAN, M.2, DONÁTH-NAGY, G.1, 
TODORAN, N.1
1University of Medicine and Pharmacy of Tîrgu Mures, Tîrgu 
Mures, Romania;
2“Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 
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INTRODUCTION: Transdermal therapeutic sys-
tems (TTSs) are innovative pharmaceutical forms 
and can be formulated for local or systemic eﬀ ect 
[1]. In our study, we analyzed the physicochemical 
compatibility between four candidate drugs to be 
included in a TTS device. Thermal stability of free 
compounds and binary mixtures of adapalene 
(ADP), levofl oxacin (LVF), meloxicam (MLX), and 
miconazole (MCZ) was analyzed by Diﬀ erential 
Scanning Calorimetry (DSC) [2]. 
MATERIALS AND METHODS: ADP, LVF, 
and MCZ were purchased from Sigma Aldrich 
(Germany), and MLX from Techno Drugs & Inter-
mediates Ltd. Mumbai (India). Thermal behavior 
of free drugs and binary mixtures (1:1) was evalu-
ated using a DSC 60 Shimadzu device, 3 mg sam-
ples (weighed in crucibles of aluminum) with 20 
°C/min heating rate. The melting points of the four 
compounds and six mixture, the stability and pos-
sible interactions between drugs were evaluated.
RESULTS: DSC curves of the binary mixtures 
showed changes in the melting point values of 
free drugs, dehydration, and some chemical inter-
actions. Dehydration was observed mainly in the 
case of LVF [3], and some endothermic changes 
with peaks characterized by lower intensities and 
shift to lower temperature values in case of ADP-
MLX. Exothermic events occur probably due to 
the formation of hydrogen bonds between two 
carboxyl groups or between chlorine atoms and 
hydroxyl/carboxyl group (ADP-LVF, LVF-MCZ, 
and MCZ-MLX). Moreover, dipole forces may oc-
cur between fl uorine-carbon and chlorine-carbon 
bonds or between fl uorine/chlorine-carbon and 
the hydroxyl-carbon bonds of MLX (LVF-MCZ 
and LVF-MLX). Possible changes such as a decar-
boxylation process (LVF-ADP), a chemical interac-
tion between the carboxyl and secondary amine 
groups (LVF-MLX), and sample decomposition 
(ADP-LVF and LVF-MCZ) were also highlighted.
CONCLUSIONS: Modifi cations of DSC curves 
of all mixtures occurs over 175°C. The fewest and 
minor changes on DSC curves are observed in 
case of ADP-MCZ and ADP-MLX mixtures; these 
two blends can be considered as potential candi-
dates for future TTS binary formulations. Also, 
others compatibility studies need to be performed.
ACKNOWLEDGMENTS: The research was 
supported by the University of Medicine and 
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DSC evaluation of ethylcellulose as 
dispersion modulator for including oxicams in 
hypromellose matrices developed for dermal use
REDAI, E.1, ANTONOAEA, P.1, TODORAN, 
N.1, CIURBA, A.1, RUSU, A.1
1Faculty of Pharmacy, University of Medicine and Pharmacy of 
Tîrgu Mures, Tîrgu Mures, Romania
INTRODUCTION: Hypromellose (HPMC) forms 
water-soluble bioadhesive fi lms by evaporating 
the water from its aqueous dispersions. The meth-
yl substituent is hydrophobic while the hydroxy-
propyl is relatively hydrophilic [1]. Addition of 
ethylcellulose (EC), hydrophobic polymer, may 
modify the HPMC solubility and consequently 
the cohesive strength achieved when oxicams 
(4-hydroxy-1,2-benzothiazine carboxamides, prac-
tically insoluble in water [2]) are included in this 
kind of matrices. This study aims the evaluation 
of meloxicam (MX) vs. tenoxicam (TX) included in 
two types of HPMC (-EC) matrices.
MATERIALS AND METHODS: Ten products 
in the form of polymeric fi lms containing 4% MX or 
TX were subjected to diﬀ erential scanning calorim-
etry (Shimadzu TA-60WS, samples of 5mg, heating 
rate of 5°C•min-1, range of 30-300 °C). Their com-
positional diﬀ erences were coded as follows: P1 
-low viscosity HPMC (24% polymer in matrix), P2 
-high viscosity HPMC (8%), P3 -EC (8%); P1-P3 and 
P2-P3 based on HPMC+EC (24% + 8%).
RESULTS: All MX matrices showed characteris-
tic DSC curves with endothermic peaks given by 
the melting point of MX. The reduction in enthalpy 
suggested the minimization of MX recrystalliza-
tion, but also the non-homogeneity in the matrix. 
These types of fi ndings were observed only for 
three TX matrices. The fl atness of DSC curves regis-
tered for TX-P2-P3 and TX-P3 matrices suggested 
that EC favoured the dispersion of TX (by dissolu-
tion or amorphization of the crystalline powder) in 
the matrix based on HPMC of high viscosity.
CONCLUSIONS: EC can diﬀ erentially modu-
late the grade of dispersions of oxicams (ingredi-
ents with low hydrophobicity diﬀ erences) in ma-
trix systems based on HPMC.
ACKNOWLEDGMENTS: This work was sup-
ported by the University of Medicine and Phar-
macy of Tîrgu Mures Research Grant no. 
275/6/11.01.2017.
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Development of bioactive compounds-loaded 
chitosan fi lms using a QbD approach
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INTRODUCTION: In the present study, a Quali-
ty by Design (QbD) approach was applied in order 
to develop and optimise a bioactive compounds-
loaded chitosan fi lm formulation, intended for 
further use as an aid in the acceleration of diabetic 
wound healing.
MATERIALS AND METHODS: Chitosan was 
chosen as fi lm forming polymer, polyethylene gly-
col (PEG) was used as plasticiser, while polyvinyl 
alcohol (PVA) was added to improve the fi lm bio-
adhesive properties. A concentrated alcoholic ex-
tract consisting of a mixture of Plantago lanceola-
ta, Arnica montana, Tagetes patula, Symphytum 
oﬀ cinale, Calendula oﬃ  cinalis and Geum urba-
num was added in the formulation in order to en-
rich the fi lm with bioactive compounds.
Risk assessment strategy was applied to identi-
fy the critical formulation variables. The factors 
that registered the highest scores were the chito-
san concentration and the proportions of PEG and 
PVA, these being further introduced as inputs of a 
3 level Box Behnken design of experiments (DoE). 
The studied outputs of the DoE were critical qual-
ity att ributes of the fi lms, namely: fi lm thickness 
and transparency, swelling degree, solubility, bio-
adhesive and mechanical properties assessed 
through texture analysis.
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Solutions consisting of chitosan, PEG, PVA and 
alcoholic extract, all in various proportions ac-
cording to the DoE specifi cations, were prepared 
and casted onto polypropylene plates. The fi lms 
were obtained after drying at 40°C for 24h.
Following experimental data analysis, the De-
sign Space (DS) was established and an optimal 
formulation within the DS was prepared.
RESULTS: The antimicrobial eﬀ ects of the opti-
mised fi lm formulation, as well as of a placebo 
formulation without bioactive compounds, 
against common wound pathogens such as S. au-
reus, E. coli and P. aeruginosa were determined 
by the disk diﬀ usion method and subsequently 
compared.
The optimal fi lm formulation obtained regis-
tered a fi lm thickness of 0.092 mm, transparency 
of 1.52, solubility in water of 44.8% and a high 
swelling degree of 2157%, values within the speci-
fi cations of the quality target product profi le. 
Moreover, the optimal bioactive compounds-load-
ed chitosan fi lm formulation was found to have a 
good antimicrobial activity against the tested 
pathogens.
CONCLUSION: Taking into consideration the 
promising results obtained, we can conclude that 
in the current study, the QbD approach was suc-
cessfully applied in order to ensure a good under-
standing of the manufacturing process, as well as 
to optimise the formulation of chitosan fi lms.
P1/6
Stability Testing Of Semisolid Individual 
Preparations Containing Cacao Butt er
SZÉKELY, A., PÁL, SZ., 
TAKÁCSI-NAGY, A.
Institute of Pharmaceutical Technology and Biopharmacy, 
University of Pécs, Pécs, Hungary
INTRODUCTION: Pharmacy practice includes 
traditional and customized magistral products 
that are well-tolerated by patients, for which shelf-
life time cannot be accurately provided. In such 
cases, the product may not meet the desired re-
quirements even within the expiry date. This 
problem not only gives rise to uncertainty among 
patients and pharmacists, but is also of quality 
concern [1, 2]. Moreover, by carrying out certain 
examinations, even in the small-scale production, 
an appropriately stable pharmaceutical composi-
tion can be prepared.
The aim of this study is focused on the re-pro-
duction of a routinely used individual prepara-
tion, its physico-chemical, accelerated and real-
time stability testing to predict the rate of change 
at a proposed storage temperature.
MATERIALS AND METHODS: Five varia-
tions of the chosen ointment were freshly pre-
pared and subjected to accelerated stability testing 
at 40°C; 75±5% relative humidity and 25°C; 40±5% 
relative humidity. The preparations were moni-
tored and few units of the reference material were 
taken at 1, 3 and 6 months interval. During the sta-
bility testing process the following experiments 
and tests were conducted according to the Hun-
garian and European Pharmacopoeias: Drop point 
and freezing point measurements, extensometric 
test, microscopic examination, pH measurements 
of the watery phase, rheometric, dissolution and 
diﬀ usion tests.
RESULTS: The study revealed that the choice 
of an optimal method of preparation results in a 
more stable pharmaceutical product than the orig-
inal preparation. Even similar production meth-
ods resulted in ointments with signifi cantly diﬀ er-
ent physico-chemical parameters. Based on the 
study, we can recommend a good manufacturing 
practice, expiry date, packaging material and stor-
age conditions regarding the chosen formulation.
CONSLUSION: These results confi rmed that 
the physical and chemical stability of the oint-
ments were achieved with the appropriate choice 
of the preparing conditions.
REFERENCES:
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Formulation and Evaluation of Carvedilol 
Ointment
PILIPOVIĆ, B.1, PILIPOVIĆ, S .2, PAŠIĆ, M.1
1Bosnalijek d.d. Sarajevo, Bosnia and Herzegovina;
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INTRODUCTION: The aim of the present work 
was to study the preformulation parameters of 
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carvedilol ointment. The use of preformulation 
parameters maximizes the chances in formulation 
of acceptable, safe, eﬃ  cient and stable product and 
at the same time provides the basis for optimiza-
tion of the drug product quality. Calcium antago-
nists and beta-adrenergic receptors antagonists 
are known drugs, and for many years are widely 
used in the treatment of cardiovascular diseases. 
Some of these components also show antioxidant 
activity. For the purpose of testing potential local 
anti-infl ammatory activity of beta blocker con-
taining ointments, a 1% carvedilol ointment was 
prepared in the fatt y carbohydrate medium. We 
demonstrated that a 1% carvedilol ointment has 
anti-infl ammatory eﬀ ect.
MATERIALS AND METHODS: For the pur-
pose of testing the possible local antiinfl ammatory 
activity of ointments containing carvedilol the 
ointments with 1% of active substance in the oily 
base of the hydrocarbon were made. Particle size 
of carvedilol from manufacturer A, B, C and D 
was determined by laser diﬀ raction using a PSA 
Instrumet: Malvern Master Sizer 2000 (PSA- Parti-
cle Size Analysis).
RESULTS: The mean particle size of carvedilol 
in diﬀ erent samples.
Particle size A B C D
d(0,1) 8,62 10,57 8,21 6,06
d(0,5) 24,27 47,58 23,34 24,77
d(0,9) 372,29 208,61 163,30 251,66
CONCLUSION: The histogram of particle size 
distribution of carvedilol indicated a wide particle 
size distribution, with sub micron particles in the 
fi eld, and particles sized up to 1000 microns. Al-
though for the product such as cream/ointment, 
narrower particle size distribution is recommend-
ed due to the uniformity of content, tests have 
shown satisfactory quality of ointments in which 
carvedilol was incorporated as the active sub-
stance. No data on the topical application of the 
beta blocker were found for the purpose pharma-
cological treatment of the reduction of the infl am-
mation of the skin.
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Carvedilol ointment stability
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INTRODUCTION: The aim of the present work 
was to study the stability of carvedilol ointment. 
Carvedilol is cardio selective beta blocker and has 
been used for the treatment of cardiovascular dis-
eases for a number of years. It also shows antioxi-
dative activity. The mechanism of antioxidative 
activity of carvedilol is unknown. For the purpose 
of testing potential local anti-infl ammatory activi-
ty of beta blocker containing ointments, a 1% 
carvedilol ointment was prepared in the fatt y car-
bohydrate medium. We demonstrated that a 1% 
carvedilol ointment has anti-infl ammatory eﬀ ect.
MATERIALS AND METHODS: A 1% oint-
ment with carvedilol as the active substance was 
used in the project. Testing of the stability of the 
samples of fi nished ointments stored at 25°C 60% 
and the 40°C/75% was performed with two ana-
lytical methods: UV spectroscopy on 275 nm and 
high pressure chromatography adopted from BP 
2009 monograph.
RESULTS: chemical evaluation of ointment sta-
bility at 25°C/60% and 40°C/75% RH conditions 
show that content of carvedilol was for 3 months 
99,40%-102,50%, and for 6 months 98,50%-99,00%. 
Impurities was for25° C/60% RH for 3 months sin-
gle 0,04%, total impurities 0,08%, for 6 months 
0,03%, total impurities0,08%, and for 40°C/75% 
RH single 0,04% total impurites-0,08%, for 6 
months single 0,03%, total impurities 0,08%,
CONCLUSION: By comparing the results ob-
tained from these two methods no diﬀ erences of 
the said content were observed. In the tested oint-
ments the carvedilol content is within the limits 
prescribed for ointment monographs (95,00 to 
105,00% in accelerated aging test as well as in nor-
mal ageing test at 25°C over a period of 6 months).
From the results of the study six months of sta-
bility carvedilol ointment at 25°C and testing 
(40°C), it can be concluded that carvedilol oint-
ment is equal stable at both temperatures for 6 
months. The samples stored according to ICH rec-
ommendations did not show signifi cant degrada-
tion. Based on the obtained results, a shelf life of 
at least one year can be assigned according to the 
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ICH guideline recommendations for stability test-
ing of the new forms.
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Oscillatory rheometric detection and tracking 
of interactions between macrogol-phenolic 
compounds
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Budapest, Hungary
INTRODUCTION: Study of incompatibilities and 
interactions represents an outstanding fi eld of the 
pharmaceutical technology. Incompatibilities 
manifesting in liquefaction can even prohibit the 
application of dosage forms such as suppositories. 
Observation of interactions between macrogol 
and hydroxil-group containing compounds can be 
followed by rheometer.
MATERIALS AND METHODS: The altera-
tions of viscosity due to reaction between polyeth-
ylene glycol 6000 and phenol-group compounds 
such as salicylic acid (SA), phenyl-salicylate (PS) 
and vanillin (V) were measured using a Kinexus 
Pro oscillatory rheometer [Malvern Ltd.]. Oscilla-
tion tests were carried out to follow the changes of 
elastic and viscous moduli. Increasing amounts of 
active ingredients (0, 5, 10%) were added to a mix-
ture composed of 7:3 PEG 6000: distilled water. 
Temperature-dependent oscillation measurements 
were performed while the samples were cooled 
from 60°C to 15°C and the reduction of congealing 
point was detected.
RESULTS: Oscillatory testing occuring between 
the polyethylene glycol 6000 and phenol-group 
compounds caused alterations in rheological 
properties. Samples containing 5; 10% of the ac-
tive ingredient triggered incompatibility. Rheo-
logical modifi cations can be observed in alteration 
of complex viscosity and complex modulus de-
pendent of temperature as well.
CONCLUSION: Measurements on an oscillato-
ry rheometer can pinpoint incompatibilities mani-
festing in the fl uctuation of viscosity.
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Textural properties of matrix adhesive system 
containing plant extract
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INTRODUCTION: Transdermal patches have 
been useful in developing new applications for ex-
isting therapeutics by having several advantages 
[1]. This experimental study deals with formula-
tion of a matrix system containing extract from 
Rhodiola rosea root (provided by Calendula, Slo-
vakia). Studied polymer matrix system is aimed to 
be both, the reservoir and the controlling unit for 
transdermal plant extract delivery [2]. Adhesion 
as qualitative property of a transdermal patch is 
important in formulation process. We were fo-
cused on texture analysis with the aim to improve 
the physical characteristics of evaluated matrix 
system.
METHODS: Transdermal patches were pre-
pared by using diﬀ erent polymers: 3% Carbopol, 
5% pectin, 2% chitosan and combination of 13% 
gelatin and chitosan in concentrations 0.5%, 1%, 
1.5%. The patches were prepared by casting into 
the form with standard area as a fi lm with thick-
ness of 1mm. The size of the fi lm was standard 
(30mm x 30mm) with the dose of extract 60mg. 
Adhesion of evaluated polymer matrices we mea-
sured in two steps. In the fi rst step adhesion was 
described by the force or weight needed for sepa-
ration of two jaws connected through the polymer 
matrix by using a published procedure [3].
In the second step, by texture analyzer adhesion 
was evaluated. We used Stable Micro Texturome-
ter (United Kingdom) with modifi ed cylinder 
probes.
RESULTS: Texture profi le analysis as an ana-
lytical method can easily quantify multiple textur-
al parameters, for matrix systems this measure-
ment provides e.g. adhesion. Summarizing the re-
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sults of all measurements we found diﬀ erences re-
lated to the type of polymer and the concentration 
of polymer in all tested parameters.
CONCLUSIONS: The most promising formu-
lations were matrix systems containing chitosan 
and gelatin, which will be evaluated in further ex-
periments.
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grants: VEGA 2/0044/15 and APVV-15-0308.
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INTRODUCTION: The objective of the study 
was to develop a novel all-natural carrier, based 
on core-shell microcapsules, for topical delivery of 
berberine. This system is designed for the im-
provement of skin conditions such as acne, as an 
alternative to the conventional topical therapy.
MATERIALS AND METHODS: Berberine is 
an isoquinoline-alkaloid derivative frequently re-
ported for antimicrobial activity against Gram-
positive and Gram-negative bacteria, antiinfl am-
matory and antiandrogenic eﬀ ects. The broad 
spectrum of pharmacological activities makes ber-
berine a potential candidate in acne therapy. 
However, poor bioavailability, due to low water 
solubility has limited the clinical applications of 
berberine. This drawback could be overcome by 
the microencapsulation technology that uses mi-
crocarriers in protecting, transport and delivery of 
hydrophobic compounds.
Firstly, microparticles CaCO3/BSA were ob-
tained by coprecipitation of CaCO3 with BSA, fol-
lowed by layer-by-layer deposition of the pectine 
hydrogel formed by cross-linking of pectin with 
Ca2+ from microparticles and subsequently forma-
tion of polyelectrolyte complex pectine/chitosan. 
After removing of CaCO3 from the microparticles 
by complexation with EDTA, microcapsules with 
BSA gel in the core were obtained by thermal 
treatment. Determination of Encapsulation Eﬃ  -
ciency (%) and Loading Eﬃ  ciency (%) for berber-
ine was assessed by UV-Vis spectrometry; the 
characterization of microcapsules with/without 
encapsulated berberine, have been made by FTIR, 
XRD, CLSM and SEM. In vitro release study in 
diﬀ erent pH conditions was performed in order to 
study the release profi le of berberine from micro-
capsules.
RESULTS: The mean size of microcapsules was 
5-7 μm and the UV-Vis quantitative study of en-
capsulating and loading eﬃ  ciency showed a low 
encapsulation, specifi c for hydrophobic active 
agents. Although, the drug release profi le re-
vealed a sustained release of berberine, with best 
results for pH 4.0 sodium acetate buﬀ er.
CONCLUSION: Based on the obtained results, 
we can conclude that, the core-shell microcapsules 
made of BSA gel core and a polyelectrolyte com-
plex pectin/chitosan multilayer shell represent a 
promising carrier for targeted and prolonged de-
livery of berberine.
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Proposal of a pharmaceutical form for cosmetic 
use with volatile oil of Anethum graveolens and 
evaluation of its eﬀ ectiveness
ANDREI, F.-C.1, OLTEANU, C.2, ALEXA, E.3, 
DRAGOMIRESCU, A.1 
1Faculty of Pharmacy, University of Medicine and Pharmacy, 
Timisoara, Romania
2Favisan Laboratories, Lugoj, Romania;
3Banat`s University of Agricultural Sciences, Timisoara, 
Romania
INTRODUCTION: The volatile oil of Anethum 
graveolens (Umbeliferae) is well known and used 
for the pharmacodynamic hepatoprotective, anti-
microbial, hypoglycemic and even galactogog ef-
fect [1,2,3].
In addition, it is traditionally classically known 
for its phytoestrogenic eﬀ ect. The purpose of the 
present paper was to: 1) evaluate the chemical 
composition of the volatile oil of Anethum graveo-
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lens by GC-MS 2) formulate a pharmaceutical 
form for skincare with antiaging properties 3) to 
check the eﬀ ectiveness on the volunteers.
MATERIAL AND METHODS: The study uti-
lized GC-MS from the Banat`s University of Agri-
cultural Sciences, a cutaneous biometric apparatus 
with components: corneometry, elastometry, se-
bometry, produced by Courage-Khazaka. Volun-
teers accepted into the study were selected based 
on admission criteria.
RESULTS: The chemistry study revealed the 
following composition: 13 major components 
were identifi ed in the Anethum graveolens essen-
tial oil : Trans-beta-ocimene: 0.138, Lavandulol: 
0.065, Alpha-phellandrene: 1.499, pcymene: 0.211, 
D-limonene: 73.546, 2-Ethylacrylonitrile: 0.049, 
1-Butene: 0.007, Norbornane: 1.067, Estragole: 
0.121, Piridine: 0.064, D-carvone: 17.829, 1H-Imid-
azole: 0.014, Anethole: 4.981.The biometric assess-
ment study revealed: 1) regardless of age there is a 
gradual increase in elasticity (2) hydration and 
seborrhea increase transient only upon applica-
tion while elasticity remains signifi cantly in-
creased at the end of 60 days of testing 3) the pro-
posed cosmetic product with Anethum graveolens 
oil is compliant and does not produce adverse ef-
fects.
CONCLUSIONS: The Anethum graveolens oil 
deserves to be reconsidered as a cosmetic active 
substance and not only aromotherapic agent.
Aknowledgements: Special thanks to the Fa-
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INTRODUCTION: Microemulsions are colloidal 
dispersions with nanometric droplets size in the 
range of 5-200 nm and they are produced by spon-
taneous mixing oil and water phases [1]. Unique 
solubilization properties of microemulsions make 
them potential carriers for topical application of 
poorly water soluble drugs (e.g. clotrimazole) [2]. 
Limitation of using microemulsions as dosage 
form for topical delivery is their low viscosity. In-
corporation of microemulsion into hydrogel struc-
ture improves application features and enables to 
use them in dermal formulations [1, 3]. In this 
study, microemulsion-based hydrogels with 
clotrimazole were designed and their antifungal 
activity comparing to hydrogel with traditional 
emulsion was performed.
MATERIALS AND METHODS: Pseudo-terna-
ry phase diagrams for microemulsion regions 
were constructed using diﬀ erent oils and surfac-
tants [4]. To prepare hydrogels Carbopol® 980 
was used as a gelling agent. Antifungal activity 
was evaluated against yeast cultures Candida 
parapsilosis ATCC 22019, Candida krusei ATCC 
6528 and clinical strains belonging to C. albicans 
and C. parapsilosis species using zone inhibition 
method.
RESULTS: Based on the data obtained from 
pseudo-ternary phase diagrams, two optimal 
compositions of micromulsion were selected (oleic 
acid/Tween 80 and Capryol® 90/Tween 80). It was 
shown that in all tested yeast cultures zone inhibi-
tion of designed microemulsion-based hydrogels 
was higher than hydrogels with traditional emul-
sion.
CONSLUSION: Using microemulsion as carri-
er of clotrimazole improved antifungal activity of 
prepared hydrogels.
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INTRODUCTION: Skin, particularly the upper-
most layer-the stratum corneum-presents a formi-
dable, largely impassable barrier to the entry of 
most compounds. There are two major challenges 
in topical drug delivery. Besides the drug solubili-
zation and adequate penetration of the stratum 
corneum, the patient adherence to treatment is 
also important due to the particularly low compli-
ance in topical drug administration. Pharmaceuti-
cal excipients are able to help address these chal-
lenges. These compounds are able to deliver eﬀ ec-
tive drug solubilization and modulation of drug 
penetration through the stratum corneum. These 
excipients can be very safe and highly tolerable. 
Moreover the applied components are enabling 
the formulation of diverse topical bases with ex-
cellent texture and sensorial properties which im-
prove patient experience and promote adherence.
The objective of this study was to formulate safe 
dosage forms with enhanced cutaneous drug de-
livery.
RESULTS: Physical properties of the formula-
tions have been evaluated by various measure-
ments. A series of in vitro biocompatibility tests 
had been performed to ensure safety in applica-
tion. To complete our examination; HaCaT perme-
ability assays have been deployed as well. These 
studies have demonstrated that the formulated 
foam compositions have the ability to deliver the 
API at an increased rate compared with other ve-
hicles.
CONCLUSIONS: These results suggest that 
the these foams utilizes a nontraditional “rapid-
permeation” pathway for the delivery of drugs. It 
is likely that components within the foam act as 
penetration enhancers, and reversibly alter the 
barrier properties of the outer stratum corneum, 
thus driving the delivered drug across the skin 
membrane via the intracellular route. This is in 
contrast to traditional topical delivery vehicles, 
which must fi rst rely on hydration of the intercel-
lular spaces in the stratum corneum to achieve 
drug delivery
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INTRODUCTION: Foams, that are colloid sys-
tems where the gas phase is dispersed in the con-
tinuous liquid phase, are used in several areas in-
cluding pharmaceutics and cosmetics. Foams con-
taining active ingredients for pharmaceutical pur-
poses are mainly applied dermally, but vaginal 
and rectal, as well as solid foams are available. 
The increasing number of topical foam formula-
tions relates to the numerous advantages they 
have compared to conventional creams or oint-
ments – easier and more comfortable application 
even on large skin, sensitive or hairy areas result-
ing in bett er patient compliance. Good spreadabil-
ity without oily residues on the skin and good rate 
of drug transfer can be provided given proper 
composition and formulation.
Other than surface active agents, foams can con-
tain active pharmaceutical ingredients, solvents, co 
solvents and depending on the container – propel-
lant. Medicated foams are characterized by pharma-
copoeial tests to determine relative density and du-
ration of expansion for pressurized formulations.
MATERIALS AND METHODS: The examined 
foams were generated from emulsions composed 
of distilled water and various oil phase (eg. sun-
fl ower oil) by using distinct surface active agents 
(eg. Tween 80, Span 80). Image analysis (Nikon 
SMZ1000, Image J) of foams provides information 
on the structure, the individual cell size and 
shape, therefore can also be used to examine and 
evaluate the break down progress of the diﬀ erent 
foam compositions.
RESULTS: The impact of type and ratio of ex-
cipients was followed by the morphological pa-
rameters (shape, size distribution, width and vari-
ability, etc.) of the foam image analysis.
CONLUSIONS: Foam characteristics are infl u-
enced and can be optimized by the composition, 
the type and amount of detergent. Altering the 
amount and type of surface active ingredients ef-
fect the shape, size distribution of foam cells re-
sulting in modifi ed relative foam density.
ACTA-1803-CESPT.indb   123 2018. 09. 10.   10:12
124 Acta Pharmaceutica Hungarica – CESPT Edition – Posters  2018/3.
REFERENCES:
1.  Arzhavitina A. & Steckel H. Int. J. Pharm. 394, 
1–17 (2010)
2.  Bureiko A. et al. Adv. Colloid Interface Sci. 
222, 670–677 (2015)
P2- NANOPARTICLES 1.
P2/1
Optimization and Charecterization of 
Nanosuspension of Cilostazol by Smart Particle 
Size Reduction (Top Down) Approach
AGHRBI, I .
Semmelweis University, Budapest, Hungary
INTRODUCTION: The water solubility, dissolu-
tion rate and gastrointestinal permeability are 
fundamental parameters that control rate and ex-
tent of drug absorption and its bioavailability. Par-
ticle size reduction is one of the oldest strategies 
for improving solubility of poorly soluble com-
pounds that can be applied to nano-specifi c for-
mulation for many years. The nanonization of the 
API leads to an increase in their surface area 
which proportionally increase the dissolution rate 
and the saturation solubility, subsequently im-
prove the bioavailability of poorly water soluble 
drugs and may also decrease systemic side eﬀ ects. 
Cilostazol (CLZ) is one such molecule which be-
longs to Biopharmaceutical Classifi cation System 
(BCS) Class II based on poor solubility and high 
permeability. In USA CLZ is approved for a treat-
ment of Intermitt ent Claudication and in Japan is 
approved for a treatment of Ischemic Symptom.
MATERIALS AND METHODS: The main 
goals of this study were to compare the most com-
monly utilized top down approaches by optimiza-
tion of the milling and the high-pressure (HPH) 
parameters to achieve CLZ nanocrystals and to 
improve the long term stability of the formulation 
applying freeze drying technique. The particle 
size reduction techniques were used to improve 
dissolution rate and water solubility of Cilostazol 
(CLZ). The nanosuspension was characterized us-
ing DLS method, zeta potential measurment, spec-
troscopic methods (DSC, FTIR, XPRD), in-vitro 
thermodynamic solubility and in-vitro dissolution 
studies.
RESULTS: Nanosuspensions made by both 
techniques signifi cantly increased the dissolution 
rate and saturation solubility compared to the 
pure drug powder and the unmilled product. 
Spectroscopic studies confi rmed partial crystalline 
to amorphous transitions.
CONCLUSIONS: Both techniques are suitable 
to create nanosuspensions of CLZ, but by wet ball 
milling process lower intensity weighted mean 
hydrodynamic diameter and polydispersity index 
values can be achieved. These methods are suit-
able for improving the dissolution rate and water 
solubility by sett ing the right parameters and care-
fully choosing the right components. 
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INTRODUCTION: Wet milling technologies are 
industrially used processes. These methods are 
applicable for micronization but is usually used 
for nanonization [1].
The process we used is a combined wet milling 
technology of wet stirred media milling and plan-
etary ball milling. The nanonization of the parti-
cles was successfully achieved by optimization of 
process parameters (particle size distribution of 
100-500 nm) [2].
In this work our aim was to discover the robust-
ness of the combined wet milling process in order 
to improve the process productivity.
MATERIALS AND METHODS: Meloxicam 
(MEL) [4-hydroxy-2-methyl-N-(5-methyl-2-thiazo-
lyl)- 2H-benzothiazine-3-carboxamide-1,1-dioxide] 
(EGIS Ltd., Budapest, Hungary)
Poly(vinyl alcohol) (PVA)-Mowiol 98-4 
Mw~27000 (Sigma Aldrich Co. St. Louis, U.S.)
Wet milling process: In the milling jar from 0.50 
g to 5.00 g of MEL was suspended in 15.00 g-19.50 
g of 5% PVA solution. The milling process was 
performed using Retsch PM100 planetary ball mill 
(Retsch GmbH, Haan, Germany).
Particle size measurement: Malvern Mastersizer 
Hydro 2000S unit (Malvern Instruments Ltd., 
Worcestershire, UK).
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Diﬀ erential scanning calorimetry (DSC): Met-
tler Toledo DSC 821e thermal analysis system 
(Mett ler Inc., Schwerzenbach, Switz erland).
Thermogravimetric analysis: Mett ler–Toledo 
TGA/DSC1 (Mett ler–Toledo GmbH, Switz erland) 
instrument.
X-ray powder diﬀ raction analysis (XRPD): 
Bruker D8 Advance diﬀ ractometer (Bruker AXS 
GmbH, Karlsruhe, Germany).
RESULTS: The right quality products of the trial 
range were the samples with the MEL content 
from 2g to 4g. Amorphous content of the drug is 
inversely proportional to the amount of drug. The 
higher amount of active agent results in decrease 
of degree of amorphization.
CONCLUSION: In case of combined wet mill-
ing process, the active agent amount may be im-
portant parameter of design space because the 
material to be milled can also increase the eﬃ  cien-
cy of milling and its robustness (within a given 
particle size range) and it may aﬀ ect the retention 
of crystallinity
ACKNOWLEDGEMENT: This work was sup-
ported by Gedeon Richter Plc.’s Talentum Foun-
dation (Budapest, Hungary).
REFERENCES:
1.  Elaine M. L. Adv. Drug Deliv. Rev. 63 427–
440 (2011)
2.  Csaba B. et al. Drug Des. Dev. Ther. 12, 1–14 
(2018)
P2/3
Preparation and characterization of fenofi brate-
loaded electrospun microfi bers
SZABÓ, I . Z., CSATÁRI, T., SIPOS, E.
University of Medicine and Pharmacy Tîrgu Mures, Romania
INTRODUCTION: Drugs displaying poor water-
solubility often require high doses in order to 
reach therapeutic eﬃ  cacy. In case of drugs dis-
playing good permeability, but low solubility, im-
provement in the extent and rate of dissolution 
can improve oral bioavailability. Out of the nu-
merous methods available for solubility enhance-
ment, electrospinning has emerged as a relatively 
simple and eﬀ ective method for obtain improved 
dissolution of embeded actives.
Fenofi brate, the frequently prescribed antilipid-
emic agent from BCS class II, displays high lipo-
philicity and low water solubility, which in terms 
limits its oral absorbtion.
MATERIALS AND METHODS: Viscous poly-
meric solution for electrospinning were prepared 
by solubilizing Fenofi brate (micronized, obtained 
from a local pharmaceutical company) in Tween 
80 and mixing with 20 % (m/w) ethanolic PVP 
K29/32 solution (ISP Pharmaceuticals). Microfi -
bers were prepared by feeding the prepared gels 
with a rate of 1.0 mL/h, through a 1.2 mm internal 
diameter needle. High-voltage (aprox. 20 kV) was 
applied at 10 cm collector-needle distance. The ob-
tained fi bers were dried at room temperature and 
were analyzed in terms of fi ber diameter, mor-
phology, thermal analysis, disintegration and dis-
solution characteristics.
RESULTS: Uniform beadles fi bers were ob-
tained during the electrospinning process, with 
mean diameter of 1.52 ±0.29 μm. Given the high 
surface-to-volume ratio and high porosity of the 
fi bers, the prepared mats disintegrated instanta-
neously. Thermoanalytical characterization of the 
obtained microfi bers implied the crystalline-amor-
phous transition of the active, which, along with 
the increased specifi c area enabled rapid and com-
plete dissolution of the poorly soluble drug.
CONCLUSION: Fenofi brate-loaded electros-
pun PVP-based nanofi bers proved to be an excel-
lent choice for improving the solubility of the BCS 
II class drug, which could be a promising alterna-
tive for improving the oral bioavailability of the 
drug and subsequently reduce its dose.
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INTRODUCTION: Preparation of polymer-based 
electrospun amorphous solid dispersions is a 
promising way to enhance the dissolution of poor-
ly water-soluble drugs which lead to improved 
bioavailability in many cases [1]. However, there 
are some diﬃ  culties in practical application of 
electrospinning such as scaling-up of the technol-
ogy, stability of the electrospun product and 
achieving of the whole downstream process to 
generate tablet form [2]. During this research, the 
above mentioned challenges were investigated 
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and the current trends of the pharmaceutical fi eld, 
continues technologies were keep in mind.
MATERIALS AND METHODS: Compositions 
of PVPVA64 and 40% model drugs (spironolac-
tone, itraconazole) were dissolved in EtOH:DCM 
1:2 mixture for electrospinning experiments. Mor-
phology and amorphous form of the products 
were examined by scanning electron microscopy, 
diﬀ erential scanning calorimetry and X-ray pow-
der diﬀ raction while the dissolution measure-
ments were accomplished on a Pharmatest PTWS 
600 dissolution tester (Pharma Test Apparatebau 
AG, Germany). A well-seeming technology which 
called high speed electrospinning (Quick2000 Ltd, 
Hungary) was applied for gett ing higher produc-
tivity. Furthermore, diﬀ erent steps of a possible 
electrospinning-based continuous downstream 
process were tested by using loss-in-weight feeder, 
a Dott  Bonapace CPR6 eccentric tableting machine 
(Limbiate, Italy) and a Kaiser RamanRxn2® Hybrid 
in situ analyzer (Kaiser Optical Systems, USA).
RESULTS: Based on the results, it can be stated 
that the high speed electrospinning increased the 
productivity more than thirtyfold compared to the 
single needle method. In addition, downstream 
process of the electrospun products also seemed 
to be feasible and the experiments bear out the ap-
plicability of this technology in a continuous pro-
cess line. Nevertheless, Raman-spectroscopy mea-
surements prove that crystalline traces have re-
markable impact to the dissolution of amorphous 
solid dispersions.
CONCLUSION: High speed electrospinning 
opens a new way to the pharmaceutical applica-
tion of drug-loaded electrospun materials. Im-
proved productivity makes possible to investigate 
continuous downstream process steps of the prod-
ucts where application of in-line analytical devices 
is necessary due to the signifi cant correlation be-
tween crystalline content and dissolution.
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INTRODUCTION: Nanofi bers are a convenient 
solution to the current problems of drug delivery 
due to their high surface-to-volume ratio architec-
ture [1]. Electrospinning is the most preferred 
technique for nanofi ber fabrication due to its sim-
plicity, cost-eﬀ ectiveness and fl exibility [2, 3]. The 
objective of this project was to develop pharma-
ceutical nanofi bers with a 3D printed poly lactic 
acid (PLA) chamber using loratadine (LOR) as 
model drug and PVP (MW 1,300,000) as the fi la-
ment-forming matrix.
MATERIALS AND METHODS: Solutions of 
PVP in ethanol were used to fabricate LOR. A ratio 
of 1:1 LOR to PVP was used during the procedure. 
The solutions were electrospun in a 3D-printed 
electrospinning chamber, made of PLA. A syringe 
pump provided the solution to the nozzle inside 
the electrospinning chamber, with speed of 15 μl/
min. The potential diﬀ erence was 35 kV between 
the nozzle and the rotating grounded collector. 
Two diﬀ erent working distances were set between 
the nozzle and the fi ber collector (6.5 and 9.5 cm). 
Further, reference samples were prepared by sol-
vent evaporation (SE) of 1:1 LOR to PVP from eth-
anol solution. Diameters of the nanofi bers were 
measured by Scanning Electron Microscopy (SEM) 
image analysis. Moreover, Fourier Transform In-
frared (FT-IR) Spectroscopy was used to identify 
the interaction between PVP and LOR. Diﬀ erential 
Scanning Calorimetry (DSC) and X-Ray Diﬀ rac-
tion (XRD) analysis was carried out to assess the 
crystallinity and the changes in the crystalline pat-
tern. The in vitro release was also tested.
RESULTS: LOR loaded 4 wt% PVP solutions 
produced homogenous and intact nanofi bers. Ma-
jor bands of LOR in FT-IR were clearly observed 
in the spectrum the nanofi bers. Moreover, DSC 
thermograms indicated that LOR existed in its 
amorphous dispersed state within PVP fi bers. 
This is also supported by the disappearance of the 
melting peak at 135 °C and the complete absence 
of LOR crystals under SEM. Lastly, the XRD pat-
terns also confi rmed the amorphous nature of the 
prepared nanofi bers. The in vitro release showed 
an enhancement of LOR release.
CONCLUSION: Amorphous loratadine-PVP 
nanofi bers were produced using an inexpensive 
3D-printed electrospinning apparatus for drug 
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formulation. The produced nanofi bers had in-
creased drug release, meaning increase of bio-
availability.
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INTRDUCTION: Spray drying is an advanced, 
easy to scale-up technique of micro- or nanoscale 
multiunit carriers preparation [1, 2]. This method 
is uncomplicated, but in order to obtain product 
with desirable properties, careful adjustment of 
the spray drying parameters is required. Thus, the 
aim of the current study was to examine the inter-
ference of diﬀ erent variables in order to optimize 
spray drying of zidovudine-loaded microparticles 
(MPs) intended for local delivery, with the use of 
Fractional Factorial Design (FFD). Low-molecular 
weight chitosan and chitosan glutamate - water-
soluble chitosan derivative, were employed for 
MPs preparation.
MATERIALS AND METHODS: In order to se-
lect variables signifi cantly infl uencing MPs prepa-
ration, namely the type and concentration of the 
polymer, drug to chitosan ratio, the presence of 
additional co-solvent, inlet temperature and feed 
rate, two-level FFD with 3 center points was im-
plemented.
RESULTS: Overall, as a result of 11 experi-
ments, MPs formulations with chitosan or chito-
san glutamate were prepared and characterized in 
terms of shape, size, moisture content, encapsula-
tion eﬃ  cacy and production yield. Att ained re-
sults indicate that inlet temperature had an impact 
on the entrapment eﬃ  ciency whereas drug load-
ing was infl uenced by both drug to polymer ratio 
and inlet temperature. In turn, feed rate and type 
of chitosan used were found to be signifi cant in re-
spect of moisture content. Additionally, obtained 
model suggests that chitosan glutamate should be 
the polymer of choice for MPs preparation.
CONCLUSION: These results are useful in lim-
iting the range of selected variables, enabling to 
plan experimental domain for spray-drying ex-
periments more precisely in order to produce chi-
tosan MPs with feasible characteristics for deliv-
ery of zidovudine.
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INTRODUCTION: Baicalin is a fl avone glyco-
side, extracted from the root of Scutellaria ba-
icalensis. It was shown, that the poorly water solu-
ble and poorly permeable (BCS IV) compound has 
remarkable pharmacological eﬀ ects including an-
tioxidant, antimicrobial and antitumor actions [1]. 
The low oral bioavailability (2.2% in animal mod-
ells) of this drug could be alleviated through cy-
clodextrin (CD) inclusion complexation. CDs are 
cyclic oligosaccharides composed of 1,4-linked D-
glucopyranose units possessing a hydrophilic ex-
terior and hydrophobic cavity [2]. The physico-
chemical profi ling of baicalin (lipophilicity, acid-
base properties, solubility) is essential in order to 
develop CD-based carrier systems. The scope of 
the work was the biorelevant physicochemical 
profi ling of baicalin in terms of acid-base proper-
ties, lipophilicity, thermodynamic solubility and 
CD complexation analyzed by phase solubility, 
UV and NMR experiments.
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MATERIALS AND METHODS: The solubility 
of baicalin was characterized by phase solubility 
studies, the stability constant of the complexes 
were determined according to Higuchi-Connors. 
To ascertain the structure of the inclusion com-
plexes between baicalin and CDs, 1H NMR spec-
troscopy studies of free drug and host-guest com-
plexes were undertaken. Partition coeﬃ  cient mea-
surements were carried out by the stir-fl ask meth-
od, the determination of protonation constants 
was fullfi lled by 1H NMR–pH titration. Solid 
complexes of baicalin and CDs were formulated 
by freeze-drying and extrusion.
RESULTS: RAMEB, SB-ß and gamma-CD sig-
nifi cantly enhanced the poor aqueous solubility of 
baicalin and displayed AL and BS-type phase dia-
grams. 1H NMR confi rmed the formation of inclu-
sion complexes. Thermodynamic solubility was 
measured in various biorelevant media and com-
pared to compendial media.
Preformulation studies are necesarry to formu-
late drug delivery systems. CD encapsulation of 
drugs is well-known in the scientifi c literature; 
our results showed that baicalin can also form in-
clusion complexes.
CONCLUSION: The study proved that CDs 
are ideal carriers for baicalin. Biorelevant physico-
chemical profi ling of baicalin was carried out and 
the results can be used to determine the best for-
mulation path.
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method
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INTRODUCTION: Bovine Serum Albumin (BSA) 
is playing an increasing role as a nano Drug De-
livery System (nanoDDS) in the clinical therapy. 
Due to its biocompatibility and non-toxicity, it can 
be used as a pharmaceutical carrier for diﬀ erent 
drugs more safely versus many synthetic poly-
mers. BSA is also an excellent material to con-
struct nanoparticles (NPs) because it has good 
physicochemical stability, targetability, and chem-
ical functionality. Freeze drying is a suitable tech-
nique to improve the long-term storage stability of 
colloidal DDSs such as NPs. Our aim was to for-
mulate BSA based NPs, which have appropriate 
drug release.
MATERIALS AND METHODS: Meloxicam 
(MEL) (Egis Pharmaceuticals Plc. Hungary) a BCS 
class-2 substance as model drug was chosen to the 
experimental work and BSA fraction-V (Alfa Ae-
sar, UK) was selected as nanoDDS. BSA based 
MEL NPs were prepared by means of coacerva-
tion method [1]. The optimization of formula was 
carried out using factorial design. According to 
the design the optimal formula was prepared and 
further investigated. BSA was dissolved in phos-
phate buﬀ er (pH=7.4) and MEL dissolved in etha-
nol was added to the BSA solution under constant 
stirring. For cross-linking glutareldehide was used 
[2]. After purifi cation freeze-drying was carried 
out. The particle size and zeta potential were de-
termined. Fourier-transform infrared spectrosco-
py (FTIR), thermal analysis (TA) and X-ray pow-
der diﬀ raction (XRPD) were used as physico-
chemical characterization methods. Dissolution 
studies were carried out using UV spectroscopy to 
investigate the drug release. 
RESULTS: The desired particle size (130 nm) 
and zeta potential (-31.8 mV) was reached by opti-
mization of the formula. Based on the FTIR data 
trehalose partially prevented structural perturba-
tions in BSA upon freeze-drying. TA and XRPD 
analysis showed the NPs are thermal stabile and 
semi-crystalline. Dissolution studies showed in-
creased drug release in comparison to the physical 
mixture.
CONCLUSION: Using factorial design BSA 
based MEL containing NPs were prepared by 
means of coacervation and freeze-drying with de-
sired properties (size, zeta potential, stability). The 
optimized formulation can be applied for drug 
conjugation to help the therapeutic eﬀ ect.
ACKNOWLEDGEMENTS: This work was 
supported by Gedeon Richter Plc. – GINOP proj-
ect (2.2.1-15-2016-00007)
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Science and Technology Houari Boumediene, Algiers, Algeria
INTRODUCTION: The biopolymers are synthe-
sized in the plants or the animals by enzymatic 
way and are of this fact quickly degraded in a bio-
logical environment. Many biopolymers was stud-
ied and used in the microencapsulation of phar-
maceutical product, in this study we undertook 
the encapsulation of paracetamol by using two 
biopolymers (Gelatin and Alginate). 
The aim of the current work was to develop a 
microparticulate system based on complexe coac-
ervation between gelatin and alginate to encapsu-
late paracetamol. Various formulations were pre-
pared using the respose surface methodology to 
study the eﬀ ect of some factors on the chosen re-
sponse.
MATERIALS AND METHODS: The objective 
of this work is to study the infl uence and the inter-
action of diﬀ erent factors (surfactant concentra-
tion, fi rst homogeneisation speed and the second 
homogeneisation speed on the process of micro-
encapsulation using an experimental design for 
the preparation of paracetamol microparticles by 
complex coacervation using gelatin and alginate 
as biopolymers.
RESULTS: The morphology of all the microcap-
sules made was analyzed with a microscop. They 
appeared transparent, spherical and distinct from 
each other. The values of microencapsulation 
yield calculated for each confi guration; the diﬀ er-
ent tests show that paracetamol encapsulation 
yield varies between 31% and 75 %.
The eﬀ ects of each variable make possible the 
evaluation of their action when the parameter 
passes from its low level to its high level. The oth-
er parameter being fi xed at the center of his exper-
imental reference mark (centered value).
CONCLUSIONS: Using all the results ob-
tained in the studies carried out on the infl uence 
of the chosen parameters on the selected answer 
and with the help of the used software used, we 
can distinguish a zone of the experimental do-
main which make possible the optimization the 
microencapsulation process by complex coacerva-
tion.
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INTRODUCTION: Polymeric micelles present a 
promising tool to increase bioavailability and 
change the toxicological profi le of the encapsulat-
ed drug. Their particle size is around 80 nm, 
which is optimal for passing the physiological 
barriers. Soluplus® (BASF GmbH, Germany) is a 
novel solubilizing amphiphilic graft co-polymer 
(Mr = 90 000-140 000 g/l), which is polymerized 
from polyethylene glycol 6000 (PEG 6000), vinyl 
caprolactam and vinyl acetate in a ratio of 13:57:30, 
oﬀ ers the possibility of a good solubility enhance-
ment in combination with a fast dissolution to 
drug loaded polymer micelles. Its CMC is 7.6 mg/L 
and HLB value is approx. 13. Our current project’s 
aim is to formulate polymeric micelles with a 
model drug due to the extensive therapeutic use 
and numerous indications.
MATERIALS AND METHODS: Methanol, 
ethanol, 2-propanol, acetone and acetonitrile 
(Merck Ltd., Budapest, Hungary) as solvents were 
used for preparation of polymeric micelles [1]. 
The model drug was dissolved in the organic sol-
vents under constant stirring and 1% NaOH was 
used for sett ing the pH [2]. Each solution was in-
vestigated at alkaline and neutral pH using 10% 
hydrochlorid acid adjusting the pH on 7.0. To 
form the micelle Soluplus® was added to the solu-
tion. The organic solvent was evaporated with 
vacuum distillery and the polymeric micelles pre-
cipitated. The particle size and zeta potential was 
measured using Malvern nanoZS instrument 
(Malvern, Wercestershire, UK). To investigate, 
whether the formed polymer micelles contain a 
drug, absorption spectroscopy methods were 
used.
RESULTS: The precipitate was easily dissolved 
unlike the original material which was a good sign 
that we improved the solubility. The particle size 
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is acceptable by the EMA regulations, 50% of the 
particles are under 100 nm size, they are around 
the ideal 80 nm even before membrane fi ltering it. 
The zeta potentials are the appropriate value, they 
promise complying stability. Spectroscopic stud-
ies showed fast drug release of the formulation.
CONCLUSION: We can conclude Soluplus® is 
a good excipient for the preparation of polymer 
micelles. Formulating polimer micelles can im-
prove the solubility of poorly soluble agents, 
which can be useful for developing “value added” 
preparations.
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INTRODUCTION: Recently, the formulation of 
natural drugs such as plant extracts and essential 
oils (EO) has been highly studied due to their mul-
titude bioactivities and their lot oﬀ  applications 
from food fl avor industry to pharmaceutical and 
cosmeceutical applications [1].
In aims of Design and Development of EO mi-
crocarriers, Ionic Gelation (IG), highly recom-
mended for the encapsulation of hydrophobic bio-
active molecules, can be applied and optimized to 
ensure high drug encapsulation yield with re-
sponse stability to facilitate its semi-industrial 
scaling-up [2].
MATERIALS AND METHODS: To obtain EO 
microcarriers with small particles size and high 
drug loading capacity, the studied EO was micro-
encapsulated by cross-linking a biodegradable 
polymer under several experimental conditions. 
Process optimization was carried out using the 
Response Surface Methodology to investigate 
fourth experimental parameters (polymer concen-
tration, cross-linking agent concentration, mixing 
time and mixing velocity) and the statistical analy-
sis was performed using one-way analysis of vari-
ance (ANOVA) and the Mean comparison of Poly-
dispersity Index (PI), volume-weighted mean par-
ticle diameter (d43) and Surface Weighted Mean 
particle diameter (d32) was carried out using T-
test [3]. All analyses were repeated in triplicate.
RESULTS: Both the loading capacity and the 
particles size of the obtained microcapsules 
were evaluated to optimize the ionic gelation 
process. Laser diﬀ ractometry (Mastersizer 2000, 
Malvern Instruments Ltd) was used to assess 
the physical characteristics of the developed mi-
crocarriers.
The selected optimal conditions allow obtaining 
microparticles with a loading capacity of 4.95 to 
15.19% with a PI range from 0.852 to 5.695, a spe-
cifi c surface area from 0.011 to 10.1 m2/g, a d32 
range of 0.595 to 547.735 μm and a d43 from 5.392 
to 714.263 μm. The RSM results combined with 
the statistical analysis allow assessing the correla-
tion between the fourth experimental parameters 
and their range on signifi cant (P-value < 0.05) or 
not signifi cant (P-value > 0.05) eﬀ ects.
CONCLUSION: Development of microcarriers 
for EO encapsulation using alginate microspheres 
was optimized to allow an interesting loading ca-
pacity, acceptable particles size, desired polydis-
persity and suitable volume/surface characteris-
tics. The designed microencapsulation process is 
statistically validated and can be easily scaling-up 
to a semi-industrial level.
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Nanostructured lipid carriers for Alzheimer’s 
disease treatment: Infl uence of solid/liquid lipid 
ratio on physico-chemical properties
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INTRODUCTION: Novel formulations based on 
embedded herbal therapeutical moieties into 
nanostructured lipid carriers (NLC) for nose to 
brain delivery are promising candidates for multi-
target therapy of Alzheimer’s disease along with 
specifi c and selective delivery to the brain tissue. 
Given that NLC eﬀ ectiveness would be deter-
mined by their physico-chemical properties, the 
aim of this study was to investigate the infl uence 
of solid/liquid lipid ratio upon them.
MATERIALS AND METHODS: NLC loaded 
with dry extract of Salvia oﬃ  cinalis L. (SE) were 
prepared by solvent evaporation method [1]. Lip-
id phase consisted of phospolipon 90H (kindly 
donated by Phospholipid, Germany) and oleic 
acid (Sigma-Aldrich, Germany) in ratio of 1 to 
0.216 (NLCS1), 0.433 (NLCS2) and 0.866 (NLCS3). 
Relative ratio of phospolipon 90H to other NLCs` 
formulation variables was 1 to 28.67, 0.167, 1.67, 
0.3 and 58.7 for ethanol (Alkaloid, Macedonia), SE, 
tween 80 (Merck, Germany), poloxamer 407 
(BASF, Germany) and water, respectively. NLCs` 
morphology (Jeol-SEM T300, Japan), particle size 
(PS) and size distribution (PSD) (Mastersizer 2000, 
UK), zeta potential (ZP) (Nano ZS, UK) and en-
capsulation eﬃ  ciency (EE%) (HPLC Agilent 1100, 
Germany) were determined.
RESULTS: SEM photomicrographs pointed 
that prepared NLCS were with spherical shape 
and smooth surface. As they were yellow-green in 
color DLS technique could not be used for PS and 
PSD, so laser diﬀ ractometry was applied. By in-
creasing the amount of liquid lipid, NLCs` PS in-
creased (132±1.8, 145±0.86 and 257±6.33 nm for 
NLCS1, NLCS2 and NLCS3, accordingly) most 
likely related to the higher density of organic solu-
tion thus resulting with larger emulsion droplets 
with lower surfactant surface coverage. Span val-
ues indicated narrow PSD for NLCS1 (1.05±0.01) 
and NLCS2 (1.04±0.06), while NLCS3 PSD 
(1.93±0.04) was a bit wider. Amount of liquid lipid 
did not have infl uence on ZP (-17.3±0.41 mV), con-
trary to the EE% (NLCS1 - 42.03±1.23, NLCS2 – 
48.94±1.85 and NLCS3 – 95.34±2.21%) probably 
due to the increase of imperfection degree in the 
solid lipid crystals, thus providing more space for 
SE encapsulation.
CONCLUSION: Infl uence of solid/liquid lipid 
ratio on NLCS physico-chemical properties was 
determined. Results indicated statistically signifi -
cant infl uence on PS and PSD, as well as EE%.
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INTRODUCTION: Vancomycin is a glycopeptide 
antibiotic which is active against gram-positive or-
ganisms. It is used particularly in the treatment 
and prophylaxis of staphylococcal infections espe-
cially caused by Methicillin-resistant Staphylococ-
cus aureus. To eliminate adverse eﬀ ects such as 
ototoxicity and nephrotoxicity of vancomycin upon 
systemic administration, local administration with 
various drug delivery systems such as micro-
spheres or nanoparticles can be utilized. Chitosan 
is a polysaccharide produced by N-deacetylation of 
chitin. Chitosan is biocompatible, biodegradable 
and non-toxic material. Fucoidan is another poly-
saccharide obtained from brown seaweeds. It has 
anticoagulant, antithrombotic, antivirus, antitumor 
and immunomodulatory, anti-infl ammatory and 
antioxidant properties. Chitosan and fucoidan due 
to their positive and negative charges in proper me-
dia respectively, forms a nanoparticle system in 
which active pharmaceutical ingredients can be en-
capsulated. In this study, vancomycin-loaded chito-
san/fucoidan nanoparticles were fabricated and for 
determination of load eﬃ  ciency of vancomycin, an 
easy and eﬀ ective method was developed.
MATERIALS AND METHODS: Nanoparticles 
were prepared using polyion complexation meth-
od. For this purpose chitosan was dissolved in 1% 
(w/v) acetic acid solution while fucoidan and van-
comycin were dissolved in distilled water. Fucoid-
an solution was then dropped to chitosan solution 
under magnetic stirring. Nanoparticles were 
seperated by centrifugation and then freeze dried.
RESULTS: Two methods were tested, UV spec-
trophotometry where samples scanned at 280 nm 
wavelength and RP-HPLC method for related 
substances in European Pharmacopeia mono-
graph for vancomycin with modifi cation.
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Determination of vancomycin amount by using 
UV spectrophotometry couldn’t be achieved due 
to interference of fucoidan remains in supernatant 
since fucoidan give absorbance at same wave-
length for vancomycin. By using RP-HPLC, one 
principal peak was obtained with the injection of 
sample in the chromatographic system and it was 
identifi ed as vancomycin with standart solution.
CONCLUSION: RP-HPLC method can be used 
for determination of vancomycin which remains 
in solution.
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INTRODUCTION: Solid lipid microparticles 
(SLMs) combine several features that are impor-
tant for successful delivery of drugs to the lungs 
in the form of dry powders for inhalation (DPIs). 
Due to the presence of lipid excipients, SLMs can 
be tailored to have the appropriate fl owability and 
their low density further provides decrease in the 
aerodynamic diameter of DPI particles [1]. The 
aim of this study was to evaluate, according to the 
Quality by Design (QbD) principles, the infl uence 
of the processing and formulation parameters on 
the properties of the prepared SLMs.
MATERIALS AND METHODS: SLMs were 
prepared by the melt emulsifi cation method. 
Emulsions consisting of salbutamol-sulfate (SS), 
water and 5% of the lipid phase were prepared, 
according to the two level resolution V design by 
varying the four parameters: lipid type (glyceryl 
dibehenate or stearyl alcohol), surfactant Polox-
amer 188 concentration (0.4 or 1.5%), high-shear 
mixing time (2 or 8 minutes) and drying method 
(freeze or spray drying). Particle size was deter-
mined by the laser diﬀ raction technique (Master-
sizer, Malvern, UK) and fl owability was evaluated 
by calculating Carr‘s index (CI) and Hausner ra-
tio. The SS content was assayed by liquid chroma-
tography tandem - mass spectrometry (TSQ 
Quantum Access MAX).
RESULTS: The results revealed that by pro-
longing the high-shear mixing time particles of 
smaller size were obtained (11-15 μm); whereas 
the span was higher in the case of glyceryl dibe-
henate formulations (2.6 vs 2.0 for stearyl alcohol). 
CI was less than 25% in almost all formulations, 
indicating good fl ow properties [2]. The SS load-
ing in SLMs that were freeze dried was 0.5-2.5%, 
in comparison to the 8.9-11.5% for the spray dried 
particles, which was expected due to the SS hy-
drophilic properties.
CONCLUSION: Based on the obtained results, 
it can be concluded that both formulation and 
processing parameters need to be considered for 
development of SLMs with the properties appro-
priate for DPIs.
ACKNOWLEDGEMENTS: Presented work 
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INTRODUCTION: Pulmonary drug delivery is a 
non-invasive approach in the treatment of respira-
tory or systemic diseases. It allows direct target-
ing of the natural therapeutic agents such us api-
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genin. This fl avonoid has remarkable antioxidant 
activity, moreover, is able to inhibit cell prolifera-
tion, migration and induce apoptosis in lung can-
cer cells (H1299, H460 and A549) [1]. The eﬀ ective-
ness of an inhaled bioactive component depends 
of the particle size, morphology and aerosol char-
acteristics, as well as pulmonary physiology. Bio-
degradable nanoparticles oﬀ er improved drug sol-
ubility, increased local drug concentration and 
targeted site of action [2].
MATERIALS AND METHODS: To prepare 
biodegradable nanoparticles, locust bean gum and 
chitosan biopolymers were used. High pressure 
homogenization was applied to encapsulate api-
genin. The physical properties of the particles 
such as size, charge and drug loading eﬃ  ciency 
were measured. The dissolution of Api was deter-
mined with Franz cell apparatus in simulated 
lung fl uid. The samples were further lyophilized 
with carrier and residual water content was mea-
sured by Karl-Fischer titration. The morphology 
of dry powders was observed with scanning elec-
tron microscopy. In vitro aerodinamical proper-
ties of the carrier-based dry powders were investi-
gated by next generation cascade impactor (NGI).
RESULTS: The developed biocompatible 
nanoparticles had adequate size and apigenin 
could be eﬀ ectively loaded with high pressure ho-
mogenization. The optimized freeze-drying con-
ditions were suitable to produce particles with 
low residual moisture content and the particle size 
was maintained following a rapid rehydration. 
The dissolution was enhanced compare to the raw 
apigenin. The in vitro aerosol characterization in-
dicated that the excipients play an important role 
in the deposition of biopolymer based nanoparti-
cles.
CONCLUSION: The developed biodegradable 
particles may have great potential for pulmonary 
drug delivery of bioactive agents.
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INTRODUCTION: Cystic fi brosis (CF) is an auto-
somal recessive hereditary disease that can’t be 
cured by the current state of science. There are a 
chronic bacterial infection and infl ammatory epi-
thelial cell layer in the lung. NSAIDs (e.g. meloxi-
cam potassium, MXP) have relevance in CF [1]. 
Dry powder inhalers (DPIs) are an evolving sector 
due to their many advantages. Based on formula-
tion there are two groups of DPIs. For the exploita-
tion of their benefi cial features, the aim of our 
work was the development of novel combined DPI 
formulations, thus the use of a spray dried drug 
on a (surface modifi ed) carrier. We expected a fa-
vorable change in interparticle interaction and 
thus improved aerosolization and high lung depo-
sition (determined by Fine Particle Fraction (FPF)).
MATERIALS AND METHODS: MXP (Egis 
Plc., Hungary) was applied as a model drug. 
Spray drying was used to enhance the aerosoliza-
tion properties of this agent (MXPspd). Inhalac® 
70 (IH 70) was used (MEGGLE Group, Germany) 
as a carrier. Magnesium stearate (MgSt) (Sigma-
Aldrich, Hungary) was applied as a surface modi-
fi er of the carrier. The surface treatment of the car-
rier and the adhesive mixtures were prepared by 
physical mixing with Turbula mixer (W. A. Ba-
chofen AG, Switz erland). Samples were prepared 
to contain MXP, MXPspd; and their powder mix-
tures with IH70 and IH70-MgSt. We investigated 
the particle size distribution, the morphology, the 
structure of the samples. The adhesion and cohe-
sion works were analyzed. The aerosolization eﬃ  -
cacy was determined with the Andersen Cascade 
Impactor.
RESULTS: The investigations revealed that the 
spray drying procedure resulted in amorphous, 
spherical MXP particles with 2 μm as mean size. 
The FPF (~60%) of these particles exceeds the tra-
ditional, carrier-based products (FPF 20-30%), 
which can be traced back to structure and mor-
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phology of the sample. Among these particles, 
there is a high cohesion work. Furthermore, appli-
cation of these particles of a surface modifi ed car-
rier – the novelty of this work – (which aﬀ ects the 
interparticle interactions) further improved the 
FPF (~72%) result.
CONCLUSION: The presented novel formula-
tion technology is a new milestone to further in-
crease the lung deposition of MXP, which can in-
crease the eﬀ ectiveness of CF therapy.
ACKNOWLEDGMENT: This project was sup-
ported by EFOP-3.6.2-16-2017-00006 project and 
Gedeon Richter Plc. Centennial Foundation.
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INTRODUCTION: Antibiotic delivery as dry 
powder inhaler (DPI) has been eﬃ  caciously stud-
ied for achievable clinical treatment of respiratory 
tract infections. DPIs are formulated from micron-
ized drug particles with aerodynamic particle siz-
es 2-5μm which is suitable size for depositions in 
the lungs. FDA guideline on this topic from 1998 
was updated to refl ect relevant standards and re-
quirements to enhance understanding of suitable 
development approaches for DPI consistent with 
the quality by design (QbD) paradigm. DPI appli-
cants be obliged to provide their development and 
manufacturing procedures according to all regu-
latory requirements applicable including for de-
sign control Q8(R2) and the quality target profi le 
(21 CFR 820.30(c)) along with critical quality att ri-
butes for fi nal product (21 CFR 820.30(d)). Stability 
tests have to performed as recommended by the 
international guidelines specifi ed in ICH Q1A 
(R2). The aim of recent study is to present an over-
view of DPI formulation of ciprofl oxacin hydro-
chloride (CIP) in a carrier free formulation by ap-
plying the QbD approach according to the FDA 
requirements.
MATERIALS AND METHODS: CIP was sup-
plied by Teva Pharmaceutical Company (Hunga-
ry). L-leucine (LEU) was obtained from Hungaro-
pharma Ltd.(Hungary). For preparing DPI, 1 g of 
CIP and diﬀ erent excipients in 10% aqueous etha-
nol (v/v) were dissolved and the feeding solution 
was prepared, than subsequently spray-dried us-
ing the Büchi Mini Dryer B-191 (Switz erland). The 
technical tool used for the Risk Assesment was 
LeanQbD® software (QbDWorks LLC, Fremont, 
CA, USA). After the physico-chemical character-
ization (size distribution, morphology, density), 
we determined the in vitro lung deposition (An-
dersen Cascade Impactor) and performed stability 
testing.
RESULTS: The application of LEU to the mic-
roparticles induced an enhancement in the aero-
dynamic behavior based on appropriate size and 
morphology, and also allows a very fast drug re-
lease. DPI with LEU exhibit acceptable aerosol 
performance for CIP, while maintaining FDA re-
quirement during storage.
CONCLUSIONS: Besides the adequate formu-
la development, this study confi rmed that the 
QbD-guided modern research methodology could 
be properly used in the early development phase 
of innovative formulations like DPIs and resulted 
in a risk-based and eﬀ ective product develop-
ment.
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INTRODUCTION: With an increase in number 
of generic preparations for inhalation, there is an 
increased need for new methods for their biophar-
maceutical characterization. The only compendial 
tests available are Aerodynamic assessment of 
fi ne particles and Uniformity of delivered dose. 
There is no oﬃ  cial test for dissolution of active 
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substance which can be highly important, espe-
cially for poorly soluble drugs frequently formu-
lated as inhalers [1]. Majority of described dissolu-
tion methods for inhalers don` t have discriminat-
ing power to detect diﬀ erences between diﬀ erent 
formulations with the same API [2].
MATERIALS AND METHODS: This paper de-
scribes new method for determining drug dissolu-
tion from inhalers. The apparatus employed is 
based on the modifi ed USP apparatus 5 with fl at 
bott omed dissolution vessel and disc containing 
polysaccharide gel membrane. Samples were col-
lected using the abbreviated cascade impactor so 
that dissolved substance originates exclusively 
from the fi ne particles fraction. Three commercial 
products containing beclomethasone dipropionate 
were tested. Aerodynamic assessment of fi ne parti-
cles was performed using the Ph.Eur. Apparatus E.
RESULTS: Results of aerodynamic assessment 
were used to calculate the fi ne particle mass and 
theoretical maximum of dissolved substance 
(100%). Obtained dissolution profi les were evalu-
ated using model dependent and model indepen-
dent methods. The dissolution profi les obtained 
were best fi tt ed to the fi rst order and Hixon-Crow-
ell model. Dissolution profi les comparison based 
on the similarity and diﬀ erence factors calculation 
(f1 and f2) indicated statistically signifi cant diﬀ er-
ences among the investigated products.
CONCLUSION: Dissolution method proposed 
revealed diﬀ erences in drug dissolution rate from 
three commercial inhalation products. Good ac-
cordance with the fi rst order and Hixon-Crowell 
dissolution models imply that the main infl uence 
of dissolution rate comes from drug particles of 
inhaler product. Characteristics of the dissolution 
process employed, including very low dissolution 
media volume, diﬀ usion through polysaccharide 
gel membrane, and sample composed of the fi ne 
particles fraction, highly mimic in vivo conditions 
and form good basis for confi dent biopharmaceu-
tical characterization of preparations for inhala-
tion.
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INTRODUCTION: Parkinson disease is one of 
the most frequent neurodegenerative disorder of 
the central nervous system which is the most eﬃ  -
ciently treated clinically by levodopa (LEVO) [1]. 
Intranasal route as a new approach is an alterna-
tive possibility for administration of LEVO in 
powder form compared to peroral intake [2]. The 
aim of the work was to select such excipient/addi-
tive which is incompatible with the LEVO and 
help to set the requirements for nasal powder us-
ing dry co-milling technology.
MATERIALS AND METHODS: The materials 
used were the following: levodopa (LEVO; Hun-
garopharma, Hungary), L-ascorbic acid (Bayer 
AG., Germany), alpha-cyclodextrin (Sigma Al-
drich, Hungary), D-mannitol (Sigma Aldrich, 
Hungary), hydroxypropylcellulose (HPMC; Sig-
ma Alrich, Hungary), poly(vinyl alcohol) (Sigma 
Aldrich, Hungary) and polyvinylpyrrolidone 
(PVP) (Sigma Aldrich, Hungary).
Co-milling was applied by PM 100 planetary 
ball mill (Retsch GmbH, Germany).
The samples were investigated by following in-
struments: Mastersizer 2000 (Malvern Instruments 
Ltd., Worcestershire, UK), Xray Diﬀ ractometer 
Minifl ex II (Rigaku Co. Tokyo, Japan), Avatar 330 
FT-IR spectrometer (Thermo Nicolet, USA), Mett ler 
Toledo DSC-821e instrument (Greifensee, Switz er-
land) and Agilent 1100 HPLC (LabX, Canada).
RESULTS: Target size range (5-40 μm) was 
achieved in each LEVO:additive product. Between 
of LEVO and additive, hydrogen bond was detected 
(LEVO:PVP, LEVO:L-ascorbic acid and LEVO:D-
mannitol) and eutectic mixture was formed in case 
of LEVO:L-ascorbic acid mixture. Among the prod-
ucts tested the LEVO:PVP mixture showed the fast-
est drug release (t10min=65,7 %). It was found that 
LEVO did not decompose during co-milling pro-
cess and the quantity of active agent in the products 
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did not decrease investigated according to acceler-
ated stability test (ICH Q1C guideline).
CONLUSIONS: PVP was selected as additive 
to prepare the mixture of LEVO:PVP by co-milling 
technique and this product is suggested for intra-
nasal administration. It may be a new LEWO con-
taining dosage form to ensure fast eﬀ ect in crisis 
therapy.
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INTRODUCTION: Nasal delivery receives much 
att ention as an att ractive route of drug administra-
tion. The anatomy and physiology of the nasal 
cavity are recognized as the most critical factors 
in drug delivery system design, especially muco-
ciliary clearance that limits drug-to-mucosal sur-
face contact time [1]. However, the crucial parame-
ter for the treatment outcome is drug deposition 
within the nasal cavity [2]. The purpose of this 
study is to set the basis for the development of 
sprayable in situ gelling fl uticasone delivery sys-
tem and to recognise the formulation and admin-
istration parameters with the highest impact on 
nasal deposition patt ern.
MATERIALS AND METHODS: Pectin based 
in situ gelling fl uticasone suspensions have been 
prepared using Tween 80 as a suspending agent 
and mannitol as a tonicity agent. Sodium hyaluro-
nate was evaluated as potential gel-structuring 
and bioactive formulation constituent. In situ gell-
ing systems were characterised in terms of sus-
pended particle size (Olympus BH-2 microscope, 
Japan), rheological properties (Rheometer MCR 
102, Anton Paar, Austria), sprayability/droplet size 
distribution (Malvern Spraytec, UK) and nasal de-
position patt ern (human nasal cavity model, Ko-
ken. Co. Ltd., Japan).
RESULTS: Pectin based in situ gelling fl utica-
sone suspensions have been succesfully prepared. 
Under formulation and administration parame-
ters employed, appropriate window of droplet 
size distribution and spray angle was reached re-
sulting in targeted deposition patt ern within the 
nasal cavity.
CONCLUSIONS: Screening studies revealed 
the parameters to be included in experimental de-
sign aiming to elucidate their relation with in situ 
gelling system properties/deposition patt ern. Such 
an approach potentiates the development of fl uti-
casone in situ gelling system with built-in quality 
att ributes in a cost and time-saving manner.
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INTRODUCTION: Polymeric microparticles have 
an increasing importance as drug delivery sys-
tems in the fi eld of medicine because of their con-
trolled release properties [1]. Polymeric micropar-
ticles can be applied intranasally for the delivery 
of drugs to reach the systemic circulation or di-
rectly the brain tissues [2, 3]. The aim of this study 
was to prepare and investigate synthetic polymer 
based microparticles, soluble at the pH of nasal 
mucosa, ensuring controlled release of meloxicam, 
a non-steroidal anti-infl ammatory drug.
MATERIALS AND METHODS: Eudragit® 
L30D-55 (Evonik, Germany), the aqueous disper-
sion of an anionic copolymer based on methacryl-
ic acid and ethyl acrylate with 30% dry substance 
was used as a matrix former. Empty and meloxi-
cam-containing microparticles were produced by 
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emulsifi cation/solvent evaporation method apply-
ing spray-drying (Büchi Mini Dryer B-191, Swit-
zerland). In case of drug containing samples, 
meloxicam was dissolved in dimethyl sulfoxide 
and the solution was emilsifi ed in the polymer 
dispersion using high intensity ultrasound (Hiel-
scher UP 200S Ultrasonic processor operating at 
200 W, Germany). Particle size distribution, mor-
phology, drug content and structure of micropar-
ticles, and in vitro release of meloxicam at the pH 
of nasal mucosa were determined.
RESULTS: The results revealed that microsized 
(D90 = 16.8 μm) polymeric particles had monodis-
perse particle size distribution, suiting the re-
quirements (10-40 μm), and nearly spherical shape 
in case of meloxicam containing samples. The 
drug content of microparticles was determined, 
which was approximately 70%. During the struc-
tural characterization of meloxicam containig 
products, the molecularly dispersed form of drug 
was experienced, because the charateristic peaks 
of meloxicam on the X-ray diﬀ ractogram and the 
endothermic peak of the thermoanalytical curve 
disappeared. In vitro investigation exhibited 70% 
of dissolved amount of drug in fi rst 15 min at pH 
5.6.
CONCLUSIONS: It can be concluded, that Eu-
dragit® L30D-55-based microparticles are suitable 
for intranasal application, ensuring controlled 
drug release.
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INTRODUCTION: Lamotrigine (LAM) as anti-
epileptic agent is currently used in monotherapy 
for partial seizures and bipolar disorder by tablet 
form. Its intranasal powder formulation could of-
fer an alternative administration way, due to the 
bett er adhesion and absorption ability through 
the nasal mucosa. In our previous studies we de-
termined and validated the Design Space of a dry 
milling method for producing nasal powders that 
containing nanonized LAM [1]. The aim of pres-
ent work was the in vitro and in vivo characteriza-
tion of the optimized nasal powder.
MATERIALS AND METHODS: LAM, a slightly 
water soluble antiepileptic agent was donated by 
Teva Pharmaceutical Industries Ltd., Hungary. PVA 
as water soluble synthetic polymers was purchased 
from ISP Customer Service GmBH, Germany. 
Co-grinding using a Retsch PM 100 apparatus 
(Germany) was applied for sample preparation. A 
physical powder mixture was prepared as a refer-
ence sample in the same weight ratio: 0.8. After 
the characterization of the habit and structure, we 
focused on in vitro and in vivo investigations. The 
dissolution rate of the fi nal product under nasal 
conditions were also determined at 267 nm by ATI 
UNICAM UV–VIS. In vitro permeability testing 
was performed using a Side-Bi-Side horizontal 
diﬀ usion cell (Crown Glass, USA). In vivo study 
of LAM was carried out in Sprague–Dawley rats 
(n=4). A dose of 550 μg drug per animal was ad-
ministered into the left nostril. The quantifi cation 
of the drug content in the plasma and in the brain 
was performed with a HPLC system.
RESULTS: Co-grinding of LAM with PVA pro-
duced a nasal powder formulation with around 
100 nm of LAM nanoparticles. In vitro investiga-
tions have demonstrated a fast drug liberation of 
nanosized LAM (100% after 10 min). By the in 
vivo test in the brain tissues we detected 10 times 
higher Cmax (12.322 μg/g) for nanonized LAM 
compare with the physical mixture and 2 times 
higher drug level compare with the i.v. adminis-
tration. This high Cmax value was reached at 3 min 
by nasal administration compare with i.v. admin-
istration where the Tmax was 10 min.
CONCLUSION: We observed correlation be-
tween in vitro and in vivo results therefore con-
cluded that the developed intranasal powder con-
taining nanoparticles may be a novel antiepileptic 
application form of LAM.
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INTRODUCTION: Self-emulsifying drug deliv-
ery systems (SEDDS) are water-free dosage forms 
consisting of an isotropic mixture of oils and sur-
factants. Following dilution with the aqueous me-
dia (lacrimal fl uid) with gentle agitation (as occurs 
with blinking) a fi ne oil-in-water emulsion is cre-
ated at the site of administration [1]. Vancomycin 
is a glycopeptide antibiotic indicated for severe in-
fections caused by Gram-positive bacteria. The 
substance is marketed as a powder for extempora-
neously reconstituted solution for infusion and up 
to now no ophthalmic dosage form is commercial-
ly available [2]. Current project is focusing on the 
development of ocular self-emulsifying suspen-
sion of an instable drug which requires moisture 
protection during storage. It was previously indi-
cated that SEDDS may be a promising strategy for 
ophthalmic delivery improving the shortcomings 
of entirely oil-based systems [1].
MATERIALS AND METHODS: SEDDS carri-
ers were obtained by dissolving Cremophor EL, 
Tween 20 or Span 80 in Miglyol oil (1% or 5% 
w/w). Vancomycin was incorporated in SEDDS 
(1% w/w) by grinding in a mortar (solid particles 
size < 25 μm). The self-emulsifi cation performance 
upon dilution with deionized water was evaluat-
ed visually. Microscopic images of placebo, van-
comycin-loaded and reconstituted SEDDS formu-
lations were obtained using fl uorescent micro-
scope (Nikon Eclipse i50, Tokyo, Japan).
RESULTS: The SEDDS suspensions diluted 
with water were reported to spontaneously form 
fi ne emulsions exhibiting an immediate dissolu-
tion of vancomycin. Individual systems diﬀ er 
slightly upon two features: reconstitution time 
and mean droplet size. Preliminary studies re-
vealed that the formulations should meet the re-
quirements for storage stability. The full chemical 
stability studies are ongoing. The appropriate 
HPLC analytical methodology has been devel-
oped for vancomycin quantitative determination.
CONCLUSIONS: The developed formulations 
seem feasible and might be further assessed with 
other methods (e.g. microbial assay). Subsequent 
research will focus on obtaining detailed formula-
tion characteristics which are indispensable to be 
determined before proceeding to in vivo testing.
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ibuprofen-loaded cationic nanoemulsion using 
3D in vitro corneal model
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INTRODUCTION: Dry eye disease is a multifac-
torial disease of the ocular surface characterized 
by instability and increased osmolarity of the tear 
fi lm, ocular surface infl ammation and damage [1]. 
Current strategies are focused on the development 
of O/W nanoemulsions since their nanosized lipid 
dispersed phase can improve the tear fi lm stabili-
ty [2]. Moreover, cationic nanoemulsions bear the 
poteintial to increase both, precorneal drug resi-
dence time and corneal epithelium related absorp-
tion. Current project is focused on the develop-
ment of ibuprofen-loaded cationic nanoemulsion 
optimized for its biocompatibility and therapeutic 
potential using 3D in vitro cell model.
MATERIALS AND METHODS: Nanoemul-
sions were produced using microfl uidizer (Model 
M-110EH-30, Microfl uidics, USA). The oil phase 
was composed of Mygliol 812, lecithin S45 and 
ibuprofen, and the aqueous phase of Cremophor 
EL, low molecular weight chitosan, glycerol and 
water. Nanoemulsions were characterized in 
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terms of droplet size and zeta potential (Zetasizer 
3000 HS, Malvern Instruments, UK), pH, osmolar-
ity, in vitro release and stability. 3D in vitro model 
based on human corneal epithelial cells (HCE-T, 
Rikken, Japan) was used in biocompatibility, mu-
coadhesion and therapeutic potential screening.
RESULTS: Within this project, formulation and 
process parameters of nanoemulsion preparation 
have been optimized. Ibuprofen-loaded cationic 
ophthalmic nanoemulsions with droplet size of 
163,3 ± 0,7 to 185,0 ± 2,1 nm, polydispersity index 
of 0,11 ± 0,02 to 0,21 ± 0,02 and zeta potential of 
16,4 ± 0,6 to 36,5 ± 1,4 mV have been successfuly 
prepared. Chitosan coating was shown to provide 
pronounced mucoadhesivity while showing com-
patibility with 3D HCE-T cell model.
CONCLUSION: This study showed the poten-
tial of cationic nanoemulsions to be developed 
into a value-added delivery platform of ibuprofen 
for eﬃ  cient symptomatic and causative dry eye 
disease treatment.
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INTRODUCTION: Ninety percent of the oph-
thalmic formulations on the market are eye drops 
and ointments thanks to their simple administra-
tion. These formulations have very low, 2%–5% 
bioavailability. Steroidal anti-infl ammatory drugs 
are lipophilic drugs; they dissolve very poorly in 
water. The water solubility can be improved with 
cyclodextrins (CD).
The aim of this work was to combine the advan-
tages of CD and a mucoadhesive thiolated polymer, 
thiolated poly(aspartic acid) (PASP-CEA) by the 
chemical immobilization of CD onto PASP-CEA.
MATERIALS AND METHODS: PASP-CEA 
was functionalised with 6-deoxy-6-monoamino-β-
cyclodextrin (MABCD). The formation of the CD-
drug complex in the gels was analyzed by X-ray 
powder diﬀ raction. The ocular applicability of the 
polymer was characterized by means of physico-
chemical, rheological and drug diﬀ usion tests. Os-
molality, refractive index, and pH were measured 
in aqueous solutions of PASP-CEA and PASP-CEA-
CD [1]. The drug diﬀ usion profi le of PR was deter-
mined with a vertical Franz diﬀ usion cell system.
RESULTS: The solubility of PR increased lin-
early as the CD concentration increased. The X-
Ray diﬀ ractogram of the formulations showed an 
amorphous patt ern. The osmolality, pH and re-
fractive index of the polymer solution confi rmed 
the ocular acceptability of the formulations. 
During the rheological investigations, the 
PASP-CEA solution displayed a fast solution-to-
gel transition in the presence of an oxidant. The 
immobilization of MABCD on the polymers did 
not hinder the gelation process.
The complexation of PR with CDs improves PR 
solubility in aqueous medium. The complexes dif-
fuse in the formulation and can carry the PR mol-
ecules through the aqueous mucin layer [2]. The 
PASP-CEA-CD-PR complex prolonged the drug 
diﬀ usion through synthetic and improved it 
through amniotic membrane [3].
CONCLUSIONS: The chemical bonding of 
MABCD to the PASP-CEA polymer did not 
change the complexation of the CD with PR, while 
the hydrogel preserved its mucoadhesion. The dif-
fusion studies indicated that the grafting pro-
longed the drug release and the best release pro-
fi le was obtained with the combination of free and 
grafted CD.
ACKNOWLEDGEMENT: The authors wish to 
thank CycloLab Ltd. (Budapest, Hungary) for pro-
viding the samples of MABCD.
REFERENCES 
1.  Budai-Szűcs et al. Eur. J. Pharm. Bio-
pharm.113, 178187 (2017)
2. Loftsson et al. Int. J. Pharm. 225, 1530 (2001)
3. Budai-Szűcs et al. Polymers (Basel) 10, (2018)
P3/13
Formulation of steroid containing eye drops 
with cyclodextrin derivatives and mucoadhesive 
preservative system
BÍRÓ, T.1, HORVÁT, G.1, BOCSIK, A.2, GRÓF, 
I .2, URBÁN, E.3, DELI, M.2, CSÁNYI, E.1, 
SZABÓ-RÉVÉSZ, P.1, CSÓKA, I .1, AIGNER, Z.1 
ACTA-1803-CESPT.indb   139 2018. 09. 10.   10:12
140 Acta Pharmaceutica Hungarica – CESPT Edition – Posters  2018/3.
1Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary;
2Biological Research Centre HAS, Institute of Biophysics, 
Szeged, Hungary
3Department of Clinical Microbiology, University of Szeged, 
Szeged, Hungary
INTRODUCTION: For the purpose of increasing 
the eﬃ  ciency of the ocular drug delivery, the en-
hancement of water-solubility and the contact time 
of the drug are essential [1]. The most commonly 
used preservative is benzalkonium-chloride (BK). 
The cornea-cell apoptosis and irritation inducing ef-
fects of BK are already published. An alternative ad-
ditive, like Zn-containing materials, could replace 
BK, due to the antimicrobial eﬀ ect of Zn2+-ion [2]. In 
this work, prednisolone (PR) containing eye drops 
were formulated with mucoadhesive, preservative 
zinc-hyaluronate (ZnHA) and PR-cyclodextrin inclu-
sion complex, which approach can be used for the 
development of innovative eye drop formulations.
MATERIALS AND METHODS: The PR-
hydroxypropyl-β-cyclodextrin (HPBCD) and PR-
hydroxypropyl-γ-cyclodextrin (HPGCD) complex-
es were investigated by phase solubility study. The 
cytotoxicity of the samples was tested on human 
corneal epithelial cell lines (HCE-T) by MTT-test 
and impedance-based cytotoxicity assay. The per-
meation of PR was studied in vitro using dialysis 
membrane and HCE-T cell line. The mucoadhesive 
force was measured by tensile-test. The antimicro-
bial eﬀ ectiveness was tested by a standard method 
of the European Pharmacopoeia (EP).
RESULTS: PR-cyclodextrin complex formation 
can be assumed according to the phase-solubility 
test. The determined apparent stability constant of 
PR-HPGCD is higher than in the case of the PR-
HPBCD inclusion complex. The data of cytotoxicity 
test on HCE-T cell lines are acceptable, such as the 
microbiological stability, which meets the require-
ment of EP. The in vitro drug-permeability assay 
shows the increased penetration of PR through the 
dialysis membrane and HCE-T cell line. According 
to the tensile-test, the mucoadhesive properties of 
the ZnHA containing samples could prolong the 
therapeutic eﬀ ect on the eye surface.
CONCLUSION: Considering the results, it can 
be stated that our work could be an innovative ap-
proach for the development of novel, steroid con-
taining, mucoadhesive, properly preserved oph-
thalmic solutions with increased bioavailability.
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INTRODUCTION: Incorporation of mucoadhe-
sive polymers is one of the most used strategies to 
prolong the residence time between the ocular ve-
hicles/lubricants and ocular surface. Improvement 
in residence time aims to decrease the frequency 
of the lubricant administration [1]. The aim of this 
study was to develop ocular lubricants with ap-
propriate physicochemical and mucoadhesive 
properties containing hydroxypropyl guar gum 
and chitosan.
MATERIALS AND METHODS: Compounded 
ocular lubricants containing HP-guar (HP GG; 
0.25 %, 0.5 %, 1.0 %), medium molecular weight 
chitosan (MCS; 0.5 %) and their combination HP 
GG 0.25 %/MCS 0.5 % were investigated. The 
commercial eye drops Systane® Ultra Lubricant 
(SU) containing HP GG were also tested. The for-
mulations were evaluated for clarity, pH and os-
molality. The viscosity measurements were per-
formed using a rotational rheometer at 20 and 34 
°C (after addition of the simulated tear fl uid-STF) 
in a ratio of 40:7. Potential mucoadhesive proper-
ties were investigated using turbidimetric and 
mucin-particle method [2]. The mucoadhesiveness 
of the polymer solutions was estimated by calcu-
lation of mucoadhesion index [3].
RESULTS: The pH and osmolality were within 
the acceptable range for ophthalmic preparations. 
All formulations were clear, except formulation 
with 1.0 % HP GG. The formulation containing 
combination of polymers (HP GG/MCS) showed 
signifi cantly higher viscosity (49.6 mPa•s) than 
viscosities of formulations with single polymer 
(7.4 mPa•s for HP GG and 6.8 mPa•s for MCS). 
After dilution with STF, a 2-fold increase in vis-
cosities of formulation with 0.25 % HP GG and SU 
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drops were observed. The both turbidimetric and 
mucin-particle method revealed that combination 
of MCS and HP GG had synergistic eﬀ ect on mu-
coadhesion of this solution. Mucoadhesion index 
of HP GG/MCS formulation (63.3 %) was higher 
than for the vehicle containing only MCS (31.3 %).
CONCLUSION: The formulation containing 
combination HP GG 0.25 %/MCS 0.5 %, may be 
considered as a promising ocular lubricant with 
optimal viscosity and mucoadhesive properties. It 
can be concluded that HP GG and MCS show pos-
itive synergistic eﬀ ect and addition of HP GG re-
sulted in bett er mucoadhesive properties of this 
ocular lubricant.
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INTRODUCTION: Parenteral nanoemulsions 
(NEs) containing PEG-ylated phospholipids (PEG-
PLs) can increase target site concentration of the 
incorporated active substance by increasing circu-
lation time of the oil droplets. The aim of this 
study was to develop PEG-ylated NEs (PEG-NEs) 
with the smallest droplet size and size distribu-
tion using the experimental design strategy.
MATERIALS AND METHODS: PEG-NEs 
were prepared by high pressure homogenization 
method at 50°C. Oil phase (soybean oil, benzyl al-
cohol, medium chain triglycerides, soybean leci-
thin and butylhydroxytoluene) was added to wa-
ter phase (glycerol, polysorbate 80, sodium oleate 
and highly purifi ed water) and homogenized with 
high-pressure homogenizer (EmulsiFlex-C3, Aves-
tin Inc., Canada). PEG-PL – PEG2000-DSPE/
PEG5000-DPPE, was added to the oil or water 
phase at 0,1%/0,3% concentration. A D-optimal 
factorial experimental design was used to estimate 
main and interaction eﬀ ects of two formulation 
factors (PEG-PL type and concentration) and two 
process variables (homogenization pressure – 500 
bar/800 bar, and number of cycles – 5/10/15) on 
NE droplet size (Z-Ave) and polydispersity index 
(PDI). To fi t the experimental data, the fi rst-order 
polynomial model was applied. Results obtained 
for each response were statistically evaluated us-
ing Design-Expert software (Stat-Ease Inc., MN). 
Zeta potential (ZP) was also measured in order to 
assess the stability of PEG-NEs.
RESULTS: Concordant with applied experi-
mental design, 25 NE formulations were prepared. 
Mean droplet size of all NEs was in the range of 
105–172 nm, with PDI below 0.2 and ZP about –40 
mV, suggesting that developed NEs were suitable 
for parenteral use. Experimental design results 
showed that generated models for Z-Ave and PDI 
of NEs were signifi cant (p<0.05), indicating that 
these responses were well described by the pro-
posed models. Further, not only investigated fac-
tors alone, but also their interactions were shown 
to signifi cantly aﬀ ect NE characteristics.
CONCLUSIONS: This study shows the useful-
ness of D-optimal factorial design in NE develop-
ment. Both investigated PEG PL types and con-
centrations homogenized for 10 cycles at 800 bars 
showed the best results and were selected for fur-
ther NE research. 
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INTRODUCTION: 2D and 3D printing methods 
are of emerging interest in the pharmaceutical in-
dustry, since their oﬀ er enormous advantages 
from the aspect of dosing accuracy, modifi cation 
of the drug release kinetic and personalized medi-
cine [1]. Genina et al. revealed that the ink param-
eters (e.g spreading on non-porous substrates) 
may infl uence both printing accuracy and the be-
haviour and stability of the printed drugs [2]. Cur-
rent project is focusing on the investigation how 
the physicochemical characteristics of the applied 
medicated ink infl uence the printing and dosing 
accuracy, the penetration into and the distribution 
inside a porous substrate.
MATERIALS AND METHODS: PVP K25 and 
Polysorbate 80 was used for sett ing of the viscosi-
ty and surface tension of the ink according to 32 
full factorial design, which contained brilliant 
blue dye as model material to help to follow the 
ink distribution of the texture of carrier matrix. 13 
mm in diameter tablets with diﬀ erent porosity 
were compressed from Pearlitol SD200 (Roquett e, 
France) lubricated with 1% of magnesium stearate 
using a hydraulic press (Specac, UK) and 2, 3, 4 
and 5 tons compression force. The surface tension 
and spreading parameters of the ink on the sub-
strate surface was tested with an optical contact 
angle tester (OCA20, Dataphysics, Germany). The 
printing experiments were conducted with a self-
developed printing apparatus.
RESULTS: The results revealed that the viscosi-
ty plays considerably higher role in the ink behav-
iour than surface tension. The highest dose/print-
ing time was achieved with inks with high viscos-
ity and surface tension, however this combination 
acts negatively on printing accuracy since the 
drop formation is not balanced with the trigger 
signal. Low viscosity promotes the ink penetra-
tion into the substrates which acts positively on 
the printing and drying speed but aﬀ ects the 
printing patt ern negatively especially in highly 
porous substrates.
CONSLUSION: There are complex interrela-
tions between ink parameters and properties of 
porous substrates, which allows multiple ways for 
tailoring individualized delivery systems.
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INTRODUCTION: 3D printing is a modern 
method which can be used in numerous areas for 
example in the industrial pharmacology. With the 
use of 3D printing complex and personalized 
products can be made on-demand. The examined 
implants are manufactured by fused deposition 
modelling 3D printing technique at the University 
of Claude Bernard, Lyon.
MATERIALS AND METHODS: Our aim was 
to determine the biocompatibility of the implants 
because implanted devices must be biologically 
compatible with the tissues. The aim is to maxi-
malise the benefi t and minimize the risk [1]. Bio-
compatibility can be examined by MTT cell viabil-
ity test and biofi lm formation [2-3]. Another aim is 
to gain information about the structure of the im-
plants. Material structure can be examined by 
PALS (positron annihilation lifetime spectrosco-
py) this results will determine the free volume in 
the implants.
RESULTS: The implants were not only made 
up by diﬀ erent polymers but eight diﬀ erent side 
chain was connected by a chemical reaction to the 
base frame. More than 45 diﬀ erent implants were 
examined. Our results indicate how this modifi ca-
tion eﬀ ect the cytotoxicity and biofi lm forming 
ability of the implants.
CONCLUSIONS: Based on the results we can 
select the best implants which are appropriate to 
further examinations.
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INTRODUCTION: The three dimensional print-
ing (3DP) in the pharmaceutical domain consti-
tutes an alternative, innovative approach com-
pared to the conventional production methods. 
With roots in engineering, it was considered for 
pharmaceutical applicability based on the need to 
improve product quality and enable therapeutic 
personalization. Fused deposition modelling 
(FDM), is a simple, cost-eﬀ ective 3DP technique, 
however the FDM apparatuses are adapted for re-
stricted number of commercially available fi la-
ments, that are either non-biocompatible or yield 
limited dissolution kinetics. The transfer of phar-
maceutical polymers to FDM desktop printers is 
possible [1, 2], but the technological barriers are 
yet to be established. The study set to defi ne the 
requirements of the FDM printability, using as 
technical support custom made, pharmaceutical 
polymer based fi laments. The therapeutic suitabil-
ity of the 3DP tablets was assessed with regards to 
assuring a once a day posology.
MATERIALS AND METHODS: Carvedilol 
was used as a model API. Several retard polymers 
with known applicability in hot melt extrusion 
(HME) were tested, the actual screening process 
constituting the FDM printability. Unassociated 
polymers were compared with polymeric blends 
in terms of productivity. The technological pro-
cess implied the use of FDM (Craftbot Plus, Craf-
tunique, Hungary) coupled with HME (Haake 
Minilab, Thermo Fisher Scientifi c, USA). Printabil-
ity was defi ned by means of thermal, rheological 
and mechanical measurements. The resultant 3DP 
tablets were tested for API crystal form and in vi-
tro dissolution kinetics.
RESULTS: Results showed that FDM printabili-
ty is multifactorial, with britt leness, melt viscosity 
and fl exibility as primary limitation factors. Up to 
65000 Pa*s (at 0.1 rad/s angular frequency) com-
plex viscosities can be transferred to FDM, how-
ever, the upper viscosity limits require optimal 
fl exural modulus values for productivity. The 3DP 
tablets released the API in an extended rate, com-
parable to the Coreg CR (carvedilol phosphate) 
dissolution kinetics.
CONCLUSIONS: Manufacturability and quali-
ty are dependent upon printability. Polymeric 
blends, with printability improvement, enable 
broader processing conditions. HME+FDM shows 
potential of consistent quality by the reduction in 
critical material att ributes and process parameters.
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INTRODUCTION: Fused deposition modeling 
(FDM) is a method of fi lament deposition that in-
volves successively melting and cooling thermo-
plastic materials [1]. Three-dimensional printing 
(3DP) technology is based on computer designs 
and it is an eﬀ ective strategy to overcome some 
problems of conventional pharmaceutical forms, 
such as poor dose fl exibility [2].
MATERIAL AND METHODS: Firstly, fi la-
ment with Hydrochlorothiazide, Hypromelosis 
and Polyvinyl Alcohol (PVA), at a weight ratio of 
10:10:80, was made in Filabot EX2 Filament Ex-
truder (Filabot, SAD). The selected size (X=10 mm, 
Y=10 mm and Z=3.885 mm) and shape of the 
printlets were designed with UltimakerCura 3.2.1 
software. Printlets were fabricated with the previ-
ously drug-loaded fi laments using a fused-deposi-
tion modeling (FDM) 3D printer Ultimaker 3 (Ul-
timaker B.V, Netherlands) with infi ll 100% and 
line patt ern. During printing, printing tempera-
ture and speed were varied according to D-opti-
mal design (Design Expert 7.0.0, StatEase.). The 
temperature varies from 180 to 250 degrees, and 
ACTA-1803-CESPT.indb   143 2018. 09. 10.   10:12
144 Acta Pharmaceutica Hungarica – CESPT Edition – Posters  2018/3.
printing speed from 50% to 100%. Total number of 
experiments were 11.
RESULTS: Prerequisite of successful and repro-
ducible printing is consistent fl ow through the 
FDM 3D printer nozzles. Commercial fi laments 
were not used during the experiments and this led 
to the clogged nozzles if the temperature of print-
ing was not appropriate, so the nozzles must be 
cleaned more often than usual. The best printlets 
were fabricated when printing temperature was 
215 degrees and printing speed 50%. With other 
temperature and speed values, printing was un-
successful. The average weight of the printlets ob-
tained under the best conditions was 0.1805 mg, 
average length was 9.57 mm and average thick-
ness 3.7 mm. The tablet strength data show values 
between 72 and 140 N.
CONCLUSION: In this study, we represent 
that printing temperature and speed are critical 
parameters that enable successful fabrication of 
printlets. It is necessary to fi nd optimal process 
parameters for every type of fi lament, where ex-
perimental design can be useful method for defi n-
ing parameters of interest.
ACKNOWLEDGMENT: This work was sup-
ported by the Ministry of Education, Science and 
Technological development of Republic of Serbia 
under the project TR 34007.
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INTRODUCTION: Fused deposition modeling 
(FDM) is an extrusion-based 3D printing tech-
nique easily accessible, versatile, low-cost and 
shows good potential for fabrication of single-unit 
dosage forms [1]. FDM allows variation of the 
type, dose, and distribution of the active ingredi-
ent as well as the size, shape, geometry, and densi-
ty of the fi nal product [2]. Because of the increas-
ing interest for FDM in the pharmaceutical re-
search area, the development and fabrication of 
fi laments with active ingredient have become very 
important. Widely used technique for incorporat-
ing the active ingredient into the fi lament is hot-
melt extrusion (HME). The aim of this paper is to 
produce fi laments containing active ingredient 
and 3D printing of the tablets using FDM technol-
ogy.
MATERIALS AND METHODS: Mixtures of 
dronedarone hydrochloride (DNR), poly(ethylene 
glycol) (PEG) and poly(vinyl alcohol) (PVA) fi la-
ment in various proportions were used. The mix-
tures are prepared as a mixture of powders and as 
a solid dispersion. Melt fl ow rate of mixtures and 
thermogravimetric analysis of DNR were per-
formed. The fi laments were produced by HME. 
Diameter of prepared fi laments was measured 
and swelling test was performed. Thermal proper-
ties of fi laments and prepared mixtures were ex-
amined using diﬀ erential scanning calorimetry. 
Prepared fi laments were used for 3D printing of 
tablets by FDM. An in vitro drug release assay 
was performed from the obtained tablets. The con-
tent of dronedarone in fi laments and tablets was 
determined using UV/Vis spectrophotometry.
RESULTS: The results indicate that the 10% 
PEG-containing solid dispersion mixture has the 
highest melt fl ow rate. The fi lament prepared 
from a solid dispersion containing 10 % PEG has 
the most straightforward structure; it shows the 
slightest deviation from the target fi lament diam-
eter (1.75 mm). The compact structure of the tablet 
obtained from the fi lament contributes to a uni-
form in vitro release of the DNR from matrix dur-
ing 24 h. It also shows the slightest deviation from 
the targeted DNR content in the tablet.
CONCLUSION: According to all observed 
properties, a blend containing 10% PEG, 10% 
DNR and 80% PVA fi lament is most appropriate 
for HME and FDM tablet printing.
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INTRODUCTION: Periodontitis is a chronic in-
fl ammatory disease aﬀ ecting the gingiva. Anaero-
bic bacteria have a major role in its development. 
Being the most prevalent cause of adult tooth-loss 
without a properly eﬀ ective therapy, a convenient 
method is needed for the treatment of the disease. 
The aim of the recent research was to create a sub-
gingivally employable lipid based delivery system 
for the local delivery of antibiotics.
MATERIALS AND METHODS: For the prepa-
ration of the formulations lipid bases, waxes as 
structure-building components, a surfactant, poly-
mers and diﬀ erent antimicrobial agents were 
used. Various methods were used to fi nd the opti-
mal composition of the systems. The physical 
properties were characterized by diﬀ erential scan-
ning calorimetry, wett ability, swelling and degra-
dation measurements and cone penetration tests. 
Drug release measurements and antimicrobial 
tests were carried out to evaluate the eﬀ ectiveness 
against oral pathogen bacteria and to assess the 
possibility of sustained release.
RESULTS: Results of DSC measurements show 
that at higher wax concentrations, total melting of 
the systems can be avoided, and a soft but coher-
ent structure may be present at body temperature. 
According to the results, the concentration of the 
surfactant may not have remarkable infl uence on 
the melting point of formulations.
Higher concentrations of the surfactant increase 
the wett ability and decrease the consistency of the 
systems, while increasing the amount of the wax 
does the opposite.
Swelling and degradation measurements indi-
cate that a minimum concentration of wax is need-
ed and the higher the concentration of the wax the 
lower the degree of swelling and slower the deg-
radation.
The results of the drug release tests show that 
with a higher concentration of wax, sustained re-
lease of drugs and, together with the results of an 
antimicrobial study, a one-week antimicrobial ef-
fect against oral pathogen bacteria may be possi-
ble.
CONCLUSION: The optimal concentration of 
the components allows sustained release of antibi-
otics, which may provide a long-lasting antimicro-
bial eﬀ ect and can contribute to the establishment 
of an eﬀ ective and convenient therapy.
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INTRODUCTION: Periodontitis is a chronic in-
fl ammation of the teeth supporting tissues, in-
volving endogenous collagenolytic enzymes, es-
pecially matrix metalloproteinase 8 (MMP-8) [1]. 
Topical application of active principle directly into 
the periodontal pocket represents a satisfactory 
approach, presents many advantages and involves 
the use of a controlled release device with muco-
adhesive properties [2]. Phytoconstituents as fl a-
vonoids, catechins, saponins, tannins, essential 
oils can have a high anti-infl ammatory and anti-
oxidant potential and they could exert an eﬀ ect of 
inhibiting MMP-8 activity at the periodontium 
level.
MATERIALS AND METHODS: The purpose 
of this work was to formulate a nanoparticulate 
mucoadhesive polyherbal gel (NMPH gel), based 
on Echinacea purpurea, Camelia sinensis, Filipen-
dula ulmaria and Calendula oﬃ  cinalis extracts 
and to evaluate in vivo eﬃ  cacy regarding clinical 
parameters, histopathology and immunologic 
profi les (serum and salivary levels of MMP-8). 
The designed NMPH gel formulation consisting 
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of Carbopol 940 and Kolliphor P407 was prepared 
and evaluated regarding the rheological proper-
ties and in vitro adhesive capacity (assessed by 
measuring the time of detachment of the sample 
from a synthetic membrane). The total polypheno-
lic content of the polyherbal extract was estimated 
using Folin-Ciocalteu reagent and the content of 
epigallocatechin-3-gallate was analysed by HPLC 
coupled with Mass Spectrometry. The in vivo test-
ing of the NMPH gel was performed using an ex-
perimental model of induced periodontitis in rats, 
by placing the ligatures around the inferior inci-
sor.
RESULTS: The studied NMPH gel showed rhe-
ological and in vitro adhesion properties suitable 
for application in the periodontal pocket that can 
provide adherence to the gum for a prolonged pe-
riod of time, ensuring an increased concentration 
in total polyphenols at this level. The experimen-
tal results showed that topical application of de-
signed NMPH gel reduced the local infl ammatory 
response induced by periodontitis, led to clinically 
and histopathologically healing of gingival lesions 
and determined a decrease in serum and salivary 
levels of MMP-8.
CONCLUSION: The results suggest that the 
prepared NMPH gel may be favorable for topical 
application in periodontal therapy.
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Preparation of mucoadhesive alginate fi lms – 
comparison of solvent casting and freeze thaw 
method
SZEKALSKA, M., CHYŻY, A., WINNICKA, K.
Department of Pharmaceutical Technology, Medical University 
of Białystok, Białystok, Poland
INTRODUCTION: Mucoadhesive fi lms are rela-
tively new drug dosage form, which might be ap-
plied to the oral, buccal, gingival and vaginal mu-
cosa. They are designed for drugs characterized 
by poor absorption or having local action. Proper-
ties of fi lms are signifi cantly aﬀ ected by method 
of preparation and type of polymer [1, 2]. Sodium 
alginate (ALG) is natural, non-toxic and biocom-
patible polymer from polysaccharides group. Due 
to its unique properties – gelation, swelling and 
mucoadhesion – ALG is a valuable excipient used 
to design various drug dosage forms [3]. In order 
to improve polymer properties, cross-linking us-
ing diﬀ erent methods might be conducted. Novel 
method of ALG gelation includes freeze-thaw 
technique [4]. In this work, ALG fi lms were pre-
pared by solvent casting and freeze thaw method 
and the infl uence of preparation technique on the 
properties of obtained formulations was exam-
ined.
MATERIALS AND METHODS: In the fi rst 
step, mixtures containing diﬀ erent concentrations 
of ALG (1%, 2%, 3%) and glycerol (used as plasti-
cizer) were prepared and poured into plexiglas 
moulds. In the freeze thaw method freezing at 
-20°C for 18 h and thawing at room temperature 
for 6 h, for three consecutive cycles were conduct-
ed [5]. After drying, fi lms were cut into pieces of 
2×3 cm. Obtained formulations were evaluated for 
size, morphology, thickness, mechanical proper-
ties and swelling degree. Mucoadhesiveness of the 
fi lms was evaluated using bovine buccal mucosa 
to imitate in vivo conditions.
RESULTS: ALG fi lms prepared using both 
methods were characterized by weight, size, and 
thickness uniformity. However, fi lms formulated 
by freeze thaw method possessed bett er mechani-
cal, swelling and mucoadhesive properties.
CONSLUSION: Designed ALG fi lms fulfi ll the 
criteria for mucoadhesive formulations and seem 
to be promising dosage form for local drug ad-
ministration.
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Formulation of an innovative buccal 
mucoadhesive drug delivery system with 
sodium alginate polymer fi lm
PAMLÉNYI, K., SOVÁNY, T., KRISTÓ, K., 
REGDON, G. JR.,
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INTRODUCTION: Mucoadhesive systems such 
as oral mucoadhesive fi lms have an increasingly 
greater role in the pharmaceutical industry. These 
systems make the application easier for the pa-
tients because patients do not have to swallow 
them. It is a very important viewpoint, for exam-
ple, in the case of children or persons who have a 
swallowing problem. Another advantage of these 
drug delivery systems is that they do not have a 
fi rst-pass eﬀ ect in the liver because active sub-
stance absorption takes place from the buccal mu-
cosa, so it enters the systemic circulation. The cur-
rent project is focusing on preparing oral mucoad-
hesive fi lms, which are suitable for binding to the 
buccal mucosa and for providing the absorption 
of the active substance.
MATERIALS AND METHODS: Sodium-algi-
nate was used to make a polymer fi lm. This fi lm 
was made in 2, 3, 4 w/w% concentrations with dis-
tilled water. Later the other polymer solution con-
tained glycerol. Glycerol was used in 1, 3, 5 w/w% 
as plasticizer in the polymer fi lms. The formula-
tion was made in 2 steps. On the fi rst day we pre-
pared the polymer solution from sodium alginate 
and distilled water and mixed it with 80 rpm. The 
following day we added glycerol and ho-
mogenised and moulded it in a rubber ring. The 
rubber ring contained 8 g and 10 g of polymer so-
lution. The dried, ready polymer fi lms were inves-
tigated, the thickness of the fi lms was examined 
with a screw thread micrometer and tensile 
strength was tested with a device and software 
developed in our Institute (Szeged, Hungary).
RESULTS: The investigation revealed the 
4w/w% sodium-alginate polymer fi lms had too 
much viscosity and were easily broken. When we 
used glycerol, the fi lms were fl exible. The results 
showed that the plasticizer has a great role in the 
structure of polymer fi lms. The strength force of 
the polymer fi lms which contained glycerol was 
lower but their thickness was higher than without 
glycerol.
CONCLUSION: In the case of a high sodium-
alginate concentration, the fi lms are too fragile 
and have greater thickness. When using a high 
glycerol concentration, the fi lms are very fl exible 
and thicker than in the case of a high sodium-algi-
nate concentration. The optimal structure was ob-
tained by using 3w/w% sodium-alginate and 
3w/w% glycerol.
P4/10
Structural and thermoanalytical analysis of 
innovative, chitosan based mucoadhesive fi lms
MÓDRA, SZ.1, SOVÁNY, T.1, SÜVEGH, K.2, 
KRISTÓ, K.1, REGDON, G. JR.1 
1Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary;
2Laboratory of Nuclear Chemistry, Eötvös Lóránd University, 
Budapest, Hungary
INTRODUCTION: Nowadays, mucoadhesive 
buccal fi lms are in the foreground because they 
are easy to apply, and with this formulation we 
can avoid the fi rst pass eﬀ ect, which causes that a 
lower amount of active ingredient can reach the 
same eﬀ ect. Our aim was to examine the structure 
and the thermoanalytical properties of the fi lms.
MATERIALS AND METHODS: During the 
formulation of mucoadhesive fi lms, we used chi-
tosan (CH) as the polymer basis of the fi lm. Ascor-
bic acid (AscA), which provided the acidic pH, be-
sides its permeation enhancer properties, was 
used in diﬀ erent concentrations (2-5%). We com-
pared the AscA eﬀ ects on the properties of these 
fi lms to fi lms made with acetic acid (AA). Glycerol 
(Gly) was used as a plasticizer. The fi lms were for-
mulated by the solvent casting method. We exam-
ined the free volume of the fi lms with positron an-
nihilation lifetime spectroscopy (PALS), and the 
Fourier transform infrared spectrometer (FTIR) 
spectra give us useful information as well. The 
thermoanalytical examination includes TG-MS 
and DSC measurements.
RESULTS: The PALS and the FTIR spectra 
show us that the higher amount of AscA cannot 
build into the structure of the fi lms, the free vol-
ume increases, which is confi rmed by the FTIR 
spectra. We detected the thermoanalytical curves 
of the main substances and the fi lms, which gives 
us further information about the structure and the 
thermal degradation.
CONCLUSIONS: The optimal AscA amount is 
the lower concentration when the dissolution is 
provided by the acidic pH, but it still can build 
into the structure of the fi lms.
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Design, Development and Characterization of 
Chitosan Film as Eﬀ ective Oral-Macromolecule 
Delivery System Using New Multifunctional 
Plasticizer
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INTRODUCTION: Nowadays, numerous bioac-
tive proteins and peptides are going through clin-
ical trials and more than 30 have been approved 
by the FDA for commercialization [1]. However, 
the transportation of protein drugs in the body is 
limited because of their high molecular weight 
and to their short life-time due to immune re-
sponse and enzymatic degradation [2]. The use of 
chitosan as a delivery system may improve the 
oral bioavailability of proteins via the protection 
against the GI environment and ensure appropri-
ate residence time at the absorption site due to its 
mucoadhesive properties [3]. Citric acid (CA), may 
serve as solubility enhancer, plasticizer, perme-
ation enhancer and also inhibits intestinal serine 
proteases [4].
MATERIALS AND METHODS: Chitosan 
80/1000 (Heppe, Germany), acetic acid (AA) and 
CA were used as solubility enhancer, glycerol, 
propylene glycol and polyethylene glycol were 
used as plasticizers, mucin as reagent for the mu-
coadhesive test and all other used reagents were 
of analytical grade. Chitosan fi lms were prepared 
by dissolving the polymer (2% w/v) prepared 
with the use of acetic acid (2% v/v) as prescribed 
by Liu et al [5] as reference and with the use of cit-
ric acid (2-7 w/v%). The solutions were cast onto 
Tefl on surface and then dried at room tempera-
ture for 24 h. The minimal fi lm forming tempera-
ture of the fi lms was investigated with a Rhopoint 
Rhopoint, UK, the hardness and mucoadhesive 
properties were measured with a self-developed 
texture analyzer.
RESULTS: The results revealed that CA is an 
eﬀ ective solubility enhancer and plasticizer for 
chitosan, which produces thicker but more fl exible 
and adhesive fi lms in comparison with AA based 
chitosan fi lms.
CONCLUSION: It could be concluded that CA 
is a novel multifunctional plasticizer for chitosan, 
to develop oral fi lms or drug layering/coating of a 
solid dosage forms of macromolecules.
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Quality By Design Approach for Optimizing 
The Formulation And Characterization of 
Prepared Buccal Films
AKSU, N. B.1, HÖKENEK, N.2, YEGEN, G.1, 
ÜSTÜNDAG OKUR, N.2 
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INTRODUCTION: Quality by design (QbD) is a 
systematic approach to optimize pharmaceutical 
preparations and to improve the control over and 
the quality of the production process. The quality 
by design approach consistently yields a product 
with desired characteristics and built in quality 
[1]. The aim of the study is to optimize the charac-
terization results of the prepared buccal fi lm for-
mulations with QbD.
MATERIALS AND METHODS: Chitosan (1% 
w/v), sodium alginate (1% w/v) and carbopol 
(0.5% w/v) were used as polymers in combination 
and individually. Glycerine, PEG 400 and propyl-
ene glycol as plasticizing agents are mixed with 
the polymers at diﬀ erent ratios (5%, 10%, 15%, 
20% w/v). Buccal fi lm formulations were prepared 
by using solvent casting technique [2]. The fi lms 
were characterized by using Critical Quality att ri-
butes (CQA’s), moisture loss, thickness, uniformi-
ty of weight, and swelling studies. In these stud-
ies, Formrules V 3.32 were used as commercial ar-
tifi cial intelligence software tools to obtain a fi lm 
formulation with optimum characterization. 
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FormRules V 3.32 is a data mining software pack-
age developed by Intelligensys Ltd. that makes 
use of the neurofuzzy logic as its basic technology 
[3].
RESULTS: The optimal formulations, provided 
by the FormRules software, contain 1% chitosan 
as polymer and 5% PEG 400 as plasticizer. The 
best match between program results and prepared 
formulations is F5-coded (1% chitosan and 5% 
PEG 400) formulation.
CONCLUSION: This work shows that QbD ap-
proach studies, using CQA’s and especially Statis-
tical tools are very helpful to achieve a greater un-
derstanding for formulations
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Oral thin fi lms dissolution testing device
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INTRODUCTION: Oral thin fi lms are relatively 
new oral formulation for drug delivery. Fast act-
ing and avoiding fi rst pass metabolism is the main 
advantage over the conventional oral route formu-
lations. There is still a lack or analytical methods 
to suﬃ  ciently characterize the dissolution diﬀ er-
ences between fi lms. Because the fi lms are fast 
dissolving conventional dissolution methods that 
can be found in pharmacopeias are not suitable, 
due to its large volume and turbulent media fl ow. 
The main purpose of this study was to develop a 
bett er method that can give repeatable and dis-
criminatory results, even for small changes in the 
fi lm formulation.
MATERIALS AND METHODS: Dissolution 
system consisted of double chamber fl ow through 
cell separated by a membrane. In the donor cham-
ber a fi lm was placed and fi rmly fi xated by the 
edges of the fl ow cell. A constant hydrostatic pres-
sure was applied to the fl ow cell, provided by a 
custom made constant leveling device. Dissolu-
tion media was drained through the donor cham-
ber and the acceptor chamber, causing the disso-
lution of the fi lm formulation. Media used was 
circulating in a closed loop trough the chamber 
until the fi lm has dissolved completely. Eluted 
media from the fl ow cell was sampled and ana-
lyzed using UV-VIS spectroscopy.
RESULTS: Advantage of presented method 
compared to the other fl ow through fi lm dissolu-
tion system is in wett ing of the fi lm from both 
sides during the dissolution process. Sigmoid 
curve of the dissolution rate was observed. Swell-
ing phase of the dissolution is visible from the re-
sult. System variables such as media fl owrate 
trough the acceptor chamber and donor chamber 
pressure were varied to show their impact on dis-
solution process. It was found that the system is 
robust because the most vital variables are the one 
that can be easily controlled. Wett ing of the fi lm 
from both sides was found to be an important fac-
tor aﬀ ecting the dissolution process.
CONCLUSION: A new dissolution method for 
oral thin fi lms was presented. Main method ad-
vantage is that the fi lm is wett ed from both sides 
during dissolution process and it was shown to 
give a discriminatory result. It is a promising new 
tool for researches to evaluate their fi lm formula-
tions.
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P5- ORAL CONTROLLED 
DELIVERY
P5/1 
Exploring the usability of modifi ed gelatin fi lms 
for preparation of gastroresistant soft capsules
MACIEJEWSKI, B., SZNITOWSKA, M.
Department of Pharmaceutical Technology, Medical University 
of Gdańsk, Poland
INTRODUCTION: Incorporation of enteric prop-
erties into the shell of gelatin-based capsules is a 
challenging task. Although there are patent appli-
cations describing modifi ed shell compositions, 
there is still lack of detailed description of such 
approach in the scientifi c literature. The following 
work is a continuation of previously published 
studies [1, 2], aimed for investigating and describ-
ing the possibilities of preparing gastroresistant 
soft gelatin capsules, by incorporation of acid-re-
sistant substances into the shell material.
MATERIALS AND METHODS: Several gela-
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tin-based fi lm compositions were obtained, using 
various acid-insoluble polymers and commercial 
mixtures intended for enteric coating of tablets: 
Aquacoat CPD (FMC Biopolymer), Eudragit L30 
D-55 (Evonik), Opadry Enteric (Colorcon). The 
gelatin-polymer compositions have been proved 
to be resistant to disintegration in acidic media [1, 
2]. Microscopic (optical, AFM) and mechanical 
analyses were performed. Selected compositions 
were modifi ed with addition of carrageenan, gel-
lan or gum arabic. Such modifi ed fi lms were in-
vestigated in terms of pH, viscosity and mechani-
cal properties. Soft capsules, with the shell com-
posed of gelatin and CAP, fi lled with pigment in 
MCT oil, were prepared and subjected to disinte-
gration test.
RESULTS: The results show good homogeneity 
of obtained fi lm compositions. Mechanical study 
shows alteration of elastic moduli and mechanical 
strength of the fi lms by addition of the secondary 
gelling agents. Also adhesion properties of the 
fi lms have been enhanced by addition of co-gell-
ing substances. The obtained soft capsules proved 
to be resistant to disintegration in acidic media for 
2 h. The acid-phase of the test was followed by 
test at pH 6.8, in which all capsules disintegrated 
within 15 min.
CONCLUSIONS: Polymer fi lms can be pre-
pared with use of the investigated compositions. 
The physical properties of the fi lms can be easily 
modifi ed by addition of secondary gelling agents, 
to suit the requirements of soft capsule manufac-
turing process. Using several compositions, it is 
possible to form soft capsules resistant to disinte-
gration in acidic media.
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Development and characterization of modifi ed-
release capsules based on hot-melt technologies
VASVÁRI, G.1, HAIMHOFFER, Á.1, BÁCSKAY, 
I .1, BÉNYEI, A.1, VÁRADI, J .1, SOVÁNY, 
T.2, REGDON, G. JR.2, VECSERNYÉS, M.1, 
FENYVESI, F.1 
1Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary;
2Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
INTRODUCTION: The convenience for patients 
and professionals to administer oral sustained-re-
lease capsules and tablets are well-known [1]. The 
enhancement of bioavailabilty and sustain drug 
release formulations can be achieved by using 
molten dispersions [2]. PEGs, semisynthetic glyc-
erides, fatt y acid and alcholos and their conjugates 
are favoured to be used as thermoplastic or melt-
able materials.
METHODS: Fine grade of ethylcellulose, Gelu-
cire 50/13 and cetostearyl alcohol in their powder 
forms were mixed with model drugs (para-
cetamol-ACP, metronidazol-MNZ and diclofenac 
sodium-DS) and fi lled into capsules. The fi lled 
capsules were heated at 63°C to create monolithic 
lipid matrices. DSC, TG, NIR pXRD was used to 
characterise the lipid matrices beside dissolution 
tests and texture analysis.
Custom made jacketed dispensing vessel cre-
ated to melt, disperse and foam the PEG and 
stearic acid based dispersion of metronidazol. 
Hot foams formed monolithic matrices in the 
capsules. Foam cell characteristics and cell size 
distribution were investigated using SEM. Float-
ing time and dissolution tests with texture analy-
sis measurements were conducted to test in vitro 
buoyancy.
RESULTS AND DISCUSSION: By in situ ma-
trix formation, solid solution of DS was formed 
based on pXRD and DSC measurment, while ACP 
and MNZ remained partially in their undissolved 
forms. Thermal analysis confi rmed thermal stabil-
ity of the materials. Prolonged dissolution was 
achived for all API following First-order kinetics. 
Softening of the lipid matrix was only when only 
Gelucire was used with DS.
Foaming of MNZ dispersions resulted in de-
creased density namely from 1.22-1.28 g/ml to 
0,77-0,92 g/ml. Stearic acid decreased erosion and 
improved hardness. SEM pictures showed closed-
cell systems with some interconnected cavities, 
sizes were in the range of 68 and 260 micron. 
Labrasol and stearic acid ratio was found to deter-
mine the dissolution time, ranging from 7 hours to 
more than 10 hours.
CONCLUSIONS: Hot-melt techniques are suc-
cessfully provide opportunities to create swellable 
or erodible lipid matrices with targeted release 
profi les. Lipid matrices can be formulated without 
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fi lling liquid dispersion into capsule shells. Fast 
and eﬃ  cient foaming of molten and viscous mate-
rials could be used to prolong drug release and 
gastric residence time.
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Enteric fi lm coating of capsules with freeze-
dried fecal supernatant in Clostridium diﬃ  cile 
infection
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INTRODUCTION: The increase of Clostridium 
diﬃ  cile infection (CDI) over the last 15-20 years 
raised to an epidemic proportion, and the cases 
were found less sensitive to the applied antibiot-
ics. One of the most successful alternative meth-
ods of the therapy is the fecal microbiota trans-
plantation (FMT), which was fi rst reported in the 
4th century in China against food poisoning or se-
vere diarrhea. The fi rst scientifi c approach of ad-
ministration against CDI was only carried out in 
1983 in form of an enema. Later it was confi rmed, 
that fecal infusion via nasogastric tube can be 
more eﬀ ective [1]. Increasing the patient compli-
ance, our experiments aimed to fi nd more conve-
nient administration methods of this therapy, 
such as enterosolvent capsules fi lled with freeze-
dried fecal supernatant.
MATERIALS AND METHODS: The freeze-
dried fecal supernatant, which was obtained from 
healthy donors, was fi lled in ‘00’ size capsules. Us-
ing a prefabricated capsule holder dip coater tem-
plate and multiple immersing technique, the sur-
face of the capsules was coated by diﬀ erent pro-
portion of Eudragit® L30-D55 and triethyl-citrate 
dispersion. After proper drying an enterosolvent 
fi lm coating was formed on the capsules.
RESULTS: According to the results of dissolu-
tion tests, less than 5% of the capsule content was 
released in acidic medium, then the release was 
completed after changing the medium to phos-
phate buﬀ er. After gett ing ethical permissions, ad-
ministration to humans in co-operation with the 
Department of Infectology, successful therapy of 
the CDI was carried out.
CONCLUSION: Our experiments are promis-
ing in the fi eld of CDI, yet there are a lot of tech-
nological optimization tasks to solve in the future. 
Patients found this type of administration much 
more convenient than the nasogastric infusion, 
which encourage us to continue our research.
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API - excipient interaction studies in solid 
matrix systems
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INTRODUCTION: The solid dosage forms are 
still the most preferred types of medicines in the 
pharmaceutical market. One of the current chal-
lenges for the pharmaceutical industry is to pro-
vide matrix systems with variable properties re-
garding to the individual patient needs. To fulfi l 
this personalized medicine related request a novel 
approach of pharmaceutical design may be ap-
plied with a more detailed investigation of physi-
co-chemical property-based interactions between 
the drug and the applied excipients. The main aim 
of this research work is the bett er understanding 
of these interactions and fulfi lling the require-
ments of the ‘Functionality related properties of 
materials’ concept of Quality by Desing.
MATERIALS AND METHODS: The binary 
drug-excipient systems were produced by a Spe-
cac hydraulic press (Specac Inc, UK) with 1, 3 and 
5 tons compression force. The eﬀ ect of the interac-
tions on the surface free energy of mixtures were 
determined with an optical contact angle tester 
(Dataphysics GmbH, Germany). FT-IR and NIR 
measurements were applied for the exact determi-
nation of the nature of interactions. The infl uence 
on dissolution and drug liberation was examined 
with a custom-made dissolution equipment.
RESULTS: The results revealed that the deter-
mination of surface free energy may be a good in-
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dicator of the diﬀ erent kind of drug-excipient in-
teractions. The spectroscopic results proved the 
presence of hydrogen bonds in some matrix sys-
tems. As it was expected, the strength of the bonds 
increased with the increment of the applied pres-
sure. The dissolution studies confi rmed the infl u-
ence of bond-strength on both the drug liberation 
speed and quantity of liberated drug.
CONCLUSION: According to the above-men-
tioned results, it can be declared that in addition to 
the physico-chemical properties of the drug deliv-
ery systems the underlying chemical interactions 
between API and excipient also play a vital role in 
the drug liberation process. Regarding to more ef-
fi cient drug design and computational modelling 
the importance of these interactions is highlighted.
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Comparison of hydrophilic polymers 
functionality in formulation of mucoadhesive 
matrix tablets
KURĆUBIĆ, I ., JOKOVIĆ, S ., JOVANOVIĆ, M., 
ĐURIŠ, J .
University of Belgrade, Faculty of Pharmacy, 
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Belgrade, Serbia
INTRODUCTION: The aim of this study was to 
examine the functionality of hydrophilic poly-
mers with mucoadhesive properties in formula-
tion of matrix tablets with modifi ed release of pro-
pranolol hydrochloride [1]. Swelling and erosion 
of hydrophilic matrices may aﬀ ect both release 
rate and mucoadhesive properties.
MATERIALS AND METHODS: The hydro-
philic matrix tablets were prepared by direct com-
pression method using hydroxypropylmethylcel-
lulose (HPMC), polyethylene oxide polymer 
(PEO) or carbomer in varying amounts (20 or 
60%). Mucoadhesive strength was measured on 
the modifi ed weight scale by using samples of the 
porcine gastric tissue. Swelling and erosion stud-
ies of matrix tablets were analyzed and proprano-
lol hydrochloride release rate was determined in a 
reciprocating cylinder apparatus (with or without 
the presence of the gastric tissue) for 210 minutes.
RESULTS: Matrix tablets formulated with 60% 
of PEO polymer have had the highest degree of 
mucoadhesion (~ 500 N/m2) leading to prolonged 
adhesion of tablets to the tissue through the disso-
lution test. Tablets with 60% of HPMC absorbed 
the highest amount of water (308% of the initial 
tablet weight) and had the slowest erosion rate 
(2,98%/hour). Comparative analysis and modeling 
of dissolution profi les demonstrated that propran-
olol hydrochloride release rate was reversely pro-
portional to the swelling rate, and tablets with 
60% HPMC had the slowest drug release rate.
CONSLUSION: Matrix tablets formulated with 
60% of PEO or HPMC are characterized by high 
swelling capacity and limited erosion which leads 
to the high degree of mucoadhesion and sustained 
propranolol hydrochloride release. These fi ndings 
are a good basis for the further development of 
mucoadhesive delivery systems.
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Formulation of a multiple oral dosage form 
containing BCS IV group API and natural 
polymers as excipients
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INTRODUCTION: The aim of this study is acy-
clovir (AC), API with problematic pharmacokinet-
ics. Oral doses of AC range from 200 to 800mg ev-
ery 4 hours for 5-10 days, considering uncon-
vinient from the perspective of patient’s compli-
ance. The reason is low bioavailability due to low 
solubility, low permeability and short retention 
time of dosage form in the specifi c part of GIT [1].
Natural polymers currently researched for the 
development of novel drug delivery systems, such 
as mucoadhesive, control drug release, dosage 
form retains in the stomach for longer period of 
time, what helps to improve bioavailability and 
reduce drug wastage [2].
MATERIALS AND METHODS: Microcap-
sules were prepared by the phase separation (co-
acervation). Polymers used for the encapsulation 
of AC were gelatin and pectin; glycine and glutar-
aldehyde for crosslinking process.
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Powder containing AC and lactose was wet 
massed with the psyllium mucilage dispersion 
and screened through a sieve (0.84 mm). Psyllium 
mucilage was extracted according to Sharma and 
Koul’s method [3].
Prepared microcapsules and granules were 
fi lled in hard gelatin capsules; each capsule con-
tained 200mg of AC.
Dissolution tests were performed with Basket 
apparatus in simulated gastric fl uid (pH 1.2) with-
out pepsin. Samples were withdrawn every 5 min-
utes for 2 hours and analysed for AC content spec-
trophotometrically at 255nm.
RESULTS: In the fi rst 45 minutes, the cumula-
tive release of AC was 37,18% from microcapsules 
and 80,23% from granules; after 2 h were 40,7% 
from microcapsules and 82,5% from granules, 
while the conventional tablets available on the 
market release 99,86% AC after 20 minutes.
CONCLUSIONS: We have reached prolonged 
release of AC due to microcapsulation/granula-
tion process using natural polymers. Microcapsu-
lation prolonged the release considerably more. 
Our future eﬀ orts will lead to the study of muco-
adhesive properties of mentioned polymers.
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INTRODUCTION: There is a number of drugs 
which oral bioavailability is increased when en-
capsulated into microvesicules. That could be 
due to accumulation at brush-border membrane 
of enterocytes, intestinal uptake of micron size 
particles through paracellular passage, endocyto-
sis by enterocytes, and absorption via gut associ-
ated lymphoid tissue. Bile acids and their deri-
vates can increase the bioavailability of diﬀ erent 
drugs like insulin, calcitonin, gliclazide, and ce-
fi prom. Bile acids can also increase cefotaxime 
permeability through mucosa by the formation 
of micelles.
MATERIALS AND METHODS: Hydrophilic 
peptide-like drug cefotaxime was used as a model 
drug. It was studied the infl uence of microve-
sicules formation with bile acids 3alpha,7alpha-
dihydroxy-12-keto-5beta cholanate (MKC) on ce-
fotaxime pharmacokinetics. Microvesicules load-
ed with cefotaxime with and without MKC were 
prepared by the rotary fi lm evaporation method. 
Wistar laboratory rats were dosed orally with 15 
mg/kg cefotaxime. Cefotaxime was dosed in the 
form of solution without or with MKC (2 mg/kg) 
or in the form of microvesicules without or with 
MKC. Blood samples were taken into the heparin-
ised tubes from the tail vein. Plasma was separat-
ed and analysed by HPLC method [1]. Pharmaco-
kinetics parameters were calculated by WinNon-
Lin software.
RESULTS: After the oral administration of ce-
fotaxime solution with MKC Cmax and AUC were 
2-fold higher than after administration cefotaxime 
solution alone. After the administration of cefotax-
ime encapsulated in microvesicules with MKC, 
Cmax was 12- and AUC was 9-fold higher than 
administration of cefotaxime solution alone. After 
the administration of cefotaxime encapsulated in 
microvesicules without MKC, Cmax was 1,5 and 
AUC 2-fold higher than after administration cefo-
taxime solution alone. Pharmaceutical formula-
tion of cefotaxime in the form of mikrovesicules 
with MKC had higher oral bioavailability in com-
parison to cefotaxime solution and cefotaxime en-
capsulated in mikrovesicules without MKC.
CONCLUSION: Bile acids microvesicules 
could be useful pharmaceutical formulation for 
the enhancement of hydrophilic peptidomimetic 
drugs oral absorption.
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The infl uence of sodium dodecyl sulfate on 
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INTRODUCTION: Interactions between sodium 
dodecyl sulfate (SDS) and hydroxypropyl methyl-
cellulose (HPMC) are described in the literature [1].
The aim of this study was to assess the infl u-
ence of SDS on dissolution of diclofenac sodium 
(DF-Na) or paracetamol (PCM) from HPMC ma-
trix tablets. Due to diﬀ erent solubility of model 
drugs diﬀ erent infl uence of SDS is expected; and 
the impact of possible SDS-HPMC interactions, 
which were also monitored in experiments, is ad-
ditionally anticipated.
MATERIALS AND METHODS: 400 mg tab-
lets, comprising 75% HPMC (Metolose 90SH 
4000SR), 25% DF-Na or PCM and 0.5% of magne-
sium stearate were prepared by direct compres-
sion. Dissolution studies were carried out in USP 
II paddle apparatus (Agilent 708-DS, Agilent 
Technologies, USA) at 37 ± 0.5 °C and 75 rpm. As 
dissolution media, 900 mL of 4-times diluted Mc-
Ilvaine buﬀ er pH 4 without or with SDS of diﬀ er-
ent concentrations (0.05–2% (w/v)) were used. 
Turbidity determination was used for SDS-HPMC 
interaction evaluation. Dispersions with diﬀ erent 
combinations of HPMC (0.3–1 g/L) and SDS (0.01–
0.5%) were prepared and their transmitt ance was 
measured at 500 and 800 nm.
RESULTS: Drug release increases with increas-
ing concentration of SDS for both, DF-Na and 
PCM with the exception of media with 0.05% SDS. 
However, PCM tablets are much less aﬀ ected by 
increasing concentration of SDS than tablets with 
DF-Na. These diﬀ erences can be att ributed to dif-
ferent solubility of tested drugs at selected media 
pH value. Namely, SDS has higher solubilisation 
eﬀ ectiveness if the solubility of drug is lower. 
Transmitt ance of HPMC and SDS dispersions is 
considerably lower at SDS concentrations close to 
0.05% for all tested combinations with HPMC. The 
observed turbidity is probably a consequence of 
SDS-HPMC interactions which might be refl ected 
also in dissolution profi les in the same SDS con-
centration range.
CONCLUSION: The infl uence of SDS on disso-
lution was more expressed in the case of drug 
with lower solubility. According to turbidity mea-
surements of HPMC and SDS dispersions, SDS-
HPMC interactions might have an additional in-
fl uence on model drugs dissolution performance.
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An investigation into drug release from 
high drug loaded granules prepared with 
poly(ethylene) oxide and carbomer
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INTRODUCTION: Multiparticulate drug-deliv-
ery systems represent fl exible platform for modi-
fi ed drug release providing reduced risk of dose-
dumping, inter- and intraindividual variations. 
High drug loading formulations are generally pre-
ferred, however reproducible drug release re-
mains a challenge, especially in the case of highly 
soluble drugs [1, 2]. The aim of this study was 
preparation of sustained release granules with 
high caﬀ eine load and low concentration of 
poly(ethylene) oxide or carbomer as swellable 
polymers.
MATERIALS AND METHODS: Granules con-
taining 80 or 90% caﬀ eine and 5 or 10% 
poly(ethylene) oxide (PEO, Polyox WSR303) or 
carbomer (Carbopol 971P) were prepared by 
kneading with water or ethanol as granulation liq-
uid, respectively. Microcrystalline cellulose 
(MCC) was added as fi ller, where applicable. 
Swelling index of the investigated samples was 
determined based on the volume increase after 
24h-exposure to aqueous media. Drug release test-
ing was performed in the rotating basket appara-
tus at 75 rpm, in water as medium.
RESULTS: The granules exhibited notable dif-
ferences regarding swelling properties, which 
were more prominent in carbomer samples. The 
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highest swelling index (10-fold volume increase) 
was observed for the sample containing 80% caf-
feine, 10% carbomer and 10% MCC (C2), while 
granules containing 90% caﬀ eine and 10% car-
bomer (C4) swelled the least. Samples prepared 
with PEO exhibited modest swelling index which 
was not notably aﬀ ected by the composition. Simi-
larly to carbomer granules, the lowest swelling in-
dex was observed for the sample containing 90% 
caﬀ eine and 10% PEO (P4). Addition of MCC con-
tributed to sample processability.
All the investigated samples exhibited sus-
tained drug release with the amount of caﬀ eine 
released after 8 hours ranging from 35% (sample 
C2: 80% caﬀ eine, 10% carbomer) to 85% (samples 
with 5% PEO). Carbomer granules exhibited zero-
order drug release kinetics, which corresponds to 
their high swelling index.
CONCLUSIONS: High drug-loaded, sustained 
release granules have been prepared with relative-
ly low polymer concentration. Samples containing 
carbomer exhibited higher swelling index and ze-
ro-order drug release kinetics.
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INTRODUCTION: The increase in apparent sol-
ubility of amorphous active pharmaceutical ingre-
dients is an advantage [1], however the inherent 
stability stays as a major limitation and thus the 
formation of solid dispersions with polymers hav-
ing high glass transition temperatures has been 
introduced.
The work presented herein is aimed at amor-
phization of bicalutamide upon either high energy 
ball milling or spray drying with Kollidon®VA64 
and determination of the interplay between phase 
transition, particle size reduction and dissolution 
of the drug in solid dispersions and tablets. 
MATERIALS AND METHODS: Bicalutamide 
(BCL, Hangzhou Hyper Chemicals Limited, Chi-
na) was processed with Kollidon® VA64 (BASF, 
Germany). Sodium lauryl sulfate (SLS, BASF, Ger-
many) was used to prepare dissolution medium. 
The samples were prepared using planetary ball 
mill Pulverisett e 7 (Fritsch, Germany) and Büchi 
Mini Spray Dryer B-191 (Switz erland). Molecular 
structure of solid dispersions were tested by the 
use of Mett ler–Toledo DSC1 STARe System (Swit-
zerland), X-ray diﬀ ractometer Rigaku Mini Flex II 
(Japan) and the Nicolet iS10 FT-IR spectrometer 
(Thermo Fisher Scientifi c, USA). Particle size was 
determined using Phenom Pro desktop electron 
microscope (Nederlands) and Mastersizer 3000 
(Malvern, UK), while the dissolution was ana-
lyzed in the pharmacopeial paddle dissolution ap-
paratus Vision Elite8 (Hanson Research, USA) 
equipped with VisionG2 AutoPlus Autosampler. 
Solid dispersions were compressed using a single 
punch tableting machine (Korch EK0, Germany).
RESULTS: The results show that both applied 
processes led to amorphization of bicalutamide 
which is suﬃ  ciently stabilized by Kollidon® VA64. 
The eﬀ ect of tableting on molecular structure of 
solid dispersions was assessed.
Particle size and morphology were aﬀ ected by 
the applied processes. Particle size reduction were 
more signifi cant for the spray-dried samples as 
they exhibited smaller particles with narrower 
distribution.
The dissolution profi les of BCL varied depend-
ing on the composition of the binary system, how-
ever ca. 10-fold enhancement was obtained in 
comparison to pure drug.
CONCLUSION: Co-milling and spray drying 
of bicalutamide with Kollidon® VA64 led to amor-
phization and signifi cant improvement of the 
drug dissolution.
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INTRODUCTION: Since lamotrigine has a good 
permeability and low solubility, the formulation 
composition is very important for the release of the 
active principle. Interactions between lamotrigine 
and excipients can cause fl uctuations in blood con-
centration of lamotrigine, which may lead to ad-
verse eﬀ ects [1]. The objective of this study was to 
evaluate the eﬀ ects of excipients (fi ller, disinte-
grant and lubricant) and storage humidity condi-
tions on physical characteristics and dissolution 
rates of lamotrigine immediate release tablets.
MATERIALS AND METHODS: A 23 full facto-
rial design (3 factors on 2 levels) was used in ana-
lyzing the eﬀ ects of formulation composition (lac-
tose or microcrystalline cellulose used as fi llers, 
magnesium stearate as lubricant, sodium starch 
glycolate as disintegrant). Formulations were test-
ed according to the 9th European Pharmacopoeia. 
In vitro dissolution test was performed in two me-
dia pH 1.2 and pH 6.8 (USP40), content analysis 
was carried out by UV/VIS spectrophotometry at 
267 and 304 nm [2]. ANOVA test was used for re-
sults comparison.
RESULTS: Tablet formulations with microcrys-
talline cellulose (MCC) exerted bett er compress-
ibility, friability and disintegration. Lactose for-
mulations, in both media, released more than 85% 
of lamotrigine in the fi rst 15 minutes, except T3 
(high disintegrant, low lubricant content). MCC 
formulations showed lower release of lamotrigine, 
as only T8 (high lubricant and high disintegrant 
content) released more than 85% of lamotrigine in 
the fi rst 15 minutes, in both media. In reduced 
(30%) and elevated (75%) humidity conditions, 
MCC tablets showed reduced dissolution rate of 
lamotrigine, while no signifi cant changes were ob-
served for lactose tablets.
CONCLUSION: Low concentrations of magne-
sium stearate and sodium starch glycolate led to 
slightly higher dissolution rate of lamotrigine, 
lower strength, friability and disintegration for 
lactose tablets. However, for MCC tablets this led 
to higher dissolution rates and strengths and had 
no signifi cant eﬀ ect on friability and disintegra-
tion. The obtained results demonstrate the impor-
tance of understanding interactions of excipients 
and active substances.
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INTRODUCTION: Lamotrigine is an antiepilep-
tic drug, placed in group II of the Biopharmaceuti-
cal Classifi cation System. The composition of the 
tablet formulation can signifi cantly aﬀ ect dissolu-
tion profi le of the active substance. Although la-
motrigine was shown to be stable under heat, hu-
midity, and daylight stress factors, storage condi-
tions may alter the dissolution profi les of la-
motrigine tablets indirectly, through their impact 
on excipients [1]. We aimed to compare the disso-
lution profi les of brand and generic lamotrigine 
tablet formulations, as well as the infl uence of ele-
vated and reduced moisture content at room tem-
perature on the tablet characteristics and dissolu-
tion profi les of lamotrigine.
MATERIALS AND METHODS: Four formula-
tions were tested before exposure to conditions of 
elevated (75±5%) and reduced (30±5%) moisture, 
as well as one and four weeks after exposure to 
these conditions. Tablet characteristics and la-
motrigine dissolution rates were tested according 
to the requirements of European Pharmacopoeia 
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(Ph. Eur. 9) and American Pharmacopoeia 
(USP40). The dissolution profi les were tested in a 
medium of pH 1.2 and pH 6.8, and the content of 
lamotrigine was determined spectrophotometri-
cally. Dissolution profi les were compared using 
model-independent and statistical method.
RESULTS: Formulation D in all tested condi-
tions exerted diﬀ erent dissolution profi le in com-
parison to formulations A, B and C. The eﬀ ect of 
75% moisture on lamotrigine release was more 
pronounced than the eﬀ ect of 30% moisture. Un-
der conditions of elevated moisture, the formula-
tion D in the medium pH 6.8 released only slight-
ly more than half of the declared content, and in 
other formulations less than 85% of the content 
was released in the fi rst 15 minutes.
CONCLUSION: Exposure of tablets to the ele-
vated moisture conditions may aﬀ ect the tablet 
characteristics and the dissolution profi le of la-
motrigine. Therefore, keeping tablets out of the 
original package should be handled with caution, 
as it may potentially aﬀ ect the therapeutic eﬃ  cacy 
of lamotrigine tablets.
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INTRODUCTION: During new medicinal prod-
ucts development appropriateness and acceptabil-
ity in children must be considered. Several clinical 
trials showed very good acceptability of sprinkle 
formulations (pellets, minitablets) in paediatrics 
[1]. This dosage form in most cases requires co-ad-
ministration with vehicles, like soft foods, to im-
prove swallowability. However, food could infl u-
ence the bioavailability of active substance [2]. In 
this study pellets with diazepam were formulated 
and in vitro disintegration and dissolution tests 
for pellets dispersed in water soluble gels were 
conducted to show any possible infl uence on per-
formance of the primary drug formulation.
MATERIALS AND METHODS: Pellets with 
diazepam were prepared by extrusion and sphe-
ronisation technique (Caleva, UK) from mixture 
containing 0.5% of active ingredient, lactose and 
microcrystalline cellulose, wett ed with water in a 
high shear mixer. Disintegration test was per-
formed using a texture analyser disintegration rig 
(Stable Micro Systems, UK). Dissolution test was 
carried out in basket apparatus (100 rpm) with 500 
ml of 0.1M HCl as dissolution medium (Pharma 
Test, Germany). Pellets (1 g containing 5 mg of di-
azepam) were placed in the basket, either loose or 
dispersed in 0.5% Carbopol 974P (PAA) or 2% 
high viscosity carmellose sodium (CMC) gels.
RESULTS: In the fi rst step spheronisation pro-
cess was optimised and the best particle size distri-
bution and sphericity were obtained for 30 g batch-
es spheronised for 8 min with 1500 rpm bowl rota-
tion speed. Particles 1-1.25 mm were chosen for 
further studies. Diazepam pellets were character-
ised by disintegration time within 3 min in water 
and 4 min in 1% CMC gel. Dissolution tests 
showed similar dissolution rate (80%of the dose 
dissolved in 10 min) for loose pellets and dispersed 
in PAA, due to carbomer viscosity decreasing in 
acidic pH. Whereas, pellets dispersed in CMC gel 
exhibited very slow release of diazepam (only 10% 
was dissolved during 0.5 hour dissolution test).
CONCLUSIONS: The study showed that high 
viscosity water soluble gels like carmellose sodi-
um used to facilitate drug administration could 
delay drug dissolution in acidic pH (stomach). 
While polyacrylic acid could be an excellent vehi-
cle for sprinkles because of strong reduction of 
viscosity in acidic pH.
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INTRODUCTION: Liquisolid systems (LSS) are 
dry-looking, powdered forms of liquid drugs or 
drug solutions/suspensions [1]. Liquisolid admix-
tures can be used for tablet production, but both 
good fl owability and good compression proper-
ties have to be achieved. The published results 
dealing with the compression of liquisolid mix-
tures and preparation of LSS by using equipment 
commonly applied in pharmaceutical industry are 
still very scarce [2, 3]. The aim of this study was to 
investigate the fl owability, resistance to crushing 
and wett ing properties of LSS prepared by using 
three diﬀ erent carriers. The suitability of fl uid bed 
processor as the equipment for preparation of LSS 
was also evaluated.
MATERIALS AND METHODS: Microcrystal-
line cellulose (MCC), Neusilin® US2 and Fujicalin® 
(Fuji Chemical Industry Co, Ltd, Japan) were used 
as carriers, colloidal silicon dioxide as a coating 
agent, and polyethylene glycol 400 as a liquid 
phase. Liquid content in LSS prepared correspond-
ed to the optimum load factor (Lo) determined for 
each carrier. Liquisolid admixtures were prepared 
in Mycrolab fl uid bed processor (OYSTAR Hütt lin, 
Germany) and compressed on eccentric tablet ma-
chine EKO Korsch (Korsch AG, Germany).
RESULTS: LSS prepared in fl uid bed processor 
showed both bett er fl owability and bett er mechan-
ical properties than those prepared by using mor-
tar and pestle. Considerably bett er fl ow properties 
were observed when Neusilin® US2 and Fujicalin® 
were used as carriers. Liquisolid compacts with 
Neusilin® US2 showed the best mechanical prop-
erties, despite having the highest liquid content 
(Lo values for Neusilin®, Fujicalin® and MCC were 
1.09, 0.3 and 0.2, respectively). The lowest wett ing 
time was observed in the case of compacts pre-
pared with Fujicalin®. Higher degree of water up-
take was observed at lower liquid loads, irrespec-
tive of the carrier used. 
CONCLUSION: The results of the present 
study indicate that Neusilin® US2 can be used as a 
carrier in liquisolid tablets with high liquid con-
tent. Fluid bed processor was found to be suitable 
equipment for production of LSS.
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INTRODUCTION: Recent studies favour the in-
crease of drug delivery systems’ biocompatibility 
[1]. However, the selection of natural-origin excipi-
ents suitable for dermal application is somewhat 
limited, mainly due to their poor sensorial prop-
erties. Microbial levan is a water soluble complex 
fructan att ributed with a broad spectrum of po-
tential applications (e.g. co-stabilizer, fi lm-former, 
antioxidant, cross-linker, plasma expander, etc.) 
[2]. This study is focused on levan’s contribution 
to rheological properties of topical emulsion sys-
tems stabilized with either synthetic or natural-
origin mixed emulsifi ers.
MATERIALS AND METHODS: The addition 
of levan obtained from Bacillus licheniformis 
NS032 strain was varied (0, 0.2, 1 or 3%, w/w) in 
creams stabilized with: 1) a synthetic/anionic 
mixed emulsifi er (Cetostearyl Alcohol (Type A), 
Emulsifying – comprising Cetostearyl Alcohol & 
Sodium Cetostearyl Sulfate), and 2) natural/non-
ionic mixed emulsifi er of the alkyl polyglucoside 
type SepineoTM SE 68 (Cetearyl Alcohol & Cetea-
ryl Glucoside, Seppic, France). Rheometer Rheo-
lab MC 120 (Paar Physica, Germany) was used for 
the evaluation of changes in colloidal structure 
and preliminary physical stability of both types of 
the investigated samples in a predetermined peri-
od of time (initially, after 1 and 3 months storage).
RESULTS: Levan proved to be a co-stabilizer 
compatible with both anionic and non-ionic emul-
sifi ers, not compromising the initial shear-thin-
ning fl ow behaviour with moderate to pro-
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nounced thixotropy. Although levan is known for 
self-assembling in compact globules, these struc-
tures managed to retain suﬃ  cient fl exibility and 
successfully complement both the matrix-type (in 
case of anionic mixed emulsifi er) and lamellar liq-
uid crystalline-type colloidal structure (generated 
by the non-ionic emulsifi er). Apart from compara-
tive analysis of the fl ow curves, fi ne time-depen-
dant changes in hysteresis values successfully re-
vealed a deeper impact of levan addition.
CONSLUSION: Increase in levan concentra-
tions does not result in linear changes of key rheo-
logical parameters, which implies that even the 
lower amounts may successfully tailor pharma-
ceutical formulations.
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INTRODUCTION: Polymeric fi lms as drug carri-
ers should exhibit biocompatibility, suﬃ  cient drug 
loading, fl exibility, stability, target residence time, 
and adequate drug dissolution rate. These func-
tional properties could be improved by the addi-
tion of minerals, such as clays [1]. Among them, 
halloysite nanotubes (HNTs) are particularly at-
tractive, owing to their biocompatibility, specifi c 
nanotubular structure and excellent dispersibility 
in solutions of polymers. The objective of this 
work was to investigate the infl uence of HNTs on 
chitosan fi lm properties relevant for local delivery 
of antibiotics.
MATERIALS AND METHODS: Chitosan and 
chitosan-HNTs composite fi lms were prepared by 
casting and solvent evaporation technique. Brief-
ly, required amount of HNTs was dispersed in 
1.5% (w/w) chitosan (MW 253.7 ± 7.8 kDa; deacet-
ylation degree >85%) and 0.5% (w/w) tetracycline 
hydrochloride (TH) solution (chitosan/HNTs ratio 
= 3/1). The dispersion was casted into acrylic 
molds and dried at room temperature. Obtained 
fi lms were cut into 25 x 25 mm pieces, subjected to 
mass and thickness determination, FT-IR, me-
chanical, and thermal analysis, and in vitro drug 
release studies. For comparison, chitosan fi lms 
were prepared by following the same procedure 
without addition of HNTs.
RESULTS AND DISCUSSION: TH-loaded 
composite fi lms were 89.12 ± 6.83 μm thick while 
their mass was 76.70 ± 3.29 mg. The addition of 
HNTs caused decrease of elongation at break from 
60.94 ± 5.05 % to 21.65 ± 2.65 % and increase of me-
chanical resistance, that was tensile strength from 
24.66 ± 2.56 MPa to 134.8 ± 13.21 MPa and elastic 
modulus from 40.45 ± 2.16 MPa to 633.79 ± 128.37 
MPa, as a result of interactions between HNTs and 
chitosan confi rmed by FT-IR analysis. DTA and 
TG studies revealed increased thermal stability of 
the composite fi lms in comparison to the chitosan 
fi lms. The composite fi lms exhibited more sus-
tained release than chitosan fi lms, with t50% < 5,5 
h (t90% > 8 h) and t50% < 2 h (t90% > 8 h) in phos-
phate buﬀ ers 5.8 and 7.4, respectively. The ob-
served infl uence of pH on TH release from the 
composite fi lms could be ascribed to pH-sensitive 
interaction between HNTs and chitosan.
CONSLUSION: Halloysite-functionalized chi-
tosan fi lms demonstrated bett er potential for local 
delivery of antibiotics in comparison to chitosan 
fi lms owing to the improved thermal stability, me-
chanical and drug-release properties.
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INTRODUCTION: The SWOP (SWitch-Oil-
Phase) emulsions are oil-in-water emulsions 
which are characterized by fast inversion into wa-
ter-in-oil emulsions during application on the skin 
and consequent formation of a water-resistance 
layer over the skin [1]. Flavonoids quercetin (QUE) 
and dihydroquercetin (DHQ), as well as 
β-carotene (βC) are used in cosmetics as antioxi-
dants. Additionally, these compounds show pro-
tective eﬀ ects against ultraviolet radiation. There-
fore, their incorporation into SWOP emulsion 
could result in a new waterproof sun protection 
product. The aim of this study was to prepare 
SWOP emulsion with 0.5% QUE (SQUE), 0.5% 
DHQ (SDHQ) and with combination of 0.5% DHQ 
and 0.2% βC (SDHQβC), and to evaluate DPPH 
(2,2-diphenyl-1-picrylhydrazyl) radical scavenging 
ability of incorporated antioxidants in comparison 
to the pure compounds.
MATERIALS AND METHODS: For this pur-
pose, in vitro colorimetric DPPH assay was used 
[2, 3]. Results were expressed as the concentra-
tions of antioxidants that scavenged 50% DPPH 
radicals, and analysed by one-way ANOVA, fol-
lowed by Tukey’s post hoc test (p=0.05).
RESULTS: QUE and DHQ incorporated into 
SWOP emulsion exhibited strong anti-DPPH ac-
tivity, without signifi cant statistical diﬀ erence 
compared to the pure compounds. The SC50 val-
ues of incorporated and pure QUE were 3.48±0.10 
and 3.37±0.03 μg/mL, respectively. The SC50 val-
ues of DHQ incorporated in SDHQ and SDHQβC, 
and of pure DHQ were 5.36±0.27, 5.06±0.14 and 
5.02±0.10 μg/mL, respectively. Neither incorporat-
ed nor pure βC showed anti-DPPH activity at test-
ed concentrations (0.40-8.00 μg/mL). The SC50 val-
ues of tested SWOP emulsions, i.e. SQUE, SDHQ 
and SDHQßC were 0.70±0.02, 1.07±0.05, 1.01±0.03 
mg/mL, respectively.
CONCLUSION: QUE and DHQ incorporated 
into SWOP emulsion retain their strong anti-
DPPH activity, i.e. investigated SWOP emulsion is 
a suitable vehicle/base for the tested fl avonoids. 
On the other hand, although known for its antiox-
idant activity, βC showed no anti-DPPH activity, 
which is in agreement with fi ndings of some other 
authors [4]. Therefore, DPPH assay is not suitable 
for the testing of antioxidant activity of βC incor-
porated into SWOP emulsion.
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INTRODUCTION: In order to enhance dermal 
availability of the anti-acne drug adapalene (ADA) 
into target areas, microemulsion (ME) formulation 
appeared to be a promising tool [1]. The aim of 
this study was to evaluate the composition infl u-
ence of previously formulated MEs [2, 3] based on 
naturally occurring nonionic surfactants - alkyl 
polyglucosides, on in vitro release of ADA.
MATERIALS AND METHODS: For the prepa-
ration of MEs, oil (propylene glycol monocapry-
late, glycerol monocaprylate or glycerol monocap-
rylocaprate) was added to the mixture of surfac-
tant (decyl glucoside or caprylyl/capryl glucoside) 
and cosurfactant (propylene glycol) and mixed for 
15 min. Then, proper amount of water was added 
and mixed for another 15 min. ADA (0.1% w/w) 
was dissolved in previously prepared MEs. pH, 
conductivity and viscosity of all MEs were mea-
sured. The microstructure of the selected vehicles 
was assessed by using electrical conductivity mea-
surements and diﬀ erential scanning calorimetry 
in cooling mode. In vitro drug release studies 
were conducted using Franz Diﬀ usion cells.
RESULTS: All MEs were transparent, low-vis-
cous (26.81-42.18 mPa*s) colorless liquids. In order 
to be dermatologically acceptable, measured pH 
values (above 8) had to be adjusted. According to 
the electrical conductivity and DSC measure-
ments, bicontinuous microstructure was assigned 
to each ME. In vitro drug release profi les exhibit-
ed slow release rates during the fi rst 1-2 hours and 
the last 4 hours. The type of surfactant seemed to 
play an important role, since ADA release from 
ME based on caprylyl/capryl glucoside was lower 
than from the sample based on decyl glucoside. 
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Monoglycerides signifi cantly increased the 
amount of the drug released, although the infl u-
ence of glycerol monocaprylocaprate, having 
slightly longer alkyl chain length than glycerol 
monocaprylate, was more pronounced.
CONCLUSIONS: Since ADA release from bi-
continuous MEs was sustained, drug retention 
within the skin for prolonged period and a reduc-
tion of drug concentration dependent irritation 
could be expected. However, the selected formu-
lations need to be subjected to further permeation 
and penetration studies.
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INTRODUCTION: Although every review on le-
van suggests its hydratig potential there is a lack 
in published data dealing with this issue [1]. 
Therefore, we were interested to investigate le-
van’s hydrating eﬃ  cacy, when incorporated in dif-
ferent vehicles, with the use of in vivo and in vitro 
methods.
MATERIALS AND METHODS: Diﬀ erent vehi-
cles, of gel and emulsion type were prepared. 
Cream samples contained 0% (placebo), 0.5% or 1% 
(w/w) of levan. As for gels, beside placebo and 
samples with levan, two more samples- one with 
10% (w/w) of glycerol and one with 10% (w/w) of 
glycerol and 1% (w/w) of levan were prepared. Per-
formed in vitro occlusion test used the glass bea-
kers, purifi ed water and a sample-covered fi lter pa-
per (32±0.5°C for 48h). The occlusion factor was cal-
culated after 4, 24, and 48h. Additional test, per-
formed only with creams, used the pig ear skin and 
Franz cells with similar procedure. In vivo eﬃ  cacy 
study was conducted as 6- and 24-h study (Corneo-
meter®CM825, Courage&Khazaka-Germany).
RESULTS: Occlusion investigation indicates 
that the addition of levan contributes to the occlu-
sion eﬀ ect of gels and emulsions. On the other 
side, samples with levan induce a decrease in stra-
tum corneum hydration, compared to initial val-
ues and placebo samples, and this decrease is more 
pronounced within gels. Although not signifi cant, 
the decrease is evident after 1 and 4h, while after 
6h the results went back to initial values. For emul-
sions, 24-hour study showed that the addition of 
levan enabled a prolonged hydration eﬀ ect.
CONCLUSIONS: All obtained results indicate 
that levan is able to att ract and bond water, thus 
acting more like a fi lm-forming rather than hy-
drating agent, especially within gels. Levan shows 
diﬀ erent eﬀ ects depending on the vehicle used. Its 
ability to bond water and to make a fi lm on the 
skin surface in investigated emulsions contributes 
to the prolonged hydrating eﬀ ect. Finally, results 
indicate that levan could be used as an excipient 
which enables prolonged and/or modifi ed deliv-
ery of actives.
ACKNOWLEDGEMENT: The authors would 
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Development, Republic of Serbia, through Projects 
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INTRODUCTION: The structure and function 
of baby skin is signifi cantly diﬀ erent from the skin 
of adults. The infant skin is made up of three lay-
ers, but each layer is thinner and more vulnerable. 
The skin of infants and children is extremely ex-
posed to the harmful eﬀ ects of the environment: 
pathogenic microorganisms, thermal and mechan-
ical eﬀ ects and chemical agents. The barrier func-
tion can be improved with a proper emollient 
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treatment, so it is an important target to develop 
preparations which support the barrier function 
of baby skin.
The parameters of skin physiology undergo dy-
namic changes during the fi rst 3 months of life, es-
pecially during the neonatal period. These rapid 
changes during the fi rst months after birth are re-
fl ected in measurements of biophysical parame-
ters, such as TEWL and skin-surface pH, as well 
as measures of the total water content of the SC, 
water gradient through the SC and water absorp-
tion and desorption rates in the skin.
The aim of this work was the formulation and 
investigation of a science-based semi-solid formu-
lation with zinc oxide content that is readily avail-
able in everyday pharmacy practice and which 
may support the barrier function of baby skin.
MATERIALS AND METHODS: In our re-
search work we investigated the moisturizing ef-
fect and the transepidermal water loss (TEWL) of 
the developed formulation with Corneometer and 
Tewameter. Furthermore, we measured the in vi-
tro UVB Protection Factor (Sun Protection Factor/
SPF) of the preparations. Zinc oxide as a topically 
used excipient acts as a protective coating in case 
of mild skin irritations and abrasions. It can pro-
mote the healing of chapped skin and diaper rash. 
Zinc oxide works as a mild astringent, sun protec-
tion agent and has some antiseptic properties.
RESULT AND CONCLUSION: On the basis of 
our results, the zinc oxide containing cream in-
creased the skin hydration in the short term but 
could not provide a long-lasting moisturizing ef-
fect. The application of zinc oxide in the used con-
centrations decreased the transepidermal water 
loss signifi cantly. Furthermore, based on transmit-
tance results, increasing zinc oxide concentration 
increases the protection against UV radiation. 
However, 25% zinc oxide provides SPF 7 which is 
not enough to a perfect skin protection.
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microemulsion-gels based on essential oils and 
sucrose esters: formulation, evaluation and in 
vitro skin permeation of drug
OLARIU, I .1, MUT, A.-M.1, CONEAC, G.1, 
VLAIA, V.1, LUPULEASA, D.2, SZABADAI, 
Z.3, ANGHEL, D. F. 4, STANGA, G.4, VLAIA, L.1
1”Victor Babes” University of Medicine and Pharmacy, 
Timisoara;
2”Carol Davila” University of Medicine and Pharmacy, 
Bucharest;
3National Institute for Research and Development in 
Electrochemistry and Condensed Matt er, Timisoara;
4“Ilie Murgulescu” Institute of Physical Chemistry of the 
Romanian Academy, Bucharest
INTRODUCTION: Among various vehicles in-
vestigated in the last decades for fl uconazole (FZ) 
topical delivery, microemulsions (MEs) and mi-
croemulsion-gels (MEGs) have att racted great in-
terest due to their thermodynamic stability and 
high capacity to solubilize the drug and to in-
crease its penetration through the skin. Selecting 
biocompatible excipients in their formulation, 
make MEs/ MEGs prospective non-toxic and non-
irritating vehicles for safe topical drug delivery. 
This study aims to develop topical innovative FZ-
loaded MEs based on natural, biodegradable and 
biocompatible excipients, namely essential oils 
(EO), sucrose esters (sucrose laurate, SL or sucrose 
palmitate, SP) and chitosan. EO were selected also 
for their reported antifungal activity in order to 
enhance fl uconazole’s therapeutic eﬀ ect.
MATERIALS AND METHODS: FZ as active 
ingredient, three EO (clove oil, oregano oil or cin-
namon oil) mixed with isopropyl myristate (1:1) 
as oil phase, SL or SP as non-ionic surfactants, 
isopropyl alcohol as cosurfactant, chitosan as gell-
ing agent and 2% acetic acid solution as aqueous 
phase were used to prepare ten MEG formula-
tions. The FZ solubility in two synthetic oils (iso-
propyl myristate and ethyl oleate) and nine EO 
with intrinsic antifungal activity (eucalyptus, 
lemongrass, clove, cinnamon, peppermint, laven-
der, sweet fennel and oregano oil) were studied. 
The selection of the oil phase and cosurfactant 
were based on their maximum solubilizing capac-
ity of the drug and surfactant respectively. Pseu-
doternary phase diagrams were constructed us-
ing the micro plate dilution method in order to 
identify the ME existence domains, from which 
ten ME formulations were selected. The infl uence 
of the formulation variables (type and percentage 
of EO and sucrose ester) on the physicochemical 
and rheological MEGs properties and on the in 
vitro FZ permeation through pig ear skin were 
studied.
RESULTS: The results of in vitro FZ skin per-
meation and antifungal activity studies confi rmed 
the superiority of two MEG formulations based 
on cinnamon EO and SP or SL, and also a MEG 
formulation based on oregano essential oil and SP; 
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these MEGs conducted to the highest values of the 
fl ux and inhibition zone diameter.
CONCLUSION: The studied biocompatible 
MEGs based on EO and SP or SL and gellifi ed 
with chitosan proved to be versatiles carriers for 
simultaneous topical delivery of two bioactive 
components (FZ and EO). 
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INTRODUCTION: Oleogels are defi ned as the 
semi-solid systems, in which an organic liquid 
phase is immobilized by a three-dimensional 
network composed of gelator fi bers [1]. Their 
preparation and use have recently generated a 
great interest for scientifi c and technological rea-
sons [1, 2].
This work evaluates the infl uence of oleogels 
composed from cholesterol as oleogelator and two 
diﬀ erent liquid phases – castor oil and liquid par-
aﬃ  n on the release of poorly soluble drug - allyl-
amine antimycotic Terbinafi ne hydrochloride.
MATERIALS AND METHODS: Oleogels were 
prepared by dispersion of cholesterol in castor oil 
or liquid paraﬃ  n at 60°C and cooled to room tem-
perature under continuous stirring. Prepared 
oleogels were characterized in terms of their rheo-
logical properties using rotary viscometer.
Because of the limited solubility, terbinafi ne 
(0.5% w/w) was solubilized in O/W microemul-
sion and subsequently dispersed in oleogels in the 
ratio 1:4.
Infl uence of formulation on the release was deter-
mined using Franz diﬀ usion cells through the cellu-
lose membrane. The amount of permeated drug 
was analyzed spectrophotometrically at 224 nm.
RESULTS: The permeation profi le indicates 
some correlation between the rheological proper-
ties and the drug release. Oleogels with liquid 
paraﬃ  n had lower viscosity compared to oleogels 
with castor oil. The drug release data also show 
that the highest amount of terbinafi ne was re-
leased from oleogels of cholesterol in liquid paraf-
fi n. The results indicate that the lower viscosity 
can lead to bett er drug motility which improves 
drug fl ux across the membrane [3].
CONCLUSION: The release of the drug de-
pended on its diﬀ usion according Higuchi kinetic 
model (R2 = 0.9871). The highest cumulative 
amount of Terbinafi ne hydrochloride (45.13 μg/
cm2) was released from the formulation of choles-
terol (3% w/w) and liquid paraﬃ  n.
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INTRODUCTION: Enantiomers of chiral drugs 
might often diﬀ er in their pharmacological, toxi-
cological and pharmacokinetic properties [1]. 
Considering that skin is naturally chiral enviro-
ment of optical active molecules of ceramides in 
stratum corneum, the diﬀ erent permeation of chi-
ral compounds is possible to expect. Any ste-
reoelctivity in transdermal absorption would af-
fect the pharmacological activty of racemate. The 
Racemic fl urbiprofen, is eﬀ ective nonsteroidal an-
ti-infl ammatory agent and exhibits stereoselctivi-
ty in action and disposition [2]. Topically applied 
fl urbiprofen is used for treatment of gingival in-
fl ammation and soft tissue rheumatism [3]. Our 
preliminary studies confi rmed stereoselectivity 
in transdermal permation of single enantiomers 
of fl urbiprofen through rat skin [4]. The object of 
our work was the evaluation of infl uence of ste-
reochemistry of chiral alcohol enhancer on the 
transport of racemic (RS)-fl urbiprofen and its sin-
gle enantiomers.
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MATERIALS AND METHODS: The perme-
ation study was performed through porcine skin 
by using Franz diﬀ usion cells. The donor vehicle 
consisting of fl urbiprofen in PBS and of alcohol 
chiral enhancers (from butan-2-ol to decan-2-ol). 
The acceptor phase containing PBS buﬀ er. The en-
antiomers of fl urbiprofen were determined using 
stereoselective HPLC method.
RESULTS: The infl uence of alcohols chirality 
on the permeation of fl urbiprofen enatiomers was 
tested. In presence of diﬀ erent alcohol enhancers 
the permeation profi les of the enantiomers of fl ur-
biprofen from its racemic form were comparable 
When donor solution contained pure enantiomers, 
the marked diﬀ erences were observed between 
the permeation rates o (R)-fl urbiprofen and (S)-
fl urbiprofen. The most eﬀ ective for skin perme-
ation were combination to the same stereochemis-
try of drug enhancer: (R)-fl urbiprofen with (R)-al-
cohols and (S)-fl urbiprofen with (S)-alcohols. The 
highest enhancing eﬀ ect was detected for (R)-hex-
anol.
CONCLUSION: The infl uence of chiral alco-
hols on diﬀ erent permation of fl urbiprofen enan-
tiomers was observed in permeation of its single 
enantiomers. The signifi cant diﬀ erence in perme-
ation of enantiomers from racemic fl urbiprofen 
was not proved.
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INTRODUCTION: In our previous work, three 
NSAIDs (meloxicam, tenoxicam and indometha-
cin) were individually included in four types of 
polymeric matrices (PM 1-4), based on hyprom-
ellose, as part of new formulations development 
process [1]. Three of them (PM 1-3) were further 
subjected to the release/permeation test by the 
Franz method, determining the in vitro release 
profi les. This study aims to analyze their release 
kinetics mechanism.
MATERIALS AND METHODS: The release 
profi les grouped by the type of matrix and ex-
pressed as mean of each point of profi les were fi t-
ted in DDSolver, over the period of time at which 
no more than 60% of the NSAID dose was re-
leased, using the Korsmeyer Peppas (KP) function 
in three variants: KP (model M1), KP with Tlag 
(M2), and KP with F0 (M3); and Akaike index 
(AIC) as goodness of fi t parameter [2]. Statistical 
analyzes were performed in GraphPad Prism.
RESULTS: The NSAIDs release kinetic was 
found as being based on non-Fickian processes 
(nKP < 0.89). In all cases, the diﬀ usion of NSAID 
in the matrix mass depends both on the hydration 
and relaxation of the polymer [3]. Analysis of vari-
ation between data groups (two-way Anova, al-
pha = 0.05) showed that the type of matrix insigni-
fi cantly infl uences the mechanism of releasing. M2 
fi ts the best all of the analysed profi les, AIC hav-
ing in all cases the smallest values (18.2 - PM1, 
18.3 - PM2, 6.94 - PM3). The constant of the release 
process (kKP-Tag) decreases in the order of PM2 < 
PM1 < PM3.
CONCLUSION: The three studied types of hy-
promellose matrix release in vitro the NSAIDs by 
the same type of kinetics. The calculated parame-
ters will be used further in formulation optimiza-
tion studies.
ACKNOWLEDGMENTS: This work was sup-
ported by the University of Medicine and Phar-
macy of Tîrgu Mures Research Grant no. 
275/6/11.01.2017.
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INTRODUCTION: Indomethacin is an active 
substance which administered orally is bioavail-
able and absorbable in the blood fl ow even if its 
water solubility is extremely low (0.937 μg/mL). In-
domethacin absorption is based on high permea-
bility of the biological membrane for this type of 
molecule (Mr - IND: 357.79 g/mol), and it is fa-
voured also by its lipophilic character (log P - 
IND: 0.91 at pH 7.4 and 4.27 at pH 2.0) [1, 2]. The 
most important barrier for the released substance 
from a transdermic therapeutic system (TTS) is 
the corneous layer which at its surface has an acid 
pH with a protection physiological role. The aim 
of the current study consisted in a comparative 
analysis of the eﬀ ects on the permeability through 
the biological pig skin membrane at the pH of 5.5 
and 7.4, and the evaluation of the infl uence of dif-
ferent concentrations of propylene glycol from the 
TTS.
MATERIALS AND METHODS: Indomethacin 
(Sigma Aldrich Milan, Italy); HPMC15000 (Shin-
Etsu Chemical Co., Ltd. Tokyo, Japan); propylene 
glycol (Scharlau Chemie, Barcelona, Spain); ultra-
pure water (Millipore Direct-QSdistiller), ethanol 
(Chemical Company, Romania); Tween20 (Sigma 
Aldrich Co., France). Two formulations of dermal 
fi lms based on 1.5 % of HPMC15000 and with a 
composition of 10 % (FI1) and 30 % (FI2) propyl-
ene glycol were prepared through evaporation 
technique of the solvent. For the determination of 
indomethacin permeation through the biological 
membrane, Franz Cell diﬀ usion method was used: 
receptor medium: phosphate buﬀ er pH 5.5 and 
7.4.
RESULTS: The analysis of the indomethacin 
diﬀ usion from the proposed formulations showed 
that at pH 5.5 a concentration of 30 % propylene 
glycol in FI2 favoured the permeation of drug 10 
% higher than the FI1, but also infl uenced nega-
tively the fl ow through the biological pig skin 
membrane. In comparison, the pH approaching to 
neutrality increased three times the quantity of 
permeated drug in FI1 and 20 times in FI2. It has 
been observed that at a pH of 7.4 a higher concen-
tration of propylene glycol in FI2 increased 10 
times the fl ow rate through the testing membrane 
compared with FI1.
CONCLUSION: Permeation of indomethacine 
through the biological membrane from the formu-
lations is infl uenced by the pH of the acceptor me-
dium and also by the propylene glycol concentra-
tion.
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INTRODUCTION: The development of pharma-
ceutical dosage forms containing miconazole ni-
trate (MN) intended for external use can bring 
various benefi ts to patients who are resistant to 
classical antifungal forms [1], since this active sub-
stance accumulates in the skin, acting as a slow 
release product [2]. This study aims to evaluate 
the in vitro capacity of MN to permeate through 
two types of membranes (nylon - Ms vs. skin of 
pig ear - Mb) during its releasing from two matri-
ces based on hydroxyethyl cellulose (HEC).
MATERIALS AND METHODS: Samples of 
2.54 cm2 containing 40 mg MN (Sigma Aldrich, 
Germany) in 8% (FI) and 11% (FII) polymeric ma-
trices of HEC (Ashland, Germany) with 4.0% (FI) 
and 3.6% (FII) of polyethylene glycol - PEG 400 
were prepared in form of fi lms with thickness of 
0.23 mm (FI) and 0.30 mm (FII), by casting and 
solvent evaporation technique. The in vitro per-
meation curves of MN (mg•cm-2 vs. h) were deter-
mined by Franz method (cell of 14 mL, phosphate 
buﬀ er at pH 7.4 with 0.045% sodium lauryl sul-
phate, 32±0.5 °C), assessing the MN from acceptor 
sample (5 mL) at 273 nm (Spectrometer UVD 3200, 
Labomed Inc., USA). The results were statistical 
analysed using GraphPad Prism.
RESULTS: Area under the permeation curves 
(AUC) was calculated for the period of 1 h to 24 h 
and had the following values: 164.5 (FI-Ms), 152.7 
(FII-Ms), 78.61 (FI-Mb) and 62.44 (FII-Mb); with 
AUC-FI vs. AUC-FII statistically signifi cant diﬀ er-
ences only for Mb (p = 0.0154; unpaired t test, con-
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fi dence interval of 95%), case in which the vari-
ance was insignifi cant (Anova one way, Tukey’s 
test). The rate of MN permeation (mg•cm-2•h-1), 
expressed by the slope of the regression line, was 
signifi cantly lower through Mb (0.28 - FI, 0.22 - 
FII) than through Ms (0.43 – FI, 0.38 – FII), with la-
tency time (h) only in the Mb case (1.2 - FI, 0.89 – 
FII).
CONCLUSION: Compared with the synthetic 
membrane, the biological membrane reduces to 
almost half the in vitro permeation of MN re-
leased from HEC matrices, the diﬀ erences found 
between the two dermal analyzed systems being 
mainly determined by the thickness of the mem-
brane and the PEG content, used in formulations 
both as plasticizer and as promoter of absorption.
ACKNOWLEDGMENTS: This work was sup-
ported by the University of Medicine and Phar-
macy of Tîrgu Mures Research Grant no. 
275/6/11.01.2017.
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essential oil for onychomycosis topical treatment
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INTRODUCTION: The topical therapy of wide-
spread onychomycosis is a long process (10-12 
months) and has low cure rate [1]. The hard kera-
tin act as a barrier to drug diﬀ usion, and its hy-
drophilic structure also reduces the diﬀ usion of 
high molecular weight and lipophilic drugs. In or-
der to enhance the penetration of drugs we can 
use diﬀ usion enhancers or an appropriate formu-
lation. The azole derivatives have broad antifun-
gal spectrum and it can show synergism with es-
sential oils (EOs) [2]. Tioconazole and melaleuca 
alternifolia EO have been chosen for this research. 
They can be applied as simple solution of tiocon-
azole in EO, as solution of both in organic solvent 
as diﬀ usion enhancer or in a form of emulsion. 
Pickering emulsions (PEs) are stabilized with 
nanoparticles (NP) instead of surfactant, which 
are used to stabilize conventional emulsions. With 
appropriate choice of nanoparticles and prudent 
formulation a selective and sustained drug deliv-
ery system can be prepared.
Our aim was to formulate tioconazole and Me-
lalecua alternifolia essential oil PEs, which are 
suitable for onychomycosis topical treatment and 
examine their diﬀ usion properties in a nail model 
membrane.
MATERIALS AND METHODS: Silica NPs 
modifi ed with ethyl groups were prepared by 
modifi ed Stöber method, they have been charac-
terized with DLS and TEM. We have determined 
solubility of tioconazole in Melaleuca alternifolia 
essential oil, and we have apply their mixture to 
perform formulation of PEs. We have tested the 
ratio of oil phase to silica NPs and their concentra-
tion on the resulting droplet size and stability of 
PEs, which were determined with DLS measure-
ments. In vitro diﬀ usion studies in Franz cells 
through model membranes have been performed 
with all formula (solution, conventional emulsion 
and PE). Dissolution studies have also been per-
formed.
RESULTS AND CONCLUSION: The droplet 
size of emulsion has a correlation with the NPs to 
oil ratio, we are still working on the diﬀ usion and 
dissolution tests and fi nal results and conclusion 
will be shown at the conference.
REFERENCES:
1.  Ameen M. et al. British Journal of Dermatolo-
gy 171, 937-958 (2014)
2.  Rosato A. et al. Phytomedicine. 16, 972-975 
(2009)
P6/14
Nystatin-Flucytosine Liposomes for Fungal Nail 
Infection Treatment
VUKMAN, N., SALEM, A., PÁL, SZ., NAGY, 
S., SZÉCHENYI, A.
Faculty of Pharmacy, Institute of Pharmaceutical Technology 
and Biopharmacy, 
University of Pécs, Pécs, Hungary
INTRODUCTION: Onychomycosis is challeng-
ing to treat [1]. Flucytosine has wide antifungal ac-
tivity, however resistance has limited its use as 
monotherapy, necessitating combination or novel 
drug delivery [2]. Nystatin-fl ucytosine combina-
tion was reported to be synergistic [3], but their 
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use is diﬃ  cult due to diﬀ erent solubilities and li-
pophilic nature of nystatin. Liposomes are appro-
priate for drug combinations as they are capable 
of encapsulating both lipophilic and hydrophilic 
drugs [4]. Liposomal loaded anti-fungal fi lm was 
reported to have superior activity, making lipo-
somes a promising anti-fungal nail infection ther-
apy [5].
MATERIALS AND METHODS: The eﬀ ect of 
nystatin on liposomal integrity was studied. Lipo-
somes of diﬀ erent Phospholipon 90G and 90H 
phospholipids, cholesterol and nystatin ratios 
were prepared by reverse phase method. The opti-
mum nystatin containing formulation was used to 
prepare fl ucytosine encapsulated liposomes. Brief-
ly, components dissolved in ether were then in-
jected with a fl ucytosine water solution. The 
formed water in oil emulsion was sonicated, and 
instantly injected into buﬀ er, forming water in oil 
in water double emulsion. After further sonica-
tion, ether was evaporated by a rotary evaporator 
resulting in a liposomal suspension. Liposomes 
were characterized in terms of encapsulation, size 
and zeta potential. Dissolution, permeation, sta-
bility and microbiology studies followed to allow 
optimum formulation identifi cation.
RESULTS: Liposomes with diﬀ erent size and 
drug loads were produced and evaluated regard-
ing diﬀ usion properties in nail model membrane. 
Preliminary results showed a good control over 
the size of the liposomes, which infl uenced the 
diﬀ usion properties in the model membrane.
CONSLUSION: Presently we are working on 
the experiments. Final results and conclusion will 
be presented at the conference.
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INTRODUCTION: Papaverine hydrochloride 
(PaHCl) is an old, well-known drug with spasmo-
lytic activity but it has therapeutic eﬀ ect in erectile 
dysfunction, too. As an intracavernous injection, it 
is not used in urologic clinics today because the 
side eﬀ ects of the injection are pain, scarring or 
priapism [1]. Our purpose was to develop and test 
a topical semi-solid preparation containing PaHCl 
[2], which provides an alternative administration 
option, eliminating the undesirable side eﬀ ects of 
the injection.
MATERIALS AND METHODS: Lyotropic liq-
uid crystal (LLC) systems were formulated as a 
semi-solid preparation with diﬀ erent concentra-
tions of PaHCl. The characterization of the LLC 
structure was performed by polarization micros-
copy using a Leica image analyser and rheological 
measurements. The drug diﬀ usion and penetra-
tion tests were performed with in vitro synthetic 
membrane and an ex vivo human epidermis using 
Franz diﬀ usion cell. The human skin was investi-
gated by Raman microscope to visualize the API 
in diﬀ erent skin layers.
RESULTS: The results of diﬀ usion and penetra-
tion showed reverse concentration dependency. 
The in vitro and ex vivo studies correlated with 
each other and the results of Raman microscopy. 
The LLC structure infl uenced the penetration re-
sults, the lower viscosity and lamellar structure 
increased the penetration through the skin.
CONCLUSION: Based on our results, a PaHCl 
containing topically used LLC formulation may 
be a suitable and eﬀ ective alternative to the inject-
able formulation.
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INTRODUCTION: Pulmonary administration of 
drugs is increasingly investigated and used as a 
novel and alternative drug delivery pathway. Cul-
ture models of the respiratory system are not only 
important to study drug transport and absorption, 
but they are useful tools to bett er understand the 
pathomechanism of pulmonary diseases, like cys-
tic fi brosis. To mimick the in vivo complexity of 
the bronchial and alveolar epithelium and the un-
derlying blood vessels co-culture systems are 
needed. Another important aspect of these models 
is the reconstitution of the air-blood barrier of the 
respiratory system. The establishment of the air-
liquid interface in culture inserts is diﬃ  cult. Our 
research hypothesis was, that artifi cial sputum 
medium (ASM) containing mucin, would provide 
a physiological microenvironment on the top of re-
spiratory epithelial cells and this would help to 
create a bett er air-liquid interface culture model. 
Our aim was to establish and characterizein vitro 
respiratory epithelial models using human alveo-
lar and human bronchialepithelial cellsco-cul-
turedwith human endothelial cellsin diﬀ erent con-
ditions and to test them with a model pharmacon.
MATERIALS AND METHODS: For the respi-
ratory co-culture model systemshuman A549 al-
veolar epithelial cells [1], human CFBE bronchial 
epithelial cells [2], and human endothelial cells 
were used. To optimize the culture systems ASM, 
liquid/liquid and air/liquid conditions, and vari-
ous pH and NaHCO3 levels were tested. The bar-
rier properties were characterizedbytransepitheli-
al electrical resistance measurements and permea-
bility studies for marker molecules and a model 
pharmacon. The morphological properties were 
analyzed by immunohistochemical staining for 
junctional proteins.
RESULTS: The presence of endothelial cells in-
duced bett er barrier properties in respiratory epi-
thelial cells, as refl ected by the higher resistance 
and lower permeability values for paracellular 
marker molecules. The co-culture conditions also 
increased the tightness of interepithelial junctions 
visualized by immunostainings. We also found ef-
fects on the co-culture systems when we tested 
ASM, liquid/liquid and air/liquid conditions, and 
various pH and NaHCO3 levels.
CONLUSION: We successfully established and 
characterized new in vitroco-culture models for 
respiratory epithelium for which we provided 
physiologically relevant conditions and microen-
vironment. Theseair-blood barrier models are 
suitable for permeability studies and could con-
tribute to the development of new methods to in-
crease drug penetration across barriers and to 
more eﬃ  ciently treat diseases.
ACKNOWLEDGEMENTS: The work was 
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INTRODUCTION: Melatonin (MEL), a circadian 
synchronizing hormone, could provide a valid 
therapeutic strategy for treatment of gingivitis 
and periodontitis due to its antioxidant, antiin-
fl ammatory, immunomodulatory and osteogenic 
actions [1]. To further enhance its therapeutic po-
tential, MEL was loaded into PEGylated nanopar-
ticulate (NP) delivery system based on 
poly(methyl vinyl ether-co-maleic acid) anhydride 
(PVM/MA). This water-insoluble, mucoadhesive, 
non-toxic, synthetic co-polymer is able to form NP 
by simple solvent displacement and could be easi-
ly functionalized with diﬀ erent ligands [2]. NPs 
densely coated with low molecular weight poly-
ethylene glycol (PEG) are able to readily penetrate 
the mucus layer, thus overcoming its barrier prop-
erties and rapid NP clearance from the application 
site [3].
MATERIALS AND METHODS: PEGylated 
NPs were prepared by solvent displacement 
method [2] and functionalised with PEG 4000, 
6000 and 10 000 at 1:0.15 PVM/MA to PEG ratio, 
while MEL loading was performed at 1:10 and 1:5 
MEL to PVM/MA ratio. NPs were characterised in 
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terms of the particle size and zeta potential. The 
level of PEGylation was determined by HPLC, 
while MEL encapsulation eﬃ  ciency was calculat-
ed after UV/VIS quantifi cation of unloaded MEL. 
NPs in the solid state were prepared by freeze-
drying using sucrose, trehalose and glycine at 1-5 
% (w/v) as cryoprotectors.
RESULTS: Unloaded PEG coated NPs were 
monodisperse with an average size in the range of 
195.8 (NPPEG 4000) up to 219.3 nm (NPPEG 
10000) and negative zeta potential of -40 mV. Su-
crose at 5% (w/v) concentration appeared as the 
best cryoprotector. The NPs production yield var-
ied from 51.9 – 56.5%. The highest PEGylation lev-
el of 93.0% was obtained for PEG 6000 coated NPs 
after 1h of incubation. The highest encapsulation 
eﬃ  ciency of MEL in such NPs of 11.45% was ob-
tained at indole to PVM/MA ratio of 1:5, resulting 
in particles of 164.3 nm in size and negative zeta-
potential of -37.7 mV.
CONCLUSION: MEL loaded PVM/MA NPs 
coated with PEG 6000 showed of acceptable size 
and surface characteristics for mucopenetration 
and can be considered as a potential novel oromu-
cosal delivery system for gingivitis and periodon-
titis treatment.
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INTRODUCTION: Evaluation of the internaliza-
tion behavior of nanoparticles is of crucial impor-
tance for their safety and eﬃ  cacy. It can guide us 
through the experimental design of NPs with en-
hanced active targeting and low toxicity. Having 
the background, the aim of this study was to com-
pare the internalization behavior of biodegrad-
able, folate- and hyaluronan-decorated, as well as 
ligand-free, fl uorescently labeled NPs, composed 
of high Mw triblock PLGA-PEG-PLGA copolymer.
MATERIALS AND METHODS: The prepara-
tion of NP and their fl uorescent labeling were de-
scribed elsewhere [1]. The binding of FA and HA 
to the PLGA-PEG-PLGA polymer was performed 
using EDC/NHS chemistry. Particle size, size dis-
tribution and zeta potential of the NPs were deter-
mined by DLS. CLSM was used to acquire images 
from Caco2 cells exposed to the nanoparticles af-
ter 4 and 24h of incubation. The cellular uptake in 
Caco2 cells was quantifi ed by measuring fl uores-
cence intensity on microplate reader after 4h and 
24h of incubation at 4 and 37°C.
RESULTS: The average hydrodynamic diame-
ter for NP, NP-FA, NP-HA was 110.13±0.81nm, 
107.86±1.3nm and 121.45±2.05nm, respectively, 
with unimodal size distribution for all formula-
tions (PDI<0.2). The zeta potential was negative 
for all formulations, ranging from -19.43±1.09mV 
for NP, -12.14±2.17mV for NP-FA and 
-28.1±1.13mV for NP-HA.  LSM images revealed 
that all formulations were internalized by Caco-2 
cells, and the quantitative analysis demonstrated 
that 28.6% of the NP-FA, 20.3% of NP-HA and 
18.6% of the NP were internalized in the fi rst 4h at 
37°C. After 24h incubation time, the internalized 
fractions of NP-FA, NP-HA and NP were slightly 
increased to 32.6%, 23.1% and 25.4%. Further, neg-
ligible NPs internalization at 4°C for all the sam-
ples, most probably points to possible ATP depen-
dence of the internalization process. In the scope 
of the same study we are also trying to under-
stand the kinetic and extent of NPs internalization 
using diﬀ erent cancer cell lines, compare the re-
sults and improve knowledge for the design of 
more eﬃ  cient cancer targeting nanomedicines.
CONCLUSION: Att achment of FA and HA to 
PLGA-PEG-PLGA polymer, didn’t aﬀ ect the 
physical characteristics of the produced nanopar-
ticles and probably induced changes in their sur-
face. The ligand decorated NPs demonstrated fa-
vorable internalization behavior in Caco2 cells, 
which probably was ATP dependent. 
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INTRODUCTION: Multi-walled carbon nano-
tubes (MWCNTs) were previously produced (by 
an original procedure of reduction of Li molten 
salts on a graphite cathode), subsequently exposed 
to X-rays (140 kV X-ray tube in a dose 716 mGy/cm) 
and adequately characterized [1, 2]. In this study, 
the eﬀ ect of irradiation on their physicochemical 
properties and drug release was evaluated, after 
loading with risperidone (Risp).
MATERIALS AND METHODS: Solution of Risp 
in DMSO/water was added to (non-) irradiated MW-
CNTs and the dispersions were stirred for 24 h. Af-
terwards, the MWCNTs-Risp were isolated by ultra-
centrifugation, rinsed 3× and dried at 37 °C. Encap-
sulation eﬃ  cacy (EE) and drug content (DC; theoret-
ical value 25%) were measured with UV/VIS (λ=280 
nm) by calculating the loss of drug after the loading 
procedure. Particle size distribution and zeta poten-
tial were evaluated by Nano-ZS. The in vitro release 
was studied through a dialysis membrane, in PBS 
pH 7.4 (at 37 °C). The drug release data were fi tt ed 
into various mathematical models to determine the 
drug release kinetics. To fi nd out the mechanism of 
drug release, 60% of drug release data was fi tt ed in 
the Korsmeyer-Peppas (K-P) model.
RESULTS: EE was slightly higher in non-irradi-
ated MWCNTs (79% vs. 73%), while similar values 
for DC (approx. 20%) were observed. Diﬀ erences 
in surface charge (-22 mV vs. -34 mV) and average 
size (220 nm/PdI 0.39 vs. 740 nm/PdI 0.60) for non-
irradiated and irradiated MWCNTs-Risp, accord-
ingly, were determined. The cumulative percent 
of Risp release was similar for both formulations, 
being approx. 70% after 24 h. However, the initial 
burst release was higher in irradiated formulation, 
21.6% vs. 9.6% after 2 h. The fi rst order was the 
best fi t model for the Risp release from the non-ir-
radiated MWCNTs (R2=0.999; k=0.05 h-1), while 
for irradiated formulation, a square root one 
(R2=0.999; kH=13.7 h-1/2). The “n” for the K-P mod-
el was between 0.45 and 0.89, indicating non-Fick-
ian diﬀ usion in drug release.
CONCLUSION: Risp loaded MWCNTs were 
prepared, with capability to sustain Risp release 
rate. The exposition of the MWCNTs to X-ray irra-
diation aﬀ ected their physicochemical properties. 
Signifi cantly higher burst release was observed 
during the fi rst 2 h, indicating more loosely drug 
att ached to the surface of the irradiated MWCNTs.
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INTRODUCTION: Multi-walled CNTs (MW-
CNTs) were produced as etoposide (Eto) carriers 
and functionalized by maleic acid anhydride 
(MA-MWCNTs) and polyethylene glycol 1500 
(PEG-MWCNTs) to enhance their biocompatibili-
ty, encapsulation tendency and modify drug re-
lease. Maleic acid copolymers have been already 
known by their antitumor activity, while PEG for 
providing optimal half-life circulation time, high 
uptake in tumors and low in other cells [1]. The 
aim of the study was to characterize these f-MW-
CNTs for their physicochemical properties and in 
vitro drug release.
MATERIALS AND METHODS: MWCNTs 
were previously prepared, functionalized and ad-
equately characterized [2]. Solution of Eto in 
DMSO/water was added to the f-MWCNTs and 
the dispersion was stirred for 24 h. Afterwards, 
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the f-MWCNTs-Eto were isolated by ultracentrifu-
gation, rinsed 3× and dried at 37 °C (48 h). Encap-
sulation eﬃ  cacy (EE) and drug content (DC) were 
measured with UV/VIS (λ=282 nm) by calculating 
the loss of Eto after the loading procedure. Particle 
size distribution and zeta potential were evaluat-
ed by Nano-ZS. The in vitro release from all series 
was studied through a dialysis membrane, in PBS 
pH 7.4 as a dissolution medium, at 37 °C. The 
drug release data were fi tt ed into various mathe-
matical models to determine the drug release ki-
netics. To fi nd out the mechanism of drug release, 
60% of drug release data was fi tt ed in the Kors-
meyer-Peppas (K-P) model.
Results: EE for the formulations was between 
56% (MWCNTs-Eto) and 60% (PEG-MWCNTs-
Eto). High DC was achieved, being between 15% 
and 17% (theoretical 25%), respectively. Negative-
ly charged MWCNTs were produced [-19 mV 
(MA-MWCNTs-Eto) and -25 mV (MWCNT-Eto)], 
with average size from 191 nm (MA-MWCNTs-
Eto) to 280 nm (PEG-MWCNTs-Eto). The cumula-
tive percent of Eto release was between 81% (MW-
CNTs-Eto) and 71% (PEG-MWCNTs-Eto) after 24 
h. All formulations showed an initial burst release 
and prolonged release in the later stage. For the 
formulations, the best fi t model was fi rst order. 
The “n” exponent for K-P model was between 0.45 
and 0.89, indicating non-Fickian diﬀ usion mecha-
nism in drug release.
CONCLUSION: Eto loaded MWCNTs were 
prepared, with suitable physicochemical proper-
ties and capability to sustain Eto release rate. The 
functionalization of MWCNTs showed potential 
to increase drug loading and slow down drug re-
lease.
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INTRODUCTION: Nanotechnology has its fun-
damental impact in developing all areas of sci-
ence, especially in drug formulation and delivery, 
which is known as nanopharmaceutics. Moreover, 
conventional drugs often have poor pharmacoki-
netic and biopharmaceutical properties and other 
problems such as poor stability, toxicity, poor sol-
ubility in aqueous media and poor bioavailability 
[1]. Whereas, nanotechnology-based drug delivery 
systems may enhance shelf-life and acceptability 
by increasing either uptake eﬃ  cacy or patient 
compliance [2]. Furthermore, nanotechnological 
methods may help to improve the solubility, ab-
sorption, bioavailability, and stability of drug mol-
ecules [1].
MATERIALS AND METHODS: Titanate 
nanotubes (TNTs) were synthesized with a hydro-
thermal method, and then composites were 
formed with atenolol (ATN) and hydrochlorothia-
zide (HCT) using various solvents. Ethanol, meth-
anol and 0.01M HCl solution or ethanol and 1M 
NaOH solution were used to produce TiATN and 
TiHCT composites, respectively. The physico-
chemical properties of the samples were investi-
gated by using TEM (FEI, OR, USA) and SEM (Hi-
tachi, Japan) imaging to analyze the texture, opti-
cal contact angle tester (DataPhysics GmbH, Ger-
many) to determine the surface free energy, FT-IR 
spectrometer (Thermo Fisher Scientifi c Ltd., MA, 
USA) and DSC/TG apparatus (Mett ler-Toledo Ltd, 
Hungary) to detect the interaction between drugs 
and TNTs.
RESULTS: The results revealed that the 
strength of interactions is highly connected to the 
solubility of the drug in the applied solvent. Ac-
cording to SEM and TEM pictures, a strong re-
crystallization of the drug is observable from a 
worse solvent. This phenomenon acts negatively 
on the strength of interactions, which was sup-
ported by the results of the spectroscopic and 
DSC/TG measurements. The strength of interac-
tions also exhibited considerable infl uence on the 
surface characteristics of the products, which basi-
cally determines their processability and their be-
havior in a biological environment.
CONCLUSION: TiATN and TiHCT composites 
were successfully prepared by using HCL 0.01M 
and NaOH 1M as solvents, respectively, which 
suggests that the selection of the appropriate sol-
vent will basically determine the eﬀ ectiveness of 
the composite formation process and product 
quality.
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INTRODUCTION: Liposomes, a type of nano-
delivery systems, are used for targeted drug deliv-
ery [1]. Nowadays, the main intention of nano-
technological researches is to provide new thera-
peutic and diagnostic options and alternate routes 
for drug delivery besides the conventional intra-
venous method.
The aim of our research project is to fi nd a pos-
sible method for the administration of adenosine 
triphosphate (ATP) into human body through lipo-
somal formulations [2] to treat acute pancreatitis.
The objectives of this work is to create formula-
tions made from the proper liposomal wall con-
tents, incorporate propidium iodide, a cell dye as 
a marker, then ATP molecule as a biologically ac-
tive substance into liposomes.
MATERIALS AND METHODS: Propidi-
um iodide containing liposomes were designed 
and the formulations were prepared by thin-fi lm 
hydration method. Instrumental investigations 
were conducted. Particle size distribution was de-
termined via dynamic light scatt ering technique. 
Zeta potential was verifi ed to check the charge of 
the vesicular surface. Drug incorporation capacity 
and cell penetration ability was measured through 
propidium iodide cell dye incorporation into lipo-
somes and using fl uorescence microscopy. Cell 
penetration was surveyed on human embryonic 
kidney 293T cell line.
RESULTS: Liposomal formulations were pre-
pared with vesicles under 100 nm from diﬀ erent 
combinations of wall contents. Most of the mea-
sured zeta potential values were slightly negative. 
The products were tested on cell cultures beside 
drug incorporation capacity and cell penetrating 
ability measurements. Our results confi rmed that 
the liposomal formulations are able to penetrate 
pancreatic cells.
CONCLUSION: Due to the utilization of prop-
idium iodide marker we were able to test the cell 
penetrating ability of our formulations. We would 
like to prepare further, pancreatic cell penetrating 
and ATP molecule containing liposomal formula-
tions. Examination of other nano-delivery systems 
could broaden our opportunities.
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INTRODUCTION: Tumor-targeted co-delivery of 
the cytotoxic agents and natural compounds 
might be a valuable strategy to improve their anti-
tumor activity and to lower the extent of the side 
eﬀ ects. Our previous studies have shown that cur-
cumin (CURC) and doxorubicin (DOX) co-encap-
sulation in long circulating liposomes (LCL-
CURC-DOX) determines synergistic inhibitory ef-
fects on C26 carcinoma cell proliferation [1, 2]. In 
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the current study, the physico-chemical and bio-
logical properties, as well as the antitumor activi-
ty in C26 colon carcinoma bearing mice were ex-
plored, for an optimized LCL-CURC-DOX formu-
lation.
MATERIALS AND METHODS: Optimized 
LCL-CURC-DOX were prepared and character-
ized in terms of size, surface charge, drug loading, 
in vitro drug release, hemolityc activity and stabil-
ity in simulated biological fl uids. Further, treat-
ments consisting of LCL-CURC (5 mg/kg), LCL-
DOX (2.5 mg/kg), LCL-CURC-DOX (5 mg/kg, 2.5 
mg/kg) or free drugs at equivalent doses, were i.v. 
administered at day 7 and 10 after C26 cell inocu-
lationin mice, and their eﬀ ects on tumor growth 
were evaluated. The mechanisms responsible for 
this antitumor activity were evaluated through 
markers specifi c for supportive processes in tumor 
microenvironment such as infl ammation, invasion 
and apoptosis.
RESULTS: LCL-CURC-DOX had appropriate 
physico-chemical properties for i.v. administra-
tion, were stable in simulated biological fl uids and 
hemocompatible. This formulation demonstrated 
the highest antitumor eﬃ  cacy among all treat-
ment tested. The antineoplastic eﬀ ects were due to 
inhibition of the activity of the transcription fac-
tors, NF-kB and AP-1, and to alteration of Th1/Th2 
cytokine balance in TME, in favor of the Th1 arm.
CONCLUSION: Our results proved that the 
developed nanoformulation, based on the co-en-
capsulation of CURC and DOX in long-circulating 
liposomes, met the requirements of a modern 
drug delivery system for future colorectal cancer 
therapy.
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INTRODUCTION: The important current focus 
in production of cosmetics is usage of vitamin E 
(E), a natural antioxidant protective for tissues 
from UV radiation, delays photoaging and pro-
vide moisturizing eﬀ ect. Encapsulation is needed 
for its protection from high temperature, oxygen, 
and light, during storage, and also for a potential 
ability to control its release and delivery. Prepara-
tion of microcapsules of desired characteristics 
depends on various factors (size and nature of the 
core substance, wall material, techniques and pa-
rameters of encapsulation) [1, 2]. The study aimed 
to evaluate chitosan/sodium lauryl ether sulfate 
(Ch/SLES) microcapsules with E as a delivery sys-
tem for skin care.
MATERIALS AND METHODS: Microcap-
sules were prepared by complex coacervation. Ini-
tially, a 20% O/W emulsion with E (10% solution 
in medium-chain triglycerides), stabilized with 
the mixture of Ch (0.1 %) and SLES [3], was ob-
tained by Ultra Turrax T25 homogenization. The 
emulsion, without or with a crosslinker, formalde-
hyde (FA) or glutaraldehyde (GA), was spray 
dried. The in vitro release profi le of E from the mi-
crocapsule samples (0.1 g) was studied in 100 g of 
ethanol 80%, under continuous stirring at room 
temperature. The dissolved E in supernatant ali-
quots (2 ml) was analyzed during 90 min, by the 
Halo DB-20S UV-VIS spectrophotometer.
RESULTS: The obtained release profi les were 
analyzed by fi tt ing in diﬀ erent mathematical 
models and in all samples correlate the best with 
Korsmeyer-Peppas model. The diﬀ usion expo-
nent n values (0.05-0.23) indicated non-Fickian 
diﬀ usion. We assumed that release of E was 
based on a combination of rinsing from the sur-
face of the microcapsules [4] and diﬀ usion 
through the capsule wall. For microparticles with 
GA, n was the lowest, the release was rapid and 
the amount of release of the substance was high-
er (i.e., more pronounced rinsing process), com-
pared with FA and microcapsules without the 
crosslinker, where release of E was more con-
trolled by diﬀ usion.
CONCLUSION: E vitamin release from Ch/
SLES microcapsules followed Korsmeyer-Peppas 
kinetics. The selection of the crosslinker infl u-
enced their surface properties, the surface amount 
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and permeability of the capsule wall for E vita-
mine diﬀ usion.
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INTRODUCTION: Due to nanosizing results in 
the creation of new interfaces and in a positive 
Gibbs free energy change, nanoliposomal disper-
sion is a thermodynamically unstable system with 
tendency of agglomeration or vesical growth. 
Also, upon the addition of nanoliposomes (NLs) 
to biological fl uids, there is an almost immediate 
fouling of their surfaces with proteins and other 
cellular apparatus forming a layer known as pro-
tein corona (PC), which determines the eventual 
properties of NLs [1].
MATERIALS AND METHODS: In order to in-
vestigate the eﬀ ect of LIPOID PE 18:0/18:0-PEG 
2000 (PEG) on the in vitro stability of NLs and PC 
complex formation, two formulations (lechitin: 
cholesterol:PEG = 8.7:1:1.7 and 9:1:0.17 for S1 and 
S2, respectively) loaded with rosmarinic extract 
were prepared by the modifi ed lipid fi lm hydra-
tion technique [2]. Prepared NLs (200 μl) were in-
cubated in 800 μl phosphate buﬀ er pH 7.4 or hu-
man plasma at 37 OC for 2, 6 and 24h and ana-
lyzed in terms of particle size, particle size distri-
bution and zeta potential (Zetasizer Nano-Series, 
Malvern Instr. Ltd., UK).
RESULTS: In physiological relevant medium 
with pH 7.4, the diameter (D) of freshly prepared 
NLs was 107.2 and 113.7 nm with a relatively nar-
row size distribution (PDI~0.27) and zeta-average 
of -18.5 and -45.1 mV, for S1 and S2, respectively. 
No signifi cant diﬀ erences were observed during 
the examined period of 24h. Obtained results 
showed that the concentration of PEG infl uenced 
the mean size and zeta potential of NLs. In human 
plasma, D of NLs was 111 and 123.6 nm with 
PDI=0.3 and zeta-average of -18.5 and -17.5 mV. S1 
was stable during the period of 24h. In opposite, 
during the examination period of 24h, S2 showed 
slight reduction in the zeta potential (- 16.7 mV 
during fi rst 2 h). After 6 h and gradually onto 24 h, 
the zeta potential became more negative (-20 mV). 
This could be due to PC complex formation. In 
late time intervals, probably there was a displace-
ment of the plasma proteins present onto hard co-
rona layer and formation of soft corona complex 
with the NLs [1].
CONCLUSION: Due to the steric stabilization, 
NL formulation prepared with suﬃ  cient amount 
of PEG showed satisfactory stability in relevant 
mediums and potential for prolonged circulation 
time, thus enabling eﬀ ective drug deposition to 
the target site.
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INTRODUCTION: Red raspberry seed oil is a 
rich source of anti-infl ammatory polyunsaturated 
fatt y acids and antioxidants while hydro-glycolic 
extracts made from raspberry fruit are known for 
carotenoids, vitamin C and tannins. To use their 
biological potential in eﬀ ective skin care products 
we formulated low energy nanoemulsions (LE-
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NEs) as prospective carriers for unstable mole-
cules.
MATERIALS AND METHODS: LE-NEs were 
prepared using Emulsion Phase Inversion Method 
(EPI) at room temperature (RT). LE-NE region 
was detected by phase diagram study with Poly-
sorbate 80 as a surfactant, red raspberry seed oil 
extracts (RO) as oil phase with added Tocopheryl 
acetate of varied concentrations (costabilizer) and 
water titrated in small aliquots to surfactant-oil 
mixtures. We tested 4 diﬀ erent RO (cold pressed-
refi ned, -unrefi ned, CO2-organic and non-organ-
ic). The infl uence of polyols (glycerol, propylene 
glycol, butylene glycol, pentylene glycol) as cosur-
factants and antioxidant hydro-glycolic fruit ex-
tracts (Red raspberry–RE and French oak–FE) was 
investigated by varying concentrations in the wa-
ter phase. The NEs were confi rmed visually, by 
DLS (droplet size and PDI), pH and conductivity 
measurements, polarized light (PLM) and optical 
microscopy (OM). All stable NEs were kept at RT 
and retested monthly, up to 3 months. Antioxi-
dant activity of the selected samples was con-
fi rmed by ß-carotene-linoleic acid assay, while 
DPPH one interfered with the NE structure.
RESULTS: SOR and SER were the same for all 4 
types or RO extracts (NEs droplet sizes: 120 to 150 
nm, PDI = 0.1). The most crucial parameter for 
NEs formation and stability was the type of RO 
extract since PLM and OM revealed the presence 
of large structures (10-20 μm) undetected by DLS 
measurements in NEs prepared with CO2 RO ex-
tract organic. It was found that the polyol type 
and concentration should be specifi cally adjusted 
for each RO extract, while glycerol was the only 
one suitable for all 4 oils. Addition of antioxidant 
extracts (RE, FE) to the water phase improved an-
tioxidant activity of LE-NEs.
CONCLUSION: LE-NEs are promising carriers 
due to low energy production/inexpensive equip-
ment, with very complex structure aﬀ ected by the 
minimal composition changes such as the ones we 
observed employing natural extracts of the same 
INCI name but supplied from diﬀ erent sources.
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Lecithin-based low-energy nanoemulsions 
with eucalyptol as a co-stabilizer: interfacial 
phenomena examination by electron 
paramagnetic resonance spectroscopy
NIKOLIC, I .1, MITSOU, E.2, 
PAPADIMITRIOU, V.2, LUNTER, D. J .3, 
XENAKIS, A.2, DANIELS, R.3, SAVIC, S.1
1Department of Pharmaceutical Technology and Cosmetology, 
University Belgrade, Belgrade, Serbia;
2Institute for Biology, Medicinal Chemistry and Biotechnology, 
National Hellenic Research Foundation, Athens, Greece;
3Institute of Pharmaceutical Technology, Eberhard Karls 
University, Tübingen, Germany
INTRODUCTION: Owing to the physicochemi-
cal and biological benefi ts associated with their 
structure, and a palett e of possible applications, 
there is a growing interest in the biocompatible 
nanostructured vehicles intended for the use in 
pharmaceutical, cosmetic and food industry. Low-
energy nanoemulsions (LE-NEs) could be posted 
among other colloidal vehicles that have emerged. 
However, apart from confi rmed advantages, safe-
ty aspects should be considered due to the surfac-
tants used as stabilizing agents. With the view to 
lowering the surfactant content, eucalyptol (EUC), 
well established penetration enhancer, solvent, 
fragrance and taste modifi er, was tested in terms 
of its eﬀ ects to the interfacial properties of select-
ed LE-NEs.
MATERIALS AND METHODS: LE-NEs with 
diﬀ erent surfactant-to-oil ratios (SORs) were for-
mulated applying spontaneous emulsifi cation as a 
preparation technique, using medium-chain tri-
glycerides (MCT) or a mixture of MCT and EUC 
(1:1) as the oil phase, and a combination of soy-
bean lecithin and polysorbate 80 (1:9) as stabiliz-
ers. Droplet size analysis was conducted via dy-
namic light scatt ering and laser diﬀ raction. An in-
sight to the interfacial properties of selected LE-
NEs was realized through electron paramagnetic 
resonance spectroscopy (EPR), using 5-doxyl stea-
ric acid (5-DSA) as a spin probe.
RESULTS: With regard to the fi nding that SOR 
is an important formulation parameter for LE-NE 
preparation, displacement of MCT with EUC 
played a signifi cant role in this process. The low-
est SOR value able to give the LE-NE for the sys-
tem with MCT was 0.75, whereas, in case of MCT-
EUC blend, it was 0.3. Additionally, LE-NEs with 
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EUC exhibited signifi cantly lower mean droplet 
size compared to those without terpene. EPR ex-
periment refl ected the extent of the interfacial 
membrane rigidity/fl exibility at the microenviron-
ment of the spin probe. A signifi cant increase in 
the mobility of 5-DSA was observed in the formu-
lation with EUC, suggesting that interfacial fl exi-
bility exhibited prominent infl uence on the LE-NE 
formation.
CONCLUSION: Presence of EUC strongly af-
fected the fl exibility of the interface and signifi -
cantly lowered the mean droplet size of the LE-
NEs These results revealed the co-stabilizing abili-
ty of EUC. Additional assessment is needed to 
throw more light to potential interactions at the 
interface.
REFERENCES:
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P8- SOLID DOSAGE FORMS
P8/1
Enhancing particles mixing in cubic mixer using 
by baﬄ  es
BOUHAOUCHE, A., MANCER, D., DAOUD K.
University of Sciences and Technology Houari Boumediene, 
Algiers, Algeria
INTRODUCTION: Tumblers have been widely 
used in particle mixing due to many advantages 
such as, large handling capacity and there simple 
structure.
However, serious segregation phenomenon of-
ten appears when bidisperse or multi-disperse 
particles that diﬀ er largely in properties are mixed 
by the use of this kind of equipment.
Using baﬄ  es in the rotating drums is an eﬀ ec-
tive method to improve the mixing quality, espe-
cially for cohesive materials.
The eﬀ ect of cohesion strength and baﬄ  e length 
was investigated by Zhou et al [1] using DEM sim-
ulation method. Jiang et al [2] investegate the ef-
fect of baﬄ  es form and dimensions by numerical 
simulation.
In this work an experimental study was carried 
out to investegate the eﬀ ect of baﬄ  es insertion on 
mixing performance in cubic mixer, for diﬀ erentes 
experimentales conditions.
MATERIALS AND METHODS: Mohydrate 
lactose 200 M and micronized sodium bicarbonate 
were used as cohesive mixing system, to investi-
gate the eﬀ ect of a fl at baﬄ  es (-) lenght in cubic 
mixer. The experimental conditions studied are 
the rotational speed (10 and 20 rpm) and the fi ll 
level (35 and 50% (v/v)) with top bott om loading 
profi le. The mixing time and the RSD curves were 
used to caracterize the mixing homogeinity.
RESULTS: The baﬄ  e length played a signifi -
cant role on mixing and the increase of baﬄ  es 
lenght enhanced mixing especially at 50% of fi ll 
level. On the other hand, at low fi ll level a shorter 
baﬄ  es are needed to get a good mixing. The in-
crease of the rotationnel speed can be good for the 
mixing quality at 35% of fi ll level.
CONCLUSION: From the results it can be con-
clude that the baﬄ  es insertion enhance mixing 
performance for optimized conditions. And it de-
pends strongly on the experimental conditions 
and baﬄ  es dimensions.
REFERENCES:
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P8/2 
Measurement of the density distributions in 
ribbons containing paracetamol and various 
excipients by X-ray μCT and correlation to the 
minimum solid fraction
LACHMANN, M.1, WIEDEY, R.2, SRČIČ, S .1, 
DREU, R.1
1University of Ljubljana, Ljubljana, Slovenia;
2Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
INTRODUCTION: Dry granulation is often used 
when water sensitive APIs have to agglomerated 
and roller compaction is the preferred metod. 
However, compacts from this process often suﬀ er 
from one disadvantage. Depending on the roll de-
sign the density distribution within the compacts 
diﬀ ers from center towards the edge of the rib-
bons. This can lead to wider particle size distribu-
tions of the granules after subsequent milling. The 
presented work shows how density distributions 
of ribbons, measured by X-ray μCT, diﬀ er in corre-
lation to the fi llers used for their production.
MATERIALS AND METHODS: Formulations 
contained paracetamol (50%), croscarmellose so-
dium (2%), magnesium stearate (1%) in combina-
tion with fi llers for direct compression (47%). The 
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fi ller types used were: anhydrous dibasic calcium 
phosphate, alpha-lactose monohydrate and micro-
crystalline cellulose. Roll comopaction was carried 
out on a Freund Vector TFC 220 compactor at 
varying roll speed (3 – 6 RPM) and compaction 
forces (10 kN to 30 kN) to yield ribbons of 2.0 
thickness .X-ray μCT of specimens of about 2.5 cm 
in length were subjected to analysis by X-ray mi-
cro-computed tomography (CT alpha, Procon X-
Ray, D).
RESULTS: Ribbons made with MCC were 25 
mm wide if prepared at lower force and at higher 
force were close to 28 mm wide. Lactose ribbon 
width was found to be 23 mm and 26 mm respec-
tively. Samples made with calcium phosphate 
were 22 mm to 26 mm wide. Solid fraction of the 
ribbons containing calcium phosphate were found 
to cover a wider range with a minimum solid frac-
tion around 0.55 and a maximum at a solid frac-
tion atf 0.87. Lactose ribbons have lower porosity 
(1- solid fraction) of 0.12 to 0.3 and MCC ribbons 
between 0.16 and 0.35.
Discussion: The “loss” on ribbon width could 
be att ributed to two mechanisms. Firstly well 
fl owing materials (lactose, calcium phosphate) are 
escaping the compaction zone due to poor sealing 
of the rolls while this eﬀ ect is reduced at higher 
compaction speed. Secondly less compcatible ma-
terials are pre-compacted less by the feeding-au-
ger, especially at low compaction speed.
CONCLUSION: Excipients of diﬀ erent com-
pactibiilty and fl owability have a siginfi icant im-
pact on the quality att ributes of the obtained rib-
bons.
REFERENCES: 
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P8/3
Co-processing by fl uid-bed melt granulation 
for improving tableting properties of lactose 
monohydrate
MEDAREVIĆ, D., KRSTIĆ, S ., LAZOVIĆ, A., 
DJURIŠ, J ., IBRIĆ, S .
Department of Pharmaceutical Technology and Cosmetology, 
Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
INTRODUCTION: Direct compression is pre-
ferred method for tablet production due to its sim-
plicity, the fewest processing steps and the lowest 
requirements for processing equipment. Since ap-
plication of direct compression requires good fl ow-
ability and compactibility of tableting mixture, it is 
of utmost importance to provide high excipients 
functionality in terms of fl owability and compact-
ibility [1]. This study was aimed to developed co-
processed excipients, suitable for direct compres-
sion without need for addition of external lubri-
cants, as they can adversely aﬀ ect tablet mechani-
cal properties, disintegration and drug release.
MATERIALS AND METHODS: Co-processing 
of mixture containing lactose monohydrate, calci-
um hydrogen phosphate dihydrate and croscarm-
ellose sodium was performed by fl uid-bed melt 
granulation using 10 or 20% of three diﬀ erent 
binders with lubricant properties: poloxamer 188, 
glyceryl palmitostearate and polyethylene glycol 
4000. Obtained granulates were tested in terms of 
their fl owability and particle size distribution, fol-
lowed by testing tableting behaviour using Gam-
len D-series dynamic powder compaction analys-
er (Gamlen Instruments, UK).
RESULTS: Granules of more uniform size were 
obtained with higher proportion of binder. Flow-
ability of all prepared granules was signifi cantly 
bett er compared to lactose monohydrate and com-
mercial co-processed excipient Ludipress®. Lower 
work of compression for all co-processed mix-
tures, compared to Ludipress®, indicates on lower 
resistance of these mixtures to the applied com-
pression force. Tablets prepared by compressing 
mixture granulated with 20% of polyethylene gly-
col 4000 and 20% of poloxamer 188 exhibited the 
highest tensile strength amongst all co-processed 
samples. Mixture granulated with 20% of polox-
amer 188 showed more robust compression be-
haviour, i.e. tensile strength do not vary signifi -
cantly with variation of the compression force. 
Co-processing with either of the binder signifi -
cantly reduced adhesion of materials to the parts 
of tableting machine. Ejection stress lower than 5 
MPa indicates on good lubricant properties of the 
prepared granulates and that it is not necessary to 
add external lubricants.
CONCLUSION: Co-processing by fl uid-bed 
melt granulation was successfully used to prepare 
co-processed excipients suitable for direct com-
pression without need for addition of external lu-
bricants.
REFERENCES:
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P8/4
Self-organized criticality in granule fl owability 
examinations
FARKAS, GY.1, PINTYE-HÓDI, K.2, PÁL, SZ.1
1Institute of Pharmaceutical Technology and Biopharmacy, 
University of Pécs, Pécs, Hungary;
2Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
INTRODUCTION: Self-organized criticality 
(SOC) phenomenon is a cardinal property of dy-
namical systems. Flow properties of powders and 
granules can be described by this theory in the 
pharmaceutics. These systems display a specifi c 
augmentation reaching a critical point where ava-
lanche behavior of the particles can be observed. 
The complex behavior of these systems can be 
partly described with simple power laws [1].
MATERIALS AND METHODS: Diﬀ erent 
granulation sets were made with two dissimilar 
characteristic active pharmaceutical ingredients 
(paracetamol and prednisolone) according to our 
factorial design. Lactose, povidone, microcrystal-
line cellulose and talc were used as excipients 
(materials were supplied by Molar Chemicals 
Kft.). Examination of fl ow property (using ASTM 
funnel and a glass plate) was supplemented with 
a visual analysis. Professional camera (Canon 
EOS D1200) and a black background were ap-
plied. Flowing of the granules was recorded us-
ing 1280x720 resolution with 50 fps. Frames were 
extracted from the videos and analyzed (Carl 
Zeiss`s AxioVision) recording the appearing ava-
lanches. Our results were compared to a hypo-
thetical power law function. Angles of repose 
were measured too. Experimental and hypotheti-
cal relative frequency - avalanche size distribu-
tion functions were created to reveal the most im-
portant connections. Talcum as a potential infl u-
ential material of the SOC behavior and fl owabili-
ty was examined.
RESULTS: Parameters of the hypothetical and 
experimental functions were calculated and com-
pared. The experimental functions display cut oﬀ  
region and the distributions have an infi nite mean. 
The characteristics of the active pharmaceutical in-
gredients can infl uence the scaling parameter of 
the function which can lead to changes in the fl ow 
properties, in the avalanche-eﬀ ect. Smaller angles 
of repose were measured in case of granules con-
taining paracetamol.
CONCLUSION: Diverging behavior of granule 
fl owability from the ideal power law function can 
provide additional information during pharma-
ceutical formulation.
REFERENCES:
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P8/5
Eﬀ ect of magnesium stearate on the 
physicochemical properties of co-processed 
lactose using compaction simulator.
OZALP, Y., J IWA, N.
Near East University, Faculty of Pharmacy, Department of 
Pharmaceutical Technology,
Lefk osa/TRNC., Turkey
INTRODUCTION: Manufacturing the solid dos-
age form of an orally administered drug requires 
lubrication to enhance manufacturability, ensur-
ing that critical quality att ributes of the drug 
product are maintained during manufacture.[1] 
The eﬀ ect of lubricant (Magnesium Stearate) on 
the compaction characteristics of a model drug 
(Ibuprofen DC 85) in combination with co-pro-
cessed lactose based excipients (Cellactose® 80 and 
MicroceLac® 100) are studied. 
MATERIALS AND METHODS: A study was 
designed to develop and optimize tablet formula-
tions manufactured by direct compression. The 
formulations contained 200mg of Ibuprofen DC 
85, varying proportions of Cellactose® 80 (75% al-
pha-lactose monohydrate and 25% powdered cel-
lulose), MicroceLac® 100 (75% alpha-lactose 
monohydrate and 25% microcrystalline cellulose) 
and Magnesium Stearate in diﬀ erent concentra-
tions. Tablets were produced at pressures between 
46MPa and 274MPa using Stylcam Compaction 
Simulator with a 11.8 mm fl at faced Euro B punch. 
RESULTS: The lubricant sensitivity of the ma-
terials was determined using the R values (i.e. the 
ratio of the maximum lower punch force to the 
maximum upper punch force). It was seen to be 
the highest with the formulation containing Cel-
lactose® 80 at 137 MPa. 
Evaluation of ejection force and compaction 
pressure data demonstrates that there is improved 
ejection force as the lubricant concentration is in-
creased until a plateau is reached.
The results obtained were evaluated and it was 
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revealed that the change in lubricant % has a di-
rect eﬀ ect on the tablet tensile strength. The drug 
compactability was improved with the mixture 
containing MicroceLac® 100 and the crushing 
strength was the highest when the lubricant 
amount was 0.5%. 
CONCLUSION: The R values were closer to 
unity when the pressure applied was higher, this 
indicated increased eﬃ  ciency of magnesium stea-
rate as a tablet lubricant at higher pressures. Mag-
nesium Stearate concentration was optimized at 
0.5% using values obtained from tensile strength 
in order to enhance manufacturability without af-
fecting disintegration and dissolution of the drug 
product.  
REFERENCES:
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Use of Compaction Simulator to Determine 
the Eﬀ ect of Filler on the Compactability 
Characteristics of Paracetamol as a Model Drug
ONAYO, M. M., JIWA, N., OZALP, Y.
Near East University, Faculty of Pharmacy, Department of 
Pharmaceutical Technology, Turkey
INTRODUCTION: In this study the poor fl ow-
ability and bad compressibility characteristics of 
the model drug were observed. Dry granulation 
can be used in order to change powder properties 
of paracetamol using slugging process which has 
positive impact on fl owability and compressibility. 
MATERIALS AND METHODS: Paracetamol 
(Tianjin Bofa Co.) was slugged (Korsh XP1) with 
punch diameter of 20mm, crushed and sieved us-
ing 0.68mm sieve size. The study was carried out 
to determine the use of two diﬀ erent fi llers (Star-
lac® and Flowlac® 100). The approach used in this 
study entailed a series of tablet designs which 
were formulated by addition of active material 
with fi ller(s) in diﬀ erent concentrations and 2% 
Stearic Acid as lubricant. Tablets were compressed 
at diﬀ erent forces with diﬀ erent fi ller concentra-
tions. Angle of repose, Carr’s Index, Hausner Ra-
tio, and fl ow rate were the physical and rheologi-
cal properties of the powders that were evaluated. 
Stylcam (R200 Medel Pharm.) compaction simula-
tor was used to produce tablets (11.8mm fl at faced 
Euro B punch) and obtain compaction data at a 
range of pressures (105 MPa-205 MPa).
RESULTS AND DISCUSSION: The eﬀ ects of 
tableting pressure on mechanical properties: 
thickness, friability, weight variation and crushing 
strength were evaluated in order to obtain the 
tabletability profi le of the individual formulations. 
Tensile strength vs Compaction pressure was plot-
ted and the results of Starlac® showed greater ten-
sile strength at all compaction pressure points (at 
205MPa tensile strengths for Starlac® and Flowlac® 
tablets was 1.2MPa and 0.8MPa respectively).
The compactibility of granulated Paracetamol 
was improved by the increase in concentration of 
fi ller (30-50%), hence tensile strength increased. 
Results obtained were evaluated using Force- Dis-
placement curve in order to explain the compres-
sion phenomenon of the formulations.
CONCLUSION: The data produced by the 
compaction simulator supports that use of fi llers 
improves the compactability characteristics of 
granulated paracetamol. Summarily, the fi ndings 
revealed that Starlac® performed bett er in terms of 
powder, compaction and tablett ing properties.
REFERENCES: 
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Eﬀ ect of magnesium aluminometasilicates 
on compaction properties of pharmaceutical 
formulations
KOMÍNOVÁ, P., TRAN, D. T., ZÁMOSTNÝ, P.
University of Chemistry and Technology Prague, Prague, Czeh 
Republic
INTRODUCTION: Many of the powder excipi-
ents, which are used in pharmaceutical industry, 
exhibit poor fl ow properties. Therefore, glidants 
are usually added into the powder mixtures to al-
leviate the fl ow problems. Despite their advantag-
es in terms of improved fl ow, the presence of gli-
dants aﬀ ects the process of tablet compression, as 
well as fi nal tablet strength or dissolution rate. Gl-
idants aﬀ ect the energy side of the compression 
due to the reduction of the friction within the 
powder or reducing required volume reduction. 
The tensile strength of tablets from binary mix-
tures containing glidant is in general decreased 
related to the strength of tablets prepared from 
the other excipient alone. The measured decrease 
of the tensile strength of the tablets is considered 
to be the result of reduced interparticle bonding.
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MATERIALS AND METHODS: This work 
was focused on studying the infl uence of novel 
family of glidants - magnesium aluminometasili-
cates (Neusilin®). Several blends containing the 
model excipient (microcrystalline cellulose) and 
various magnesium aluminometasilicate grades 
were prepared. Their impact on tablet compres-
sion process was characterized using Gamlen 
GTP-1 compaction analyzer. The force – displace-
ment data at various pressures were used for the 
evaluation. Sotax Multitest 50 was used for tensile 
strength determination. The eﬀ ect of the glidants 
was studied in terms of its various grades, concen-
tration and in terms of mixing time.
RESULTS: The results from force – displace-
ment record revealed that certain parameters such 
as the punch detachement force and factor of elas-
ticity are aﬀ ected by mixing time, but there is no 
monotonous trend. Energy of plastic deformation 
increased at longer mixing time. The energy of 
plastic deformation and the factor of elasticity 
were also compared for diﬀ erent grades and con-
centrations of magnesium aluminometasilicate gl-
idants. Concerning the tensile strength, all tested 
glidants aﬀ ected the tablet strength value, but 
there was no signifi cant dependence on mixing 
time.
CONCLUSION: The study compared the com-
pression properties of microcrystalline cellulose 
blends containing Neusilin® family glidants. In 
general, those glidants aﬀ ect the compression 
properties less than traditional colloidal silica gli-
dants. This in combination with their good fl ow 
enhancing ability makes the tested magnesium 
aluminometasilicates suitable for using as glidants 
in formulations for direct tablet compression.
P8/8
Infl uence of the mechanical properties of dry 
binders on the tabletability
ARNDT, O-R., KLEINEBUDDE, P.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich 
Heine University, Düsseldorf, Germany
INTRODUCTION: Dry binders are important for 
direct compression to ensure adequate tensile 
strength and friability of tablets. Dry binders are 
also necessary for roll compaction / dry granula-
tion (RCDG) to reduce the fraction of fi nes [1]. A 
rational selection of dry binders would be desir-
able, to save costs and improving the robustness 
of tablets. A screening of dry binders in formula-
tions with paracetamol identifi ed eﬃ  cient binders 
for roll compaction and tableting [2]. Now, the me-
chanical properties of binders were related to the 
tabletability of formulations containing 10% bind-
er.
MATERIALS AND METHODS: HPC (HPC 
SSL SFP, Nippon Soda), COP (Kollidon VA64 F, 
BASF SE) and MCC (Vivapur 105, JRS Pharma) 
were used as dry binders. Tablets made of pure 
binders were compressed to 8 mm fl at-faced tab-
lets with a weight of 130 mg using a compaction 
simulator (Styl`One Evolution, Medelpharm). The 
compaction simulator was used to determine the 
breaking force of these tablets. Therefore, the tab-
lets were radially compressed at compression 
speeds of 3.5 mm/s and 0.01 mm/s. Tablets made 
out of 89 % DCPA (DICAFOS A150, Budenheim), 
10 % dry binders and 1% magnesium stearate 
were compressed to 8 mm fl at-faced tablets with a 
weight of 200 mg using a rotary die press (Pressi-
ma, IMA Kilian, Germany).
RESULTS: Tablets made out of pure COP and 
MCC tablets tended to break, while tablets made 
out of HPC were deformed to new compacts with-
out breakage. Furthermore, a viscoelastic behav-
iour is obvious, due to the lower development of 
strength at a slower compaction speed for HPC. 
These fi ndings can be connected to the tabletabili-
ty of DCPA-based tablets. HPC generated at lower 
pressures relative high tensile strengths, while the 
tabletability was lower at higher pressures com-
pared to MCC and COP. HPC is softer than COP 
and MCC, which provides rather strong compacts 
at lower pressures. This might also be the reason, 
why HPC was most suitable for RCDG (2), be-
cause the pressure during RCDG is comparably 
low.
CONCLUSION: Force-displacement curves of 
tablets made out of pure binders were analysed 
and related to tabletability plots, to gain a deeper 
understanding of the binding behaviour of dry 
binders.
REFERENCES:
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Evaluation of excipients and processing agents 
intended for the compression of pellets into 
tablets
SÁNTHA, K.1, FÜLÖP, V.1, JAKAB, G.1, 
GORDON, P.2, BALOGH, E.1, ANTAL, I .1
1Department of Pharmaceutics, Semmelweis University, 
Budapest, Hungary
2Department of Electronics Technology, Budapest University of 
Technology and Economics, Budapest, Hungary
INTRODUCTION: Eﬃ  cient compression of 
coated pellets is a formidable task developed long 
since due to the considerable forces involved dur-
ing procedures, the obstacle of segregation while 
mixing, as well as the rather frail nature of the 
coating. [1] Solving the relevant issues, however, 
could provide us with an easy-to-use and fl exible 
dosage form possessing many therapeutical ad-
vantages, such as multiple-unit pellet systems 
(MUPS). [2] Using fi ller materials, such as micro-
crystalline cellulose (MCC) and a hydrophobic 
emulgent the formulation of a cushioning process-
ing agent designed to mix freely with drug-con-
taining pellets and able to prevent damage to pel-
let coating was proposed.
MATERIALS AND METHODS: Multiparticu-
late tablets containing model drug (potassium 
chloride) were prepared from fi ller materials, with 
the incorporation of hydroxypropyl-methylcellu-
lose binding agent and V/O emulgent. Texture 
analysis and physical characterisation of excipi-
ents were conducted, while homogeneity of com-
pressed tablets was determined by imaging tech-
niques (microscopy, microfocus X-ray). Damage 
to pellet coating was examined via drug release 
test.
RESULTS: Texture analysis showed the novel 
processing aid rating the highest in plasticity. 
Moreover, the drug dissolution profi le was not al-
tered signifi cantly after compression based on 
similarity (f2 value) evaluation. Homogeneous 
tablets could be prepared from multiple formula-
tions, while only the ones made with the formu-
lated cushioning agent were in accordance with 
the regulations of Ph. Eur. 8.
CONCLUSION: The results of this study show 
that the formulation of a cushioning excipient able 
to protect the pellet coating while mixing homo-
geneously is possible. Further adjustment, incor-
porating additional materials could provide man-
ufacturers with a reliable, cost-eﬀ ective method to 
produce pellets in tablet dosage forms.
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Eﬀ ect of the compression speed on the 
mechanical properties of co-processed excipients 
for direct compression
MUDRIC, J .1, MEDAREVIC, D.1, IBRIC, S.1, 
DJURIS, J .1
1Department of Pharmaceutical Technology and Cosmetology, 
University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
INTRODUCTION: Co-processed excipients 
(CPEs) are combinations of two or more excipients 
that possess superior properties compared to the 
physical mixture of same combination of excipi-
ents [1]. Eﬀ ects of two meltable binders, Compri-
tol® 888 ATO (COM) and polyethylene glycol 4000 
(PEG 4000), and compression speed on the me-
chanical properties of CPEs prepared by the melt-
granulation were investigated in this study.
MATERIALS AND METHODS: CPEs were 
composed of lactose monohydrate (70%), calcium-
hydrogen phosphate (15%), sodium starch glyco-
late (5%) and 10% of the meltable binder (PEG 
4000 or COM for co-processed excipient A or B, 
respectively). CPEs were made by the melt-granu-
lation, and compared to the physical mixtures of 
the same composition. Tableting properties were 
compared by powder compaction analyzer under 
the compaction pressure of 104 MPa at diﬀ erent 
speeds (60 mm/min, 80 mm/min and 100 mm/
min). Properties of materials were estimated by 
calculating the tensile strength, porosity, detach-
ment and ejection stress.
RESULTS: CPEs have demonstrated diﬀ erent 
mechanical properties in comparison to the physi-
cal mixtures. Co-processed excipient A (CPEA) in 
comparison to the co-processed excipient B 
(CPEB), had higher tensile strength (1,05-1,21 vs. 
0,75-0,81 MPa), detachment (1,27-4,53 vs. 0,59-2,20 
MPa) and ejection stress (1,94-6,05 vs. 1,22-2,57 
MPa). The tensile strength of tablets made of 
CPEA (1,05-1,21 MPa) and physical mixture of the 
same composition (0,85-1,08 MPa) has increased 
with compression speed. The optimal compres-
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sion speed, based on the values of detachment 
and ejection stress, was found to be 80 mm/min. 
CPEB demonstrated superior mechanical proper-
ties in comparison to the physical mixture of the 
same composition at compression speed of 80 
mm/min. With the increase in compression speed 
the porosity of tablets made of physical mixtures 
have decreased, whereas in the case of CPEA and 
CPEB lower values of porosity are noticed at 80 
mm/min.
CONCLUSION: Mechanical properties of di-
rectly compressible co-processed excipients pre-
pared by the melt granulation method are infl u-
enced by the compression speed. Excipient co-
processed with PEG 4000 has superior mechanical 
properties in comparison to COM used as the 
meltable binder. 
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Infl uence of diﬀ erent type of tablett ing machine 
on process tableting co-processed excipient 
mannitol/maltodextrine
ARANĐELOVIĆ, A.1, MILETIĆ, T.2, IBRIĆ, S .1
1Faculty of Pharmacy, Belgrade, Serbia
2Hemofarm A.D., Beogradski put bb., Vrsac, Serbia
INTRODUCTION: Designing a robust process of 
tablett ing which can be transferred onto diﬀ erent 
tablett ing presses can be very challenging. This 
study investigates the infl uence of diﬀ erent types 
of tablett ing machines on the resulting parameters 
which closely describe tablett ing process.
MATERIALS AND METHODS: For the pro-
duction of tablets mannitol granulated with 5% 
maltodextrin and 1% of magnesium stearate were 
used. Process tablett ing was performed on rotary 
tablet press simulator, Stylcam 200R, using four 
simulations of diﬀ erent tablett ing machines 
(Killian Pressima, Fett e P2000, Kilian Synthesis 
330 and Kilian Synthesis s250). Tablet compres-
sion was performed using compression force 12 
kN and Stylcam speed 35 rpm. Following respons-
es were observed: upper punch force, upper 
punch displacement, as a graphical presentation 
using „Stylcam 200R“ software. Comparison of 
real dwell time, real relaxation time, ejection force 
and simulated tablett ing speed was also per-
formed.
RESULTS: During tablett ing process, capping 
was observed only when simulating KSynthesis 
330. Based on responses comparisons, it can be ob-
served that various diﬀ erences between compac-
tion profi les exist, especially between Pressima 
and Fett e P200 on the one side and KSynthesis 330 
and s250 on the other side.
KSynthesis 330 simulation resulted in shortest 
dwell time, and highest ejection force due to the 
highest simulated speed. The shortest compres-
sion time and the relaxation time before the next 
compression cycle exposed tablets to higher stress 
which lead to capping. This study confi rmed that 
diﬀ erence in compaction events can aﬀ ect process 
performance: consolidation, dwell and relaxation. 
Therefore it is important to assess which tablett ing 
speed is working for a given formulation and a 
tablett ing machine, in order to avoid problems 
during scale-up.
CONCLUSION: This study proved to be useful 
as it provided additional knowledge regarding ta-
bett ing process development. Based on presented 
results, it could be concluded that transfer process 
tablett ing can be performed easily from Pressima 
to Fett e P200, KSyntesis s250 and for KSyntesis 
330 some additional considerations are necessary 
to assess if the scale-up would be possible [1].
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Comparison of Orodispersible Minitablets 
Based on galenIQ™721 For Pediatric Use
LURA, A.1, SUAREZ-GONZALES, J .2, 
BREITKREUTZ, J .1
1Heinrich Heine University Duesseldorf, Institute of 
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INTRODUCTION: Acceptance studies approved 
the benefi t of orodispersible Minitablets (ODMT) 
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for the treatment of pediatrics [1]. There is already 
literature about ODMT based on Ludifl ash® [2, 3]. 
Isomalt (galenIQ™721) is known for advantages in 
technological respect but also in physicochemical 
regard [4, 5].  The aim of this study was to deter-
mine the feasibility of galenIQ™721 as an excipi-
ent for ODMT in comparison to established 
Ludifl ash®-Formulations. Hydrochlorothiazide 
(HCT) and Enalapril (EM) were chosen as model 
APIs, as these drugs are listed in the WHO List of 
Essential Medicines for Children [6].
MATERIALS AND METHODS: Minitablets 
based on galenIQ™721 (BENEO-Palatinit) or 
Ludifl ash® (BASF) were compressed on a rotary 
die press Pressima (IMA-Kilian) using a 19-tip 2 
mm punch. Drug load of 30.8 % HCT and 16 % 
EM was chosen. ODMTs were analyzed regarding 
their tensile strength, disintegration time with a 
modifi ed method [2], content uniformity accord-
ing to Ph.Eur. 2.9.6. Dissolution studies were per-
formed in demineralized water with a basket ap-
paratus stirred at 50 rpm using a UV-Probe by 
Ocean Optics USB4000.
RESULTS: ODMTs based on galenIQ™721 
were developed successfully and can be compared 
to ODMTs based on Ludifl ash®. Mechanical prop-
erties of the ODMT were acceptable and content 
uniformity was accomplished. Regarding the dis-
integration time, all of the ODMTs disintegrate 
within 30 sec and fulfi ll the requirements of the 
Ph.Eur. and FDA. The dissolution studies show a 
plateau for EM after 3 min and HCT after 13 min 
for ODMTs based on galenIQ™721 indicating full 
drug release. The diﬀ erence in these dissolution 
profi les can be explained with the drug load, dis-
solution rate and solubility of the used APIs in 
water. 
CONCLUSION: The development of ODMT 
with galenIQ™721 was feasible and comparable 
to established ODMT-formulations with Ludi-
fl ash®. The excipient galenIQ™721 seems to be 
suitable for the production of ODMT.
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Formulation and characterization of lurasidone 
hydrochloride orally disintegrating tablets
BARBARIĆ, J ., BRNADIĆ, G., FILAKOVAC, 
M., MALEKINUŠIĆ, N., TOMLJANOVIĆ, I ., 
ŽIŽEK, K.
University of Zagreb, Faculty of Chemical Engineering and 
Technology, Croatia
INTRODUCTION: Lurasidone hydrochloride 
(LRS HCl) is an atypical antipsychotic drug used 
for the treatment of schizophrenia and bipolar de-
pression. Compliance of patients suﬀ ering from 
mental illnesses often poses a signifi cant problem 
making administration and dosing of a drug quite 
challenging. In order to facilitate drug administra-
tion, a novel oral drug delivery system, an orally 
disintegrating tablet (ODT) of lurasidone hydro-
chloride has been prepared and characterized 
within this research. This type of tablet disinte-
grates in the oral cavity before swallowing in less 
than 3 minutes [1].
MATERIALS AND METHODS: Various 
tablett ing mixtures have been prepared by melt 
granulation technique using Uni-Glatt  (Glatt 
GmbH, Germany) fl uid bed granulator. Mixtures 
were compressed to 8 mm diameter tablets using 
TDP-5T single punch tablet press (Zhejiang, Chi-
na). Following materials were used: mannitol 
(MAN), microcrystalline cellulose (MCC) PH102, 
lactose anhydrous, croscarmellose sodium (CS), 
polyethylene glycol (PEG) 4000, magnesium stea-
rate (MS) and lurasidone hydrochloride (LRS 
HCl). Mass and hardness uniformity and disinte-
gration tests were performed in order to deter-
mine the optimal formulation parameters. Con-
tent uniformity and dissolution tests were carried 
out to study the eﬀ ect of croscarmellose sodium (a 
superdisintegrant) on tablet disintegration rate 
and solubility of LRS HCl. Drug content has been 
determined using an appropriate UV/Vis spectro-
photometric method. The eﬀ ect of superdisinte-
grant addition method (in-situ or spray-coating 
method) has been studied as well. 
RESULTS: Tablets produced using combination 
of mannitol and microcrystalline cellulose proved 
to have the most favorable ratio of hardness and 
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disintegration time. Therefore, such combination 
of excipients was used in the experiments in 
which LRS HCl was embedded in the tablett ing 
mixture. Content uniformity test has shown sig-
nifi cant deviation from the target value in tablets 
produced using in-situ addition method. Dissolu-
tion profi les show a slight increase in drug solu-
bility in tablets where superdisintegrant was used.
CONCLUSION: Tablets in which superdisinte-
grant was added by in-situ method show the low-
est disintegration time. When compared to other 
formulations, a slight increase in drug solubility 
was noticed as well.
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Characterization of tableting properties for hot 
melt coated granules
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INTRODUCTION: Granules, as intermediate 
product in the preparation of tablets, can be com-
pressed uncoated or after coating. Hot melt coat-
ing (HMC) is a novel technique which has numer-
ous advantages in comparison to conventional 
coating methods [1]. Lipid coating of HMC gran-
ules can modify drug release, mask bitt er taste of 
a drug substance and infl uence granules tableting 
properties [2]. The aim of this study was to inves-
tigate tableting properties of paracetamol gran-
ules coated with glycerol distearate (Precirol® 
ATO5).
MATERIALS AND METHODS: HMC 
paracetamol granules obtained in a modifi ed fl u-
id-bed apparatus (Mycrolab fl uid bed system, 
Hütt lin, Germany) under diﬀ erent process param-
eters setups (15 samples), uncoated granules and 
physical mixture of granules ingredients were 
compressed using Gamlen D series (Gamlen In-
struments Ltd, UK) at the compaction loads of 
100-500 kg. Work of compaction, elastic recovery, 
tensile strength and ejection stress were calculated 
from the instrument generated data. Tablets hard-
ness was tested using Erweka tablet hardness tes-
ter TBH125D (Erweka GmbH, Germany). All mea-
surements were done in triplicate.
RESULTS: The work of compaction revealed 
favourable compression characteristics of the coat-
ed granules and physical mixture, but physical 
mixture showed poor compactibility as indicated 
by increased elastic recovery and low tablets hard-
ness. Tablets obtained from HMC granules 
showed increased tensile strength in comparison 
to the uncoated granules and physical mixture. 
Also, tablets made of HMC granules exhibited sig-
nifi cantly lower ejection stress (less than 1 MPa for 
all samples) than those made of uncoated gran-
ules, demonstrating good lubrication.
CONCLUSIONS: The estimated tensile 
strength, as well as the ejection stress indicated 
advantageous tableting properties of HMC gran-
ules in comparison to the uncoated granules and 
physical mixture of granules ingredients. Addi-
tional advantage of the investigated HMC gran-
ules is that compression and ejection processes do 
not require the addition of external lubricant due 
to lubricant property of Precirol® ATO5.
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Evaluation of physicochemical and tableting 
properties of rutin-cyclodextrin complexes
PACZKOWSKA, M.1, BIALEK, K.2, 
MCDONAGH, A.2, CIELECKA-PIONTEK, J .1, 
TAJBER, L.2
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INTRODUCTION: Rutin is a fl avonoid, common-
ly used as an anti-infl ammatory, antimicrobial 
and antioxidant active agent. Rutin is poorly water 
soluble and has low bioavailability. One of the ap-
proaches employed to improve solubility and bio-
availability of drugs is by combining them with 
cyclodextrins (CD). CD are cyclic oligosaccharides 
which are recognized as useful pharmaceutical 
solubilizers, able to increase solubility and oral 
bioavailability.
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The aim of the study was to prepare and char-
acterize the physicochemical and micromeritic 
properties of rutin-β-cyclodextrin and rutin-
hydroxypropyl-β-cyclodextrin complexes with a 
subsequent feasibility study on tableting.
MATERIALS AND METHODS: Complexes 
were prepared by kneading and co-grinding 
methods in the molar ratio of 1:2 (rutin:CD). 
Characterization of systems by using spectral 
(FT-IR, XRPD) and thermal (DSC) methods was 
carried out.
To obtain rutin-CD tablets, a direct compres-
sion method was used. Properties such as hard-
ness and porosity were examined. Tabletability, 
compressibility and compactibility profi les were 
established. Also disintegration and dissolution 
tests for tablets were performed.
RESULTS: Analysis of the rutin-CD systems by 
XRPD, FT-IR and DSC showed a considerable de-
gree of interaction between rutin and ß-CD or HP-
ß-CD. The prepared tablets were fl at, pale yellow 
in color and had smooth texture without any 
cracks. Tablets disintegrated by dissolution within 
the required time (below 15 min). Dissolution 
rates were higher for rutin-CD systems compared 
to pure rutin.
CONCLUSIONS: Cyclodextrins are good ex-
cipients for improving the biopharmaceutical 
properties of rutin. Their characteristics lead to 
the formation of complexes and tablets with bett er 
dissolution performance of the active.
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P9- QUALITY BY DESIGN AND IN-
SILICO MODELLING
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In silico and experimental evaluation of 
solubility and lipophilicity of new succinimide 
derivatives
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INTRODUCTION: In the early stage of drug se-
lection it is highly important to determine solubil-
ity and permeability (depending strongly on mol-
ecules lipophilicity) since over 85% of drugs on 
the market are applied orally.
MATERIAL AND METHODS: RP TLC was 
used for study of the retention behavior of N-(3- 
or 4- substituted phenyl)-2-methyl-2-ethyl-succin-
imide derivatives. Precoated RP-18W/UV254 
10×10 cm plates (Macherey-Nagel GmbH and Co., 
Düren, Germany) were used as stationary phase 
and binary solutions of water with acetone with a 
varying volume fraction, φ of organic solvent, 
were the mobile phase. After development, the 
spots were detected at 254 nm with UV lamp and 
Rf values were measured. For each compound an-
alyzed, logS (logarithm of solubility) and logD 
values (log of the distribution coeﬃ  cient of the 
compound at pH=7.4) were determined by the us-
age of acdlabs software.
RESULTS: Retardation factor, RM was calculated 
for each compound of 11 analyzed compounds ac-
cording to the equation: RM=log(1/Rf-1). In the lin-
ear correlation of the RM values versus φ, the chro-
matographic retention constant RM0 was obtained 
as extrapolated value to 0% point: RM=RM0+S×φ. 
Statistically signifi cant linear correlation was ob-
served between retention constants RM0 and logS 
and logD (r2=0.962, p<0.001 and r2=0.954, p<0.001, 
respectively) for the investigated compounds.
CONCLUSIONS: Experimentally obtained re-
tention constants may be used as alternative meth-
od determining lipophilicity. Retention constants 
values increase with the increment of logD and 
with the decrement of logS. All analyzed com-
pounds have desirable solubility and lipophilicity.
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Correlation of experimentally determined 
lipophilicity with in silico compartmental 
distribution of new succinimide derivatives
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INTRODUCTION: High att rition rate of potential 
drug candidates with undesirable pharmacokinet-
ic profi le requires determining of pharmacokinet-
ic behavior in the earliest stages of drug candi-
dates selection [1].
MATERIAL AND METHODS: Retention be-
havior of N-(3- or 4- substituted phenyl)-2-methyl-
2-ethyl-succinimide derivatives was observed by 
applieng RP TLC method. As stationary phase 
precoated RP-18W/UV254 10×10 cm plates (Mach-
erey-Nagel GmbH and Co., Düren, Germany) 
were used while mobile phase was binary solu-
tions of water with acetone (varying volume frac-
tion, φ of organic solvent). The spots were detect-
ed at 254 nm with UV lamp and Rf values were 
measured. For each compound analyzed, volume 
of distribution, Vd (L/kg) and plasma protein 
binding, PPB (%) were determined by the usage of 
acdlabs software.
RESULTS: For each investigated compound re-
tardation factor, RM was calculated by application 
of the formula: RM=log(1/Rf-1). When RM values 
were correlated versus φ, the chromatographic re-
tention constants RM0 was calculated after extrap-
olating to 0% point: RM=RM0+S×φ. Linear corre-
lation was determined between retention con-
stants RM0 and Vd (r2=0.941, p<0.001) while U-
shape correlation was found between RM0 and 
PPB (r2=0.779, p<0.001) for the compounds ana-
lyzed.
CONCLUSIONS: Volume of distribution of the 
compounds analyzed strongly depends on the 
molecules lipophilicity while aﬃ  nity for binding 
for plasma proteins fi rst decreases with increment 
of lipophilicity (and decrement of acidity) down 
to some point when it starts to increase described 
with U-shaped correlation. All compounds inves-
tigated have desirable volume of distribution and 
aﬃ  nity for plasma proteins.
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Mechanistic interpretation of inhaled 
budesonide deposition and absorption in rats 
using in silico tools
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University of Belgrade, Belgrade, Serbia
INTRODUCTION: Inhalation products have re-
ceived much att ention in recent years [1], but the 
lack of adequate testing methods hampered the 
development of new formulations. In this context, 
in silico physiological modeling may faciliate this 
process. The purpose of this study was to investi-
gate the ability of in silico simulation tools to pre-
dict deposition and absorption of inhaled aero-
sols, using budesonide as a model drug and rat 
model physiology.
MATERIALS AND METHODS: In silico mod-
eling tools included MPPD model (v. 3.04, ARA 
Inc, USA) for the prediction of drug deposition in 
the lungs and GastroPlusTM software (v. 9.0.0007, 
Simulation Plus Inc, USA) to estimate budesonide 
absorption profi le. The necessary input parame-
ters were obtained from literature or in silico esti-
mated. Model predictability was assesed by com-
parison with the in vivo data [2, 3].
RESULTS: The applied simulation strategy 
resulted in the (i) design of two compartmental 
model that adequately describes budesonide ab-
sorption after intravenous and oral administra-
tion; (ii) design and exploration of inhalation 
model in terms of identifying the key parame-
ters aﬀ ecting the drug bioperformance. The re-
sults indicated that small lung fl uid volume and 
low drug solubility may be the limiting factors 
for budesonide dissolution and absorption in 
rats. However, in case of formulations with im-
proved solubility, drug dissolution have a pre-
dominant eﬀ ect on drug absorption rate and 
concomitant pharmacokinetic behaviour (as re-
fl ected in decreased Cmax and AUC values and 
increased tmax values with prolonged drug re-
lease rate).
CONCLUSION: In silico tools oﬀ er great po-
tential for the prediction of inhaled drugs phar-
macokinetics in both animals and humans, but in 
order to upgrade these tools, we need to improve 
our knowledge on animal physiology and correla-
tion between animal and human physiology.
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In vitro and in silico aerodynamical evaluation 
of carrier-free porous inhalable particles
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INTRODUCTION: Dry powder inhalers (DPIs) 
have been among the fastest developing inhaler 
types in the past decades. The newest researches 
report about several high potency carrier-free for-
mulations with low density and optimal aerody-
namic properties [1]. Based on this, present work 
focused on the in silico aerodynamical modelling 
of the DPI samples of inhalable carrier-free hollow 
particles prepared with spray drying procedure 
[2]. We also aimed to test the in vitro aerodynami-
cal stability 1, 10 and 20 weeks after spray drying.
MATERIALS AND METHODS: The active in-
gredient was the meloxicam (Egis Pcl., Hungary), 
from which carrier-free porous particles were pro-
duced with optimised spray drying procedure us-
ing L-leucine, sodium hyaluronate and ammoni-
um carbonate as excipients. Beside the physico-
chemical properties (size distribution, morpholo-
gy, density), we determined the in vitro aerody-
namics (Andersen Cascade Impactor, 28.3 L/min) 
and performed in silico modelling of the samples 
(Stochastic Lung Model applied to COPD pa-
tients). 
RESULTS: The low density (< 0.20 g/cm3 tap 
density) carrier-free DPI samples showed the 
same high aerosolization properties (FPF > 69 %) 
even weeks after the spray drying (no signifi cant 
diﬀ erence). With the in silico modelling we could 
also determine the exhaled fraction of the particles 
which was not possible with other methods be-
fore.
CONCLUSION: In this research we presented 
the aerodynamic properties of carrier-free DPI 
samples, by a combination of methods including 
the novel in silico assessment for a precise aerody-
namical behaviour determination.
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Application of a network of artifi cial neurons on 
a mixture of powder in a High Shear granulator
GHAMRI, W., DAOUD, K.
University of Sciences and Technology Houari Boumediene, 
Algeria
INTRODUCTION: Despite the advancement of 
knowledge about the granulation of pharmaceuti-
cal powders in a high shear granulator (High 
Shear), there is no theoretical support to date to 
establish the relationship between the properties 
of raw materials as well as that the process param-
eters on the quality of the granules obtained (po-
rosity, dissolution, etc ...).
MATERIALS AND METHODS: The HIGH 
SHEAR granulator, designed according to the 
specifi cations of the DELTA directive, makes it 
possible to granulate masses of product ranging 
from 1 to 3 kg. In the case of this study, the granu-
lations are carried out in a 10L stainless steel bowl 
and on a powder mass of 2 kg, which corresponds 
to a fi lling rate of the order of 2/3 usually encoun-
tered in industry for a mixer -granulator with high 
shear.
RESULTS: This work is achieved by the use of 
artifi cial neural networks. The results of the model 
tests showed a strong ability to predict the eﬀ ects 
of process variables.
CONCLUSION: This approach can be a pre-
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lude to integrating this method into a much 
broader process called ProcessAnalyticalTechnol-
ogy (PAT); indeed, the mastery of the quality of 
the fi nished products passes by the continuous 
mastery of the critical parameters of the granula-
tion.
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Establishment of requirements for the target 
measurement uncertainty to validate procedures 
for the control over the process equipment 
cleanliness
LEONTIEV, D., GRYZODUB, O., VOLOVYK, N.
Ukrainian Scientifi c Pharmacopoeial Center for Quality of 
Medicines, Kharkiv, Ukraine
INTRODUCTION: The analytical procedures to 
control the cleanliness of process equipment 
should be scientifi cally justifi ed and validated. 
The uncertainty concept can be used as a scientifi c 
basis to assess the quality of analysis results [1]. 
This work aimed at establishment and verifi cation 
of requirements for the target measurement un-
certainty of analysis results (Ut) with the level of 
reliability of 95% based on the risk assessment of 
incorrect decisions on compliance.
MATERIALS AND METHODS: UV-spectrom-
etry, HPLC, titrimetry, oxidisable substances, 
mathematical statistics.
RESULTS: Having applied normalised coordi-
nates as described in the chapter “5.3.N.2. Valida-
tion of analytical procedures and tests” of the 
State Pharmacopoeia of Ukraine [2], we obtained:
X(i)=C(i)/C(m)*100; Y(i)=r(i)/r(m)*100%
where:
C(i) – concentration of the analyte in the test so-
lution; C(m) – maximum acceptable concentration 
of the analyte (MAC); r(i) – the analytical signal in 
the test solution; r(m) – the analytical signal of the 
analyte in the concentration equal to the MAC.
Given that the procedure becomes unreliable if 
the detection or quantitation limit (DL or QL, re-
spectively) is close to the MAC, we propose to use 
the following requirements:
DL/MAC>=1/2 (or 50%) – for limit tests;
QL/MAC>=1/3 (or 33%) – for quantitative tests.
According to ICH guidelines, DL and QL are 
assessed from the results of the linearity study:
DL=3.3S/b; QL=10S/b
where S – standard deviation of the analytical 
signal; b – the slope of the regression line. This 
corresponds to the level of reliability of 95%. In 
normalised coordinates, the expanded uncertainty 
(U) is:
U=S/b*1.645 (one-tailed confi dence interval; 
95% reliability level). Combining equations given 
above, we obtain the following requirements for 
Ut:
Ut<=16% – for limit tests;
Ut<=5% – for quantitative tests.
Using the set requirements, we performed vali-
dation of 23 analytical procedures in the concen-
tration range of residues of APIs from 150 ppm 
(calcium gluconate, titration) to 0.01 ppm (anal-
gin, spectrometry). The analytical procedures 
were shown to be fi t for their purposes.
CONCLUSION: We established requirements 
for the target measurement uncertainty for the use 
in cleaning validation that proved to be feasible 
and practical.
REFERENCES:
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Risk Assessment based nano-sized liposome 
formulation development
PALLAGI, E., JÓJÁRT-LACZKOVICH, O., 
NÉMETH, ZS., SZABÓ-RÉVÉSZ, P., CSÓKA, I .
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
INTRODUCTION: Risk Assessment (RA) is the 
key element of the Quality by Design (QbD) based 
pharmaceutical developments. The QbD method 
is a holistic, systemic, science and knowledge fo-
cused manner of the pharmaceutical formulation 
and production process, which is highly recom-
mended by the regulatory authorities [1]. Lipo-
somes oﬀ er several potentials in the modern drug 
delivery. Liposomes in nano-size range can reach 
new targets and can be applied by alternative ad-
ministration routes. The conventional formulation 
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of the liposomes may be replaced by the up-to-
date QbD and RA based formulation procedure 
[2], which is presented by the authors in this 
study.
MATERIALS AND METHODS: The steps of 
the QbD and RA based formulation were the fol-
lowing: defi nition of the quality target product 
profi le, knowledge space development dedicated 
to the aims, selection of the critical parameters re-
lated to the targeted product quality, materials 
and selected process, performing of the initial RA 
(QbD LEAN Software®, QbDWorks LLC, USA), 
design of the experiments based on the RA results, 
performing the liposome production, liposome 
product testing (size, size distribution, surface 
etc.) (Mastersizer S 2000, Malvern Instruments 
Ltd, UK and Hitachi S-4700 FE-SEM, Hitachi 
High-Technologies Europe GmbH, Germany) and 
evaluation of the testing results.
RESULTS: After the proper target determina-
tion and cause-and-eﬀ ect relationship evaluation, 
the critical parameters were determined and the 
RA was performed. RA results, like the theoretical 
ranking of critical factors by their calculated im-
pact score, were presented in Pareto charts and 
factors with highest estimated impact are present-
ed in the relative severity-relative occurrence dia-
gram. The RA based liposome production was 
successful, the investigation results showed that 
the prepared samples fi t to the preliminary aimed 
quality.
CONCLUSION: The QbD approach were used 
in liposome formulation. The targeted liposome 
was prepared by a risk-based manner, focused on 
the most highly risk rated critical elements. Re-
garding the theoretical screening of the critical 
factors successful sample preparation by lower ex-
perimental eﬀ ort was reached.
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Development of the approach for method 
transfer for assay of desloratadine in fi coated 
tablets
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Kharkiv, Ukraine
INTRODUCTION: Analytical procedures 
should be developed taking into account the risk 
of making incorrect decisions on compliance 
with specifi cations [1]. Transfer of analytical pro-
cedures (TAP) should be based on the knowledge 
about the specifi cs of the object of analysis. The 
acceptable level of the risk can be assessed using 
the concept of uncertainty described in chapter 
„Validation of Analytical Procedures and Tests” 
of the State Pharmacopoeia of Ukraine (SPhU) 
[2]. There is a high risk of obtaining inhomoge-
neous tablet mass when conducting assay in 
fi lm-coated tablets. Therefore, the development, 
validation, and transfer of analytical procedures 
should be carried out using both model solutions 
and real tablets. This work aimed at developing 
the metrologically sound TAP for assay of deslo-
ratadine.
MATERIALS AND METHODS: A laboratory 
batch of Alerdez (Borshchahivskiy CPP), fi lm-
coated tablets of desloratadine (5 mg per tablet); a 
procedure for assay of desloratadine validated ac-
cording to the SPhU approach; an SPhU reference 
standard of desloratadine (assigned value of 
99.7% for spectrophotometry assay); a spectropho-
tometer Lambda 25, 1-cm cuvett e (Perkin Elmer); 
an analytical balance (Mett ler Toledo XP 205DR); 
a pH-meter (Metrohm); volumetric apparatus ISO 
Class A were used. An analytical procedure: spec-
trophotometry, 0.1 M HCl, concentration of deslo-
ratadine 0.020 mg/ml (optical density at 282 nm of 
about 0.64).
RESULTS: The following risks were detected:
a) when validating the procedure using model 
solutions, the requirements for validation charac-
teristics were met yet the uncertainty associated 
with the sample weight/dilution taking exceeded 
that adopted by laboratory practice;
b) when grinding the tablets, acceptable homo-
geneity was achieved for a sample weight equiva-
lent to 4 tablets. For smaller sample weights, we 
observed an unacceptably high variation in the as-
say results.
CONCLUSION: An experiment scheme was 
developed considering aforementioned risks, and 
TAP for assay of desloratadine in fi lm-coated tab-
lets with content limits of ±5% was conducted. The 
procedure relies on the uncertainty concept and 
metrologically justifi ed criteria, which allows us 
to control the acceptable level of risk.
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Real-time feedback control of continuous 
pharmaceutical processes using Raman 
spectrometry and image analysis
MADARÁSZ, L., NAGY, B., DÉMUTH, B., 
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NAGY, ZS. K.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
INTRODUCTION: Continuous pharmaceutical 
manufacturing, both at API production and for-
mulation technology, is rapidly gaining interest as 
a promising way to improve eﬃ  ciency, reduce op-
erating costs and ensure easier scale-up and short-
er time-to-market. Continuous manufacturing 
combined with real-time analytics and process 
control might be the new standard for newly de-
veloped pharmaceutical manufacturing processes 
in the next decades, which is highly promoted by 
the authorities as well as by the big pharma com-
panies. The academia must support these eﬀ orts 
by developing new, innovative continuous tech-
nologies, real-time analytics and real-time control 
strategies to achieve the aimed Process Analyti-
cally Controlled Technologies (PACTs). In this 
work, two feedback controlled continuous manu-
facturing technologies are presented, fi rst a Ra-
man spectroscopy-based control of continuous 
powder blending followed by tableting and a real-
time image analysis-based control of continuous 
twin-screw wet granulation (TSWG).
MATERIALS AND METHODS: Continuous 
blending and TSWG experiments were conducted 
using multipurpose twin-screw equipment (Quick 
2000 Ltd, Tiszavasvári, Hungary). A Kaiser Ra-
manRxn2® Hybrid in situ analyzer (Kaiser Optical 
Systems, Ann Arbor, USA) coupled with PhAT 
(Pharmaceutical Area Testing) probe was utilized 
to acquire the spectra of the homogenized powder 
and tablets. TSWG was monitored and controlled 
by real-time imaging and analysis using a process 
camera and an image analyzer software devel-
oped in-house.
RESULTS: The in-line Raman spectroscopic 
monitoring showed that the applied twin-screw 
continuous blender was capable of producing 
blends with high homogeneity and uniform com-
position. Moreover, technological malfunctions 
could be detected by the proposed PAT method. 
The Raman spectroscopy-based feedback control 
of the API feeder was also established, which 
guarantees the required API content during the 
continuous blending.
CONSCLUSIONS: The results prove the feasi-
bility of Raman spectroscopy and dynamic image 
analysis for monitoring and control continuous 
twin-screw processes such as continuous blending 
and TSWG. 
P9/10
Optimization of freeze-drying process by 
evaluation the role of time and temperature 
in lyophilization of biocompatible polymer 
hydrogels
SZERŐCZEI, D., LENGYEL, M., BALOGH, E., 
ANTAL, I .
Department of Pharmaceutics, Semmelweis University, 
Budapest, Hungary
INTRODUCTION: Freeze-drying is a technique 
of drying frozen materials by sublimation of wa-
ter. Low moisture content, prolonged storage sta-
bility, light-weight, porous and hygroscopic solid 
product can be achieved. Freeze-drying is a time- 
and energy-intensive process. With the appropri-
ate optimization a lot of time and money can be 
saved. Higher applied temperature ensures faster 
freeze-drying cycle, but can cause the damage of 
the samples. For process development, it is neces-
sary to know the critical properties of the formu-
lation, considering both the drug and the excipi-
ents. Glass transition temperature of amorphous 
materials or eutectic temperature in case of crys-
talline substances are important to know, because 
the structure can collapse above this temperature 
[1]. Freeze-dried biopolymer hydrogel can be pro-
duced using alginic salts [2].
MATERIALS AND METHODS: Medium vis-
cosity sodium alginate (Sigma-Aldrich) hydrogels 
were prepared with purifi ed water swelling on 
25°C for 24 hours. The gels were lyophilized in 
COOLSAFE™ 110-04 freeze dryer (ScanVac, Den-
mark) at diﬀ erent programs. The moisture content 
of freeze dried products were evaluated with Karl 
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Fischer titrator (787KF titrino, Metrohm AG, Swit-
zerland). After reconstitution of dry samples, oth-
er investigations were made such as viscosimetry 
with Kinexus Pro Rheoviscosimeter (Malvern In-
str. Ltd, UK) and molecular weight measurements 
by dynamic light scatt ering method with Zetasizer 
Nano ZS (Malvern Instr. Ltd, UK).
RESULTS: The physical and chemical proper-
ties of sodium alginate hydrogels depended on 
the length of freeze-drying cycles included the 
time of freezing, primary drying and secondary 
drying. The application of higher temperature en-
sured a faster drying and a lower moisture con-
tent, but the unreasonably high temperature 
caused the collapse and damage of samples. Vis-
cosity and molecular weight also changed after ly-
ophilization at some cases.
CONCLUSIONS: The length of freeze-drying 
cycle can be shortened to a limited period of time 
to achieve a dry product. Applying higher tem-
perature can accelerate drying, but also can cause 
the damage of the structure.
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QSRR modeling of Liquid Chromatography 
separation of Ziprasidone compounds
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INTRODUCTION: Ziprasidone is an atypical an-
tipsychotic drug with an aﬃ  nity to the adrenergic 
(α1), histamine (H1), serotonin (5-HT2), and dopa-
mine (D2) receptors [1]. The fi rst quantitative 
HPLC analysis of ziprasidone and its fi ve main 
impurities (I-V) was developed and validated by 
our research group [2]. The main aims of the pre-
sented chemometric study was to develop the 
QSRR model for the prediction of the chromato-
graphic retention of the other ziprasidone deriva-
tives, or metabolites.
MATERIALS AND METHODS: The mini-
mum energy conformations of the analyzed com-
pounds were obtained by the Molecular Orbital 
PACkage/Parametric Method Vs.3 (MOPAC/
PM3). Molecular descriptors were computed for 
the optimized molecular models with use of the 
MarvinSketch 5.1.5.0 program, the Chem3D Ultra 
7.0.0 program, CS Gaussian 98 program using the 
B3LYP hybrid functional. The QSRR study was 
performed with use of the Soft Independent Mod-
eling of Class Analogy SIMCA P+ 12.0 program 
[3], for the Partial Least Square (PLS) Regression 
analysis [4].
RESULTS: The retention times (tR) of ziprasi-
done and its impurities (obtained with the devel-
oped HPLC gradient method) [2], and the com-
puted molecular parameters of the examined com-
pounds were used to build the QSRR models. De-
scriptors with the highest VIP values were select-
ed for PLS-QSRR model building. Optimal 
combination of the most relevant descriptors (MS, 
SAS, LogP, LogDpH 2.5, LogDpH 1.5 and Log-
DpH 4.0) for PLS models building were chosed on 
basis of the R2, Q2, RMSEP values of the obtained 
PLS models. The obtained statistical parameters of 
the PLS-QSRR model (r2=0.913) pointed out to a 
good prognostic capacity of the developed QSRR 
model.  The developed PLS-QSRR model was 
used to predict separation of ten (TS1-TS10) zipra-
sidone derivatives (organic impurities, metabo-
lites and potential degradation products) in RP-
HPLC system. Based on the obtained results, the 
PLS-QSRR model proposed two structures as po-
tential for unknown impurity (tR: 11.270 min) in 
the test solution [2], and one of them (TS1) was 
confi rmed by UPLC-MS-MS study. 
CONCLUSION: The high agreement between 
LC-MS results and the QSRR prediction have con-
fi rmed good prognostic potential of the created 
QSRR models. Furthermore, the predicted tR val-
ues for TS1-TS10 basically diﬀ ered from those for 
ziprasidone and its impurities (I-V) which indi-
cates that the developed QSRR model can be suc-
cessfully used for the separation of ziprasidone 
from the other ziprasidone derivatives.
ACKNOWLEDGMENTS: This work was sup-
ported by the Ministry of Education and Science 
of the Republic of Serbia Contract No. 172033.
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Formulation strategy of anti-microbial peptide 
(AMP) delivery systems
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INTRODUCTION: Antimicrobial peptides 
(AMPs) are small and diverse peptides which 
were initially isolated in the 1980s; Great eﬀ orts 
are done to bring AMPs into therapy with increas-
ing in resistance development to conventional an-
tibiotics. Due to the complexity in stability, safety 
and eﬃ  cacy of AMPs, novel formulation strate-
gies, methodologies and delivery systems are re-
quired [1, 2].
MATERIALS AND METHODS: As a part of 
the pre-formulation evaluation of AMP containing 
dosage forms, SWOT analysis was used to evalu-
ate the formulation possibilities and carrier op-
tions, followed by an Ishikawa diagram for illus-
trating the factors aﬀ ecting the quality of an AMPs 
containg drug delivery system. Finally a theoreti-
cal initial risk assesment (RA) [3] was made.
RESULTS: Pre-formulation design was per-
formed within the QbD framework. Results of the 
SWOT analysis showed weaknesses such as low 
metabolic stability, regulatory barriers and high 
costs can be defeated by diﬀ erent opportunities 
which biochemistry and nanotechnology oﬀ er for 
the development of more stable peptides. Besides, 
threats such as loss of antimicrobial activity and 
cytotoxicity of AMPs still should be considered 
and tested. The Ishikawa diagram illustrates all 
the elements (eg. characteristics of the drug and 
diﬀ erent methods, etc) which can have an infl u-
ence on the quality of the AMPs. This diagram 
was used to select the critical factors, and theoreti-
cal initial RA was performed.
CONCLUSION: The pre-formulation evalua-
tion of the AMP containing dosage forms is essen-
tial in order to ensure products with the pre-
defi ned quality.
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biopharmaceutical and pharmacokinetic 
properties of model drugs exhibiting low 
solubility and low permeability
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INTRODUCTION: Data mining is a process of 
discovering patt erns and hidden connections in 
large data sets by using statistics, artifi cial intelli-
gence and machine learning tools [1]. The aim of 
this study was to investigate and identify factors 
determining drug classifi cation based on diverse 
set of input data related to physicochemical, bio-
pharmaceutical and pharmacokinetic properties 
of the selected model drugs exhibiting low solu-
bility and low permeability.
MATERIALS AND METHODS: Database 
consisting 18 drugs which have been recognized 
as having solubility and permeability limited 
absorption (generally classifi ed as BCS class 4 
drugs) has been prepared following extensive 
literature search and critical evaluation of data 
available. The investigated input parameters 
were: MW (molecular weight); HB (sum of hy-
drogen bond donor and acceptor counts); cLogP 
(calculated partition coeﬃ  cient); PSA (polar sur-
face area); D/S (dose/solubility ratio); Peﬀ  (eﬀ ec-
tive permeability); Fa (fraction drug absorbed); 
AUC/D (area under the concentration-time 
curve/dose ratio); Cmax/D (peak plasma con-
centration/dose ratio); EoM (extent of metabo-
lism), and t1/2 (drug half-life). The analysis has 
been performed using fi ve parameter combina-
tions: (i) clogP, PSA, HB, MW; (ii) D/S, Fa, Peﬀ ; 
(iia) D/S, Fa, EoM; (iii) Fa, AUC/D, Cmax/D, 
t1/2; (iv) combination of all the investigated pa-
rameters. Hierarchical clustering on principal 
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components has been employed using Software 
R, v. 1.1.447.
RESULTS: The number of clusters determined 
by the software for each combination of input 
variables ranged from 3 to 6. The following pa-
rameters contributed signifi cantly to cluster sepa-
ration for each of the investigated combinations: 
(i) clogP and MW; (ii) and (iia) D/S; (iii) AUC/D; 
(iv) AUC/D and clogP. Although overall match be-
tween clusters obtained using diﬀ erent parameter 
combinations was moderate, it is interesting to 
note that: a) furosemide, hydrochlorothiazide, 
chlorothiazide and ciprofl oxacin HCl, as well as b) 
famotidine, cefi xime and cefuroxime axetil have 
been grouped in the same cluster irrespective of 
the parameter combination used for data analysis.
CONSLUSIONS: Data mining provide useful 
insight into the similarities between diﬀ erent par-
titionings leading to recognition of several sub-
groups within the data set related to model drugs 
generally classifi ed as BCS class 4.
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Wurster Granulation PAT monitoring by NIR: 
calibration vs PCA trend approach
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INTRODUCTION: One of the main points of in-
vestigation to optimize a coating process, is to 
precisely determine and monitor the process 
trend.
The aim of this study was the feasibility to ap-
ply a NIR device to a fl uid bed coating process. 
Specifi cally, the possibility to correlate the same 
NIR response to the moisture content and to the 
sprayed solution amount.
MATERIALS AND METHODS: In this study, 
a placebo batch of cores was coated by Wurster 
coating using fl uid bed (FV-VFC Lab3) equipped 
with a Viavi MicroNIR PAT-U device. Three runs 
were performed. The process was replicated to 
demonstrate the robustness of this method. The 
spectra were collected by the NIR probe every 5 
seconds. Data were analyzed and processed by 
Unscrambler© software.
PCA Analysis: The fi rst data analysis on the 
spectra collected was the PCA. The PCA locates 
the combination of directions in this space on 
which the data are more dispersed, this gives the 
most quantity of information about the variability 
of the process parameter during time. The second 
combination of directions on which the data are 
most dispersed will be considered the second 
PCA and it will be perpendicular to the former 
one and so on. Thus, a new multidimensional 
space will be defi ned, having the PCAs as dimen-
sions. This will align every sample on a precise 
path that allows to follow the process trend dur-
ing time.
RESULTS: Every deviation can show immedi-
ately an anomaly occurred during the process. 
The interpolation of this graph shows clearly the 
diﬀ erent phases of the granulation: heating, spray-
ing, drying. Using a NIR device, it is possible to 
monitor the process using a “trend” approach: ob-
serving the changes of the on-line response profi le 
it is possible to analyze the infl uence of the diﬀ er-
ent process parameters and defi ne the limits of 
specifi cations. Furthermore, it is possible to defi ne 
a calibration curve suitable to be used for the 
scale-up phase and to keep the production of each 
batch under control.
CONSLUSIONS: The possibility to follow on-
line the process trend is very valuable to avoid 
wasting process time, energy and raw materials, 
and to optimize the process parameters and to ob-
tain a higher quality product. 
The process optimization and the possibility to 
keep it under control is very important for the re-
producibility of the fi nal product during time.
This study demonstrated the possibility to fol-
low the process trend.
This could open up the possibility to apply this 
technology to other techniques, and to implement 
a full integration of the NIR device with the equip-
ment software to get a complete automatic process 
control.
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P10- PREFORMULATION AND 
EXCIPIENTS
P10/1 
Varrying conditions of in vitro 
method for assessment of active substances 
permeability
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INTRODUCTION: In vitro metods have impor-
tant role in the development of new active sub-
stances, as screening methods, but also as sup-
portive metods in biowaiver request submision. 
They have advantages in these cases in terms of 
speed, simplicity and lower costs [1]. The possibil-
ity of method variation of published dynamic 
model of diﬀ usion cells with artifi cial mem-
brane[2] was tested in this study.
MATERIALS AND METHODS: Spectrophoto-
metric assay was validated for determination of 
concetrations in receptor and donor solution dur-
ing permeability studies of one representative of 
active substance from each BCS class: caﬀ eine, 
naproxen sodium, metformin hydrochloride and 
hydrochlorothiazide. Apparent permeability coef-
fi cients were determined for these substances, 
with varying support membrane pore size and the 
origin of lecitine in solution for membrane im-
pregnation (egg and soy lecitines were used) com-
pared to the published method.
RESULTS: Comparison of the obtained results 
for naproxen sodium with the published results 
indicate that the pore size of the supportmem-
brane is not the determining factor for the appar-
ent permeability coefi cient. The results of the per-
meability determinations of the tested substances 
indicate that the lecitine composition in the solu-
tion for impregnation has certain infl uence. It is 
determined that the corelation coefi cient of the 
implemented method with the percent in vivo ab-
sorption in humans (R2 = 0.9692 for egg lecitine 
and R2 = 0.9239 for soy lecitine in impregnation 
solution) is higher than the literature accounts ob-
tained with the other in vitro methods.
CONCLUSION: Based on the examination of 
varying method conditions of dynamic model of 
difusion cells with artifi cial membrane that was 
carried out, further assessment of method suitabil-
ity has grounds with the aim of method valida-
tion, that could be used for permeability screening 
purposes of new substances intended to be incor-
porated in solid oral dosage forms.
REFERENCES:
1. Volpe D.A. AAPS Journal 12, 670–678 (2010)
2.  Corti G. et al. Eur J Pharm Sci 27, 354–362 
(2006)
P10/2 
Application of PAMPA gastrointestinal model to 
predict permeability of sumatriptan in free form 
and in system with cyclodextrin derivatives
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of Medical Sciences, Poland;
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INTRODUCTION: Parallel artifi cial membrane 
permeability assay (PAMPA) gastrointestinal 
model is a method which is used as an in vitro 
model of passive transcellular permeation for ac-
tive pharmaceutical substances.
The aim of the present work was to examine the 
utility of PAMPA gastrointestinal model in pre-
dicting permeability of sumatripran and its sys-
tems with cyclodextrins.
MATERIALS AND METHODS: Due to low 
solubility and bioavailability as model drug su-
matriptan was chosen. The PAMPA was tested for 
sumatripran (SUM) as well as its inclusion com-
plexes with β-cyclodextrin (BCD) and 
hydroxypropyl-β-cyclodextrin (HPBCD).
Permeability studies of sumatriptan and its sys-
tems were conducted through artifi cial membrane 
using a PAMPA gastrointestinal model at pH 1.2, 
4.5 and 6.8. The system consisted of a 96-well mi-
crofi lter plate and a 96-well fi lter plate and was di-
vided into two chambers: a donor and an accep-
tor, separated by a 120-μm-thick microfi lter disc 
coated with a 20% (w/v) dodecane solution of a 
lecithin mixture (Pion, Inc.). The substances were 
dissolved in donor solution. The plates were put 
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together and incubated at 37 °C for 2h. After time 
plates were separated and the concentrations of 
substances in donor and acceptor chambers were 
measured. The apparent permeability coeﬃ  cients 
(Papp) were calculated. Compounds with Papp < 
1 x 10-6 cm s-1 were classifi ed as low-permeable 
and those with Papp > 1 x 10-6 cm s-1 as high-per-
meable compounds.
RESULTS: Sumatriptan showed low values of 
apparent permeability coeﬃ  cients under all study 
conditions. A twofold rise in permeability oc-
curred during the inclusion of SUM into HPBCD 
(e.g. (0.16±0.01) x 10-6 cm s-1 and (0.40±0.02) x 
10-6 cm s-1 at pH 1.2 for SUM and SUM-HPBCD 
complex, respectively).
CONLUSIONS: Based on the results, PAMPA 
gastrointestinal model was found as useful tool to 
compare permeability of sumatriptan in free form 
and in systems with cyclodextrin derivatives. 
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INTRODUCTION: Low solubility of antibiotics is 
one of the main limitation in their eﬀ ectiveness. 
Modifi cation their physicochemical properties in 
the result of introduction them into binary sys-
tems with polymers can be a solution of men-
tioned limitation. Hydroxypropyl-ß-cyclodextrin 
(HPBCD) as well as Pluronic® are known as solu-
bilizer agents. While (hydroxypropyl)methylcellu-
lose (HPMC) has been found as prolonge release 
substance. Increased and prolonged release of an-
tibiotic from pharmaceutical matrix is expected to 
maintain its constant eﬀ ective concentration for a 
longer period of time and thus lead to its more ef-
fective absorption.
The aim of the present work was to study the 
infl uence of hydrophilic biopolymers (HPBCD, 
Pluronic, HPMC) on tedizolid dissolution and 
permeability through artifi cial membrane of gas-
trointestinal tract model.
MATERIALS AND METHODS: Tedizolid sys-
tem with HPBCD was prepared in molar ratios 1:1 
while systems with Pluronic® and HPMC in 
weight ratio 1:1 and 1:5.
In vitro dissolution studies of tedizolid were 
performed according to European Pharmacopoeia 
by using an Agilent 708-DS Dissolution Appara-
tus. As the acceptor solution, 0.1M HCl (pH 1.2) 
and phosphate buﬀ er (pH 4.5 and 6.8) stimulating 
gastrointestinal environmental was used. All dis-
solution profi les were compared with model inde-
pendent mathematical approach using a similarity 
factor.
Permeability studies of tedizolid systems were 
conducted through artifi cial membrane using a 
model of parallel artifi cial membranes permeabili-
ty assay system (PAMPA). The apparent permea-
bility coeﬃ  cients (Papp) were calculated.
RESULTS: Dissolution rates of tedizolid were 
signifi cantly diﬀ erent depending on kind of hy-
drophilic biopolymers which was used. Further-
more, excipients impacted also on the tedizolid 
permeability through artifi cial membranes.
CONLUSIONS: Based on the results, it was 
found that the presence of hydrophilic biopoly-
mers signifi cantly infl uence on tedizolid solubility 
increasing and prolonging its release from the re-
ceived systems. Modifi cated release manifests also 
in extended membrane penetration of tedizolid 
from its polymeric systems.
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INTRODUCTION: For formulation development 
traditional (USP) dissolution tests have been used 
in the pharmaceutical industry to compare perfor-
mance of diﬀ erent drug formulations before con-
ducting in vivo studies. Although dissolution tests 
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provide a simple way of testing formulations, the 
in vivo predictive power of these tests are ques-
tionable [1]. When a poorly water-soluble API is 
formulated to enhance its dissolution additives, 
such as surfactants, polymers and cyclodextrins 
have an eﬀ ect not only on dissolution profi le, but 
also on fl ux through the membrane. The aim of 
this study was to represent how simultaneous dis-
solution-absorption studies can be used for com-
paring diﬀ erent formulations containing the same 
API.
MATERIALS AND METHODS: 3 formula-
tions of Itraconazole: Sporanox solution (100 mg), 
Sporanox capsule (100 mg) and Losanoc capsule 
(50 mg), were tested using MacroFLUX Receiver 
chamber integrated with permeation membrane, 
overhead stirrer and fi ber optic UV probe was in-
serted in the standard 250 mL vessel of USP 2 ap-
paratus. A fi lter-supported artifi cial membrane 
(Double-Sink PAMPA) with 3.69 cm2 area was 
separating the dissolution compartment from the 
receiver compartment containing 20 mL of Accep-
tor Sink Buﬀ er at pH 7.4 (ASB, Pion Inc). Real time 
concentration monitoring in both dissolution and 
absorption chambers was enabled through fi ber 
optic UV probes (Pion Inc).
RESULTS: The dissolution and fl ux results of 3 
marketed Itraconazole formulations were com-
pared in fasted and fed state to each other and to 
the in vivo study results published in the litera-
ture. The in vitro test was found to be sensitive 
enough to show diﬀ erences between formulations 
caused by the use of diﬀ erent excipients and rank 
order the formulations in fasted and fed state as 
well. The results of the food eﬀ ect study in case of 
the Sporanox capsule and the solution are in good 
agreement with the in vivo data.
CONCLUSION: In contrast with traditional 
(USP) dissolution tests in case simultaneous disso-
lution-absorption studies the eﬀ ect of formulation 
excipients, dose and food on dissolution and also 
on membrane transport can be measured. This 
knowledge is essential for generic formulation de-
velopment for fi nding the right additives to be 
able to meet the bioequivalence criteria.
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INTRODUCTION: Clopidogrel bisulfate (CB) is 
an anti-platelet drug for the treatment of patients 
with a high risk of myocardial infarction and be-
longs to BCS II class drugs. Solid dispersion (SD) 
is a dispersion of one or more active ingredients in 
hydrophilic inert carrier matrix and it is one of the 
most promising and eﬃ  cient techniques for drug 
dissolution improvement [1-3].
The aim of this study was to assess the infl u-
ence of type and concentration of hydrophilic 
polymer on the CB dissolution rate.
MATERIALS AND METHODS: Four diﬀ erent 
hydrophilic polymers (Macrogol 6000 (Polyglycol 
6000 S), povidone (Kollidon® 30), copovidone 
(Kollidon® VA 64) and poloxamer 407 (Kolliphor® 
P 407) and two CB: polymer ratios (1:1 and 1:3) 
were used to formulate SD using solvent evapora-
tion method, with ethanol as a solvent (96% v/v).
In vitro dissolution testing was performed in 
USP apparatus 1, with mixing speed 75 rpm, in 
phosphate buﬀ er pH 6.8, 900 ml, as a medium. All 
samples contained 75 mg of CB (therapeutic dose). 
Concentration of CB was determined by HPLC-
UV method after 15, 30, 45 and 60 minutes. Disso-
lution profi les were compared to dissolution pro-
fi le of CB pure drug.
RESULTS: Results showed that all analyzed SD 
formulations, except CB:poloxamer 407 (1:1), had 
bett er dissolution than the pure CB drug. There was 
a signifi cant increase in % drug dissolved in SD for-
mulations 1:3 ratios compared to pure CB with the 
function of time. The obtained results indicated that 
with the increase in concentration of polymer in for-
mulation, the dissolution rate of drug was in-
creased. This could be due reduction of particle size 
and an increase in the eﬀ ective surface area over 
which the drug distribution increases accompanied 
by an enhancement in drug dissolution [4].
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CONCLUSIONS: Preparation of binary SD 
with investigated polymers at weight ratio 1:3 sig-
nifi cantly enhanced the dissolution rate of the 
drug compared to pure CB. SD with PEG 6000 
and copovidone were the most eﬀ ective, with con-
centration of dissolved drug of about 63% after 60 
min. This study has shown that the proper selec-
tion of type and concentration of hydrophilic 
polymer played important role in increasing the 
dissolution rate of CB.
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INTRODUCTION: Solubility is a physicochemi-
cal property, the determination of which is critical 
in drug discovery and development as it can aﬀ ect 
both technological and biopharmaceutical perfor-
mance of the drug. Very high throughput and 
very low compound consumption are realistic 
with the determination of “kinetic solubility” 
where the tested compounds are always pre-dis-
solved in organic solvents like dimethyl sulfoxide 
[1]. This inevitably results in several imperfections 
of the obtained data [2]. We have therefore investi-
gated and challenged the limitations of “thermo-
dynamic solubility” measurements by modifi ca-
tions of the traditional shake fl ask method.
MATERIALS AND METHODS: A simple 
technique based on the shake-fl ask method but 
with minimal use of the tested substance was de-
veloped. The thermodynamic solubilities of model 
compounds verapamil, propranolol, theophylline 
and digoxin were determined and compared to 
the available literature data.
RESULTS: The solubility values determined 
with the novel method agreed well with the previ-
ously published solubility data. This agreement 
includes also the time necessary to reach satura-
tion and the pH dependence of solubility. We 
have observed that the lowest volume of suspen-
sion for the determination of drug solubility does 
not have to be limited by the eﬃ  ciency of the me-
chanical mixing. Medium, but not high through-
put is achievable; however, the unavoidable hin-
drance of true thermodynamic solubility measure-
ments remains the handling of solids.
CONCLUSION: Very low suspension volumes 
at 50 μL or less can be adequately mixed to pro-
vide solubility determination of model com-
pounds in 24 hour experiments. The consumption 
of the solid substance tested does not have to be 
higher than 5 mg for a biopharmaceutically valid 
determination of thermodynamic drug solubility.
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INTRODUCTION: A new renaissance started in 
the research and application of cyclodextrins a 
few years ago. The number of novel derivatives 
are increasing and new applications has been ap-
peared [1]. By the help of fl uorescent derivatives 
the cellular interactions of cyclodextrins can be vi-
sualized and their biological activity can be moni-
tored [2]. PET radiotracer labelled derivatives help 
to understand the in vivo distribution and phar-
macokinetics of cyclodextrins. The aim of our 
study was to test the pharmacokinetic properties 
of fl uorescein-isothiocyanate labelled hydroxypro-
pyl-beta-cyclodextrin (FITC-HPBCD) and to study 
its internalization on diﬀ erent cell lines. We also 
aimed to synthetize and test 68Ga-labeled NODA-
GA-HPBCD.
MATERIALS AND METHODS: FITC-HPBCD 
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was the product of Cyclolab Ltd, while 68Ga-la-
beled NODAGA-HPBCD was synthetized at the 
University of Debrecen. Pharmacokinetic analysis 
was carried out on BALB/c mice. Small animal 
PET imaging and ex vivo organ distribution stud-
ies were carried out. Cellular internalization was 
followed by fl uorescent microscopy.
RESULTS: The blood concentration of HPBCD 
decreased rapidly after i.v. administration in the 
function of time, showing fast elimination. Accu-
mulation of FITC-HPBCD in diﬀ erent organs 
could not be measured in tissue homogenates at 
the end of the experiment. In vivo imaging tech-
niques confi rmed fast elimination. The cellular in-
ternalization of FITC-HPBCD was detected by fl u-
orescent microscopy on Caco-2, HaCaT and HU-
VEC cells. Endocytosis of FITC-HPBCD in the pri-
mary human endothelial cell line, HUVEC can ex-
plain the fi rst step of tissue distribution of 
cyclodextrins.
CONCLUSION: The in vivo behaviour of fl uo-
rescent cyclodextrins can be examined by fl uores-
cent and PET techniques, thus these derivatives 
are suitable for pharmacokinetic measurements. 
Our data are in accordance with earlier results 
and reveals that HPBCD can be internalized by 
several cell types.
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ABSTRACT:  Introduction: Preservatives are 
substances that are added to the product to pre-
vent it from spoilage. They act by inhibiting spe-
cifi c enzymes of the bacteria or inhibiting the 
growth of the bacteria. Nowadays we can experi-
ence increased att ention from the consumers to-
wards the safety of diﬀ erent pharmaceutical ex-
cipients such as preservatives. There are more and 
more complaints reported by patients of irritation 
that may be related to the the preservative content 
of the formulations. This is why it’s important to 
test their biocompatibility and see whether they 
are harmful or not.
MATERIALS AND METHODS: We tested 
three of the most commonly used groups of pre-
servatives: parabens, sorbates and salicylates. All 
preservatives were dissolved in PBS. The solutions 
of the paranbens contained other excipients as 
well to bett er simulate real pharmaceutical formu-
lations. To test for the cytotoxic eﬀ ect we used 
MTT assay and RT-CES assay. MTT assay is based 
on the mithochondrial activity of viable cells. The 
cells convert the MTT paint to formazan precipi-
tate. RT-CES assay is based on measuring the elec-
trical impedance in the presence of the tested com-
pound. This way we can get information of the 
cell growth rate. The experiments were executed 
on Caco-2 cells. The Caco-2 cell line is great to 
model the gastrointestinal tract.
RESULTS: The cytotoxicity of the methyl para-
ben is changing, depending on what other excipi-
ents we used in the solutions. Both MTT assay and 
RT-CES results confi rm that. In the case of sor-
bates according to the MTT assay results there is 
no diﬀ erence between the cytotoxicity of the salts. 
According to the RT-CES results only potassium 
sorbate is safe to use and sodium sorbate seems to 
be toxic to human cells.
CONCLUSIONS: The cytotoxicity depends on 
the composition, there is no general cytotoxicity 
value that can describe a compound, it needs to be 
checked every time when a new pharmaceutical 
drug is formulated.
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INTRODUCTION: Ionotropic gelation occurring 
as a consequence of chemical reaction between 
ionic gel-forming polymer solutions and counter 
ions is a possible method for the production of 
drug-loaded microcapsules. Several factors play 
signifi cant role in the course of coacervation: tem-
perature, ion concentration, polymer concentra-
tion, pH. The observation that the crosslinking ion 
concentration of the coacervation medium infl u-
ences gelation is published in the case of gelatin, 
agarose, pectin, alginate. The most examined rela-
tion is Ca2+- alginate in complex coacervation [1, 2].
In our experiments the phenomenon was stud-
ied in the presence of various di-/trivalent cations 
to observe the role of type and concentration of 
the ions on the gelation and phase separation.
MATERIALS AND METHODS: Diﬀ erent gel-
forming polymers were investigated, among these 
the most examined sodium alginate along with 
Ca2+, Mg2+, Fe2+, Fe3+, Al3+ and Bi3+ ions to determine 
the optimal parameters for coacervation. Potentio-
metric titration (Hanna HI902C Automatic Potenti-
ometric Titration System, Hanna Instruments, 
USA) aided the specifi cation of the most proper 
parameters of phase separation. The optimal con-
ditions were applied to form microspheres with 
Büchi B-390 Microencapsulator (Büchi GmbH, 
Switz erland) using vibrating nozzle technique. The 
morphological parameter testing was carried out 
using laser diﬀ ractometry (Malvern Instruments, 
Malvern, UK), scanning electron microscopy (Hit-
achi 2360 N Hitachi Ltd., Tokyo, Japan) microscop-
ic image analysis (Nikon SMZ 1000 and ImageJ 
Software) to defi ne the particle size distribution 
and shape determination of the produced beads. 
RESULTS: Our investigations proved the dif-
ferent ability of cations in the formation of stable, 
spherical beads with alginate, which may oﬀ er the 
opportunity to choose the most convenient excipi-
ents and parameters in the microencapsulation of 
active ingredients related to drug release.
CONCLUSION: The experiments provide 
source for the development of a stable m: icroen-
capsulated drug-carrier system.
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INTRODUCTION: Chrysin is a poorly soluble 
biofl avonoid with several biological eﬀ ect and can 
be found in several plant extract including also 
propolis and honey. It has anti-infl ammatory, anti-
oxidant and anticancer activity [1, 2]. Our aim was 
to test the chrysin solubilisation capacity of diﬀ er-
ent β-cyclodextrin derivatives and prepare com-
plexes to examine their biological activity, espe-
cially on the NF-κB pathway. 
MATERIALS AND METHODS: Cyclodextrins 
were the product of Cyclolab Ltd, all other re-
agents were from Sigma-Aldrich. Chrysin-cyclo-
dextrin complexes were produced by liophylisa-
tion in diﬀ erent molar ratios. Phase-solubility test 
was performed with β-, (BCD) Hydroxypropyl-β-, 
(HPBCD) Sulfobutylether-β-, (SBEBCD) and 
Randomly-methylated-β-cyclodextrin (RAMEB) 
and the concentration of dissolved chrysin was 
determined by HPLC method.  Cytotoxicity of the 
complexes was tested by MTT test and the inhibi-
tion of NF-κB pathway activation was investigat-
ed by immunofl uorescence, labelling the p65 sub-
unit. 
RESULTS: Phase-solubility experiments 
showed, that each cyclodextrin increased the solu-
bility of chrysin, but there were signifi cant diﬀ er-
ences among the derivatives. SBEBCD, RAMEB 
and HPBCD were able to eﬀ ectively solubilize 
chrysin, while BCD showed limited capacity. MTT 
test revealed that up to 100 μM concentration the 
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examined complexes were not cytotoxic on Caco-2 
cells. Investigating the NF-κB infl ammatory path-
way we found, that the pre-treatment of Caco-2 
cells with chrysin-cyclodextrin complexes de-
creased the TNF-α-induced nuclear translocation 
of p65. 
CONCLUSION: In conclusion, cyclodextrin de-
rivatives are able to eﬀ ectively improve the water 
solubility of chrysin and the formed complexes 
are not cytotoxic in the tested concentration range. 
The complexes are able to inhibit the main infl am-
matory pathway, NF-κB and cyclodextrins had no 
negative infl uence on the eﬀ ect. 
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INTRODUCTION: One of the crucial factors in 
patients’ compliance with orally taken medicine is 
defi nitely the drug taste. As many active pharma-
ceutical ingredients exhibit an unpleasant taste, 
taste-masking becomes particularly important [1]. 
On the other hand, the taste of chocolate has be-
come one of the most popular fl avors throughout 
the world. The main fat type used in chocolate 
production is cocoa butt er. However, in order to 
reduce costs and implement new functionalities to 
confectionery systems, various vegetable fats and 
oils are being used as cocoa butt er replacement. 
So, this may potentially make a cheap alternative 
carrier for drugs with an unpleasant taste.
But in order to achieve a quality confectionery 
product, one of the most important factors to fol-
low and measure is its solid fat content (SFC) [2]. 
The aim of this work was to measure the impact of 
particle size distribution of sugar and/or cocoa 
particles on SFC of vegetable oil, as this mixture 
may make a potential drug carrier for drugs with 
unpleasant taste.
MATERIALS AND METHODS: Diﬀ erent 
blends were prepared by using palm oil and sugar 
and cocoa particles of diﬀ erent sizes. SFC mea-
surements were conducted by pulsed NMR on a 
Bruker Minispec SFC analyzer by direct method 
(AOCS (Cd 16-b-93)). The liquid mixtures of oil 
with sugar, cocoa, and sugar and cocoa were 
transferred into pNMR tubes, cooled in a water 
bath from 65 °C to 20 °C at a rate of 0.5 °C/min 
and then left in a temperature cabinet at 20 °C for 
7 days. Before analysis, pNMR tubes with samples 
were heated to 65 °C for 30 min. The analyses 
were conducted in triplicates for each sample.
RESULTS: Results of the pNMR measurements 
showed that the only signifi cant diﬀ erence in SFC 
occurred in samples containing only sugar. 
Among these samples, those with smaller parti-
cles had higher solid fat content. Samples contain-
ing only cocoa or sugar and cocoa particles did 
not show signifi cant diﬀ erence in SFC due to dif-
ferent particle size distribution.
CONCLUSION: Since particle addition had 
only minor or no eﬀ ect on the SFC, this matrix 
may present a good starting point for the inclu-
sion of a thermostable active pharmaceutical in-
gredient, in order to create an att ractive drug dos-
age form with the taste-masking ability.
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P10/12 
Photostability of hydrophilic vitamins
RAKUŠA, Z. T., GROBIN, A., KRISTL, A., 
ROŠKAR, R.
Faculty of Pharmacy, University of Ljubljana, Ljubljana, 
Slovenia
INTRODUCTION: Hydrophilic vitamins are es-
sential nutrients, which, in case of inadequate in-
take or increased requirements, should be added 
as supplements. Multivitamin products are avail-
able in solid and liquid dosage forms for enteral 
and parenteral administration. Due to vitamins 
reactive nature, stability issues arise, which are 
more evident in dissolved state. Hydrophilic vita-
mins are generally light-sensitive, though, more 
detailed and systematic data on their photostabili-
ty is not available in the literature [1].
MATERIALS AND METHODS: Hydrophilic 
vitamins in forms, most commonly present in 
pharmaceuticals were tested: vitamin C, B1, B2, 
B3, B5, B6, B7, B9 and B12.
Vitamins were determined according to a vali-
dated stability-indicating method using Agilent 
UHPLC Infi nity 1290 instrument with a DAD de-
tector. Chromatographic separation was per-
formed on a XSelect CSH C18 column (150 × 4.6 
mm, 3.5 μm) with a gradient elution mode con-
sisting of 25 mM NaH2PO4 and MeOH.
Photostability testing was performed in a Mem-
mert ICH 260 L climate chamber in accordance 
with ICH Q1B guidelines [2] and was consisted of 
two parts: forced degradation and confi rmatory 
testing of each vitamin`s aqueous solution. Confi r-
matory testing was additionally performed on 
various vitamin combinations in diﬀ erent concen-
trations (in proportions such as in multivitamin 
products).
RESULTS: Forced degradation study revealed 
that hydrophilic vitamins are generally light-sensi-
tive. Vitamin B2 and B9 were found most suscepti-
ble to photodegradation. Vitamins photostability 
was found temperature and pH dependent. Their 
photostability was also evaluated in various combi-
nations to reveal interactions and possible incom-
patibilities. Most of them were found more stable 
in presence of other vitamins. The stabilization ef-
fect was most often due to vitamin C. However, 
some vitamins, such as vitamin B9 and B12 were 
more prone to photodegradation when in combina-
tion with others, especially with vitamin B2.
CONCLUSIONS: Overall, hydrophilic vita-
mins (individually or in combinations) were 
found light-sensitive. The obtained results oﬀ er 
valuable information regarding vitamins stability 
in parenteral nutrition admixtures. 
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3Department of Pharmaceutical and Pharmacological Sciences, 
University of Padova, Italy;
4Helminth Drug Development Unit, Swiss Tropical and Public 
Health Institute, Basel, Switz erland
INTRODUCTION: Praziquantel (PZQ) is the fi rst 
line drug used in endemic countries for the treat-
ment of schistosome infections and is included in 
the WHO Model List of Essential Medicines for 
Children. Several approaches have been under-
taken to reduce the high PZQ therapeutic dose 
thanks to its solubility enhancement. Among 
them, some strategies involving the drug mecha-
nochemical activation (MA) provided improved 
biopharmaceutical properties, thanks to diﬀ erent 
crystal modifi cations of PZQ [1, 2]. In this study, 
the association of MA and the spray congealing 
(SC) technology was evaluated for developing a 
child-friendly PZQ dosage form with bett er prod-
uct handling and Praziquantel biopharmaceutical 
properties compared to MA materials.
MATERIALS AND METHODS: To obtain 
(PZQ) Form B, having improved solubility and 
bioactivity [2], PZQ was neat ground in a Retsch 
MM400 vibrational mill. in addition, A 1:1 PZQ: 
Povidone coground was prepared in the same vi-
brational mill under cryogenic conditions, for fa-
vouring amorphysation upon milling [1]. Then, 
microparticles, using the self-emulsifying agent 
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Gelucire® 50/13 as carrier, were produced by the 
SC technology. Both the activated powders and 
the corresponding loaded microparticles were 
characterized for morphology, wett ability, solubil-
ity, dissolution behaviour, drug content and drug 
solid state (HSM, DSC, PXRD and FT-IR). Finally, 
samples were in vitro tested in comparison to 
PZQ against S. mansoni newly transformed schis-
tosomula (NTS) and adults.
RESULTS: As a consequence of incorporation 
in the self-emulsifying agent by SC, the MPs con-
taining both MA systems showed a further in-
crease of biopharmaceutical properties compared 
to the milled powders. The in vitro antischisto-
somal activity showed that MPs enabled PZQ re-
lease, while maintaining its bioactivity.
CONCLUSIONS: The microparticles contain-
ing PZQ Form B are a promising product for de-
signing a new PZQ formulation. 
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Micellisation of Binary Mixture of Surfactants 
Sodium-Deoxycholate and Sodium-Decyl 
Sulfate in Water Solution: Thermodynamic 
Description
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INTRODUCTION: This paper covers experimen-
tal determination of the critical micelle concentra-
tion (cmc) of the mixed micelles of Sodium-Deoxy-
cholate (NaDC) and Sodium-Decyl Sulfate (SC10), 
as well as the calculation of the parameters which 
describe thermodynamic stability of the exam-
ined mixed micelles.
MATERIAL AND METHODS: The solutions 
of NaDC and SC10 were used to produce mixtures 
of surfactants, in various molar ratios. Critical mi-
celle concentrations of the obtained mixed mi-
celles were determined by using spectrofl uoro-
metric analysis, on the following temperatures: 10, 
25, 35 and 50 °C [1,2].
RESULTS: Experimentally obtained cmc values 
of binary micelles were lower than ideal cmc val-
ues calculated for the respective binary mixtures, 
which proves the existence of interactions be-
tween NaDC and SC10 in the real mixed micelles. 
Negative values of the interaction parameter and 
the excess Gibbs energy (calculated by Regular 
Solution Theory) were obtained at all the exam-
ined temperatures. These results confi rm the exis-
tence of att ractive interactions between the diﬀ er-
ent components of the mixed micelle. Values of 
the excess Gibbs energy calculated by Rodenas´s 
model independent method were negative for 
most examined mixed micelles. Testing the sym-
metry of the function, which represents depen-
dence of excess Gibbs energy on mole fraction of 
the more hydrophobic surfactant in the mixed mi-
celles, showed the necessity of using two-para-
metric functions.
CONCLUSION: The occurrence of synergism 
in mixed micelles of NaDC and SC10 most proba-
bly is the consequence of the thermodynamic sta-
bilisation of micelles, due to the creation of hydro-
gen bonds among sulphate groups of SC10 and 
hydroxyl groups of NaDC.
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INTRODUCTION: Substandard and/or falsifi ed 
medicines are a growing global threat for health 
and they cause serious social and economic dam-
age. According to the new reports from WHO 
(2017), in the low- and middle-income countries 
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the failure rate of substandard and falsifi ed medi-
cal products is approximately 10.5% [1, 2]. Medi-
cines purchased over the Internet could be fake in 
50% [3, 4].
The current project is focusing on the develop-
ment of a technology to mark an individual trace-
able 2D code directly on the surface of the tablet to 
make it easier to diﬀ erentiate between fake and 
genuine drugs. As the demand for natural materi-
als is growing, the research was extended to natu-
rally colored polymer fi lms, too. Usually coatings 
contain titanium dioxide and talc for suﬃ  cient 
coverage, which makes precision laser coding 
more diﬃ  cult. New natural fi lms, the subjects of 
our examination, do not include the excipients 
mentioned above. In this research we would like 
to make a comparison of physical-chemical prop-
erties after the laser marking procedure between 
the conventional and natural colored coatings.
MATERIALS AND METHODS: HPMC coat-
ing polymers: Sepifi lm PW Red, Green, White and 
Sepifi lm Naturally Colored Pink and Green (Sep-
pic S.A.) were marked by ArF excimer pulse laser 
and semiconductor laser. After marking polymer 
fi lms, analytical quality control was made by Ra-
man spectroscopy, thermal gravimetric analysis 
and scanning electron microscope.
RESULTS: Structural change was seen by Ra-
man spectroscopy both in conventional and natu-
ral polymer fi lms treated with the semiconductor 
laser, while the excimer laser did not cause signifi -
cant alteration in the fi lms. Thermogravimetry 
showed no signifi cant result for the diﬀ erent fi lms. 
The pre- and post-laser structure was examined 
by SEM as well.
CONSLUSION: This study examined how con-
ventional coating materials behave compared to 
coatings with natural paint during laser marking. 
The results demonstrated that marking tablets by 
excimer laser could be the right instrument for 
naturally and conventionally colored coating 
polymers, too.
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Transport and biotransformation of gliclazide in 
probiotic bacteria
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INTRODUCTION: Gliclazide is a drug character-
ized by large interindividual diﬀ erences in thera-
peutic response. However, the cause of these dif-
ferences is not fully explained. It is known that in-
terindividual diﬀ erences in gut microfl ora compo-
sition may aﬀ ect drug metabolism and therapeu-
tic response (1). Thus, the aim of the present study 
was to investigate the transport and biotransfor-
mation of gliclazide in probiotic bacteria in in vi-
tro conditions.
MATERIALS AND METHODS: Samples of 
gliclazide with probiotics were incubated for 24 
hours at 37 °C. The intracellular and extracellular 
concentrations of gliclazide were determined in 
seven time points by high-performance liquid 
chromatography. Gliclazide biotransformation by 
enzymatic activity of probiotic bacteria was pre-
dicted by appropriate software packages.
RESULTS: During the twenty-four-hour incu-
bation with probiotic bacteria, in all time points, 
statistically signifi cantly lower concentrations of 
gliclazide in extracellular content were observed 
compared to controls. In addition, the total con-
tent of gliclazide, as a sum of intracellular and ex-
tracellular concentrations, was statistically signifi -
cantly lower compared to control throughout the 
whole studied period. Proposed metabolic path-
ways of gliclazide biotransformation by the action 
of probiotic bacteria involve reactions of hydroly-
sis and hydroxylation.
CONCLUSION: Based on the obtained results, 
it can be concluded that part of gliclazide is trans-
ported into probiotic bacteria, while part of drug 
is metabolized by the activity of bacterial en-
zymes. Interactions of gliclazide with probiotic 
bacteria at intestinal level might be the cause of in-
terindividual variations in drug response that is 
still to be confi rmed in in vivo conditions.
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logical Development of Vojvodina No. 114-451-
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INTRODUCTION: The unique structure and 
physicochemical properties of bile acids have en-
abled them to be used in the development of 
drugs, as excipients and drug carriers that could 
improve, control and localize drug delivery [1]. 
Hydrophobicity is the main determinant of bile 
acids toxicity and depends on the number, posi-
tion and orientation of the hydroxyl groups. Re-
placement of hydroxyl groups by keto groups in 
the structure of bile acids makes them more hy-
drophilic and less toxic and thus suitable for the 
use as drug excipients [2]. We aimed to analyze 
the impact of non-toxic bile acids, the most hydro-
philic natural bile acid ursodeoxycholic acid 
(UDCA) and semi-synthetic 12-monoketocholic 
acid (MKC) on pharmacological (cytotoxic) activi-
ty of antitumor drug vorinostat against colon 
cells.
MATERIALS AND METHODS: Human colon 
adenocarcinoma HT-29 cells were used to assess 
the cytotoxicity of vorinostat, alone or in combina-
tion with bile acids UDCA and MKC, using the 
colorimetric MTT assay. Multiple drug eﬀ ects 
were examined by calculating the combination in-
dex (CI) using CompuSyn software. CI1 is evi-
dence of antagonism.
RESULTS: Vorinostat exhibited a modest cyto-
toxic activity (IC50 = 5.1 μM), while UDCA and 
MKC were shown to be non-toxic against HT-29 
cells (IC50 352 μM and 212 μM, respectively). The 
co-incubation of cells with clinically relevant con-
centrations of vorinostat (1 μM and 2 μM) and 
non-toxic (IC20) concentrations of UDCA (50 μM) 
and MKC (35 μM) over 48h resulted in signifi cant 
increase of cytotoxicity. Calculated CIs of 0.05 and 
0.04 for UDCA, in combination with 1 μM and 2 
μM vorinostat respectively, demonstrated that 
UDCA exerted strong synergistic activity with 
vorinostat in concentrations that can be achieved 
in vivo. MKC also managed to sensitize cells to-
wards activity of vorinostat, with more pro-
nounced eﬀ ect in a combination with 2 μM vori-
nostat (CI = 0.04) than in a lower concentration (CI 
= 0.10).
CONCLUSIONS: Response to vorinostat may 
be altered by combining it with bile acids as drug 
excipients. The mechanisms responsible for this 
synergistic eﬀ ect should be more in-depth investi-
gated.
ACKNOWLEDGEMENT: This work was sup-
ported by HORIZON 2020 Project No. 690876 and 
the Project for Scientifi c and Technological Devel-
opment of Vojvodina No. 114-451-2072-/2016-02.
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INTRODUCTION: Cyclodextrins are widely 
used excipients for increasing water solubility, de-
livery and bioavailability of lipophilic drugs. Us-
ing fl uorescent cyclodextrin derivatives we 
showed previously, that cyclodextrins are able to 
enter Caco-2 intestinal cells by endocytosis, but 
the diﬀ erent fl uorescent labelling have not been 
compared on the same cyclodextrin derivative. On 
the other hand the consequences of the cellular in-
ternalization of cyclodextrins have not been re-
vealed yet.
MATERIALS AND METHODS: Our aim was 
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to compare the cellular internalization of fl uores-
cein and rhodamine labeled hydroxypropyl 
(HPBCD) and randomly-methylated beta-cyclo-
dextrins (RAMEB). Using fl uorescent microscopy 
and fl ow cytometry we tested the endocytosis of 
the fl uorescent cyclodextrins on Caco-2 cells. We 
also examined the eﬀ ect of these cyclodextrins on 
Nf-kappa B pathway and autophagy on Caco-2 
cells.
RESULTS: Both fl uorescein and rhodamine la-
beled derivatives are able to enter the intestinal 
Caco-2 cells by endocytosis in a comparable man-
ner. Cooling almost perfectly inhibited endocyto-
sis, while the application of rott lerin inhibited sig-
nifi cantly the uptake of cyclodextrins. We investi-
gated the possible activation of nf-kappa B path-
way, which is important in regulating cellular re-
sponses. Cyclodextrin pretreatment did not 
activate the translocation of the p65 subunit of nf-
kappa B heterodimer into cell nuclei both in cell 
monolayers or undiﬀ erentiated cells. After 
HPBCD and RAMEB treatments the presence of 
autophagosomes is detectable on fl uorsecent mi-
croscopic images, similar to control samples.
CONCLUSIONS: The type of fl uorescent label-
ling does not infl uence the internalization of 
HPBCD and RAMEB cyclodextrin derivatives. 
FITC and rhodamine conjugates showed similar 
intracellular localization. The endocytosis of cy-
clodextrin does not activate nf-kappa B pathway, 
while the examination of autophagy induction re-
quires quantitative analysis.
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INTRODUCTION: Liraglutide is an analogue of 
Glucagon-Like Peptide-1 (GLP-1) which was ap-
proved for treatment of type 2 diabetes mellitus at 
doses of 1.2 and 1.8 after that was approved at 
dose of 3.0 mg for treatment of obesity in combi-
nation with diet and exercise. Eﬃ  cacy of liraglu-
tide for weight loss was studied for diabetic and 
non-diabetic patients as well. The objective of this 
review is to determine if liraglutide is more eﬀ ec-
tive in diabetic versus non diabetic patients.
MATERIALS AND METHODS: We conducted 
a systematic review and meta-analysis of random-
ized clinical trials (RCT) comparing Eﬃ  cacy of li-
raglutide 3.0 mg for weight loss among diabetic 
and non-diabetic patients. We searched PubMed, 
Ovid Medline, Google Scholar and Cochrane Li-
brary databases relevant published studies in Eng-
lish from March 2008 until March 2018. We esti-
mated standard Mean diﬀ erence (Std. MD) with 
95% confi dence intervals using random eﬀ ects 
model and assessed for heterogeneity (I2).
RESULTS: We screened a total of 42 studies re-
lated to liraglutide eﬃ  cacy for weight loss from 
which four studies (with 4678 patients) studies 
met our inclusion criteria. One of them studied li-
raglutide eﬃ  cacy in weight loss in diabetic pa-
tients, while the other three studied liraglutide ef-
fi cacy in weight loss in non-diabetic patients. 
Weight loss in non-diabetic patients was statisti-
cally higher (Std. MD 0.80 CI 0.74 to 0.86, P= 0.49 
I2 = 0%)
This meta-analysis of RCTs showed that weight 
loss due to liraglutide use in non-diabetic patients 
was statistically higher than it in diabetic patients.
OTHER: More trials on diabetic patients using 
liraglutide for weight loss are required. Also more 
trials on variant ethnicities are required.
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Preference and adherence to once – monthly 
versus once weekly bisphosphonates in patients 
with osteoporosis: a systematic review and meta-
analysis
ELSAYED AHMED, S.1, EBRAHEEM SAADA, A.2
1Sherbin Central Hospital, Mansoura, Egyipt;
2Dakhlia Health Adminstration
INTRODUCTION: Once-weekly and once-
monthly bisphosphonates are considered revolu-
tionary dosing intervals for osteoporosis. Many 
patients with osteoporosis went through both dos-
ing intervals but still not clear which dosing inter-
val is most favorable for patients. The objective of 
this study was to determine whether Once-weekly 
or once-monthly is more satisfi ed and results in 
more drug adherence.
MATERIALS AND METHODS: We conducted 
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a systematic review and meta-analysis of random-
ized clinical trials (RCT) comparing patients pref-
erence and drug adherence for monthly dosed 
bisphosphonates (Ibandronate and minodrenate) 
versus weekly dosed bisphosphonates (residero-
nates and alendronate). We searched PubMed, 
Ovid Medline, Google Scholar and Cochrane Li-
brary databases relevant published studies in Eng-
lish until March 2018. We estimated Preference 
diﬀ erences with 95% confi dence intervals using 
random eﬀ ects model and assessed for heteroge-
neity (I2).
RESULTS: We screened a total of 23 studies re-
lated to bisphosphonates dosing interval from 
which four (with 1004 patients) studies met our 
inclusion criteria. Two studies used alendronate, 
while one used residronates and one used both 
alendronate and resideronates as weekly bisphos-
phonates. For monthly bisphosphonates, three 
studies used Ibandronate, while one used Mino-
droate. In comparison with either once-monthly 
or once-weekly. Preference for once-monthly 
bisphosphonates was statistically higher, the 
pooled preference was (0.43, 95% CI 0.39 to 0.47, P 
= 0.61, I2 = 0%). Also adherence to once-monthly 
bisphosphonates was statistically higher (0.38, 
95% CI 0.34 to 0.42, P = 0.52, I2 = 0%).
This meta-analysis of RCTs showed that once-
monthly bisphosphonates dose interval use was 
associated with higher patient preference and 
therapy adherence compared to once-weekly for 
adults with osteoporosis.
OTHER: Studies conducted on White and 
Asian women. There is lack of researches on other 
women ethnicities also on men with osteoporosis.
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Measures (PROMs) in QbD based formulation 
development in opthalmology
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INTRODUCTION: PROMs are important to both 
the clinician and the researcher, and they may be 
used to assess health-related quality of life, or to 
assess symptoms or perception of health status. 
The development of most PROMs in ophthalmic 
research has been driven by the recognition that 
clinical tests (visual acuity, perimetry, ocular co-
herence tomography), imperfectly capture the ex-
tent to which patients are impacted by sight im-
pairment [1]. Beside this, there can be other sys-
temic, psychological, emotional and social eﬀ ects 
of both the disease and its treatment [2]. 
The aim of this “Quality by Design” (QbD) 
based study is to extend the usage of PROMs to 
the early R& D phase, together with physicians’ 
expectations and researchers’ perspectives as well. 
MATERIALS AND METHODS: Evaluation of 
scientifi c literature, guidelines and regulations 
concerning the parameters aﬀ ecting patients’ 
quality of life; an adaptation of the extended QbD 
model is proposed for the development of oph-
thalmic preparations [3].
RESULTS: The research team developed a new 
model for QbD based formulation design process 
in case of ophthalmic dosage forms. Patients’ per-
ceptions were collected by means of generalized 
and disease specifi c questionnaires; followed by 
gathering information from the health care pro-
viders about the product performance. Based on 
these evaluations an optimized formulation de-
sign can be achieved in order to have in an im-
proved therapeutic eﬃ  ciency and patient adher-
ence. A prior strategic planning according to the 
QbD framework and its adaptation to a special 
therapeutic area e.g. ophthalmology is an ad-
vanced manner to have a patient user friendly 
product on the market.
CONCLUSION: The model can be a useful 
tool in the selection of the dosage form and the crit-
ical quality att ributes from patients’ point of view.
REFERENCES:
1.  Denniston A.K. et al. Eye 28, 637–645 (2014)
2.  Dean S. et al. Br. J. Ophthalmol. doi:10.1136/
bjophthalmol-2016-309955 (2017)
3.  Csóka I. et al. Drug Discovery Today 23, 
1340–1343 (2018)
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who are mechanically ventilated
KEREC KOS, M.1, GROSEK, S.2, 3, 4, GRABNAR, I.1 
1Faculty of Pharmacy, University of Ljubljana, Ljubljana, 
Slovenia;
2Department of Perinatology, University Medical Centre 
Ljubljana, Ljubljana, Slovenia
ACTA-1803-CESPT.indb   206 2018. 09. 10.   10:12
 2018/3. Acta Pharmaceutica Hungarica – CESPT Edition – Posters 207
INTRODUCTION: Fentanyl dosing in children is 
complex, as pharmacokinetic (PK) and pharmaco-
dynamic (PD) parameters diﬀ er signifi cantly from 
adults and also among pediatric population. We 
aimed to develop a PK-PD model of sedation with 
fentanyl in mechanically ventilated critically ill 
children.
MATERIALS AND METHODS: We included 
49 children (less than 2 years) with severe acute 
bronchiolitis, who were mechanically ventilated 
and received intravenous infusion of fentanyl for at 
least 3 days. During the infusion 5 blood samples 
were taken. Sedation and anaesthesia were moni-
tored by COMFORT-B scale and bispectral index 
(BIS). COMT Val158Met, ABCB1 C3435T and 
OPRM1 A118G genetic polymorphisms were deter-
mined. Population PK model of fentanyl was de-
veloped using NONMEM software. Sequential PK-
PD model of sedation was developed by modelling 
the relationship with COMFORT-B score and BIS.
RESULTS: The fi nal pk model of fentanyl was a 
two compartment model with the estimated vol-
ume of central compartment 109 L/70 kg, volume 
of peripheral compartment 39.9 L/70 kg, clearance 
36.6 L/h/70 kg, and distribution clearance 87.1 
L/h/70 kg. The clearance was infl uenced by body-
weight and postmenstrual age (PMA). The later 
refl ects maturation of clearance independently 
from the eﬀ ect of body weight, which was includ-
ed in the model by allometric scaling. We estimat-
ed that clearance achieves 50% of the adult value 
in a full-term newborn aged 3.5 weeks.
PK-PD relationship with COMFORT-B and BIS 
were adequately described by a sigmoidal Emax 
model. The tolerance was modelled as an interac-
tion with partial agonist accumulated in a hypo-
thetical tolerance compartment. In the model for 
COMFORT-B COMT genotype infl uenced intrinsic 
potency of fentanyl, which was almost 80% higher 
in carriers of variant allele compared to homozy-
gous wild-type. In the model for BIS eﬃ  cacy of fen-
tanyl was 14.8% higher in patients with ABCB1 
variant homozygote genotype. PMA infl uenced in-
trinsic potency and eﬃ  cacy of fentanyl. Conse-
quently, in older children higher doses of fentanyl 
were required to achieve the same level of sedation.
CONCLUSION: In the developed PK-PD mod-
els bodyweight, PMA, COMT and ABCB1 gene 
polymorphisms infl uenced the levels of sedation 
achieved by continuous infusion of fentanyl in 
critically ill children who were mechanically ven-
tilated. The model enables individualization of 
fentanyl dosing in the studied population.
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ATP Bioluminescence for surface 
contamination control in hospital pharmacy 
premises
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2Institute of Microbiology and Immunology, Faculty of Medicine, 
University of Ljubljana, Ljubljana, Slovenia;
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INTRODUCTION: In order to control the quality 
of hospital pharmacy clean rooms we implement-
ed a new alternative and rapid bioluminescence 
method for measuring the overall ATP, and indi-
rectly bioburden of surfaces in the hospital envi-
ronments [1]. We assumed that despite the low mi-
crobial load of tested environment the method is 
suﬃ  ciently sensitive for routine use and, due to 
simplicity useful as a quick and eﬀ ective tool for 
quality control and a tool for detecting change 
and monitoring trends [2, 3].
MATERIALS AND METHODS: The testing 
was performed parallel to routine microbiological 
control. Firstly we divided our premises into sev-
eral meaningful categories, defi ned the action lim-
its, and then searched for the correlation of meth-
ods by individual categories. The basic principle 
of bioluminescence method is enzyme-catalysed 
reaction in the presence of ATP. The technique in-
cludes the sample collection, the implementation 
of the enzyme reaction and the detection of dur-
ing reaction released light by using a lab lumi-
nometer Kikkoman (Lumitester PD 30). The ob-
tained results were evaluated for relevance and 
the methods were compared with respect to per-
formance in fi nding an inadequate surface (chi-
squared test).
RESULTS: In places with more stringent re-
quirements we did not confi rm any signifi cant dif-
ferences between compared methods (p=1), while 
the new method is more sensitive in places with 
less stringent requirements (p<0.05).
CONCLUSION: The used method measures 
the overall ATP from living cells and ATP released 
from dead cells or residues of used materials. It 
represents an important approach where quick ac-
cessibility of the results is needed and which pro-
vides possibility to implement corrective mea-
sures immediately.
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INTRODUCTION: Depression is a chronic men-
tal disorder that causes changes in mood, 
thoughts, behavior and physical health. According 
to the World Health Organization (WHO) 350 mil-
lion people worldwide are said to suﬀ er from this 
mental disorder. This explains why antidepres-
sants are widely used [1, 2]. The aim of this study 
was to analyze the use of antidepressants in Ser-
bia, Norway and Finland from 2013 to 2015.
MATERIAL AND METHODS: The data about 
the use of antidepressants in Serbia, Norway and 
Finland in 2013, 2014 and 2015 was taken from the 
Agency for Drugs and Medical Devices of the Re-
public of Serbia, the sites of Norwegian Institute 
of Public Health, and Finish Agency for Drugs 
Fimea.
RESULTS: Large number of depressed patients 
and smaller number of antidepressants used in 
Serbia compared to Finland and Norway in 2013, 
2014 and 2015 can be explained by a diﬀ erent so-
cioeconomic status and diﬀ erent health system in 
those three countries. Patients in Serbia are under-
diagnosed and undertreated due to a failure of the 
primary care physicians to identify depressed pa-
tients, so that those can be treated by a psychia-
trist at the secondary health care level. Sertralin is 
the fi rst-choice medication in Serbia compared to 
escitalopram in Norway and Finland. Escitalo-
pram has the highest probability of remission of 
the investigated antidepressants and is the most 
eﬀ ective and cost-eﬀ ective pharmacological treat-
ment strategy for depression in a primary care set-
ting.
CONCLUSION: The consumption of antide-
pressants in Serbia increased in 2015 compared to 
2013, but was still signifi cantly less in Serbia in 
2013, 2014 and 2015 compared to Finland and 
Norway, pharmacotherapeutically developed 
countries. Medications consumed the most in all 3 
countries in 2013, 2014 and 2015 were selective se-
rotonin reuptake inhibitors. Sertraline was the 
most widely used antidepressant in Serbia in 2015, 
while escitalopram was mostly used antidepres-
sant in Norway and Finland.
ACKNOWLEDGEMENT: This research was 
supported by HORIZON2020 MEDLEM project 
No. 690876, the Project for Scientifi c and Techno-
logical Development of Vojvodina No. 114-451-
2072-/2016-02 and by the Ministry of Education, 
Science and Technological Development, Republic 
of Serbia, Project No 41012.
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INTRODUCTION: Cardiovascular diseases 
(CVD) are the leading cause of dying in the world. 
One of the groups for the treatment of CVD are 
hypolipidemic drugs [1]. The aim of this study 
was to analyze the consumption of hypolipidemic 
drugs in Serbia in the period from 2013 to 2015, 
and to compare this data with Norway and Fin-
land.
MATERIALS AND METHODS: The data 
about the use of drugs are taken from the oﬃ  cial 
web site from the Agency for Medicines and Med-
ical Devices Agency of Serbia, Norwegian Insti-
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tute of Public Health and Agency for Drugs of Fin-
land.
RESULTS: In Serbia, the use of hypolipidemic 
drugs is small and the drugs occupy a 4-5 % of all 
drugs in the treatment of CVD. In Norway and 
Finland consumption of hypolipidemic drugs is 
much more bigger, and among all drugs in the 
treatment of CVD the consumption of hypolipid-
emic drugs is on the second place during that pe-
riod (Norway 30% and Finland 20% of all drugs in 
the treatment of CVD). Among all hypolipidemic 
drugs, the most used drugs are statins, and among 
statins the most used drugs are simvastatin and 
atorvastatin in all three investigated countries. In 
Serbia on fi rst place in 2013/2014/2015 is atorvas-
tatin (11.68/9.47/20.98 DDD), and on second place 
in 2013/2014/2015 is simvastatin (3.67/3.53/3.36 
DDD). In Norway on fi rst place in 2013/2014/2015 
is atorvastatin (58.10/62.85/70.43 DDD), and on 
second place in 2013/2014/2015 is simvastatin 
(50.77/47.22/43.17 DDD). In Finland on fi rst place 
in 2013/2014/2015 is simvastatin (46.87/43.80/44.43 
DDD), and on second place in 2013/2014/2015 is 
atorvastatin (27.52/31.72/36.65 DDD).
CONCLUSION: In observed period it is notice-
able trend of increased consumption of statins in 
all three countries. We also notice that Serbia is the 
country with the lowest consumption of this 
drugs.
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